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Dubium sapientiae initium. 
(René Descartes) 
 
 
 
 
 
 
Imagination is more important than knowledge. 
(Albert Einstein) 
 
 
 
 
 
 
Imagination is innovation. 
(Marcel Bazié)  
 
 
 
 
 
 
Innovation distinguishes between a leader and a follower. 
(Steve Jobs) 
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Abstract 
 
Understanding migraine pathophysiology is probably the most challenging point in migraine 
management, since an efficient acute and preventive treatment should rely on clear 
pathophysiological bases. Migraine is characterized interictally by a lack of habituation of 
evoked responses, possibly due to a decreased preactivation level of sensory cortices. By 
contrast, during an attack and in chronic migraine, the preactivation level increases and 
habituation normalizes. New neurostimulation techniques could be useful to durably modify 
the activation of the underlying cortex, decreasing the repetition of attacks, giving also 
insight on the pathophysiology of migraine. 
The visual cortex plays a pivotal role in migraine pathophysiology, but its effect on the 
trigeminal nociceptive system remains poorly understood. On the other hand migraine attack 
is often associated to photophobia, but the pathophysiological relation between headache and 
the discomfort to the light, during the ictal but also the interictal phase, is unclear. 
This thesis puts a new insight into the relation between the visual cortex modulation and the 
response of the trigeminal nociceptive system, showing a possible inhibitory functional 
interrelation between these structures, via thalamic modulation.  
The hypothesis is based on our first finding investigating the modulation of the visual cortex 
by the repetitive transcranial magnetic stimulation on the nociceptive blink reflex in healthy 
subjects and migraine patients.  
This role of the activation of the visual cortex is also better understood by using the flash light 
stimulation, and thanks to the conception of a new device of flash light stimulation, we 
performed several protocols in healthy subjects and migraine patient with the final result a 
proof-of-concept trial using the flash light stimulation in migraine patients.  
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Abstract 
 
Comprendre la physiopathologie de la migraine est probablement le point le plus difficile 
dans la gestion de la migraine, car un traitement aigu et préventif efficace doit reposer sur 
des bases physiopathologiques claires. La migraine est caractérisée dans la phase inter-
critique par un déficit d'habituation des réponses évoquées, peut-être en raison d'un niveau 
de préactivation réduit au niveau du cortex sensoriels. En revanche, lors d'une attaque et 
dans la migraine chronique, le niveau de préactivation augmente et l’habituation se 
normalise. De nouvelles techniques de neurostimulation pourraient être utiles pour modifier 
durablement l'activation du cortex sous-jacent, en diminuant ainsi la répétition des attaques 
d’une part, et d’autre part donnant un aperçu sur la physiopathologie de la migraine. 
Le cortex visuel joue un rôle central dans la physiopathologie de la migraine, mais son effet 
sur le système nociceptif trigéminal reste peu clair. La céphalée migraineuse s’accompagne 
souvent de photophobie, mais la relation physiopathologique entre les deux symptômes est 
inconnue.  
Cette thèse propose un nouvel aperçu dans la relation entre la modulation du cortex visuel et 
la réponse du système nociceptif trigéminal, montrant une corrélation fonctionnelle 
inhibitrice possible entre les deux structures, par l'intermédiaire de la modulation 
thalamique. 
Cette hypothèse est basée sur nos résultats de modulation fonctionnelle du cortex visuel par 
la stimulation magnétique transcrânienne répétitive sur le réflexe de clignement nociceptif 
chez des sujets sains et chez les migraineux. 
Le rôle de l'activation du cortex visuel est mieux investigué en utilisant une stimulation 
lumineuse intermittente, grâce aussi à la conception d’un nouveau stimulateur testé chez des 
sujets sains et des migraineux avec le résultat final d'un essai-pilote utilisant la stimulation 
lumineuse intermittente comme traitement de fond de la migraine.  
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1. Introduction 
 
 
1.1. History of migraine 
 
Headache is one of the most frequent symptoms in the general population.  
Descriptions of migraine attacks and proposed treatments can be found since the 
earliest historical records. 
Trepanation has been practiced as headache treatment since the Neolithic age. In fact 
recently it was found a trepanned skull of a woman in central Italy, dating 7000 years 
ago. What is interesting in this discovery is the microscopic evidence of a new bone 
growth, proof that the patient survived to the intervention. Trepanation has been 
used as a treatment for several years, and more frequently in the Middle Ages. 
In 4000 B.C. a Sumerian poem claimed these verses ‚Take the hair of a virgin kid. Let a 
wise woman spin it on the right side and double it on the 
left. Then perform the incantation of Eridu. Bind therewith 
the head of the sick man. Bind therewith the neck of the 
sick man. Bind therewith the life of the sick man. Cast the 
water of the incantation over him that the headache may 
ascent to heaven.‛         
 
In the Ancient Egypt it was suggested to ‚take a 
crocodile made of clay, with sacred grain in its mouth, and 
an eye of faience. [The Physician] should bind it to the 
head of the patient with a strip of fine linen upon which 
was written the name of the Gods. And the physician should pray.‛  
The Ebers papyrus which mentioned migraine, shooting pain and neuralgia, dates to 
1552 B.C.:  
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‚Headache roameth over the desert, blowing like the wind.  
Flashing like lightning, it is loosed above and below.  
It cutteth off like a reed him who feareth not his god  
like a stalk of henna, it slitteth his thews.  
It wasteth the flesh of him who hath not protecting goodness.  
Flashing like a heaventhly star, it commeth like the dew:  
it standeth hostile against the wayfarer, scorching him like the day.  
This man is hath struck and like one with heart disease he staggereth.  
Like one bereft of reason he is broken.‛ 
In Mesopotamia features of a sufferer from migraine were: ‚the head is bent with pain 
gripping his temples, and his eyes are afflicted with 
dimness and cloudiness.‛ 
 In 460 B.C., Hippocrates, the most famous Greek 
physician described a migraine with aura attack: 
‚Most of the time he seemed to see something shining 
before him like a light, usually in part of the right eye. 
At the end of a moment, a violent pain supervened in 
the right temple, then in all the head and neck, where 
the head is attached to the spine. Vomiting, when it 
became possible, was able to divert the pain and render it more moderate.‛ He thought that 
migraine and other type o headaches came from ‚humors‛ – some fluids or vapours 
circulating between the liber and the brain, whose action might be controlled by the 
exercise and the sexual activity.  
In particular the presence of nausea and vomiting during a headache attack was due 
to the yellow bile (the choler humor).  
The idea that migraine was a digestive tract problem induced Hippocrates to propose 
to vomit in order to decrease the intensity of pain. He also made for the first time a 
relation between vomiting attacks of childhood and ‚bilious attacks‛ that develop in 
a migraine attack in the adult life; in fact we know now that a recurrent vomiting can 
 
Hippocrates 
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be an episodic syndrome that may be associated to migraine, described also in the 
International Headache Classification. To treat 
headache Hippocrates used the Willow Bark 
(from which aspirin is made).  
 Aretaeus of Cappodocia (30-90 A.D.) was the 
first that well described the syndrome of 
migraine and called it heterocrania, the 
composition of ‚hetero‛  different, and 
‚kranion‛ skull.  
Later Galen (131-201 A.D., Asia Minor) modified 
this definition in emicrania. The term changed to hemigranea and after this to migrainea 
and so on to migrana.  
AbuAli Sina, known by the Latins with the name of Avicenna (980-1037) wrote: ‚small 
movements, drinking and eating, and sounds provoke the pain; the patient cannot tolerate the 
sound of speaking and light. He would like to rest in darkness alone.‛ 
In the Middle Ages in Europe it was used to treat migraine attack with poultices 
applied to the scalp: the vinegar first to open the pores of the scalp and after that an 
opium solution. Another treatment was to apply some hot irons on the head. 
Thomas Willis (1621-1675), an English anatomist 
and physician, made accurate observations on 
migraine features and in particular on the 
hereditary link and trigger factors of the migraine 
attack. He thought that the cause of migraine was 
related to a vasospasm that leads to abandon the 
method of trepanation for headache. Willis wrote 
‚I think the opening of the Scull will profit nothing.‛  
The first vascular theory advanced by Willis was 
widely accepted.  
 
Aretaeus of Cappodocia 
 
 
Thomas Willis 
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In 1850s Brown-Sequard and Claude Bernard asserted that the active headache phase 
of migraine was due to sympathetic deficit of vasodilatation.  
William Richard Gowers (1845-1915) divided the treatment of migraine in 
prophylactic and acute, but he made an interesting ‚Gowers mixture‛ combining 
Nitroglycerin and alcohol to treat the acute phase.  
In the same period migraine aura became also an inspiration for authors like 
Reverend Charles Dodgson (Lewis Carroll as pen name, 1832-1898) who wrote 
‚Alice’s Adventures in Wonderland‛, for painters like Vincent Van Gogh (1853-1890) in 
the painting ‚Starry Night‛, for philosophers such as Friedrich Nietzsche (1844-1900), 
for novelists as H.G. Wells (1866-1946), James Joyce (1882-1941), Emily Dickinson 
(1830-1886).  
Nowadays migraine is not only one of the most frequent neurological diseases but 
also a source of inspiration of a new artistic movement named ‚migraine art‛.  
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1.2. Clinical features of migraine 
 
The diagnosis of migraine is essentially a clinical one.  
Migraine is characterized by the repetition of attacks where headache is the principal, 
but not the only, symptom.  
We can distinguish two main types of migraine that can occur in the same patient: 
migraine without aura and migraine with aura. The knowledge on the 
pathophysiology of migraine has increased in the last 30 years, even if we don’t know 
yet if these two types of migraine are different entities or not.  
Before 1988 the taxonomy of headaches was seldom based on precise criteria. In 1988 
the International Headache Society (IHS) established a classification of headache that 
became rapidly the first approach to diagnose headaches not only in the clinical field 
but also in research.  
A new edition was published in 2004 and the last one was issued 2013 (ICHD 3Beta, 
2013).   
The classification represents an incredible step forward in the codification of 
headache disorders. The guiding principles for the classification were:  
1) To standardize terminology in order to overcome the obstacles in the 
communication between physicians all over the world.  
2) To set up a hierarchical system of clinical manifestations.  
3) To provide precise and specific diagnostic criteria for headache disorders.  
4) To provide a useful tool for specialists, researchers and general practitioners.  
The ICHD – 3 Beta Version (2013) includes 85 different type of headache and 196 
subtypes.  
Anamnesis is the crucial phase to perform a diagnosis of migraine, in particular 
because the majority of migraineurs has a normal neurological and general 
examination, and has normal neuroimaging.  
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In this thesis are reported only diagnostic criteria of the following types of headaches: 
migraine without aura, migraine with aura and chronic migraine.  
 
Table 1.1. Diagnostic criteria of migraine without aura (code 1.1): 
A. At least 5 attacks1 fulfilling criteria B-D 
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)2;3;4 
C. Headache has at least two of the following characteristics: 
1. unilateral location 
2. pulsating quality 
3. moderate or severe pain intensity 
4. aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) 
D. During headache at least one of the following: 
1. nausea and/or vomiting 
2. photophobia and phonophobia 
E. Not better accounted for by another ICHD-3 diagnosis.  
 
Table 1.2. Diagnostic criteria of migraine with aura (code 1.2): 
A. At least two attacks fulfilling criteria B and C 
B. One or more of the following fully reversible aura symptoms: 
1. visual 
2. sensory 
3. speech and/or language 
4. motor 
5. brainstem 
6. retinal 
C. At least two of the following four characteristics: 
1. at least one aura symptom spreads gradually over 5 minutes, and/or two or more symptoms occur in succession 
2. each individual aura symptom lasts 5-60 minutes 
3. at least one aura symptom is unilateral2 
4. the aura is accompanied, or followed within 60 minutes, by headache 
D. Not better accounted for by another ICHD-3 diagnosis, and transient ischaemic attack has been excluded. 
Table 1.3. Diagnostic criteria of chronic migraine (code 1.3): 
A. Headache (tension-type-like and/or migraine-like) on 15 days per month for >3 months and fulfilling criteria B and 
C 
B. Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1 Migraine without aura and/or 
criteria B and C for 1.2 Migraine with aura 
C. On 8 days per month for >3 months, fulfilling any of the following: 
1. criteria C and D for 1.1 Migraine without aura 
2. criteria B and C for 1.2 Migraine with aura 
3. believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative 
D. Not better accounted for by another ICHD-3 diagnosis. 
  
22 
 
1.3. Epidemiology and Burden of migraine 
 
In general population the most represented type of headache is firstly Tension-type 
Headache (TTH), and then migraine and medication overuse headache (MOH).  
According to the last published Global Burden of Diseases Study (Lancet 2015), which 
updates evidences about levels and trends in disease and injury incidence, 
prevalence, and years lived with disability (YLDs) in 188 countries, from 1990 to 2013, 
migraine ranks 6th in the Top 25 causes of global Years Lived with Disability (YLDs), a 
ranking that remained stable over the last 20 years (Fig 1.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: From the Global Burden of Diseases Study 2013 (Lancet 2015). 
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The global prevalence of individuals with recurrent migraine, for more than 3 
months, has increased in 2013 (848,366,000 cases) compared to 1990 (581,025,000 
cases). The augmentation can be explained by the growing population and of course 
by better diagnostic tools and increased attention for migraine.  
Among neurological diseases, migraine ranks 2nd regarding prevalence, after tension-
type headache (1,561,446,000 cases), and followed in 3rd position by medication 
overuse headache (62,899,000 cases). However, the percentage of YLDs in migraine 
has increased by 46.1% from 1990 to 2013, while the gain is more conspicuous in other 
neurological disorders such as multiple sclerosis (116.1%), Alzheimer’s disease 
(91.8%) and Parkinson’s disease (81.2%).  
The prevalence is estimated at 14.7% in adults in Europe (8% in men and 17.6% in 
women) (Stovner et al., 2010). In children and youth people the prevalence is 
estimated in 10%, and in elderly people (64-75 years old) is between 6 and 11%.  
There is a huge disparity in prevalence between Europe and USA on the one hand, 
and Africa and Asia on the other hand, maybe due to the difficulty in diagnosing and 
treating it and also because of some cultural differences in migraine perception.  
In Wallonia-Belgium the one-year prevalence of migraine is 25.8% (Streel et al., 2015), 
and overall costs for migraine in Belgium are estimated at 860,000,000 Euros per year 
(Schoenen et al., 2006).  
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2. Migraine Pathophysiology 
 
 
In the last decades, remarkable strides forward have been made; mainly brought 
about by advanced imaging techniques which have helped to shine light upon the 
underlying causes of primary headache disorders.  
At first migraines were thought to have a vascular pathogenesis; this was 
overshadowed by the conception that a ‚neurovascular phenomenon‛ seemed to be 
the permissive triggering factor in migraines and in cluster headaches. Neuronal 
structures are involved in the pathogenesis of migraine, in which the vasodilatation is 
only an epiphenomenon.  
However, the exact pathogenic process of migraine remains to be determined.  
Since the 1940s the evolution in the concept of migraine pathophysiology has seen the 
opposition of two main theories: the vascular hypothesis and the integrated 
neurovascular model. Harold G. Wolff, a pioneer of the vascular theory of migraine, 
suggested that the aura phase was caused by vasoconstriction and the headache by 
rebound vasodilatation (Wolff et al., 1963). Lashley’s experience of his own visual 
aura led him to the concept that the Cortical Spreading Depression (CSD) of Leão was 
the primary cause (Lashley et al., 1941), and advanced the neural theory of migraine 
(Leão et al., 1944), where the vascular changes are a consequence and not directly a 
cause to the headache. Laurintzen (1994) and Olesen (1981) confirmed that during the 
migraine aura there is a hypovascularisation spreading in the parieto-occipital 
regions and changes in the vascularisation can persist also during the cephalic phase. 
Curtrer et al. (1998) demonstrated that the occipital cortex, contralateral to the visual 
aura, was involved by a decrease in the cerebral flow using Positron Emission 
Tomography (PET), at a level that didn’t reach the ischemic threshold. On the other 
hand vascular changes do not occur in all migraine sufferers (Pietrobon et al., 2003).  
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Nonetheless, the relation between migraine aura and headache remains controversial, 
and so also the ‚primum movens‛ of migraine without aura, which is the most 
frequent type of headache.  
Below we will summarize the main knowledge on the pathophysiology of migraine; 
in particular those aspects that are the most closely related to our research.  
We will distinguish the pathophysiology of the migraine attack from the interictal 
phase. Bearing in mind that migraine attacks occur periodically, factors that 
precipitate attacks are pivotal in the pathophysiology of the disorder.   
 
 
2.1. Migraine aura  
 
The clinical features of the aura have been described since a long time, but it is only 
since 1941 that researchers have tried to explain this phenomenon.  
The first was Lashley (1941) who posited that the aura was caused by a neuronal 
dysfunctioning that is composed firstly of an activation phase (phosphenes), followed 
by an inhibition phase (scotoma). This process spreads over the visual cortex at a 
velocity of 3-5 mm per minute. The same characteristics were observed also in the 
animal model of cortical spreading depression (CSD) by Leão (1944): CSD is a wave 
of brief, intensive neuronal depolarisation followed by a wave of depolarisation 
block. CSD is considered to be associated with the migraine aura phenomenon and 
can be triggered by various physical and chemical stimuli. In lissencephalic animals 
such as rodents the propagation of CSD is facilitated by the absence of 
circumvolutions in the brain, whereas in gyrencephalic animals a sulcus or a fissure 
can interrupt CSD. During the inhibitory phase of CSD there is also a decrease in 
cerebral blood flow (CBF) by 20-30%, but interestingly the area of the propagation of 
this oligemia is independent from the vascular territories.  
The visual cortex is the region where the CSD is facilitated because of a high neuronal 
density and neuron to astrocyte ratio. Astrocytes are able to buffer extracellular 
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potassium and glutamate released during CSD and hence are crucial in CSD 
termination.  
SPECT studies during visual auras triggered by the injection of xenon 133 into the 
carotid artery were first to show an oligemia comparable to that recorded during 
experimental CSD (Olesen et al., 1981 and 1991). While CSD has not yet been 
demonstrated as such in humans, metabolic changes characteristic of CSD have been 
shown in migraine patients (Cao et al., 1999; Hadjikhani et al., 2001). Using Blood 
Oxygenation Level-Dependent (BOLD) Functional magnetic resonance imaging 
(fMRI) during migraine aura induced by visual stimulation with red/green 
checkerboard, the authors found a decrease in the signal BOLD in the visual cortex 
that preceded the triggered headache even if patients did not experience a visual 
change. The question was further investigated by Hadjikhani et al. (2001) with fMRI 
during spontaneous auras that showed similar changes as those found by Cao et al. 
Occipito-parietal spreading oligemia was also reported in a migraine-without-aura 
patient undergoing visual stimulation during H2O15-PET (Woods et al. 1994). 
Nevertheless, the precise link between the spreading events that accompany migraine 
attacks and CSDs recorded in animals events is not clear (Brennan et al., 2007). Using 
MRI perfusion-weighted imaging (PWI), Sanchez de Rio et al. (1999) observed a 
reduction in the CBF in the occipital cortex but not in other areas during spontaneous 
migraine auras and did not find such CBF reduction in migraine without aura 
patients. Similarly no CBF change was found with H2O15- PET during attacks of 
migraine without aura (Weiller et al., 1995).  
A study conducted in our Headache Research Unit using quantitative EEG brain 
mapping during the ictal phase in migraineurs without aura showed depression in 
posterior alpha power, ipsilateral to the pain that was interpreted as a possible 
reflection of reduced neuronal activity (Schoenen et al., 1987) reminiscent of the 
decrease in alpha EEG activity reported during experimental CSDs by Leão’s (1945). 
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2.2. Migraine headache  
 
The fact that the migraine pain involves trigeminal nerve afferents, in particular the 
trigeminovascular system located around meningeal vessels, has been well 
documented and well accepted for several decades now. 
Trigeminovascular small calibre myelinated Aδ and unmyelinated C axons 
surrounding blood vessels of the pia and dura mater can release vasoactive peptides 
producing a sterile inflammatory reaction (Moskovitz, 1984). These structures taken 
together are termed the ‚Trigeminovascular System‛. Afferent impulses from the 
trigeminovascular system converge on 2ary nociceptors in the trigeminal nucleus 
caudalis (TCN), situated in C1 and C2, that also receive somatic afferents from the 
somatic portion of the ophthalmic nerve and C2 dermatoma. This is probably why 
the head pain in migraine is often localized in the fronto-orbital or cervico-occipital 
region (Arbab et al., 1986, Kerr et al., 1972), and can be considered a ‚referred pain‛. 
Neurons in the Gasserian ganglion contain calcitonin gene-related peptide (CGRP) or 
substance P (SP) (Uddman et al., 1985). The stimulation of the trigeminal ganglion 
induces the release of vasodilatatory peptides such as CGRP, substance P, neurokinin 
A and nitric oxide (Moskowitz et al., 1992 and 1993). The reaction termed 
‚neurogenic inflammation‛ may lower the nociceptive threshold required to 
stimulate meningeal sensory fibers (Moskowitz et al., 1990) and also act on vascular 
tissues to cause vasodilatation, plasma protein extravasation, endothelial changes, 
platelet aggregation, subsequent release of serotonin (5-hydroxytryptamine, 5-HT) 
and other mediators, white-cell adhesion and inflammation. In turn the cranial 
vasodilatation stimulates the trigeminal endings, and the latter further reinforces the 
release of vasodilator peptides. Neurogenic inflammation has not been demonstrated 
in migraine patients and recent imaging studies show that migraine attacks are not 
associated with significant vasodilatation of extra- or intracerebral arteries (Amin et 
al., 2013). By contrast, there is undisputable evidence for the ictal release of CGRP 
from meningeal 1ary nociceptors as shown by the studies of CGRP levels in external 
28 
 
jugular vein blood during migraine attacks (Goadsby et al., 1990). Specific 
antimigraine drugs, including sumatriptan, are able to supress plasma extravasation 
produced by the antidromic stimulation of trigeminal nerve terminals in rodent 
meninges (Moskowitz et al., 1991) and more interestingly, antagonists of CGRP-
receptors, such as olcegepant and telcagepant, and more recently monoclonal 
antibodies against CGRP or its receptor (Yao et al., 2013) are effective for migraine 
treatment although they have no vascular effects (Petersen et al., 2005).  
 
 
2.3. Is there a link between CSD and migraine pain?  
 
While we can produce CSD in anesthetized or evoked animals, anaesthesia may have 
profound effects on the mechanisms underlying the CSD and clearly the behavioural 
response is absent. Therefore studies in awake animals seem more appropriate to 
investigate CSD-associated behavioural changes. A single CSD has been shown to 
evoke freezing and reduce motor activity in rodents (Akcali et al., 2010; Fioravanti et 
al., 2011).  
Moskowitz et al. (1993) found that CSD in animals is associated with an increased 
ipsilateral expression of c-fos, considered a surrogate marker of pain, in trigeminal 
nucleus neurons and he postulated that the CSD is the ‚primary‛ event of a migraine 
attack, leading to the neurogenic inflammation. In 2002 Bolay et al. provided evidence 
in animal subjects that CSD activates trigeminal afferents causing inflammatory 
changes (vasodilatation, oedema and protein extravasation) in the meninges (Bolay et 
al., 2002), lending support to Leão’s theory. The authors also investigated, after 
resection of trigeminal nerve, how the expression of c-fos was increased in lamina I 
and II in the nucleus caudalis after CSD.  
At the same time this conclusion was criticized by two studies based on the direct 
measure of trigeminal second-order neurons firing after CSD (Lambert et al., 1999; 
29 
 
Ebersberger et al., 2001) both were critical of Moskowitz’s theory for methodological 
reasons.  
A recent study showed that the propagation of the CSD also involves the thalamic 
reticular nucleus (TRN) visual sector (Tepe et al., 2015) and this effect can be blocked 
by the acute administration of valproic acid, one of the most effective prophylactic 
treatments in migraine. These findings may well lead to new developments in the 
treatment for migraine that focuses on the role of thalamic nuclei and its integrative 
role in the pain matrix.   
 
 
2.4. Migraine generator  
 
The two studies cited before (Lambert et al., 1999; Ebersberger et al., 2001) sought to 
tackle the as yet unsolved question of what causes migraine attacks.  
Considering migraine as the derangement of a complex network of neural structures 
involved in pain processing can provide an answer to some extent. Pain can be 
considered as an integrative, modelled, and multidimensional sensation, with the aim 
to localise and discriminate the nature and the intensity of the threat in order to 
induce the most appropriate emotional and cognitive processing of the stimulus and 
thus lead to the best behavioural defensive response. The process inevitably involves 
numerous cerebral areas, those of somatic sensation, emotion and cognitive 
modulation, vegetative and motor action. Inhibitory and facilitatory mechanisms for 
controlling pain signals are involved in the so-called pain matrix. 
In migraine the first generator seems to be the brainstem, where the trigeminocervical 
complex (TCC), composed of the TCN and the neurons of the C1 and C2 spinal cord, 
projects. Even if the pivotal role of the brainstem was postulated several decades ago, 
the first evidence was published in 1995 by Weiller and colleagues: using H2O15-PET 
they demonstrated in 9 migraine patients during right-sided migraine attacks an 
increased blood flow in the contralateral brainstem. Similar studies confirmed these 
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results by showing an activation in the dorsal rostral brainstem in a patient with 
migraine without aura (Bahra et al., 2001), the red nucleus and substantia nigra in a 
patient with migraine with aura (Welch et al., 1998) and the dorsal lateral pons in 24 
migraine patients (Afridi et al., 2005).  
Brainstem activation, however, does not seem to be migraine-specific: it was also 
found in other chronic pain conditions (Kupers et al., 2000).  
The question to be elucidated is how the brainstem can cause enhanced responses in 
the nociceptive trigeminovascular system? Two complementary theories address this 
question: a low level of descending inhibition or a high level of descending 
facilitation. The final result is hyperexcitability of 2nd order trigeminovascular 
neurons.  
Interestingly, during migraine attacks the brainstem activation persists after injection 
of sumatriptan with complete clinical relief not only of the headache but also of 
associated symptoms such as photophobia and phonophobia (Weiller et al., 1995) and 
the nucleus cuneiformis remains hypofunctional between migraine attacks (Moulton 
et al., 2008). The brainstem could thus be the link connecting the pathophysiology of 
the migraine attack to the interictal phase. 
 
 
2.5. Genetic predisposition  
 
Migraine has been known as a familial disorder for a long time. Genetic studies have 
contributed significantly to the understanding of migraine pathophysiology. 
Migraine is known to be 50% more common among 1st degree relatives of sufferers 
than in matched controls. The risk is higher for those with more disabling symptoms 
than for those with lighter symptoms, and higher for those with migraine with aura 
than for those with migraine without aura. Studies have also shown a higher rate of 
concordance for monozygotic than dizygotic twins, and this effect is greater in 
females than males (Stewart et al., 1996). Concordance in monozygotic twins is 
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nevertheless under 100% (Larsson et al., 1995). Migraine is clearly genetically 
complex, with a non-Mendelian mode of inheritance and mutations in multiple 
genetic loci. Mutations are likely to affect changes in the threshold of susceptibility to 
migraine attacks.  
In familial hemiplegic migraine (FHM) type 1, a rare autosomal dominant form of 
migraine with prolonged hemiplegic aura, various pathogenic mutations have been 
discovered in single genes. The first mutations (FHM1) were found in the CACNA1A 
gene, a P/Q voltage gated calcium channel gene (Ophoff et al., 1996). Other mutations 
in 2 other genes have also been documented to cause related phenotypes (ATP1A2 in 
FHM2 (De Fusco et al., 2003) and SCN1A in FHM3 (Dichgans et al., 2005). ATP1A2 
codes for an alpha 2 subunit of the Na/K ATPase pump, and mutations cause changes 
in the sodium gradient across the cell membrane, with associated changes in synaptic 
neurotransmitter levels. Similarly, mutations in SCN1A affect transmembrane 
sodium flux.  
There is a known association between FHM1 and basilar-type aura symptoms, and 
between FHM1 and chronic progressive cerebellar ataxia in 50% of families.  
The FHM mutations are not found in the common forms of migraine with or without 
aura. In the latter genome-wide association studies have identified up to now 14 
genetic loci (single nucleotide polymorphisms), each of which contributes only to a 
small percentage of migraine susceptibility (Anttila et al., 2010). A number of other 
genetic associations have been reported in migraine, including with polymorphisms 
in MTHFR, ACE, ETA, and PGR genes (Lee et al., 2007; Rubino et al., 2009; Tzourio et 
al., 2001). The relative contribution of each has yet to be verified and quantified in 
different populations.  
Although family and twin studies indicate involvement of genetic factors in the 
aetiology of migraine, the exact contribution of genes and the mode of inheritance of 
such factors remain unknown. Overall, the genetic studies indicate that the common 
forms of migraine are complex genetic disorders with a multifactorial inheritance, 
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combining genetic and environmental factors that set the ‚migraine threshold‛ and 
thus can lead to the development of a repetitive pattern of attacks.  
 
 
2.6. Contribution of electroneurophysiology to migraine pathophysiology  
 
2.6.1. Generalities  
 
The electroneurophysiologic techniques (evoked potentials, electroencephalography, 
and electromyography) allow the recording of central and peripheral responses of the 
nervous system.  
During the last three decades electroneurophysiology was widely used to explore 
migraine pathophysiology. Among the different techniques, evoked potentials have 
been the most studied. Differences have been found in the latency and amplitude of 
evoked potentials, but one of most reproducible alterations found in migraineurs 
compared to healthy subjects is a ‚deficit of habituation‛, confirmed in studies using 
visual (Schoenen et al., 1995), auditory (Wang et al., 1996; Ambrosini et al., 2003), 
somatosensory (Ozkul et al., 2002), cognitive (Siniatchkin et al., 2000, 2006 and 2007; 
Kropp et al., 1993 and 1995; Schoenen et al., 1993) and nociceptive stimuli (Valeriani 
et al., 2003, de Tommaso et al., 2005; Di Clemente et al., 2005 and 2007).  
We will first discuss the data concerning latencies and amplitudes of evoked 
potentials and thereafter the results on habituation, including a short explanation of 
the phenomenon of habituation/sensitization.  
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2.6.2. Differences in latency and amplitude of evoked potentials  
 
2.6.2.1. Visual evoked potentials (VEP)  
 
In early VEP studies the responses were evoked by flash light stimulation: the main 
result was increased amplitude in migraineurs compared to controls (Lehtonen et al., 
1974; Connolly et al., 1982; Brinciotti et al., 1986), except in one study (Richey et al., 
1966).  
Using pattern-reversal visual evoked potential (PR-VEP), results are more 
heterogeneous. VEP amplitude was found to be normal, or increased between attacks 
and during the pre-ictal phase, whilst some studies reported decreased amplitudes. 
PR-VEP latencies were also found increased in some studies but not in others (see 
review by Ambrosini et al., 2006). While in one study the decreased PR-VEP 
amplitude was correlated to the duration of the disease (Khalil et al., 2000), it wasn't 
in another (Yucesan et al., 2000). It seems that there is no difference between migraine 
with and without aura, except for P100 amplitude, which was found to be reduced in 
one study (Tagliati et al., 1995) but increased in another (Shibata et al., 1997) in 
migraine with aura.  
These contradictory findings are probably due to differences in methodology and in 
patients’ diagnosis.  
Results using PR-VEP are more convincing when changes in successive blocks are 
considered, i.e. habituation that will be discussed below.  
 
 
2.6.2.2. Auditory evoked potentials (AEPs)  
 
Several studies of brainstem AEPs did not find any significant difference in latencies 
between healthy subjects and migraineurs in the interictal phase, but as with the VEP 
recordings, the results are moot and sometimes the authors found an increased 
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latency of the 5th component (Bussone et al., 1985; Drake et al., 1990) in particular 
during the ictal phase of migraine with aura (Schlake et al., 1990).  
Cortical long-latency AEPs did not show significant differences between groups of 
normal subjects and patients regarding latencies or amplitudes of N1, P2 and N2 
(Drake et al., 1989; Sand et al., 2000). 
 
 
2.6.2.3. Somatosensory evoked potentials (SSEP)  
 
Overall, no significant abnormalities were demonstrated using the standard SSEP 
after median nerve or index-finger stimulation in migraine patients, except for a 
prolonged N13 latency in the interictal phase, a prolonged N19 and reduced 
amplitudes during the aura phase (see review by Ambrosini et al., 2006).  
 
 
2.6.2.4. Contingent negative variation (CNV)  
 
CNV, an event-related potential obtained during a reaction time task, showed 
increased amplitude in migraineurs during the interictal phase that was more 
pronounced in MO patients (Schoenen et al., 1985; Maertens de Noordhout et al., 
1986; Böcker et al., 1990; Kropp et al., 1993). A positive correlation between CNV and 
risk for developing migraine based on 1st degree relatives affected by the disease was 
also documented (Siniatchkin et al., 2000 and 2001).  
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2.6.2.5. Nociceptive laser-(LEPs) or contact heat-(CHEPs) evoked potentials and 
nociceptive blink reflex (nBR)  
 
LEPs are likely generated by the cingulate cortex (Bentley et al., 2003), which belongs 
to the limbic system and is involved in the emotional aspect of pain. Studies by de 
Tommaso et al. (2005) showed increased N2-P2 amplitude when the supraorbital area 
or the dorsum of the hand were stimulated in migraine patients during an attack. 
Oral administration of nitroglycerin increased LEP P2 amplitude (de Tommaso et al., 
2004) whereas almotriptan or lycine-acetylsalicytate reduced P2 amplitude (de 
Tommaso et al., 2005).  
Amplitude of the nBR (R2 component) was found increased and its latency decreased 
in the ictal phase but not in sinusitis pain (Katsarava et al., 2002; Kaube et al., 2002). 
The abnormality disappeared after acute migraine treatment (Kaube et al., 2002).  
A recent study using CHEPs showed enhanced amplitudes in both MA and MO (Lev 
et al., 2013), but not in another study where the amplitude was decreased (Beese et al., 
2015).  
 
 
2.6.3. Habituation and sensitization: the “dual process” theory  
 
The first description of the phenomena of habituation and sensitization, and the 
coining of these terms, dates back to Thompson and Spencer in 1966. The authors 
presented nine main behavioural characteristics of habituation that are common to 
many different species.  
In the early stage of a repeated stimulation, there is initially an increased response, 
so-called sensitization, while the response decreases as the stimulation continues, so-
called habituation. Considered together these two phenomena are known as ‚dual 
process‛ theory (Groves et al., 1970). The theory was revised in 2009 (Rankin et al., 
36 
 
2009) when a 10th characteristic was added; we will be dealing only with the recent 
version.  
“Habituation is defined as a behavioural response decrement that results from repeated 
stimulation and that does not involve sensory adaptation/sensory fatigue or motor fatigue.” – 
from Rankin et al., 2009. Behavioural responses that follow the habituation process 
involve every type of stimulus, including reflexes and hormone release.  
Habituation is the most elementary form of learning, but even if the 
neurophysiological mechanisms underlying this process are not clear.  
 
 
2.6.3.1. Characteristics of habituation (Adapted from Rankin et al., 2009) 
 
1. ‚Repeated application of a stimulus results in a progressive decrease in some 
parameter of a response to an asymptotic level. This change may include decreases in 
frequency and/or magnitude of the response.‛  
2. ‚If the stimulus is withheld after response decrement, the response recovers at least 
partially over the observation time (‘‘spontaneous recovery‛).‛  
3. ‚After multiple series of stimulus repetitions and spontaneous recoveries, the 
response decrement becomes successively more rapid and/or more pronounced (this 
phenomenon can be called potentiation of habituation).‛  
4. ‚Other things being equal, more frequent stimulation results in more rapid and/or 
more pronounced response decrement, and more rapid spontaneous recovery (if the 
decrement has reached asymptotic levels).‛  
5. ‚Within a stimulus modality, the less intense the stimulus, the more rapid and/or 
more pronounced the behavioural response decrement. Very intense stimuli may 
yield no significant observable response decrement.‛  
6. ‚The effects of repeated stimulation may continue to accumulate even after the 
response has reached an asymptotic level (which may or may not be zero, or no 
response).‛  
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7. ‚Within the same stimulus modality, the response decrement shows some stimulus 
specificity.‛  
8. ‚Presentation of a different stimulus results in an increase of the decremented 
response to the original stimulus. This phenomenon is termed ‘‘dishabituation‛.‛  
9. ‚Upon repeated application of the dishabituating stimulus, the amount of 
dishabituation produced decreases (this phenomenon can be called habituation of 
dishabituation).‛  
10. ‚Some stimulus repetition protocols may result in properties of the response 
decrement (e.g. more rapid rehabituation than baseline, smaller initial responses than 
baseline, smaller mean responses than baseline, less frequent responses than baseline) 
that last hours, days or weeks. This persistence of aspects of habituation is termed 
long-term habituation.‛  
 
 
2.6.3.2. Characteristics of sensitization  
 
Sensitization is also a learning phenomenon: it is characterized by the increasing 
response to many types of stimuli, normally considered harmless, when the subject 
receives a painful stimulus. In other words it is the capacity to evoke a response to 
stimuli with an intensity under-threshold or to produce an excessive response during 
painful stimulation.  
The clinical manifestation of sensitization is allodynia or hyperalgesia. In some 
studies cutaneous allodynia was found in 79% of migraine patients (Burstein et al., 
2000).  
One can distinguish peripheral and central sensitization. Albeit the former is 
sustained by peripheral nociceptors, and the latter by trigeminal neurons projecting 
to brainstem nuclei, these two phenomena are chronologically correlated: between 5 
and 20 minutes after the beginning of the headache the subject develops a peripheral 
sensitization; between 20 and 120 minutes the central sensitization starts and reaches 
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a peak between 120 and 240 minutes (Strassman et al., 1996). The clinical 
manifestation of the allodynia begins when central sensitization occurs, suggesting 
that changes involve central and not peripheral mechanisms.  
Moreover sensitization can be persistent, in particular when the painful stimulus is 
repeated over a longer period e.g. several days, weeks, months or years, a repetition 
of pain that may occur in migraine because of the repetition of attacks. 
 
 
2.6.3.3. Habituation and sensitization in migraine  
 
Electroneurophysiology allows to study habituation and sensitization by recording 
response amplitude in sequential blocks of averagings during continuous stimulation 
and analysing its change between the 1st and the last block of responses. In migraine 
the characteristic feature is a lack of habituation in interictal phase, as opposed to 
normal habituation during the attack (Fig. 2.1). This abnormal response pattern was 
found for all stimulation modalities and might be genetically determined. 
The first study showing that habituation is decreased in migraine patients was 
conducted by Schoenen et al. (1985) using CNV: the early component was the most 
modified comparing healthy subjects and migraineurs and was confirmed in studies 
using visual or auditory oddball paradigms (see review by Coppola et al., 2007).   
PR-VEP were widely used to investigate the process of habituation in migraineurs 
and showed that the amplitude of N1-P1 and P1-N2 decreases, and thus habituates, 
during repetitive stimulation in healthy subjects but not in migraineurs between 
attacks (Schoenen et al., 1995; Afra et al., 1998; Wang et al., 1999). During the attack, 
the deficit of habituation normalizes (Afra et al., 2000). However the interictal deficit 
of habituation interictally was not confirmed by others (Oelkers et al., 1999 and 2005; 
Sand et al., 2000), which could be related to geographical genetic or environmental 
differences (Ambrosini et al., Cephalalgia 2016 in press). 
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Moreover the habituation deficit was also found in related parent-child pairs of 
migraineurs but not in unrelated pairs (Sándor et al., 1999). The deficit of habituation 
is normalized by preventive treatment with beta-blockers (Sándor et al., 2000), which 
also normalizes the increased amplitude of grand average VEPs (Diener et al., 1989), 
and by fluoxetine (Ozkul et al., 2002). High frequency repetitive transcranial magnetic 
stimulation (rTMS), that activates the underlying cortex, produced a normalisation of 
the deficit of habituation in migraineurs when applied over the occipital region, while 
low frequency rTMS supposed to inhibit the cortex, induced a potentiation (Bohotin 
et al., 2002). After 5 daily sessions of rTMS these effects last days or weeks both in 
healthy subjects and migraine patients (Fumal et al., 2006). 
Transcranial direct current stimulation (tDCS) over the visual cortex increases 
transiently habituation of the N1-P1 VEP component (Viganó et al., 2013). The late 
component of high-frequency oscillations in the gamma band (GFO 20-60 Hz) of 
VEPs also lack habituation both in MO and MA (Coppola et al., 2007).  
The amplitude-stimulus slope of AEPs is steeper in migraine patients compared to 
healthy subjects (Wang et al., 1996), though not in all studies (Sand et al., 2000), and 
this is attributed to a lack of habituation of the responses during high intensity 
stimuli (Ambrosini et al., 2003). When two auditory stimuli are delivered at an 
interval of 500 ms, the second response (P50) is reduced in healthy subjects but not 
migraine patients reflecting a deficient gating mechanism (Ambrosini et al., 2001).  
As for SSEPs Ozkul et al. (2002) found a potentiation of the N20 component after 
stimulating the median nerve, and the recovery cycle of SSEPs in children with 
migraine without aura was higher than in the controls (Valeriani et al., 2005), 
probable because of potentiation in the somatosensory cortex.  
Pain-evoked potentials equally lack habituation in migraineurs. The N2-P2 LEPs 
component showed potentiation in migraine patients (Valeriani et al., 2003, de 
Tommaso et al., 2005), but contrary to VEPs, the deficit of habituation persists during 
the attack (de Tommaso et al., 2005).  
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Three studies showed that the nBR undergoes potentiation in migraine patients 
between attacks while it habituates in healthy controls (Di Clemente et al., 2005 and 
2007; Katsarava et al., 2003); nBR and VEP abnormalities were correlated in the same 
patients suggesting a common underlying mechanism (Di Clemente et al., 2005).  
Lack of habituation was also reported for CHEPs in migraineurs (Lev et al., 2010 and 
2013; Beese et al., 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The other facet of the ‚dual process‛ theory, sensitization, is also suggested by 
studies in migraine, particularly when using noxious stimuli and in chronic migraine. 
During the migraine attack the area under the curve (AUC) of the nBR R2 is increased 
on the affected side compared to the non-affected side (Kaube et al., 2002). Similar 
results were also found in the N2-P2 components of LEPs (de Tommaso et al., 2005), 
suggesting ictal sensitization. In medication overuse headache (MOH) the first block 
of the SSEP N20-P25 component had greater amplitude than in episodic migraine 
patients or healthy controls and this correlated with the duration of disease. This was 
interpreted as a reinforcement and perpetuation of central sensitization due to the 
medication intake and the repetition of headache attacks. This is supported by the 
Figure 2.1: Summary of the pattern of habituation/sensitization for all evoked potentials 
and the main pattern of responses during repetitive stimulation, painful or not, in healthy 
subjects, episodic migraineurs in the interictal phase, episodic migraineurs ictally and 
MOH patients (from Coppola et al., 2013).  
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study of Ayzenberg et al. (2006) showing that in MOH the increased amplitude of 
trigeminal pain-related evoked potentials (PREP) normalizes after drug withdrawal.  
 
 
2.6.3.4. Significance of the habituation deficit on migraine pathophysiology  
 
Taken together, the electroneurophysiological results are key to advance toward the 
now accepted theory that the demonstrated changes are the reflection of altered 
cortical preactivation, probably due to an abnormal subcortical control by 
monoaminergic afferents (Schoenen et al., 1995). This notion was not forthwith 
understood, and authors, several years ago, thought the primary culprit was ‚cortical 
hyperexcitability‛ possibly due to decreased intracortical inhibition. This hypothesis 
was not confirmed by a series of studies performed by Schoenen and Coppola et al., 
(2007, 2009 and 2010) showing that migraine can most likely be considered as a 
thalamo-cortical dysrhythmia where an insufficient thalamo-cortical drive results 
both in initial low preactivation of sensory cortices and during stimulus repetition to 
lack of habituation, explaining why the cortex is hyper-responsive without being 
hyperexcitable. What the precise role of the thalamo-cortical dysrhythmia and cortical 
hyper-responsivity in migraine pathogenesis is remains to be determined. Since 
migraine patients are biochemically characterized between attacks by a decreased 
mitochondrial energy reserve and ATP synthesis, cortical hyper-responsivity could 
favour a rupture of metabolic homeostasis leading to activation of the pain-signalling 
trigeminovascular system and hence the migraine attack (see Schoenen et al., 1994, De 
Tommaso et al., 2014). 
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3. Photophobia  
 
 
Most migraineurs have photophobia as an associated symptom during an attack, but 
they are also overall more sensitive to light between attacks (Drummond et al., 1986; 
Friedman et al., 2009), in particular those suffering from migraine with aura (Hay et 
al., 1994). In the ICHD ictal photophobia combined with phonophobia is part of the 
diagnostic criteria for migraine, though not mandatory. 
Photophobia is not a migraine-specific symptom; in other diseases, neurological or 
not, photophobia may occur, among them blepharospasm (Hallet et al., 2008), ocular 
pathologies (Lebensohn et al., 1951), tumoral lesions compressing the anterior visual 
pathways (Kawasaki et al., 2002), trigeminal neuralgia (Gutrecht et al., 1994), and 
fibromyalgia (Martenson et al., 2015).   
The neuronal circuit involved in the pathophysiology of photophobia is poorly 
understood. However, recent evidence from animal and human studies provided 
some insight in possible pathophysiological mechanisms.  
 
 
3.1. Mechanisms of photophobia in animal experiments 
 
The control of light tolerance is located in a complex circuit involving the retina, the 
trigeminal ganglion, the periaqueductal grey matter (PAG), the rostral ventromedial 
medulla (RVM) and particularly the nucleus raphe magnus (NRM), the olivary 
pretectal nucleus (OPN), the superior salivatory nucleus (SSN), the dorsolateral 
thalamus (DLT) and the visual cortex (VC).   
Some studies in animals have shown possible interactions between these structures 
during high intensity light stimulation.   
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In 1927, Crozier and Pincus observed that neonatal rats, even prior to the opening of 
their eyes, turn away from a localized light source, which he termed ‚negative 
phototaxis‛. Interestingly this primitive reflexive behaviour occurs at a point when 
the image-forming photoreceptors are not yet functional within the retina.  
More recent studies have put forward possible explanations for the exacerbation of 
photophobia in migraine in the animal model.  
Okamoto et al. (2009) submitted anesthetized rats to light stimulation while recording 
trigeminal nucleus caudalis neurons. They found that during light exposure firing of 
these neurons was increased and the response was suppressed after injection of 
lidocaine into the ocular globe or the trigeminal ganglion, indicating that both 
structures were involved in the light-evoked nociceptive discharge. They also showed 
that the circuit involves the olivary pretectal nucleus (OPN), and inhibition blocked 
completely light-evoked trigeminal nucleus caudalis neural activity and tear 
formation (Okamoto et al., 2010).  
Further evidence comes from studies by Noseda et al. (2010). The authors injected a 
viral tracer into the globe of rats and found a direct connection between the intrinsic 
photoreceptive retinal ganglion cells (ipRGCs) and the posterior, the lateral posterior 
and the intergeniculate thalamus all three of which are not believed to be associated 
with the classical visual pathway. The same thalamic nuclei were also activated by 
stimulation of the dura, demonstrating convergent input from the retina and from 
trigeminal nociceptors. From the thalamus, afferents reach the cortex, including the 
visual cortex. Interestingly the posterior and lateral posterior thalami both receive 
direct projections from forebrain structures like the nucleus of the diagonal band of 
Broca, the dopaminergic cell groups of the hypothalamus, the ventromedial and the 
ventral tubero-mamillary nucleus of the hypothalamus (Kagan et al., 2013).  
A third possible circuit excludes the role of the optic nerve to explain how the light 
stimulus links to the nociceptive trigeminal system. Dolgonos et al. (2011) showed 
that in rats after optic nerve section, the amplitude of the blink reflex remains 
increased during high intensity light stimulation.  
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In cats, light stimulation increases the response of trigeminal nociceptors in nucleus 
caudalis via inhibition of raphe magnus (NRM) serotonergic neurons (Lambert et al., 
2008). 
Concerning the role of the rostral ventromedial medulla (RVM), where the NRM is 
located, it has been extensively studied in pain processing since the 1980s. The RVM 
contains two different nociceptive cell populations: ON-cells, which enhance the 
perception of pain and OFF-cells that have an inhibitory control on the nociceptive 
information (Fields et al., 1985). A shift in the balance between these two populations 
can lead to increased or diminished pain. In a recent study (Martenson et al., 2015) it 
was found that ON-cells and OFF-cells in the RVM are also activated by light. When 
these authors exposed rats to light stimulation, they found that the pain threshold for 
heat stimuli was lowered, suggesting a pro-nociceptive effect of intense light on the 
pain sensation. Moreover they recorded the RVM ON- and OFF-cells during heat and 
light stimulation while using lidocaine to selectively block the trigeminal ganglion, 
the posterior thalamus or the olivary pretectal nucleus. The blocking of the trigeminal 
ganglion and the posterior thalamus did not affect the response of ON- and OFF-cells 
in the RVM, while OPN inactivation led to attenuated neuronal responses to light but 
not to heat.  
Mice with increased sensitivity to CGRP (calcitonin-gene-related-peptide) 
(nestin/hRAMP1 mice) show light aversion to intracerebro-ventricular CGRP 
injection (Recober et al., 2009 and 2010). However, wild-type animals show the same 
light aversion as long as the dose of CGRP is high enough and this effect is reduced 
by administration of rizatriptan, showing how 5-HT1B/D agonists (triptans) can have 
an effect on ictal photophobia and may act by a mechanism distinct from inhibition of 
CGRP release (Kaiser et al., 2012). 
 
In summary, experimental studies in animals indicate various mechanisms by which 
light stimulation can induce discomfort and aversion. However, these results cannot 
be transposed to humans without reservation because rats are more active during the 
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night as opposed to humans who sleep during night and in whom the circadian 
rhythm plays a crucial role in the homeostasis of the organism. The pathophysiology 
of photophobia in humans may thus be underpinned by different functional 
connections.   
 
 
3.2. Mechanisms of photophobia in humans  
 
In humans it is more difficult to directly test the effect of light on the 
descending/ascending control of pain; the integration of results from 
electroneurophysiology and neuroimagery can nevertheless contribute to have an 
overview of this matter.  
During migraine attack the brainstem, in particular the dorsolateral pons is activated 
(Weiller et al., 1995; Bahra et al., 2001), and activation of the trigeminal system was 
also reported in a photophobic pain-free migraine patient (Moulton et al., 2009). A 
PET study conducted after the implantation of sub-occipital electrodes in chronic 
migraine patients, who experienced pain relief, showed activation in the rostral pons, 
in the anterior cingulated cortex, cuneus and left pulvinar during the electrical 
stimulation (Matharu et al., 2004). Furthermore in four patients who had received 
laser-assisted in-situ keratomileusis (LASIK) to treat myopia, with intense 
photophobia as a side effect, BOLD fMRI showed a greater activation of visual 
associative cortices during photic stimulation in the symptomatic eye compared to 
the non-symptomatic eye (Malecaze et al., 2001), suggesting a connection between the 
visual cortex and the pain networks.  
That in migraine the visual cortex is hyper-responsive is supported by several studies 
using electroneurophysiological methods (see Chapter 2).  
Migraineurs between attacks have more fMRI activation in the occipital cortex than 
controls at low and medium light intensities (Martin et al., 2011). Similarly, 
Boullouche et al. (2010) showed with PET that migraineurs have increased activation 
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of the visual cortex to light stimulation and that this activation is potentiated during 
painful stimulation in the trigeminal territory. Interestingly, in healthy subjects the 
visual cortex was significantly activated only when the subjects underwent trigeminal 
pain stimulation.  
 
Vanagaite et al. (1997) have proposed convergence of retinal and trigeminal 
nociceptive afferents as a possible explanation for photophobia. Direct proof of their 
hypothesis in humans is yet to be demonstrated, but in one case where the subject 
was photophobic due to corneal irritation caused by contact lenses, Moulton et al. 
(2009) found light-induced fMRI activation of various structures of the nociceptive 
trigeminal pathway, including the thalamus and anterior cingulate cortex.  
A reciprocal relation between visual input and trigeminal nociception is suggested by 
the decreased tolerance to light after painful stimulation of the ophthalmic branch of 
the trigeminal nerve (Drummond et al., 1993). Migraine patients display lowered pain 
thresholds after light stimulation (Drummond et al., 1997; Kowacs et al., 2001). In 
functional MRI studies, the top-down inhibitory effect of vision on pain evoked by 
laser-heat applied to the hand, i.e. vision-induced analgesia, is associated with lower 
activation in the somatosensory cortex SI and the operculo-insular cortex but not in 
the anterior cingulate cortex (Longo et al., 2012).  
 
The majority of studies on photosensitivity compared healthy subjects and migraine 
patients, but one study also included patients affected by blepharospasm (Adams et 
al., 2006). The difference in light discomfort to an increased light stimulation was not 
significant between the two groups of patients; however, the subjective perception of 
discomfort, tested using a questionnaire, was higher in blepharospasm than in 
migraine patients. The analogy with blepharospasm is not due to ophthalmologic 
variation of levels of xanthophyll carotenoids lutein and zeaxanthin in the retinas 
(Frandsen et al., 2012), which are lower in blepharospasm patients and higher in 
migraine patients than in the controls.  
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It has been stated that the use of a questionnaire to investigate the degree of 
photophobia is useful in clinical practice (Choi et al., 2009). However, questionnaires 
are biased by subjectivity and recall bias. Direct photosensitivity assessment with a 
light stimulus of increasing intensities is more reliable and would allow more 
objective comparisons between centres and studies. Unfortunately, there is no 
consensus at present on which type of light stimulation should be used (Klein et al., 
2015).  
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4. Migraine therapies 
 
4.1. Pharmacotherapy 
 
Migraine treatment has two facets: prophylactic or abortive. Abortive therapies used 
for acute treatment include simple analgesics, non-steroidal anti-inflammatory drugs 
(NSAIDs), and specific anti-migraine drugs such as ergots and triptans. Simple 
analgesics are frequently the first choice for mild to moderate attacks (MacGregor et 
al., 2003). Ergots have been used with some success for many years, but they may 
induce severe side effects and based on efficacy/adverse effect profile triptans should 
be preferred (Linde et al., 2006). The latter, selective 5-HT1B/D receptor agonists, have 
been proven effective in numerous studies (Ferrari et al., 2001 and 2004), particularly 
for severe attacks. Frequent use of abortive migraine medications is associated with 
medication-overuse headache resulting in daily or near daily headache (Linde et al., 
2006). Preventative treatments include β-adrenergic blockers devoid of intrinsic 
sympathomimetic activity, certain calcium channel antagonists, serotonin 
antagonists, and the anticonvulsants topiramate and valproic acid (Silberstein et al., 
2000). Most of these treatments can produce cumbersome side effects such as 
sleepiness, exercise intolerance, impotence, nightmares, dry mouth, weight gain, 
tremor, hair loss, or fetal deformities (Goadsby et al., 2006). The Table 4.1 below, 
adapted from Goadsby et al. (2006), lists some of the potential side effects of 
commonly used preventative treatments. 
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The overall efficacy rate of prophylactic migraine treatments does not exceed 60%. 
Other treatments have fewer side effects, but also somewhat lower efficacy rates like: 
riboflavin, feverfew, petasites or magnesium supplementation. Botulinum toxin type 
A is useful only in chronic migraine (Silberstein et al., 2002). Non-pharmacological 
treatments include cognitivo-behavioural therapies, massage, diets or acupuncture. 
Unfortunately, despite its high prevalence, migraine is frequently not diagnosed by a 
medical practitioner, and migraineurs therefore often resort to taking over-the-
counter medications rather than prescription drugs (Silberstein et al., 2000).  
Table 4.1: Side effects of pharmachological treatments for migraine prevention  
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4.2. Neurostimulation 
 
Due to the inefficiency of available preventative drugs and their side effect profile, 
neurostimulation methods have raised great interest in recent years because of 
technological and scientific advances allowing, for some of them, a 
pathophysiologically-based rationale in headache treatment. Neurostimulation can be 
applied to peripheral (pericranial) nerves or to central structures (the cerebral cortex). 
The pivotal limitation for peripheral neurostimulation trials is the difficulty to control 
with sham stimulation because of the sensations caused by the real stimulation.  
There are two types of neuromodulation techniques: invasive and non-invasive. 
Invasive methods are restricted to very disable chronic migraine patients. In this 
thesis we will limit the discussion to the non-invasive methods that can be used in all 
migraine patients.  
 
 
4.2.1. Peripheral nerve stimulation 
 
The analgesic effects of TENS (transcutaneous electrical nerve stimulation) are known 
since a long time (Cruccu et al., 2007), and the potential benefit of TENS in headache 
therapy has been proposed since 1985 (Solomon et al., 1985), but limitation in trials 
designs were pinpointed in a Cochrane review (Bronfort et al., 2004).  
The effectiveness of a portable transcutaneous supraorbital nerve stimulator (tSNS) 
(Cefaly®) in episodic migraine (EM) prophylaxis was proven in a randomized 
double-blind sham-controlled trial (Schoenen et al., 2013) and is supported by the fact 
that amongst 2,313 subjects in the general population who rented the device for 60 
days via the internet, 53.7% were satisfied and decided to buy it (Magis et al., 2013). 
Cefaly® could also be useful during the migraine attack and in chronic migraine, but 
RCTs are lacking. 
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Side effects are limited to the stimulation site and consist of paraesthesia and painful 
sensation with the high intensity stimulation. This is the principal reason interrupting 
the stimulation. 
New devices thought to stimulate transcutaneously the vagus nerve (tVNS) were 
developed recently and their efficacy as acute and preventive treatment of primary 
headaches is being evaluated. Preliminary results suggest that the cervical stimulator 
could help some CM patients (Magis et al., 2013).  
 
 
4.2.2. Repetitive transcranial magnetic stimulation (rTMS) 
 
rTMS can induce long-lasting changes of cortical excitability: low stimulation 
frequencies (1 Hz) have an inhibitory effect (Chen et al., 1997) whereas high 
frequencies (≥10 Hz) are excitatory (Pascual-Leone et al., 1994). In healthy volunteers 
and migraine patients, rTMS is able to durably modify excitability of the visual 
cortex, and hence to reverse the abnormalities of evoked potentials found in many 
migraineurs (Fumal et al., 2006; Coppola et al., 2012).  
In patients suffering from EM with aura, two single TMS pulses over the visual cortex 
within an hour after aura onset resulted in a pain-free response rate at 2 h of 39%, 
compared to 22% for the sham stimulation (Lipton et al., 2010).  
The efficacy of rTMS for CM prevention was investigated only in a few small studies. 
Based on the hypothesis that the left dorsolateral prefrontal cortex (LDLPFC) is 
hypoactive in chronic pain disorders, Brighina et al. (2004) studied the effect of 
excitatory high frequency (20 Hz) rTMS over the LDLPFC in 11 chronic migraineurs. 
After 12 sessions of rTMS, attack frequency, headache index, and acute medication 
intake were reduced for up to 2 months, while there was no significant improvement 
in the 5 patients receiving the sham stimulation. These results were not confirmed by 
another study where high frequency (10 Hz) rTMS over the LDLPFC in 13 CM 
patients turned out to be less effective than placebo (Conforto et al., 2013).  
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The principal risk of rTMS is to trigger an epileptic seizure, and this risk is directly 
proportional to the frequency of stimulation. Subjects with a history or at risk of 
epilepsy have thus to be excluded from such studies, as recommended for studies on 
rTMS (Belmaker et al. 2003). 
 
 
4.2.3. Transcranial direct current stimulation (tDCS) 
 
tDCS uses weak currents to modify the cells’ resting membrane potential, leading to 
focal modulation of cortical excitability. Like in rTMS, two opposite effects can be 
obtained: cathodal stimulation inhibits neuronal firing whereas anodal stimulation 
increases it. In healthy volunteers, tDCS is able to modulate resting EEG and event-
related potentials (Keeser et al., 2011), and functional connectivity of cortico-striatal 
and thalamo-cortical circuits (Polania et al., 2011). 
Anodal tDCS over the visual cortex (2 weekly sessions for 8 weeks) significantly 
reduces attack frequency and duration in EM (Viganó et al., 2013). 
Anodal tDCS over the primary motor cortex in 13 CM patients for 4 weeks produced 
a beneficial delayed effect on pain intensity and duration (120 days after stimulation) 
that was attributed to slow modulation of central pain-related structures (Dasilva et 
al., 2012). 
Central side effects of tDCS are not known. Mild and transient paraesthesia at the 
stimulation site on the scalp may occur, but blinding is usually not a problem in 
sham-controlled trials.  
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5. Aims of this thesis & hypotheses 
 
Understanding migraine pathophysiology is crucial for progress in migraine 
management, since an efficient acute and preventive treatment should rely on clear 
pathophysiological bases. Migraine is characterized interictally by a lack of 
habituation of evoked responses, possibly due to a decreased preactivation level of 
sensory cortices. By contrast, during an attack and in chronic migraine, the 
preactivation level increases and habituation normalizes. New neurostimulation 
techniques could be useful to durably modify the activation of the underlying cortex, 
decreasing the repetition of attacks, giving also insight on the pathophysiology of 
migraine. 
The visual cortex plays a pivotal role in migraine pathophysiology, but its effect on 
the trigeminal nociceptive system remains poorly understood. On the other hand, the 
migraine attack is associated with photophobia and even between attacks 
migraineurs are more sensitive to light, but the pathophysiological relation between 
migraine headache or discomfort and light stimulation is not well understood.  
To clarify this features within the complexity of migraine pathophysiology and to 
extend our knowledge on the mechanisms of photophobia in humans, we designed 
experimental protocols with the following purposes:  
1) To analyse the spontaneous blink rate in healthy subjects and migraine patients 
during and outside the attack, in a dark and in a lit room, and to understand how 
light, and thus activation of the visual cortex, influences spontaneous blinking.  
2) To modulate visual cortex activity using rTMS in healthy subjects and interictal 
migraine patients, and to study the effect on activity in the trigeminal nociceptive 
system indexed by the nociceptive blink reflex, in order to disentangle a possible 
functional connection between the two structures.  
3) To test the reliability of results using sham rTMS and repetitive magnetic 
stimulation over the greater occipital nerve in healthy subjects.  
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4) To compare the results on modulation of the visual cortex with those found 
modulating the motor cortex in healthy subjects, knowing that the motor cortex 
activation is implied in central pain control and a target for neurostimulation in 
other neurological and pain disorders.  
5) To search for visually induced analgesia in the trigeminal area in healthy subjects 
and migraine patients using Contact-Heat-Evoked-Potentials, which could reveal 
a possible role of the visual cortex in the subjective perception of pain.   
6) To assess photophobia using a custom-built flash light stimulator. 
7) To compare the effects of changing frequency, colour and intensity of light 
stimulation on the nociceptive blink reflex in healthy subjects in order to find the 
most effective stimulation pattern on the trigeminal activity.  
8) To test flash light stimulation as a possible preventive treatment in episodic and 
chronic migraine in a proof-of-concept trial.  
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Second part: Personal contribution 
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6. Subjects and methods 
 
6.1. Subjects 
 
All projects were reviewed and approved by the Ethics Committee of the CHR 
Citadelle Hospital, Faculty of Medicine, University of Liège, Belgium, and conformed 
to the Declaration of Helsinki. All participants gave their written informed consent. 
 
Healthy subjects (HS) were recruited among the students of the Faculty of Medicine, 
the staff of the Citadelle Hospital of Liège and from the general public through 
notice-boards. They were devoid of any medical condition and had no personal or 
family history of neurological disorder, especially migraine and epilepsy. The same 
inclusion criteria were employed for the light stimulation study, in order to decrease 
the risk of photosensitive epileptic seizures. All subjects were adults, except in one 
study (Chapter 8) where we included two healthy participants of 14 and 16 years old, 
whose parents gave written informed consent. 
Episodic migraine (EM) without aura patients (MO), migraine with aura patients 
(MA) and chronic migraine patients (CM) were recruited in our outpatient clinic and 
diagnosed according to the ICHD-3β criteria (2013).  
The ‚interictal phase‛ was defined as the absence of a headache attack for 72 hours 
before and after the recordings. The latter was checked by telephone.  
The ‚ictal phase‛ was defined as the presence of a headache on the day of recording 
or a maximum of 12 hours before the recording if the subjects used an abortive 
treatment. The persistence or not of the ictal phase after the recordings was also 
checked by telephone.  
The majority of studies were conducted on EM without a prophylactic treatment. CM 
patients had a stable prophylactic treatment for at least one month.  
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All patients accurately completed their calendar, in particular during the therapeutic 
study.  
To avoid hormonal interferences (Smith et al., 1999 and 2002; Inghilleri et al., 2004), 
women were recorded outside of menses. We checked for use and type of birth-
control pill.  
 
 
6.2. Materials and methods 
 
6.2.1. Spontaneous blink rate (SBR) 
 
Blinking protects the conjunctiva from drying and other possible injuries. External 
conditions such as humidity and fumes from smoking increase the blink rate (Ponder 
et al., 1928; Karson et al., 1988). Humans have an average rate of approximately 14-19 
blinks per minute when looking straight ahead (Doughty et al., 2001; Karson et al., 
1981), and make about 14,000 spontaneous blinks during a waking day.  
Variation in the SBR may be due to an ophthalmic cause: the blink rate increases with 
ocular irritation and decreases with corneal anaesthesia (Ponder et al., 1928; Tsubota 
et al., 1995 and 1996; Nakamori et al., 1997; Zaman et al., 1998; Schlote et al., 2004; 
Naase et al., 2005; Borges et al., 2010), but corneal and conjunctival anaesthesia does 
not eliminate spontaneous blinking (Naase et al., 2005), suggesting central 
physiologic mechanisms. 
The SBR is considered to be an indicator of dopaminergic activity and its regulation 
differs depending on pathological condition. Reduction in the SBR has been found in 
Parkinson’s disease (Karson et al., 1982), in progressive supranuclear palsy 
(Pfaffenbach et al., 1972), and in subjects taking dopamine receptor blockers (Karson 
et al., 1981). An increase of blinking has also been noted amongst some patients with 
Huntington’s disease (Karson et al., 1984) or blepharospasm (Karson et al., 1988 and 
1984; Valls-Sole et al., 1991).  
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The anatomical pathways and physiological connections involved in the central 
control of blinking include the parapontine reticular formation and the lateral 
geniculate nucleus, with a facilitatory effect on SBR (Karson et al., 1988; Cohen et al., 
1968). The cerebellum seems to inhibit blinking (Karson et al., 1988), and evidence 
comes from the fact that after removing the cerebellum the SBR increases in rats 
(Karson et al., 1984).  
The basal ganglia play a pivotal role in regulating the frequency of eye blinks (Karson 
et al., 1983), confirmed by a decrease of the SBR in patients with Parkinson’s disease 
in which the diminished SBR correlates with the duration of the disease (Karson et al., 
1982). 
Cortical processes are also involved because cognitive states modify the SBR: the 
number of blinks while silent is a mean of 19 per minute in healthy subjects; it can 
increase during speech or listening to 24-27 per minute and decrease during reading 
to 12 per minute (Karson et al., 1981). Moreover, the SBR can be modulated by task 
demand (Fogarty et al., 1989), mental and visual workload (Fournier et al., 1999; 
Veltman et al., 1998) and position of gaze (Cho et al., 2000). 
In animals the SBR is lower in nocturnally than in diurnally active animals, being 
one-tenth lower in nocturnal versus diurnal mammals and birds (Stevens et al., 1978; 
Tada et al., 2013).  
 
Vertical and horizontal electro-oculograms (EOG) were recorded on a Viking and 
Synergy EMG system. Ag-AgC1 electrodes were placed 3 cm above and 2 cm below 
the subject's right eye (Barbato et al., 1993 and 2000). Eye blink was defined as a 
sharp, high-amplitude wave ≥100µV and < 200 ms in duration. For the eye blink 
recording, subjects were asked to sit silently in front of a blank, neutral wall. Each 
subject had 3 minutes to adjust to the recording environment. SBR was defined as the 
number of blinks in one minute following a 3-minute adjustment period of which the 
subjects were unaware (Barbato et al., 1993). 
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6.2.2. Nociceptive blink reflex (nBR)  
 
The blink reflex (BR) is a brainstem reflex and its advantage is to provide valuable 
information on the functional integrity of the brainstem through the afferent and 
efferent pathways. 
In clinical practice BR recording is helpful to exclude structural lesions or to localize 
more accurately lesions within the brainstem. In the extreme case, the reflex can be 
abolished due to structural abnormalities, such as tumours or infarcts of the 
brainstem. Studies of the various components of the BR provide information about 
segmental and supra-segmental control mechanisms and may help to differentiate 
between the segmental and supra-segmental origin of abnormalities. 
The BR was described for the first time by Overend in 1896 by tapping one side of the 
forehead. Kugelberg (1952) analyzed the blink reflex electromyographically by 
electrically stimulating the supraorbital nerve. The best response is produced when 
the subject is alert, when the stimulus is delivered at intervals of 7 seconds or longer 
(Boelhouwer et al., 1977) and when it is recorded simultaneously over the inferior 
portion of the right and left orbicularis oculi muscle.  
The afferent limb is located in the ophthalmic division of the trigeminal nerve 
(Kugelberg et al., 1952; Cruccu et al., 1987) and the efferent limb in the facial nerve. 
The electrical stimulation of the supraorbital nerve elicits two responses: the first or 
early response, R1, is a brief ipsilateral response that occurs with a latency of about 10 
milliseconds (ms); the second or late response, R2, has a latency of about 30 ms and 
occurs bilaterally (Fig. 6.1). The R1 response is regarded as delayed if its latency 
exceeds 13 ms and R2 is regarded as delayed if its latency exceeds 41 ms. A latency 
difference between the two sides exceeding 1.5 ms for R1 and 5.0 ms or 8.0 ms for R2 
is also considered abnormal (Kimura et al., 1969; Ongerboer de Visser et al., 1974). 
Afferent impulses for the R2 response run through the descending spinal tract of the 
trigeminal nerve in the pons and the medulla oblongata before they reach the caudal 
spinal trigeminal nucleus (Kimura et al., 1972; Ongerboer de Visser et al., 1978). From 
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there, impulses are relayed to the facial nuclei in the pons. The R2 response, 
ipsilateral to the electrical stimulation, originates at the level of the medulla oblongata 
and the contralateral one in an ascending trigeminofacial connection that crosses the 
midline at the level of the lower third of medulla oblongata (Aramideh et al., 1997).  
 
 
 
 
 
 
 
 
 
 
 
In clinical practice, the supraorbital routine stimulation electrode activates Aβ, Aδ 
and probably C fibers and elicits two components, an early R1 and a late R2. We were 
only interested in the nociceptive component of the BR (nBR), i.e. R2, and used 
therefore a custom-built stimulation electrode. 
During BR recordings, subjects were asked to relax in a comfortable armchair in an 
illuminated room and to keep their eyes open.  
 
 
The nociceptive-specific blink reflex (nBR) (Fig. 6.1) was elicited according to the 
method described by others (Kaube et al., 2000; Katsarava et al., 2002), before and 
immediately after the neuromodulation session.  
We used a custom-made planar concentric electrode (central cathode: 1 mm D; insert: 
8 mm; anode: 23 mm OD) placed on the forehead close to the supraorbital foramen on 
the right side. The concentric electrode has the advantage of preferentially exciting 
Figure 6.1: Exemple of a nBR elicited with a routine bipolar electrode (left) and with the 
concentric electrode (insert) (right) 
 
 
 
 
R1 
R2 
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Aδ fibres (Kaube et al., 2000; Katsarava et al., 2002; Di Clemente et al., 2005 and 2007), 
but at the same time C-fibres and Aβ fibres may also be recruited (de Tommaso et al., 
2011).  
Recording electrodes were placed below the orbit (active) over the orbicularis oculi 
muscle and lateral to the orbit (reference) on both sides. A ground electrode was 
placed at the root of the nose. The signal was recorded with a sampling rate of 5000 
Hz and sweep duration of 150 ms (1401, Signal Averager, Cambridge Electronic 
Design). 
The electrical stimulus consisted of monophasic square pulses with duration of 0.2 
ms. We first determined perception and pain thresholds by using ascending and 
descending sequences of 0.2 mA intensity steps. 
To elicit the nBR, the final stimulus intensity was set at 1.5 times the initial individual 
pain threshold. Interstimulus intervals varied pseudo-randomly between 15 and 17 s. 
We recorded 16 rectified EMG responses that were averaged off-line. As previously 
described, the first response of each nBR recording session was excluded from the 
signal analysis to avoid contamination with startle responses (Kaube et al., 2000; Di 
Clemente et al., 2005 and 2007). The remaining 15 sweeps were averaged in 3 
sequential blocks of 5 responses. For each averaged block, the amplitude of the R2 
reflex was expressed as its area under the curve (AUC). To minimize R2 AUC 
variability due to inter-individual threshold differences we used the ratio between the 
area and the square of the stimulus intensity (AUC/i2) to express nBR amplitudes, as 
recommended by Sandrini et al. (2002). Habituation of the nBR R2 was defined as the 
percentage change of the R2 area between the 1st and the 3rd block of averages or as 
the slope of R2 area changes over the three blocks.  
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6.2.3. Visual evoked potentials (VEP) 
 
We studied broadband VEP elicited by reversal of a checkerboard pattern (B-B PR-
VEP) and digitally filtered between 1 and 35 Hz (Barlett-Hanning window, 701 filters’ 
coefficients). 
The VEP is composed of three peaks, identified according to their respective latencies 
(Fig. 6.2): N1 is the most negative peak between 60 and 90 ms after the stimulus, P1 
the most positive peak following N1 at a latency of 80–120 ms and N2 the second 
negative peak between 130 and 160 ms. The peak-to-peak amplitude of N1–P1 and 
P1-N2 was measured. 
Subjects were seated in a semi-dark acoustically-insulated room in front of the 
display surrounded by a uniform field of luminance of 5 cd/m². Prior to the 
recording, each subject was allowed to adapt to the ambient light in the room for 10 
minutes to obtain a constant pupil diameter. Stimulation was monocular (right side) 
after occlusion of the other eye. Visual stimuli consisted of full-field checkerboard 
patterns (contrast 80%, mean luminance 250 cd/m2) generated on a TV monitor and 
reversed in contrast at a rate of 3.1/s. At the viewing distance of 80 cm, the single 
check edges subtended 15 min of visual angle. Subjects were instructed to fix their 
gaze upon a red dot in the middle of the screen with the left eye covered by a patch to 
maintain stable fixation. The bioelectric signal was recorded from the scalp by means 
of pin electrodes positioned at Oz (active electrode) and at Fz (reference electrode, 
10/20 system); a ground electrode was placed on the right forearm. 
The evoked potential signals were amplified by CEDTM 1902 preamplifiers (band-
pass 0.05–2000 Hz, Gain 1000) and recorded by a CEDTM 1401 device (Cambridge 
Electronic Design Ltd, Cambridge, UK). During uninterrupted stimulation 600 
sweeps of 200 ms duration were sampled at 4000 Hz. 
The recordings were divided into six sequential blocks of 100 responses (Fig. 6.2), of 
which at least 85 artefact-free sweeps were averaged off-line (‘block averages’) using 
the SignalTM software package version 4.11 (CED Ltd). Habituation was defined as the 
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percentage change of N1-P1 or P1-N2 amplitudes between the 1st and the 6th block of 
averages or as the slope of amplitude changes over the six blocks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Exemple of a VEP recording composed of 600 average responses (above) and 
the recordings of 6 successive blocks of 100 responses showing habituation (below) 
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6.2.4. Contact-heat evoked potentials (CHEPs) 
 
The use of contact heat has several unique advantages for pain research (Chen et al., 
2001). It activates small-calibre noxious thermal afferents, in the C-fibre range, in 
addition to mechano-thermal Aδ-fibres. It elicits a diffuse nagging pain at a sufficient 
intensity. Sometimes, it can produce double pain sensations: that is to say both sharp 
and dull pain (Magerl et al., 1999; Price et al., 1996). 
The reliability and suitability of CHEPs to study the function of small fibres have 
been well documented (Itskovich et al., 2000; Chen et al., 2001; Valeriani et al., 2002; 
Granovsky et al., 2005).  
The so-called CHEPs device (Medoc Ltd., Ramat Yishai, Israel) is composed of a 
thermode, used to elicit heat pain, applied to the skin and covering a cutaneous area 
of 572.5 mm² (diameter 27 mm). The CHEPs thermode is comprised of two layers of 
stimulators working together. The external layer consists of a heating foil, and the 
lower layer is a Peltier element with two thermistors (electronic thermal sensors). The 
heating thermofoil (Minco Products, Inc., Minneapolis) is covered with a 25-µm layer 
of thermo-conductive plastic (Kapton® [DuPont, Wilmington, DE]; thermal 
conductivity at 23°C of 0.1–0.35 W/m/K) that separates the external foil from the skin. 
Two thermocouples (electronic thermal sensors) are embedded at 10 µm within this 
conductive coating, which comes into direct contact with the skin, thus providing an 
estimate of skin temperature at the thermode surface (Valeriani et al., 2002; 
Granovsky et al., 2005). The external thermofoil allows the thermode to reach a very 
rapid heating rate of 70°C/s, and the Peltier element allows the CHEPs thermode to 
reach a fast cooling rate of up to 40°C/s. It has a temperature range of 30-55°C. 
Cooling begins immediately after the thermode reaches its target stimulus 
temperature, which is set by the manufacturer’s algorithms. 
Subjects were seated in a comfortable armchair, and we tried to avoid interference 
with photophobia by dimly lighting the room.  
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The device allowed us to keep a constant baseline skin temperature of 35°C. Twenty 
brief heat stimuli were delivered (peak set at 53°C, the increment speed was of 70°C/s 
whereas the decrement was of 40°C/s, for a total stimulus duration of 707 ms) with a 
randomized interstimulus interval of 10-22 seconds. The evoked cortical responses to 
heat, i.e. the CHEPs themselves, were recorded using pin-electrodes: the active 
electrode was inserted at Cz and was referenced to Fz (according to the 10–20 system 
as aforementioned), with a band pass of 0.15-100-Hz (CED™ 1902 preamplifier and 
CED™ Micro1401 converter; Cambridge Electronic Design Ltd, Cambridge, UK). The 
ground electrode was fixed to the right hand. The impedance for all electrodes was 
kept below 5 kΩ. Twenty responses were averaged off-line and partitioned into 5 
blocks of 4 responses using Signal™ software version 4.11 (Cambridge Electronic 
Design Ltd). The latencies (in ms) and the Area under the curve (AUC) P1-P2 (in 
µVxms) of each block were measured. P1 is the first most positive point around a 
latency of 200 ms for the wrist and 150 ms for the face, N2 the following negative 
peak around 280 ms for the wrist and 250 ms for the face and P2 was the second most 
positive point around 400 ms for the wrist and 350 ms for the face. Habituation was 
defined as the AUC change of P1- P2 over the five successive blocks and the slope of 
the linear regression line of amplitude changes for the five blocks. An analysis in 
percentage between the 5th and the 1st block of 4 sweeps was also performed to 
measure habituation. 
 
 
6.2.5. Repetitive transcranial magnetic stimulation (rTMS) 
 
We used a Magstim Rapid magnetic stimulator (Magstim Co. Ltd, Whitland, Dyfed, 
UK), connected to a 2 x 7 cm figure-of-eight coil, with a maximal stimulator output of 
1.2 T.  
Using single pulses over the visual cortex, we first identified the phosphene 
threshold, defined as the lowest stimulation intensity (expressed as a percentage of 
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the maximal stimulator output) able to evoke phosphenes in at least three out of five 
pulses (Bohotin et al., 2002).  
The coil was placed in a vertical position (its handle pointing upward) on the inion-
nasion line, with its inferior limit 1 cm above the inion. Stimulation was applied 
initially at 30% of stimulator output. The intensity of the stimulation was increased by 
2%-steps until the subject reported phosphenes. Increasing and decreasing the 
intensity in 1%-steps then refined the threshold.  
In participants who did not report phosphenes at the 100% intensity level, the 
procedure was repeated with the coil placed 1 or 2 cm higher or lower and, if 
necessary, to the right or to the left, before accepting the absence of phosphenes. In 
this case, we placed the coil over the left motor area and determined the motor 
threshold. In accordance with recommended safety guidelines (Chen et al., 1997), 
stimulus intensity was set to the phosphene threshold (PhT) or to 110% of the motor 
threshold, if no phosphenes were elicited.  
We used two different stimulation frequencies in a randomised order: 1 Hz (low 
frequency rTMS) and 10 Hz (high frequency rTMS) with at least a 24 hour-interval 
between the 2 sessions, as recommended by others (Wu et al., 2000). 1 Hz rTMS was 
applied in a single train without interruption for 15 minutes. 10 Hz rTMS was applied 
in 20 trains of 40 pulses with inter-train intervals of 10 seconds. For both frequencies 
the same number of 800 pulses was delivered. 
 
 
6.2.6. Transcutaneous occipital nerve stimulation (tONS) 
 
tONS was performed using a Cefaly® device with suboccipital stimulation 
electrodes. The device attains a maximal intensity of 20 mA, but due to the 
progressive increase in intensity at the beginning of the stimulation, the mean 
intensity was 17.4 mA corresponding to an electric charge of 1.56 microCoulomb 
(µC). The frequency of stimulation was 100 Hz. 
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6.2.7. Flash light stimulator  
 
A microflash MF 9607178 stimulator (Micromed & Co., Mogliano Veneto, IT) for flash 
light stimulation was placed in front of the subjects at a distance of 15 cm; they were 
asked to look at the stimulator throughout the whole session. The stimulation was at 
27.8 lux (0.63 cd/m²) and the flash colour was yellow.  
To minimize any attenuation of light perception due to continuous stimulation 
without spatial or temporal contrast (Chapman et al., 1991; Hubel et al., 1990), the 
flash frequency was set at 8 Hz for 4 minutes in a quiet room with dimmed light. 
 
 
 
6.3. Data processing and statistical analysis 
 
All statistics were performed using STATISTICA for Windows version 8.0 (StatSoft, 
Inc. Tulsa, OK, USA). Wilcoxon’s test was applied to compare the differences 
between pre- and post-stimulation. Mann-Whitney’s test was used to compare the 
differences between groups. Spearman’s test was used for the correlation analysis. All 
results were considered significant at the 5% level (p <0.05). 
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7. Variation of the spontaneous blink rate (SBR) in light and dark in 
ictal and interictal episodic migraine patients compared to healthy 
subjects 
 
 
7.1. Introduction 
 
The first step for this thesis was to measure the spontaneous blink rate (SBR) in 
healthy subjects and migraine patients during the ictal and interictal phase, in a lit or 
dark environment.  
The SBR had not been measured in migraine patients before. It is known that its 
variation principally relies upon a dopaminergic pathway (Karson et al., 1982) and 
there is circumstantial evidence for a role of dopamine in migraine pathophysiology 
(Charbit et al., 2010; Barbanti et al., 2013). The modulation of SBR is also dependent 
on cortical and subcortical controls, in which the occipital cortex may play a role. In 
fact, it has been shown that a visual task diminishes the SBR in healthy subjects 
(Karson et al., 1983) and the decrease is proportional to the difficulty of the task 
(Phelps et al., 1981). The involvement of the visual cortex in migraine 
pathophysiology is suggested by numerous studies using electrophysiology or 
neuroimaging as well as animal models (see Chapter 2).    
In this study we searched for modulation of the SBR in the presence/absence of light. 
 
7.2. Subjects and methods 
 
We enrolled a total of 38 subjects:  
- 7 healthy subjects (HS) (4 females and 3 males, mean age 38.42 ± 12.23 [SD] years 
old), without any familiar of personal history of headache and without any other 
neurological disease.  
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- 12 interictal episodic migraineurs (EM) without any prophylactic treatment (9 
females and 3 males, mean age 27.08 ± 14 [SD] years old; 7 patients suffering from 
migraine without aura). They had a mean of 4.2 ± 4.18 [SD] headache days per 
month, duration of each attack of 39 ± 31.18 [SD] hours and a disease history of 
15.8 ± 15.28 [SD] years.  
- 10 ictal EM without any prophylactic treatment (8 females and 2 males, mean age 
34.4 ± 8.2 [SD] years old; 8 patients suffering from migraine without aura), with a 
mean of 7.2 ± 3.93 [SD] headache days per month, a duration of each attack of 
32.4 ± 17 [SD] hours and a disease history of 18.5 ± 17.63 [SD] years. 
For more details on the subjects’ recruitment see Chapter 6.1. 
 
The SBR was measured as described in Chapter 6.2, in a room lit at a luminance 
intensity of 145 Lux or in almost total darkness, 12 Lux (Fig. 7.1). The low level of 
persistent light was due to the screen of the recording device itself.  
The subjects were in a seated position and asked to relax in particular their jaw 
muscle in order to avoid chewing or swallowing artefacts. They were also instructed 
to fix their gaze on a point in front of them on a neutral wall. After 3-minutes of 
adjustment to allow the subjects to get used to wearing electrodes around the right 
eye, we started the recordings. The latter lasted 2 minutes (without artefacts) or 
longer if muscle artefacts were present. Thereafter the lights were turned off. An 
adaptation period of 3 minutes followed, during which the subject was allowed to 
reposition, to chew and to swallow. When the subject was ready, instruction was 
given to relax and the recording in the dark began. For the recording in the dark we 
employed the same timing as during light.  
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7.4. Results 
 
In the lightened ambiance the SBR in HS was 15.7 ± 8.8 [SD] per minute, in interictal 
EM patients 23.5 ± 15.8 [SD] per minute and in ictal EM patients 21.3 ± 9.75 [SD] per 
minute (Fig. 7.2). There was no statistical difference between groups at baseline.  
By contrast, in the dark we counted 10.6 ± 6.9 [SD] blinks/minute in HS, 22.6 ± 13.1 
[SD] blinks/minute in interictal EM and 16.4 ± 10.1 [SD] blinks/minute in ictal EM. We 
found a significant difference between HS and interictal MO (p=0.05), but not between 
interictal and ictal MO (Fig. 7.2).  
The percentage of variation between light and dark was -36.71 ± 22% [SD] in HS; 1.9 ± 
43.98% [SD] in interictal EM and -18.7 ± 34.74% [SD] in ictal EM. There was thus a 
decrease of SBR in the dark in HS and ictal EM. Instead, in interictal EM the 
modulation induced by the presence/absence of the light was minimal. The difference 
was significant in HS (p = 0.017).  
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Figure 7.2: Spontaneous blink rate (SBR) in healthy subjects (blue), interictal episodic 
migraineurs (EM) (orange) and ictal EM without a preventive treatment (rose), in a lightened 
ambiance (light colour) and in the dark (dark colour). The SBR decreased significantly in the 
dark in HS, but not in interictal EM.  
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7.5. Discussion 
 
The principal result of this study is that the SBR is not different between HS and EM 
in a lit environment, but in the dark the SBR decreases both in HS and in ictal EM 
patients, while in interictal EM patients there was no change.  
In humans, as in other diurnal species, in which the circadian rhythm plays a pivotal 
role in guaranteeing the homeostasis of the organism, the SBR decreases in the dark, 
as found in our healthy subjects. There may be several explanations for this finding: 
1) in the dark the attention of the subject is heightened due to a possible feeling of 
threat that the subject attempts to detect by increased concentration on the 
environment; 2) in the dark the SBR can also be decreased because of lowered corneal 
fatigue and dryness; 3) the dark is associated in humans with being a less active 
period and it is not necessary to excite the visual pathways by frequent blinking.  
Spontaneous blinks are influenced by several factors, engaging peripheral and central 
factors. Peripheral factors are essentially ophthalmic causes for increasing or 
decreasing SBR (see Chapter 6.2.1). Our subjects were free of any ophthalmic disease. 
Hence the results are probably related to central mechanisms.  
The generators of spontaneous blinking are located in the pons: a study conducted on 
subhuman primates demonstrated a triphasic discharge occurring in the pontine 
reticular formation (PRF) before each spontaneous blink (Cohen et al., 1968). From 
this region, the information is transmitted to the orbicularis oculi muscles via the 7th 
cranial nerve; the evidence for this is that unilateral facial palsy abolishes ipsilateral 
blinks.  
However, an afferent contingent is also sent to the lateral geniculate nucleus (LGN) 
that discharges after a blink (Cohen et al., 1968).  
Substantia nigra (SN) is certainly involved in the generation and maintenance of a 
normal SBR and the evidence comes from studies in Parkinson’s disease patients 
(Karson et al., 1984), in which the number of blinks per minute is lower compared to 
healthy controls. SN seems to facilitate blinking, and the cellular loss in this region, as 
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in Parkinson’s disease, is one of the causes of a decrease in the SBR (Adams et al., 
1981).The fact that we found no difference in SBR between migraineurs and healthy 
subjects does not favour a significant failure of dopaminergic mechanisms in 
migraine.  
Also gliosis in the periaqueductal grey matter (PAG), in the superior colliculus and in 
the pretectal area may cause decreased blinking as seen in progressive supranuclear 
palsy (PSP) (Adams et al., 1981). Among these structures the superior colliculus is 
strongly implicated in visual and visuo-motor functions (Denny-Brown et al., 1976). 
Its involvement is demonstrated by the fact that ‚nystagmus retractorius‛, due in the  
majority of cases to a pineal mass lesion, is associated with a decrease in the SBR.  
The cerebellum acts as an inhibitory control on the SBR: cerebellectomized rats have 
an SBR four times higher than that of controls (Freed et al., 1981).  
The occipital cortex is believed to be involved in the SBR due to the fact that blinking 
is reduced during visual fixation and increased during a visual task (Phelps et al., 
1981). Moreover, the decrease is more significant if the visual task is more difficult. 
The reciprocal relation also exists: during blinks the electrical visual activity in the 
occipital cortex is suppressed (Volkmann et al., 1979; Buisseret et al., 1982).  
A functional link between the EEG alpha activity in the occipital cortex and the SBR 
may exist (Karson et al. 1990). Studies report an inverse correlation between the SBR 
and alpha EEG power measured in the occipital cortex; in fact after sleep deprivation 
subjects exhibited a decrease in alpha EEG and an increase in the SBR (Barbato et al. 
2000). 
Stevens et al. (1978) hypothesized that blinking during waking and rapid eye 
movements (REM) during sleep may both serve to periodically excite the visual 
pathway through the contrast produced by opening and closing the eyes. This is 
supported by the fact that diurnal species exhibit an increased SBR and decreased 
REM duration whereas nocturnal species have increased REM duration and 
decreased SBR (Stevens et al., 1978). Another study supports this relation (Doughty et 
al., 2013): a progressive increase of luminance (the dark in this study was not tested) 
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does not significantly affect the SBR, while a sudden increase in luminance doubles 
the SBR. This may be due to the induction of a transient photophobic reaction.  
Interestingly, in our study, interictal and ictal migraineurs, of whom the latter are 
known to be the most photophobic, have different responses: during attacks 
migraineurs react like HS whereas between attacks they display a SBR decrease 
during the dark session. 
The observation that functional alterations, found during the interictal phase of 
migraine, normalize during the ictal phase is not new. It is well documented that 
another abnormality found in migraine during the interictal phase, the deficit of 
habituation of cortical evoked potentials, is normalized during the migraine attack 
(Afra et al., 2000). However, the two phenomena are thought to involve different 
pathways and different networks as explained above (see also Chapter 2).  
The possible relation between the SBR and EEG activity in the occipital cortex (see 
above) is reminiscent of one of the first EEG abnormalities described in migraineurs: 
the so-called ‚H response‛, i.e. an increased photic driving at high flash stimulation 
frequencies (Golla et al., 1959; Fogang et al., 2015). This response is more pronounced 
during the ictal phase than in the interictal phase (Bjørk et al., 2011).  
 
To sum up, our results showing that the SBR is higher in the dark in migraine 
patients between attacks compared to healthy subjects confirms that the visual cortex 
is dysfunctioning in the interictal phase, but tends to react normally during the 
migraine attack.  
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8. Effects of visual cortex modulation by repetitive transcranial 
magnetic stimulation on the nociceptive blink reflex in healthy 
subjects and in migraine patients 
 
 
8.1. Introduction  
 
In the previous study we explored the functional relation between the occipital cortex 
and the brainstem nuclei involved in spontaneous eye blinking and its difference 
between HS and EM patients. In the present experiment we focus attention on the 
relation between the visual cortex and more specifically the nociceptive trigeminal 
system.  
This study aims at answering the following questions:  
1. Does the visual cortex modulate the subjective perception of pain in the 
trigeminal area and/or the nociception-specific blink reflex in healthy subjects?  
2. Is the modulation of trigeminal nociception by the visual cortex different in 
migraine patients? 
 
 
8.2. Subjects and methods 
 
a) rTMS studies in healthy subjects 
We evaluated the subjective perception of pain in the first division of the trigeminal 
nerve, the ophthalmic nerve, using electrical stimulation applied to the right 
supraorbital area. Both the sensory threshold (ST) and the pain threshold (PT), 
defined as the moment where the sensation became uncomfortable and/or painful, 
were measured.  
77 
 
In addition, we measured the nBR, an objective index of a reflex activity in the 
trigeminal nociceptive system.  
Subjective and objective measurements were performed before and immediately after 
applying the rTMS at low or high frequency over the visual cortex in two different 
sessions. Low frequency rTMS (0.5-5 Hz) is supposed to have an inhibitory effect on 
the cortex while high frequency rTMS (> 5 Hz) is excitatory (Chen et al., 1997). The 
stimulation intensity was set to the phosphene threshold or to the 110% of motor 
threshold if the subject did not report phosphenes.  
 
More detailed information on the methods can be found in Chapters 6.2.2 and 6.2.5.  
 
We recruited 21 HS (12 females, 9 males, mean age 25.9 ± 8.03 [SD] years old), all 
naïve for rTMS. For more details on HS enrolling see Chapter 6.1. 
 
 
b) Control studies in healthy subjects 
In order to verify that the effects observed after rTMS were due to a genuine 
modulatory action on the visual cortex and not to a placebo effect or to possible 
activation of superficial nerves or muscles, we performed a series of control 
experiments. 
For these experiments, we enrolled 30 HS who were partitioned in three different 
sessions:  
- 13 HS (8 females, 5 males, mean age 25.38 ± 11.18 [SD] years old) received a 10 Hz 
rTMS sham stimulation over the occipital cortex;  
- 7 HS (5 females, 2 males, mean age 29 ± 10.59 [SD] years old) received repetitive 
magnetic stimulation (rMS) over the greater occipital nerve;  
- 10 HS (6 females, 4 males, mean age 25.5 ± 10.21 [SD] years old) underwent to a 
session of 1h of tONS.  
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First we used a sham stimulation paradigm. 10 Hz rTMS sham stimulation was 
delivered with the coil placed at a 90° angle to the occipital region, with its anterior 
border pressed against the scalp. The rTMS intensity was fixed at the intensity of the 
phosphene threshold or 110% of the motor threshold. Twenty trains of 40 pulses with 
an inter-train interval of 10 seconds were delivered for 5 minutes. In the sham 
situation, there is an acoustic perception of the stimulation, but no brain activation 
occurs (Klein et al., 1999).  
In the 2nd experiment we applied rMS over the right greater occipital nerve. We 
performed 1 Hz and 10 Hz rMS over the right GON by placing the figure-of-eight coil 
over the emergence of the GON just beneath the superior nuchal line. We considered 
as optimal the location where the sensation induced by the magnetic pulse radiated to 
the parietal region of the head. To make a comparable control protocol, the patterns 
of 1 Hz or 10 Hz stimulation were the same as those applied over the visual cortex 
(see Chapter 6.2.5). 
In the 3nd control experiment we used transcutaneous occipital nerve stimulation 
(tONS) (see Chapter 6.2.6). tONS was performed using a Cefaly® device (Fig. 8.1), 
applied to the occipital region. The device attains a maximal of intensity of 20 mA, 
but due to the progressive increasing in intensity at the beginning of the stimulation, 
the mean of intensity received was of 17.4 mA and a dose of stimulation of 1.56 
microCoulomb (µC). The frequency of stimulation was of 100 Hz.  
 
 
 
 
 
 
 
Figure 8.1: tONS installation 
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Before and immediately after each type of stimulation we measured sensory and pain 
thresholds in the supra-orbital area and the nBR (see Chapter 6.2.2).  
 
c) rTMS studies in migraine patients 
We recruited a total 32 episodic migraine patients: 
- 23 migraine without aura patients (MO) (14 females and 9 males, mean age 29.08 
± 9.39 [SD] years old). 
- 9 migraine with aura patients (MA) (5 females and 4 males, mean age 30.33 ± 8.77 
[SD] years old) 
All patients in this experiment were recorded in the interictal phase (see Chapter 6.1).  
Table 8.1 summarizes the demographic characteristics of included patients.  
 
 
 
 
 
 
 
 
 
 
We used the same protocol as in HS to measure trigeminal pain perception and nBR 
before and after 1Hz or 10Hz rTMS over the visual cortex.  
  
Table 8.1: Demographic characteristics of included subjects. Mean ± SD 
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8.3. Results 
 
a) rTMS studies in healthy subjects 
The results are synoptically presented in Table 8.2.  
During TMS over the visual cortex 12 participants out of 21 (57.14%, 3 males and 12 
females) reported phosphenes. The phosphene threshold (expressed as a percentage 
of the maximal stimulator output) was 66 ± 4.7% [SD]. The motor threshold was 
determined in the remaining 9 participants (42.86%, 7 males and 2 females) and was 
58 ± 8% [SD] of the maximal stimulator output. 
We observed a significant relation between the presence of phosphenes and female 
gender (p=0.04). There was no correlation between intensity of rTMS and the effect on 
the nBR. 
After 1 Hz rTMS over the visual cortex, the supraorbital pain threshold was 
significantly decreased (p=0.001) (Fig.8.2), while the sensory threshold remained 
unchanged. 
Moreover, 1 Hz rTMS significantly increased amplitude of the 1st nBR block 
expressed as AUC/i2 both ipsi- and contralaterally to the supraorbital stimulation 
(p=0.024 and p=0.036 respectively) (Fig. 8.3). By contrast, habituation was significantly 
potentiated contralaterally to the stimulated side (p=0.0002) (Fig 8.4).  
After 10 Hz rTMS we found no significant variation of sensation or pain thresholds, 
nor of nBR amplitude and habituation (Fig.8.2, 8.3, 8.4). 
 
 
 
 
 
 
 
  
Table 8.2: Means of electrophysiological data in HS  
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Figure 8.3: First block of 5 ispilateral (blue) and contralateral (green) nBR responses (area 
under the curve in mVxms ± sem) before (light bars) and after (dark bars) 1 Hz rTMS and 
10 Hz rTMS over the visual cortex in HS. * p< 0.05. 
 
Figure 8.2: Pain threshold before and immediately after rTMS over the visual cortex in HS
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b) Control studies in healthy subjects 
There were no significant changes in the ST, PT, 1st block AUC of the R2 responses 
and habituation on nBR after the rTMS sham stimulation over the visual cortex, nor 
the rMS over the occipital nerve, or of tONS over the occipital area.  
 
c) rTMS studies in migraine patients 
14 MO out of 23 (60.86%, 8 females and 6 males) stimulated with TMS over the visual 
cortex reported phosphenes. The phosphene threshold (expressed as a percentage of 
the maximal stimulator output) was 62%. The motor threshold was determined in the 
Figure 8.4: Area under the curve of ipsilateral (blue) and contralateral (green) nociceptive blink 
reflexes in 3 successive blocks of 5 averaged responses before (light lines) and after (dark lines) 1 
Hz rTMS or 10 Hz rTMS over the visual cortex in HS. Vertical brackets indicate significant 
differences before and after stimulation. ** p< 0.01. 
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remaining 9 participants (39.13%, 6 females and 3 males) and was 66% of the maximal 
stimulator output.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After 1 Hz and the 10 Hz rTMS there was no significant change neither in trigeminal 
sensory and pain threshold (Fig. 8.5), nor in the AUC of the 1st nBR block in migraine 
patients. Results were similar in migraine with or without aura (Table 8.3). 
The slope of amplitude changes over the 5 blocks of averaged responses was 
significantly modified after rTMS only for the contralateral R2 response: it increased 
after 1 Hz rTMS (p=0.0006), but decreased after 10 Hz rTMS in MO (p=0.001); it 
increased after 1 Hz rTMS in MA (p=0.049) (Fig. 8.6).  
  
Table 8.3: Means of electrophysiological data in migraine patients without aura (MO) and 
with aura (MA).* p< 0.05;** p < 0.01. 
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Figure 8.5: Pain threshold (mA) in migraine without aura (MO) (yellow) and migraine with aura 
(MA) (claret-red) patients before (light colour) and after (dark colour) 1 Hz rTMS and 10 Hz rTMS. 
No significant changes were found.  
 
 
 
Figure 8.6: Habituation of ipsilateral (left) and contralateral (right) of nBR R2 AUC over 3 blocks in 
migraine without aura patients (MO), before (light orange) and after (dark orange) 1 Hz rTMS 
(above) and 10 Hz rTMS (below) over the visual cortex.  
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8.4. Discussion  
 
a) Results in healthy subjects 
This experiment supports the existence in healthy subjects of a functional relation 
between the visual cortex and the trigeminal nociceptive system, as assessed by nBR. 
The relation seems to be inhibitory: when we apply inhibitory rTMS over the visual 
cortex there is a reduction in the pain threshold, and thus an increased perception of 
pain, and, as a corollary a facilitation of the nBR; when we apply excitatory rTMS 
over the visual cortex, the effect tends to be opposite, but does not reach the level of 
statistical significance.  
The differential effect of low and high frequency of rTMS was investigated in several 
studies. rTMS at 0.9 Hz over the motor cortex reduces the amplitude of motor evoked 
potentials (MEP) (Chen et al., 1997), whereas high-frequency rTMS (5 to 20 Hz) 
increases MEP amplitude and lowers MEP thresholds (Pascual-Leone et al., 1994). 
Occipital low-frequency rTMS was found to increase the threshold for double pulse 
TMS-induced phosphenes and to decrease visual imagery performance, suggesting 
inhibition of the visual cortex (Kosslyn et al. 1999; Boroojerdi et al., 2000). On the 
other hand the effect of 10 Hz rTMS is more controversial. When applying it over the 
motor cortex, some authors found a facilitation of MEP (Maeda et al., 2000), others no 
effect (Peinemann et al., 2000), especially when the train was longer than 2 minutes. 
In our paradigm there was similarly no detectable effect of high frequency rTMS. A 
similar effect of rTMS over the visual cortex was found in a study of visual evoked 
potentials (VEP) in healthy subjects: 1 Hz rTMS reduced amplitude of the 1st VEP 
block, while 10 Hz rTMS had no effect (Fumal et al., 2003). As a possible explanation 
for these different results, it was postulated that in normal subjects the cortical 
baseline activation level is close to the ‘‘ceiling’’, i.e. the upper limit of the cortical 
activation range, hence it cannot be further activated by excitatory 10 Hz rTMS but it 
can be decreased by the inhibitory 1 Hz rTMS. A contrario this hypothesis is 
supported by the finding that in migraine patients who may have a lowered cortical 
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baseline activation level of the visual cortex and a decrease in 1st block VEP amplitude 
at baseline, 10 Hz rTMS increases 1st block VEP amplitude whereas 1 Hz has no effect 
(Bohotin et al., 2002).  
The intensity of stimulation can influence the effect of rTMS on the underlying cortex 
(Modugno et al., 2001). In accordance with previous studies, we decided to set the 
stimulation intensity at the phosphene threshold or 110% motor threshold (Bohotin et 
al., 2002; Fumal et al., 2003). We found no difference in the effect on the nBR between 
subjects who had no phosphenes and subjects who reported them. 
 
After 1Hz rTMS we found an increased habituation of the contralateral nBR, whereas 
10 Hz rTMS had no effect. The result is surprising, as we expected to find 
sensitization and not habituation with an increase in perceived pain. The lack of 
sensitization over the three blocks after 1 Hz rTMS testifies to the complexity of the 
mechanisms of habituation/sensitization in HS. Cognitive processes may interfere: the 
subjects read the informed consent form, were aware of the recording and stimulation 
procedure, and may have anticipated the progression of the session. 
 
The sensory branches of the greater occipital nerve lie between the coil of the 
magnetic stimulator and the cranium and occipital cortex. The electro-magnetic 
pulses could activate some of these peripheral afferents of the C2 dermatoma that are 
known to project centrally on the trigeminal sensory system. Aβ afferents, if 
activated, could decrease activity of 2nd order trigeminal nociceptors via the gate 
control. Aδ afferents from C2 are known to converge on the spinal trigeminal 
nucleus, but they are most likely not activated, since the magnetic is usually not 
perceived as painful. 
The results of our control experiments show that the rTMS-induced effects on 
trigeminal pain perception and nociceptive reflexes are not due to activation of 
superficial nervous structures or muscles nor to a placebo effect.  
87 
 
The rationale to use pericranial nerve stimulation to treat headaches is that trigeminal 
and cervical afferents converge on second-order nociceptors in the spinal trigeminal 
nucleus (Bartsch et al., 2003). Invasive occipital nerve stimulation (ONS) seems 
beneficial in refractory chronic cluster headache but less so in chronic migraine 
(Magis et al., 2012). In a recent sham-controlled study transcutaneous ONS (tONS) 
was found effective in chronic migraine and chronic tension-type headache patients, 
but only in those who were not allodynic (Bono et al., 2015).  
In our group, a study of daily tONS for 2 months in 23 CM patients showed after 
treatment a 17% decrease in total monthly headache days, a 22% decrease in monthly 
migraine days and 42% of patients with at least 30% reduction in migraine days. As 
in HS, there was no significant change of nBR after tONS, but VEP habituation 
reversed to an episodic migraine pattern (Schoenen et al., 2016, Neurology, abstract 
AAN 2016). 
 
b) Results in migraine patients 
In migraine patients both 1 and 10 Hz rTMS failed to induce a significant change of 
pain perception in the trigeminal V1 area and of the nBR. However, habituation of the 
contralateral nBR response was enhanced after 1 Hz rTMS in MO and MA patients 
and reduced after 10 Hz rTMS. We will discuss these results in sequence. 
 
As mentioned before, it was shown previously in our research unit that 1Hz rTMS of 
the visual cortex has differential effects on VEP in HS and migraine patients (Bohotin 
et al., 2002): 1Hz rTMS decreases significantly the amplitude of the 1stVEP block only 
in HS but not in MO patients. Conversely, in the same study after 10 Hz rTMS, the 1st 
VEP block was not modified in HS but it was significantly increased in MO patients. 
This result was interpreted as suggesting that the preactivation excitability level of 
the visual cortex is reduced in migraineurs between attacks and cannot be further 
decreased by inhibitory rTMS, while in HS who have a normal preactivation level it is 
difficult to further activate the cortex with excitatory rTMS. Along the same line, it 
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was shown that the therapeutic effect of high frequency rTMS over the dorsolateral 
prefrontal cortex in depressive patients is related to hypoactivation of this area 
during a mental task (Eschweiler et al., 2000).  
Since low frequency rTMS over the visual cortex is not able to modify functional 
responses, i.e. VEP, of the occipital cortex itself in migraine patients, it is not 
surprising that the same stimulation was unable to change trigeminal pain perception 
and amplitude of nociceptive reflexes.  
In the present study we were not able confirm the differences in magnetophosphene 
prevalence and threshold reported previously in our group by Afra et al., 1998b. This 
could be due to the lower number of patients studied here.  
Di Clemente et al. (2007) in our group have shown that habituation of the nBR is 
decreased in migraine patients between attacks. Although our study was not 
designed to search for baseline nBR differences between HS and migraineurs, the 
comparison of Figures 8.4 and 8.6 suggests that nBR habituation is induced lower in 
migraine patients than in HS.  
Excitatory rTMS (Bohotin et al., 2002) and tDCS (Viganó et al., 2013) over the visual 
cortex are able to reverse the interictal deficit of VEP habituation in migraineurs, 
which may explain their therapeutic potential in EM. If, as discussed above, one 
accepts the concepts of a top-down inhibitory control of the visual cortex over the 
trigeminal nociceptive system in the brainstem and of an inverse relation between 
habituation and the preactivation level of the relevant neural system, one might not 
be surprised by our findings, both in HS and MO patients, that inhibitory visual 
rTMS increased nBR habituation while excitatory rTMS decreased it. The fact that 
10Hz rTMS had a significant effect on nBR habituation in migraineurs but not in HS 
may be related to the difference in visual cortex preactivation levels between the two 
groups, as discussed above. 
In conclusion these results show that:  
1. There is a functional connection between the visual cortex and the trigeminal 
nociceptive system in HS, as evidenced by the effect of inhibitory rTMS. 
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2. This connection seems to be top-down inhibitory, not only on subjective 
measurements of trigeminal pain perception, but also on an objective measure, 
the nBR. 
3. Contrary to HS, rTMS of the visual cortex in migraine patients is not able to 
significantly modify trigeminal pain perception and nBR amplitude, which we 
attribute to a different state of cortical responsivity in migraine between attacks. 
We hypothesize therefore that inhibition of the visual cortex allows a facilitatory 
discharge in the brainstem activating the trigeminal nociceptive system. By contrast, 
exciting the visual cortex may lead to inhibition of the trigeminal nociceptive system. 
Unfortunately this inhibitory effect is inconspicuous when excitatory rTMS is used. 
This could be in part due to the fact high frequency rTMS, though being an 
interesting experimental tool and therapeutic approach, activates directly the 
underlying visual cortex, and not the thalamus that may play an important role in the 
physiological connection between vision and trigeminal pain, as well as in migraine 
pathophysiology. Regarding the latter, our group has suggested indeed that, based 
on electrophysiological studies, the core of migraine pathophysiology could be a 
thalamo-cortical dysrhythmia (Coppola et al., 2005). rTMS might thus not be optimal 
for studying the relation between vision and trigeminal pain in the context of 
migraine. It might be of major interest to use a more physiological activation of the 
visual cortex via the retino-thalamo-cortical pathway. This is the reason why we have 
studied the effect of flash light stimulation in a subsequent chapter.  
On the other hand, the visual cortex might not be the best rTMS target to modify 
trigeminal pain. In clinical pain management, stimulation of the motor cortex is 
known since a long time to be an effective treatment for chronic pain. We have 
therefore explored the possible effects of motor cortex rTMS on the same nociceptive 
tests used in the study of the visual cortex. 
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9. Effects of low or high frequency rTMS over the motor cortex on the 
nociceptive blink reflex in healthy subjects 
 
 
9.1. Introduction 
 
It is well established that stimulation of the motor cortex has analgesic properties 
(Osenbach et al., 2006; Galhardoni et al., 2015) including in facial pain (Henderson et 
al., 2006). 
We felt therefore that it would be instructive to compare our results on the changes of 
trigeminal nociception induced by rTMS modulation of the visual cortex with those 
obtained after rTMS of the motor cortex.  
For this purpose we studied the effects of high and low frequency rTMS over the 
motor cortex on trigeminal pain sensation and the nociceptive blink reflex.  
 
 
9.2. Subjects and methods 
 
We recruited 15 HS for the rTMS experiments of the motor cortex. All 15 subjects (8 
females, 7 males, mean age 28.73 ± 10.87 [SD] years old) had 1 Hz rTMS while 13 of 
them also underwent 10 Hz rTMS in a separate session (6 females, 7 males, mean age 
27.30 ± 10.06 [SD] years old).  
For more details on recruited subjects see Chapter 6.1.  
Sensory thresholds (ST) and pain thresholds (PT) to the electrical supra-orbital 
stimulation were determined before the nBR was recorded (see Chapter 6.2.2).  
For each subject we determined the motor threshold, defined as the percentage of 
rTMS output necessary to produce a motor evoked potential (MEP) higher than 50 
µV amplitude in at least 4 out 5 pulses, recorded in the abductor pollicis brevis 
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muscle with surface electrodes. The stimulation intensity was set to 110% of the 
motor threshold. The stimulation protocols were similar to those used for visual 
cortex modulation (see Chapter 6.2.5 & 8).  
 
 
9.3. Results 
 
The TMS threshold to evoke a contraction of the abductor pollicis brevis in HS was 
60.53 ± 6% [SD] of the maximal output of the Magstim stimulator.  
Following low or high rTMS over the motor cortex we found no significant difference 
in sensory threshold (ST), pain threshold (PT) (Fig. 9.1) or AUC of the 1st block of the 
ipsi- or contralateral nBR R2 response (Fig. 9.2). 
However, habituation of the contralateral nBR over the three blocks of averages 
increased after 1 Hz rTMS (p=0.01) and even more so after 10 Hz rTMS (p=0.004) (Fig. 
9.3), while habituation of the ipsilateral reflex was not significantly changed. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 9.1: Pain Threshold (mA) in HS before and after 1 Hz rTMS (left) and 10 Hz 
rTMS (right) over the motor cortex. No significant changes are found.  
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Figure 9.2: First block of ipsilateral (blue) and contralateral (green) nBR R2AUC in HS after 1 Hz 
rTMS and 10 Hz rTMS over the motor cortex in HS. No significant changes are found.  
 
 
Figure 9.3: Habituation of the contralateral nBR R2 response before (light green) and after (dark 
green) 1 Hz rTMS (left) and 10 Hz rTMS (right) over the motor cortex. * p< 0.05; ** p < 0.01. 
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9.4. Discussion 
 
The study was conceived as a comparator for our previous experiment on the effects 
of rTMS over the visual cortex (Chapter 8). Its main result is that rTMS over the motor 
cortex does not cause the same changes of the nBR and pain perception as visual 
cortex modulation. Nonetheless, the motor cortex seems to increase habituation of the 
contralateral nBR R2 response, but this effect is similar with low or high frequency 
rTMS. 
The lack of effect of motor cortex stimulation on trigeminal pain perception and 
nociceptive reflex activity contrasts with the inhibitory effect of motor cortex rTMS on 
cortical potentials evoked by laser heat stimulation of the hand (Lefaucheur et al., 
2010) and its well-established beneficial effects on neuropathic facial pain (Lefaucheur 
et al., 2001, 2006 and 2008). Stimulation of the motor cortex increases cerebral blood 
flow in the ipsilateral thalamus, the orbito-frontal and the cingulate gyri and in the 
upper brainstem (Peyron et al., 1995). The motor cortex could thus exert its analgesic 
effects both by influencing the affective–emotional component of chronic pain 
(cingulate and orbitofrontal cortices) and activating descending pain control centres 
in the upper brainstem (Garcia-Larrea et al., 1999).  
It is possible that the methods we have used are not sensitive enough in healthy 
subjects to detect mild changes in trigeminal nociception.  
It is not clear how rTMS stimulation of the motor cortex increases habituation of the 
contralateral nBR. Cortical mechanisms are known to modulate blink reflexes. In 
migraine patients, there is, on the one hand, a lack of habituation of the nBR between 
attacks (Di Clemente et al., 2007). Furthermore, cortical evoked potential studies 
suggest that the preactivation level of the cerebral cortex is decreased in migraineurs 
(Schoenen et al., 2003) and the habituation deficit of visual evoked potentials and that 
of the nBR are correlated in the same migraine patients (Di Clemente et al., 2005). One 
might thus speculate that rTMS-induced activation of the motor cortex could have the 
opposite effect on nBR habituation, i.e. enhance it. 
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That excitability of the motor cortex can be abnormal in migraine patients has been 
shown in several studies. The first studies using TMS were performed in our 
Headache Research Unit (Maertens de Noordhout et al., 1992) and found that the 
motor threshold was significantly increased on the affected cortical side of patients 
suffering from migraine with aura (MA) compared to HS. In migraine without aura 
patients (MO) the same results were also found in the interictal phase, in the ictal 
phase and in menstrual migraine (Bettucci et al., 1992). Increased MT and decreased 
MEP amplitude were also found in familial hemiplegic migraine (FHM) patients 
interictally (van der Kamp et al., 1997). Afra et al. (1998) searched for differences in 
MT in MA and confirmed that MT was higher in the patients than in the controls. 
Intracortical facilitation was more pronounced in migraine patients than in the 
controls (Siniatchkin et al., 2007) and it was enhanced after 1 Hz rTMS (Brighina et al., 
2005).  
The major confirmation of this study is that it appears more appropriate to target the 
visual rather than the motor cortex in migraine therapy.  
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10. Effects of visual cortex activation by flash light stimulation on 
nociceptive blink reflex in healthy subjects and migraine patients  
 
 
10.1. Introduction 
 
An abnormal rhythmic activity between thalamus and cortex, namely thalamo-
cortical dysrhythmia, may be the pathophysiological mechanism subtending 
abnormal information processing in migraine (Coppola et al., 2013).  
Increasing the thalamo-cortical drive may induce a beneficial on trigeminal pain 
perception and brainstem excitability. We have shown in the previous chapters that 
the visual cortex can have a top-down inhibitory effect on the trigeminal nociceptive 
system. However, this could be demonstrated only in healthy subjects, but not in 
migraine patients using rTMS of the visual cortex. In order to activate the global 
visual pathway including its thalamic relays, we chose therefore to study the effect on 
trigeminal pain perception and the nociceptive blink reflex (nBR) of short flash light 
stimulation. We compared the results between healthy subjects (HS) and episodic 
migraine patients (EM).  
 
10.2. Subjects and methods 
We enrolled a total of 41 subjects: 
- 22 HS (12 females, 10 males, mean age 26.59 ± 9.29 [SD] years old). 
- 19 EM (15 without aura and 4 migraine with aura patients, 15 females and 4 
males, mean age 30.42 ± 8.26 [SD] years old) 
EM patients were recorded during the interictal phase and had the following clinical 
characteristics: number of attacks per month: 3.5 ± 2.92 [SD]; mean attack duration: 
26.52 ± 20.03 [SD] hours; disease duration 12.53 ± 9.07 [SD] years.  
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For more details on subjects’ recruitment see Chapter 6.1.  
 
Sensory threshold (ST), pain threshold (PT) and nBR were measured as described in 
the previous chapters (see Chapters 6.2.2 and 6.2.7) before and after 4 minutes of a flash 
light stimulation at 8 Hz. All recordings started after 5 minutes of adaptation to the 
dimmed light in the recording room.  
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10.3. Results 
 
The flash light stimulation increased the pain threshold in HS (p=0.008) and in 
migraine patients (p=0.034) (Fig. 10.1). It decreased AUC/i² of the 1st nBR block in HS 
(p=0.004 ipsilateral; p=0.001 contralateral) and in migraineurs (p=0.0006 ipsilateral; 
p=0.0008 contralateral) (Fig. 10.2) and increased habituation of the contralateral nBR in 
both groups (p=0.002 in HS and p=0.036 in EM) (Fig. 10.3). 
We found no significant variation of sensory thresholds using the photic stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 10.1: Pain threshold in healthy subjects (HS) (blue) and episodic migraine 
patients (orange) before (light colour) and after (dark colour) the flash light 
stimulation at 8 Hz.  
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Figure 10.2: Ipsilateral (above) and contralateral (below) 1st block AUC nBR in healthy 
subjects (blue) and episodic migraine patients (orange) before (light colour) and after (dark 
colour) the flash light stimulation at 8 Hz. 
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10.4. Discussion 
 
The main findings of this study are that flash light stimulation decreases pain 
perception (as assessed by the increased pain threshold), reduces nBR amplitude, and 
favours habituation of the contralateral nBR in both HS and migraine patients. 
They confirm our results with rTMS in HS suggesting an inhibitory control of the 
visual system on trigeminal nociception. The major difference is that this inhibitory 
with flash light stimulation is demonstrable in migraineurs, in whom we could not 
demonstrate it with excitatory rTMS of the visual cortex. The effect of flash light 
stimulation seems thus more robust on both trigeminal pain perception and the 
nociceptive blink reflex.  
Figure 10.3: Habituation of ipsilateral (left) and contralateral (right) nBR over three blocks in healthy 
subjects (blue) and episodic migraine patients (orange) before (light colour) and after (dark colour) the 
flash light stimulation at 8 Hz. 
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The mechanisms of the flash light-induced inhibition of trigeminal nociception must a 
priori be sought in the retino-geniculo-cortical pathway of vision. However, the 
connections between retina, thalamus, trigeminal system and cortex are complex and 
involve various other structures that are not part of the classical visual pathway, but 
are modulated by light.  
 
The visual cortex is undoubtedly involved in migraine pathophysiology (see Chapter 
2); it is the area in the brain where cortical spreading depression (CSD) is supposed to 
begin (see Chapter 2.1 and 2.3). If, as indicated by our results, the visual cortex exerts a 
tonic inhibitory effect on trigeminal nociception, one may hypothesize that the long-
lasting inhibition of cortical neurons during CSD may reduce this descending 
inhibition and hence release activation in trigeminal nucleus caudalis favouring the 
migraine headache. Admittedly, this would be plausible only in migraine with aura 
where CSD is well accepted to explain the aura symptoms. In migraine without aura, 
there is no convincing data showing that CSD may occur, unless one accepts the 
concept of ‚silent auras‛. Nevertheless, posterior spreading oligemia was reported by 
Woods et al. (1994) in a 21-year-old migraine without aura patient during visual 
stimulation and PET scanning. The patient developed a throbbing headache 
accompanied by nausea, mild vertigo, and photophobia, but had no obvious aura 
symptoms.  
 
The inhibitory effect of flashing light on trigeminal nociception found in our study 
was not expected based on the studies by Lambert et al. (2008) who showed in cat 
that such stimulation increases stimulus-induced activation of 2nd order 
trigeminovascular nociceptors in the spinal trigeminal nucleus via inhibition of dorsal 
raphe neurons. These authors found the same results after experimental CSD. Several 
differences may explain these opposite findings. First, the authors did not record the 
activity in the visual system, and thus the effect of the repetitive flash light 
stimulation on the visual cortex was not assessed. The visual stimuli could have 
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modified trigeminal nociception via non-visual pathways (see above) or they might 
have induced CSDs, which could have disinhibited trigeminal nociceptors via the 
mechanism explained before. Multiple CSD are known to increase the expression of c-
fos in TNC (Moskowitz et al., 1993); suggesting an activation induced by the cortical 
depression, like in our study. Therefore, if one accepts that such a spreading 
depression might have similar effects on the visual cortex and its connectivity as 
inhibitory 1 Hz rTMS used in our study, both the findings in cat and ours in humans 
would concord in showing that the visual cortex exerts a tonic descending inhibitory 
action on trigeminal nociceptors. Second, species differences in visuo-trigeminal 
interactions cannot be excluded considering the differences in vision between cats 
and humans.  
 
The connexions between visual input and the trigeminal nociceptive system are 
complex and multiple. Okamoto et al. (2009) submitted anesthetized rats to light 
stimulation while recording trigeminal nucleus caudalis neurons. They found that 
during light exposure firing of these neurons was increased and the response was 
suppressed after injection of lidocaine into the ocular globe or the trigeminal 
ganglion, indicating that both structures were involved in the light-evoked 
nociceptive discharge. They also showed that the circuit involves the olivary pretectal 
nucleus (OPN), of which inhibition blocked completely light-evoked trigeminal 
nucleus caudalis neural activity and tear formation (Okamoto et al., 2010).  
Further evidence comes from studies by Noseda et al. (2010). The authors injected a 
viral tracer into the globe of rats and found a direct connection between the intrinsic 
photoreceptive retinal ganglion cells (ipRGCs) and the posterior, the lateral posterior 
and the intergeniculate thalamus all three of which are not believed to be associated 
with the classical visual pathway. The same thalamic nuclei were also activated by 
stimulation of the dura, demonstrating convergent input from the retina and from 
trigeminal nociceptors. From the thalamus, afferents reach the cortex, including the 
visual cortex. Interestingly the posterior and lateral posterior thalami both receive 
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direct projections from forebrain structures like the nucleus of the diagonal band of 
Broca, the dopaminergic cell groups of the hypothalamus, the ventromedial and the 
ventral tubero-mamillary nucleus of the hypothalamus (Kagan et al., 2013).  
A third possible circuit excludes the role of the optic nerve to explain how the light 
stimulus links to the nociceptive trigeminal system. Dolgonos et al. (2011) showed 
that in rats after optic nerve section, the amplitude of the blink reflex remains 
increased during high intensity light stimulation.  
 
It is important to note that all studies cited above investigated the effect of provoked 
photophobia. Consequently, light stimuli were very intensive and of short duration 
(maximum 30 seconds). It is not surprising that high luminance light stimulation 
evokes a photophobic reaction. All of us can experience such a phenomenon when 
stepping into a sunny environment out of the dark. The photophobic reaction is 
associated with eye blinking as a protective mechanism. In studies investigating the 
mechanism of photophobia, this is the expected reaction in animals and humans and 
the objective is to assess the mechanisms induced by intense light.   
In our study we were primarily interested in assessing subjective and objective 
trigeminal pain perception when applying well-tolerated light stimuli. The areas 
involved within the central nervous system are likely the same, but their modulation 
may change. The light stimulation can probably inhibit or activate the same area 
depending on the stimulation protocol. This is well known for non-invasive 
neuromodulation techniques such as transcranial magnetic stimulation that has an 
excitatory or an inhibitory effect depending on stimulation frequency.  
 
That vision is able to reduce limb pain in humans is known since several years 
(Longo et al., 2009) and was called ‚visually-induced analgesia‛. The functional 
visuo-trigeminal connection described in our study could play a role in this 
phenomenon. We wondered therefore whether visually-induced analgesia can be 
demonstrated in the trigeminal territory and, in case it can, whether it is abnormal in 
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migraine patients knowing that they have functional abnormalities of both visual 
cortex and trigeminal pain processing. This led us to perform the study presented in 
the next chapter. 
  
104 
 
11. Visually induced analgesia in healthy subjects and migraine 
patients 
 
 
11.1. Introduction 
 
The visual cortex is involved in the complex process of pain processing through both 
sub-cortical and cortico-cortical projections.  
The term ‚visually-induced analgesia‛ (VIA) defines a phenomenon in which 
viewing one's own body part during its painful stimulation decreases the perception 
of pain (Haggard et al., 2013; Longo et al., 2008, 2009, 2011 and 2012; Mancini et al., 
2011 and 2012).  
The analgesic effect induced by vision occurs during direct vision but also when 
indirectly seeing the stimulated body part reflected in a mirror. VIA is absent when 
viewing someone else's corresponding body part. To the best of our knowledge, VIA 
has never been studied in the face, i.e. in the trigeminal area, where it could be 
relevant for the control of headache.  
The aim of this study was to investigate VIA in healthy subjects and migraine 
patients by using, as an index of pain, contact heat-evoked potentials (CHEPs) elicited 
after thermal stimulation of the right wrist or the right side of the forehead with or 
without viewing the stimulated body part in a mirror. 
 
11.2. Subjects and methods 
 
We recruited 11 healthy women (HS, mean age 29.45 ± [SD] 10.25 years) and 14 
patients with migraine without aura according to the ICHD 3 beta criteria (ICHD 3β, 
2013) (MO, 14 females, mean age 26.4 ± [SD] 4.55 years) (Table 11.1). MO patients had 
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no prophylactic treatment and were recorded during the interictal phase. For more 
details on recruitment see Chapter 6.1. 
 
 
 
 
 
 
 
 
 
 
CHEPs were obtained by stimulating the right wrist and thereafter the right supra-
orbital area, first while the subjects were fixing their gaze on a neutral point on the 
wall in front of them, then while they viewed the stimulated area in a mirror (Fig. 
11.1). 
 
 
 
 
 
 
 
For more details on the CHEPs technique and recordings see Chapter 6.2.4.  
To obtain a more reliable result, we chose to measure the area under the curve (AUC) 
of CHEPs components P1-P2 by multiplying amplitude (in mV) x duration (in ms). 
We compared measures of AUC with those of peak amplitudes of P1-N2 and N2-P2 
and found no difference between the two types of analysis. Habituation of CHEPs 
amplitude over the five blocks of averaged responses was calculated between the 1st 
Figure 11.1: Timing for recordings without and with mirror.  
 
 
Table 11.1: Mean demographic data  
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and the 5th block. A visual analogue scale (VAS, 0-10) was used to compare the 
thermal pain perception without and with the mirror. 
 
11.3. Results 
 
Table 11.2 displays all electrophysiological data.  
All CHEPs recordings obtained from the right forehead were analysable, while 
recordings from the wrist of 2 subjects (1 HS and 1 MO) were excluded because of 
poor signal quality. 
During right wrist stimulation, we found a decrease of 1st block AUC P1-P2 in HS 
when they were seeing their wrist reflected in the mirror compared to the control 
recording (p=0.036) (Fig. 11.2), but this was not the case in MO patients. In the latter 
the VAS pain score increased viewing the reflected wrist (p=0.04) (Fig. 11.4). 
Seeing their forehead reflected in the mirror induced a significant increase of N2 
latency in HS, as well as a decrease of 1st block CHEPs P1-P2 AUC both in HS 
(Wilcoxon’s test p=0.007) and MO groups (p=0.03) (Fig. 11.2).  
Habituation of CHEPs amplitude over the five blocks of averaged responses did not 
change, neither for the wrist, nor for the forehead stimulation (Fig. 11.3). 
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Figure 11.2: 1st block of CHEPs P1-P2 (AUC: mean±sd) in healthy women (blue) and migraine 
women (orange) after stimulation of the the wrist (left) or the forehead (right) without (light 
colour) and with (dark colour) mirror.  
 
 
Figure 11.3: Habituation of CHEPs P1-P2 (AUC)over 5 blocks of 4 averaged responses in healthy 
women (blue) and migraine women (orange) after stimulation of the wrist (left) or the forehead 
(right) without (light colour) and with (dark colour) mirror. There was no statistical difference. 
 
Figure 11.4: Pain scores (VAS: mean±sd) in healthy women (blue) and migraine women (orange) 
after stimulation of the wrist (left) or the forehead (right) without (light colour) and with (dark 
colour) mirror. 
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11.4. Discussion 
 
This study shows for the first time that the phenomenon of visually-induced 
analgesia (VIA) can be demonstrated in healthy subjects in the trigeminal area, like in 
the upper limb, as far as it is assessed by contact heat evoked potentials. However, 
the reduction of subjective pain scores, though numerically detectable, is not 
significant and habituation of CHEPs amplitude is not modified. 
In migraine patients, VIA seems normal in the cephalic area, but abnormal changes 
with the mirror-viewing are seen at the extracephalic stimulation site: no detectable 
decrease in CHEPs amplitude and an increase in pain scores.  
 
Visually-induced analgesia is a complex phenomenon for which there are several 
physiological explanations. A conflict between visual and proprioceptive 
informations could possibly induce visual analgesia, based on the suggestion that the 
experience of viewing one’s own body involves multiple dissociable elements (Longo 
et al., 2008), including the sense of ownership (i.e. ‚that is my body‛). An fMRI study 
with infrared laser stimulation showed that VIA did not involve an overall reduction 
of the cortical response elicited by the painful stimulus, but that it increased 
connectivity between the brain's pain network (formerly the ‚pain matrix‛) and 
posterior brain areas activated by the visual perception of the body (or ‚visual body 
network‛), resulting in modulation of the experience of pain (Longo et al., 2012). 
From a therapeutic point of view, well-known studies have suggested that vision of 
the body was able to reduce chronic phantom limb pain (Ramachandran and Rogers-
Ramachandran, 1996; Chan et al., 2007). In this disorder the reflection of the damaged 
body part given by the mirror helped to reorganize and integrate the mismatch 
between the subject's proprioception and the actual visual feedback, and thus, help to 
relieve phantom limb pain, probably via slow neuroplastic changes (Weeks et al., 
2010; Kawashima et al., 2013; Foell et al., 2014). Recently, the mirror therapy has been 
used not only for patients with phantom limb pain, but also for patients with complex 
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regional pain syndrome and strokes (Rothgangel et al., 2011; Ezendam et al., 2009; 
Thieme et al., 2013). 
 
The reason why we found no statistical difference in VAS pain scores in our HS 
group contrary to Longo et al. (2012) may in part be due to the fact that all of our 
subjects were females, whereas, Longo’s cohort of 14 HS comprised only 3 females. 
Gender differences in the experience of pain are known and well documented; 
women report higher pain sensitivity associated with various types of noxious 
stimuli (e.g., ischemic, pressure, electrical, and thermal) (Berkley et al., 1997; Fillingim 
1996 and 2000; Riley et al., 1998; Shinal et al., 2007). The magnitude of these effects 
varies from moderate to high depending on sample size, the nature of the stimulus 
and whether pain sensitivity is indexed by non-verbal behaviours (i.e., certain body 
movements, facial grimace) or by verbal behaviours such as pain threshold and 
tolerance reports (Berkley et al., 1997; Fillingim et al., 2009; Riley et al., 1998; Shinal et 
al., 2007). 
The reason for enrolling only women in our study was that we wanted to compare 
HS with migraine patients who are predominantly females. As a weakness of our 
study, we must mention that we did not correct VAS results for certain features like 
social context, BMI and height, which can have an effect on pain perception (Vigil et 
al., 2015).  
 
That MO patients have a decrease in CHEPs amplitude when viewing the stimulated 
body part after supra-orbital but not after wrist stimulation is surprising, as we rather 
expected to find the opposite given the known sensitisation of the trigeminal 
nociceptive system in migraine. In fact, although migraine patients may remain 
hypersensitive during the interictal phase, whole body allodynia is more pronounced 
during an attack (Burstein et al., 2000). In our study, extracephalic pain perception 
seems to be more resistant to reduction by the VIA phenomenon than trigeminal 
pain. One could hypothesize that between attacks in episodic migraine there might be 
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a ‚compensatory‛ suppression of head pain by central control mechanisms, which 
would not be the case in extracephalic territories where increased pain sensitivity 
would remain.  
 
The relation between vision and somatosensory perception is complex. VIA involves 
chiefly the primary somatosensory cortex (SI) and the operculo-insular cortex (Longo 
et al., 2012). Visuo-tactile stimulation increases the activation of the somatosensory 
cortex more than does touch alone (Dionne et al., 2010). The role of the somatosensory 
cortex is thus more complex than being a simple collector of somatosensory input. 
For example its activation through cutaneous peripheral stimulation can produce a 
transient suppression of EMG responses evoked by TMS over the motor cortex. This 
function is not surprising if we bear in mind that via the same mechanism epileptic 
patients are able to extinguish a Jacksonian seizure by vigorous cutaneous 
stimulation (Maertens de Noordhout et al., 1992).  
The connection between visual and somatosensory cortices is probably modulated by 
the thalamus. This is supported by a study (Imbert et al., 1965) showing in 
thalamectomized cats that visual stimulation activates the orbito-frontal but not the 
somatosensory cortex, suggesting that projections from the occipital cortex have to 
pass through the thalamus to be conveyed to the somatosensory cortex. Interestingly 
in this study, the lateral geniculate nucleus was intact, showing that it is not an 
obligatory relay for visuo-somatosensory connections.  
More recent studies have focused on the role of the extrastriate cortex in VIA 
(Mancini et al., 2012). Interestingly in the latter study excitatory anodal tDCS over 
extrastriate areas increased the VIA phenomenon, while cathodal tDCS had no effect. 
These results are in line with our previous study where excitatory flash light 
stimulation increased the pain threshold.  
 
In our study of healthy and migraine subjects using heat stimulation of the forehead 
there was a discordance between a visually-induced decrease of CHEPs but no 
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change of VAS pain scores that were even numerically increased in migraineurs. This 
could be explained by the fact that pain perception engages a complex multifocal 
interconnected network in the brain, while CHEPs more simply reflects activity in the 
cingulate gyrus.  
CHEPS habituation did not change while viewing the stimulated body part in our 
study neither in HS nor in MO and there was no baseline difference between the two 
groups of subjects. This is in line with another study that found a deficit of CHEPs 
habituation in migraine with aura but not in migraine without aura that was the 
exclusive migraine type enrolled in our study (Lev et al., 2013).  
 
To conclude, this study adds to the available knowledge on visually-induced 
analgesia and extends this phenomenon to the facial area as far as contact heat-
evoked potentials are used as indices of central pain processing. Facial VIA is within 
normal limits in migraine without aura, but absent at the wrist, suggesting that 
between attacks control of extracephalic pain perception could be dysfunctioning.
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12. StimLux: an alternative device to assess photophobia  
 
 
12.1. Introduction 
 
Photophobia assessment is always subjective. One can assess the degree of 
photophobia using a questionnaire or using the illuminance of the light stimulation 
(measured in Lux) for a more objective analysis. In any case the point at which a 
subject perceives the light as uncomfortable is subjective. The problem is similar 
when pain thresholds are measured using available devices (electrical, magnetic, 
algometric, cutaneous, etc.).    
A questionnaire to assess photophobia that is much discussed in the literature was 
published by Choi et al. (2009), with interesting results: it detected photophobia in 
82.5% of migraine patients.  
Tolerance to continuous light was determined in several studies (Drumond et al. 
1986; Vanagaite et al. 1997; Kowacs et al. 2001): they found that tolerance, as expected, 
is lower in migraine patients compared to HS, and lower during than between 
attacks. Using continuous light is interesting but not comprehensively adapted to 
migraine, knowing migraine patients have an abnormal photic EEG drive to 
flickering light (Bjørk et al., 2011). 
 
12.2. Why do we need a new stimulator? 
 
The StimLux (Fig. 12.1) is a prototype light stimulator, non-commercialized and 
custom-made by the principal inventor, Simona Liliana Sava, with the help of an IT 
technician, Gino Mancini.  
The reason for the conception of this stimulator was to render the light stimulation 
more precise and more flexible by allowing to vary all its main physical parameters: 
intensity, frequency and wavelength, as well as to perform a sequence of stimulations 
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while externally measuring light illumination with an integrated luxmeter. We shall 
call it ‘intensity’ in the rest of the text. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12.3. Technical characteristics of the StimLux 
 
The StimLux is a stimulator that allows the transmission of flashes of colour, 
intensity, frequency, and exposure time defined by the investigator using 
independent owner software conceived of by the inventor. The colour is chosen with 
indices ranging from 0 to 255 permitted by three LEDs, red, green, and blue. This also 
determines the radiation power. 
It is able to produce 16.7 million different colours.  
Figure 12.1. : StimLux 
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To adjust the frequency the StimLux uses an electronic card, Arduino STK 2560, that 
varies the rate at which the LEDs switch on and off. The frequency may vary from 0 
Hz (continuous light) to 30 Hz maximum.  
The intensity of the stimulation is measured by a small luxmeter placed on the 
exterior of the stimulator, close to the subject's eyes. The luxmeter continuously 
analyses the intensity in lux, calculating the mean intensity of the flash light 
stimulations, and thanks to a mathematic paradigm it includes in this calculation also 
the ‚non-exposure time‛ interval between flashes. The luxmeter was put externally 
and not internally in the stimulator to avoid the reduction in light intensity due to the 
various internal supports interposed between the LEDs and the subject’s eyes. 
We chose as a maximum power of 4200 lux has been made so as to avoid any 
collateral effects to the retina. In the literature other authors have used stimulators up 
to 10000 lux of intensity without any ophthalmologic side effects; they were unable to 
provoke a migraine attack if the subject was stimulated only by light, even if the 
stimulation was very intense and uncomfortable (Hougaard et al., 2013).  
The StimLux is connected to a PC by a USB port. We can also connect it to another 
trigger such as Signal™, by a 5V input, in order to synchronize the light stimulation 
and evoked potentials recordings. The trigger is able to switch on the StimLux but the 
sequencing of the stimulation has to be introduced into the StimLux software. 
StimLux can have an input trigger but it cannot itself trigger any other stimulator. To 
connect the StimLux to Signal we used a Jack connector 3.5V, necessary only if the 5V 
connector is not available or not recognised by the trigger machine.  
The StimLux has a steel support with two main arms that allows the regulation of the 
distance and the height of the stimulator to position it just in front of the subject's 
eyes. The anterior part of the support's base is weighted with steel to ensure stability 
when the superior arm is at its maximum extension. The posterior part of the main 
arm is also reinforced with steel for the same reason. StimLux is on wheels to be 
mobile, but it still is a prototype that can be used only in the laboratory and is not a 
portable stimulator.  
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The stimulation affects both eyes and the device does not permit to restrict the 
stimulation to a defined portion of the visual field. 
 
12.4. StimLux Software 
 
To set the exposure time the user is able to encode into the software the desired time 
in seconds. In the software we chose to have 2 principal windows: the first to encode 
the exposure time only if the colour of the stimulation does not change during the 
session; the second window allows the possibility to make consecutive sequences of 
stimulations, during which the colour, the frequency, the intensity and the duration 
can be varied as required. The maximum number of different sequences is 10 per 
session.  
The StimLux device allows to modify frequency, colour and intensity of the light 
stimulation utilising dynamic sequencing.  
 
A possible adverse effect of photic stimulation is induction of an epileptic fit. It is 
therefore of uttermost importance to exclude subjects with a personal or familial 
history of epilepsy during recruitment for StimLux studies. The risk of epileptic 
seizures increases with the increase of stimulation frequency.  
In case of a worrisome adverse effect during the stimulation an ‚Emergency power 
shut-off button‛ in the software allows to immediately switch off the stimulator. To 
protect the stimulator from short circuits it has an internal automatic power breaker. 
This function is also activated if the user would introduce excessive parameters of 
stimulation that could compromise the integrity of the stimulator. In this case the 
sequence of stimulation is not accepted and the StimLux remains switched off.  
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12.5. Assessment of photophobia using StimLux in healthy subjects and migraine 
patients. 
 
 
12.5.1. Objective 
 
The aim of this study was to determine photophobia during flash light stimulation in 
HS and episodic migraine patients (EM) during the ictal and interictal phases, using 
the StimLux at low (5 Hz) and high (20 Hz) frequency and at the two ends of the 
visual spectrum, blue (~470 nm) and red (~720 nm). The choice of colours was made 
knowing that ipRGCs are predominantly activated by blue light (see above). 
 
12.5.2. Subjects and methods 
 
We enrolled a total of 36 subjects: 
- 7 HS (3 females, 4 males, mean age 33.71 ± 10.43 [SD] years old). 
- 10 EM during the interictal phase (7 females, 3 males, mean age 36.4 ± 16.65 
[SD] years old, 8 without any prophylactic treatment and 2 with a stable 
preventive treatment). 
- 19 EM during the ictal phase (17 females, 2 males, mean age 37.26 ± 10.07 [SD] 
years old, 7 without any prophylactic treatment and 12 with a stable 
preventive treatment). 
Before the stimulation, all subjects completed the photophobia questionnaire adapted 
from Choi et al. (2009) (Table 12.1). 
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After 4 minutes of adaptation in a dark room, subjects were seated in front of the light 
stimulator, at 5 cm of distance from the eyes.  
We tested 4 dynamic sequences, 2 colours and 2 flicker frequencies with a progressive 
increase in intensity by steps of 50 Lux, beginning at 50 Lux, each step lasting 5 
seconds. The 4 sequences (Blue 5 Hz; Blue 20 Hz; Red 5 Hz; Red 20 Hz) were 
delivered in random chronological order. 
The subjects were asked to tell us to stop the stimulation when he perceived an 
uncomfortable sensation. To assess if that moment was really the threshold point, the 
stimulation continued for the following sequence that in all subject became to be 
painful and induced a photophobic reaction of closing eyes. There was a 2-minute 
rest period between successive sequences.
 
119 
 
12.5.3. Results 
 
We found no difference in scores of the photophobia questionnaire or in sensitivity to 
light stimulation sequences between patients with or without preventative treatment. 
We therefore combined the data of these patients (Fig. 12.2).  
The Mann-Whitney’s U Test disclosed a significant difference between the three 
subjects groups in the total score of the questionnaire (p=0.0001), in the 5 Hz Blue 
sequence (p=0.00009), in the 20 Hz Blue sequence (p=0.001), in the 5 Hz Red sequence 
(p=0.002) and in the 20 Hz Red sequence (p=0.004).  
Compared to HS, interictal EM patients were significantly more light-sensitive using 
the questionnaire (p=0.003), in the 5 Hz Blue sequence (p=0.004) and tended to be so in 
the 5 Hz Red sequence (p=0.055), but were not significantly different during the 20 Hz 
Blue and Red sequences.  
Compared to HS, EM patients during an attack had a greater sensitivity to light in the 
total score of the questionnaire (p=0.0001), in the 5 Hz Blue sequence (p=0.00002), in 
the 20 Hz Blue sequence (p=0.00005), in the 5 Hz Red sequence (p=0.0007) and in the 
20 Hz Red sequence (p=0.00009).  
Compared to interictal EM patients, ictal patients were significantly more light 
sensitive during the 20 Hz Blue sequence (p=0.002), the 5 Hz (p=0.027) and 20 Hz Red 
sequence (p=0.00019) and tended to be so for the 5 Hz Blue sequence (p=0.069), but 
there was no significant difference in the total score of the questionnaire.  
We found no significant correlation between the photophobia assessment using 
StimLux and frequency of headache, mean duration of attacks or duration of the 
disease. 
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Figure 12.2: Photophobia assessment using StimLux in HS (Blue), Interictal EM (yellow) and Ictal EM 
(Red) during the four tested sequences : Blue 5 Hz, Blue 20 Hz, Red 5 Hz and Red 20 Hz. The circled p 
values indicate the differences between HS and interictal EM is significant for Blue 5 Hz sequences but 
just fails to be significant for Red 5 Hz while it is not significant for the 20 Hz sequences. The difference 
between interictal and ictal is significant for all sequences except Blue 5 Hz, whereas ictal EM 
significantly differ from ictal EM in all sequences.  
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12.5.4. Discussion 
 
This study discloses various novel features. First we designed a light stimulator we 
called StimLux that allows to vary wavelength, frequency and intensity of light 
stimulation. A device allowing such a diversity of stimulation protocols is not 
commercially available. We used the StimLux to assess more precisely light 
sensitivity in healthy subjects and its abnormality in migraine patients. The device 
also allows determining which stimulation protocol is the most efficient in producing 
the inhibition of trigeminal nociception by light stimulation shown in Chapter 10.   
 
The photophobia questionnaire is useful to distinguish healthy subjects from 
migraineurs, but it lacks sensitivity to detect the difference in the degree of 
photophobia between the interictal and ictal phases of migraine.  
 The main difference between HS and interictal EM is found at low frequencies of 
stimulation (5 Hz), while the main difference between interictal and ictal EM occurs 
at high frequencies (20 Hz). Tolerance to the light is less influenced by colour than by 
frequency of the stimulus.  
The mean threshold for tolerance to the light is 50 Lux for EM patients during an 
attack, which is 3-5 times lower than the normal luminance of an artificially lit room 
and even more clearly lower than the natural ambient light on a sunny day. 
Photophobia assessed by the questionnaire or by the flash light stimulation does not 
correlate with the clinical features of migraine. Finally, light tolerance is not modified 
by the preventive pharmacotherapy of migraine.  
 
The use of a questionnaire to determine photophobia in clinical practice has been 
validated by several studies (Choi et al., 2009; Evans et al., 2008): an adequate and 
precise questionnaire on photophobia can detect 24% more photophobic migraineurs 
than the simple history taking. It seems, however, that the questionnaire should be 
more complete, especially regarding the persistence of photophobia between attacks. 
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This is the reason why we added two questions to the Choi et al.’s questionnaire with 
the possibility to enter the degree of discomfort on a scale from 0 to 10. Furthermore, 
in our experiment patients had some difficulties in answering ‚yes‛ or ‚no‛ to the 
first and second questions due to the multiple circumstances listed.  
Our findings show nevertheless that the modified photophobia questionnaire is not 
able to distinguish between the ictal and the interictal phases of migraine, contrary to 
the graded flash light stimulation with the StimLux.  
 
This is the first study that has used flash light stimulation to measure the degree of 
photophobia. In fact, the other three light stimulation studies (Drumond et al., 1986; 
Vanagaite et al., 1997; Kowacs et al., 2001) all used continuous light. The distinction 
seems particularly important since we show here that the subjects groups differed not 
only according to light intensity but to light frequency. Applying frequency as a 
variable appears therefore of greater interest than intensity. We decided to assess 
photophobia using different frequencies for several reasons: firstly in our previous 
study (Chapter 10) we used flash light stimulation at 8 Hz and we found that it is able 
to increase the facial pain threshold and to decrease the R2 response of the 
nociceptive blink reflex. Secondly, flash light stimulation, due to contrast, has a 
strong activating effect on the visual cortex.  
The stimulation frequency influences the difference between HS and interictal 
patients and also between ictal and interictal EM. Low frequency proves more 
tolerable to HS, particularly if associated with the blue colour. High frequencies are 
associated with greater discomfort in HS.  
The tolerance of interictal EM is around 150 Lux for all types of lights and that of ictal 
EM is around 50 Lux, compared to HS that showed a mean tolerance threshold 
around 300 Lux. Our results are in line with the study on photophobia by Drummond 
et al. (1986) in which all migraineurs reported discomfort at 153.5 Lux. Our study 
adds knowledge to the previous one by displaying the cut-off between ictal and 
interictal patients that Drummond et al. were unable to investigate because they used 
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only 5 intensities (1.1 Lux, 7.3 Lux, 36.3 Lux, 153.3 Lux and 500 Lux). We found that 
the tolerance threshold of ictal and interictal patients differs by 100 Lux (from 50 Lux 
to 150 Lux respectively).  
The duration of each light-sequence was set at 30 seconds in Drummond's protocol, 
in our protocol it was of 5 seconds and in those of Vanagaite and Kowacs, 2 seconds. 
In the subjects' perception, having 2 seconds of continuous light and having 5 seconds 
at 20 Hz, i.e. a total of 100 pulses, is very different. The tolerance to light was higher 
in the abovementioned studies (Vanagaite et al., 1997; Kowacs et al., 2001). This could 
be due to the greater distance (40 cm; 5 cm in our protocol), which reduces the 
luminance. Moreover the authors interposed a heat-filtering barrier between the light 
source and the subject’s eye in order to reduce the risk of corneal lesions; they probed 
intensities of 20000 Lux, far superior to the intensities we used. In addition our 
StimLux device produced binocular stimulation, which was found to causes greater 
discomfort than monocular stimulation (Vanagaite et al., 1997). 
 
Blue and red were chosen as tested colours to investigate the extremities of the visual 
spectrum, because to the best of our knowledge no study has yet analysed the 
influence of colour on the photophobia threshold. The blue colour activates the 
ipRGCs more than the other spectral wavelengths (see Chapter 10.4). 
An experiment performed in our research unit some years ago using five different 
coloured lenses (red, green, blue, yellow, grey) showed that VEP amplitude increased 
with red and green lenses in HS but not in migraine patients between attacks (Afra et 
al., 2000). This result was interpreted as reflecting a possible hypoexcitability of the 
visual cortex in migraine patients. Our findings clearly show that the red light is the 
most able to distinguish ictal from interictal photophobia thresholds, but the blue 
colour produces greater differences when comparing HS and EM.  
 
Many studies have demonstrated an altered EEG pattern in the visual areas with 
flash light stimulation, especially at the higher frequencies (Bjørk et al., 2011). Photic 
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driving induced by flash light stimulation was found increased during the interictal 
phase in migraineurs and depressed during the attack (de Tommaso et al., 1998). 
Conversely, in another study the opposite pattern was found (Bjørk et al., 2011). 
Photic driving to higher frequencies might have a protective role to permit the 
tolerance of high frequencies during the interictal phase, a control that is probably 
impaired during the migraine attack where the subject habituates with greater 
difficulty to high frequency light stimulation. It would be interesting to study the 
photic driving using different colours. 
 
In conclusion, this part of our thesis confirms that light sensitivity and tolerance differ 
between HS, interictal EM and ictal EM, and shows that the rate of the light 
stimulation can influence the photophobia threshold. 
We have shown in Chapter 10 that flashlight stimulation is able to reduce trigeminal 
nociception. It is thus of interest to determine which stimulation parameters are the 
most efficient in producing this effect. We have studied his in the next chapter using 
the StimLux device.
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13. Effects of frequency, colour and intensity of light stimulation on the 
nociceptive blink reflex in healthy subjects 
 
 
13.1. Introduction 
 
Flash light stimulation of the visual cortex inhibits tonically the trigeminal 
nociceptive blink reflex and trigeminal pain sensitivity in healthy subjects (HS) and 
episodic migraine patients (EM) (see Chapter 10). In this study we explored how 
changing frequency, wavelength and intensity of the light stimulation influences 
these effects on the trigeminal nociceptive system in HS.  
Its ultimate goal was to identify the flash light stimulation protocol that is most 
effective in reducing pain perception and nBRs in HS and could be used in a future 
trial as therapeutic strategy in migraine patients. 
The study measures changes in nBR and trigeminal pain thresholds in three 
conditions: 1) variation of frequency alone; 2) variation of colour; 3) variation of 
intensity with fixed frequency and colour. 
 
13.2. Subjects and methods 
 
For this study we recruited 11 HS (8 females and 3 males, mean age 36.45 ± 11.29 [SD] 
years old). 
One subject decided to interrupt the study and the effect of varying light intensity 
was thus assessed only in 10 HS. 
For more details on the recruitment of HS see Chapter 6.1. 
The protocol was divided into three sessions, separated by several days each.  
In each session, we first measured the sensory threshold (ST) and the pain threshold 
(PT) and then we recorded the nBR at baseline (see Chapter 6.2.2).  
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The chronological sequence of types of frequency, colour and intensity was 
randomized and blinded to the subject and the main investigator (SLS); another 
colleague drew by lot the sequence. So each subject had a different chronological 
order of stimulation to avoid the possible bias of an order effect.  
 
13.2.1. Part 1. Varying stimulation frequency  
The first step to define the most effective stimulation parameter to inhibit trigeminal 
nociception was the variation in stimulation frequency. 
As fixed wavelength we chose yellow (~580 nm) that was also used in the previous 
study of the effect of 8 Hz flash light on trigeminal nociception (see Chapter 10). 
As fixed intensity we chose 2000 Lux, i.e. the mean intensity that the flash light 
prototype StimLux delivers. This choice was empiric.  
The only variable was the frequency of stimulation. We tested five different 
frequencies: 8 Hz, 10 Hz, 12 Hz, 15 Hz and 20 Hz. We chose 20 Hz as the upper limit 
because the risk of inducing an epileptic fit increases at higher frequencies. The total 
duration of the flash light stimulation for each analysed parameter of light was 7 
minutes. 
The five sessions were performed on the same day, separated by at least 15 minutes. 
 
13.2.2. Part 2. Varying colour 
In this part of the experiment the only variable parameter was the colour of the light 
stimulation.  
We tested six different colours: violet (~390 nm), blue (~470 nm), green (~530 nm), 
yellow (~580 nm), orange (~610 nm) and red (~ 730 nm).  
As fixed parameters we chose a frequency of 12 Hz based on the results obtained in 
Part 1 and intensity at 2000 Lux. 
Five sessions were performed on the same day, separated by at least 15 minutes. For 
the yellow colour we used the data obtained in Part 1 at 12 Hz. 
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13.2.3. Part 3. Varying intensity 
As fixed parameters we used a 12 Hz frequency and violet (~390 nm) as colour.  
As variable parameter we tested six different intensities: 500 Lux, 1000 Lux, 1500 Lux, 
2000 Lux, 3000 Lux and 4000 Lux.  
Five sessions were performed on the same day; separated by at least 15 minutes. For 
the 2000 Lux intensity we considered the data obtained in Part 2. 
 
All subjects tolerated the flash light stimulation without any adverse effect and 
finished all sessions. A Visual Analogue Scale (VAS) from 0 to 10 cm was used in all 
experiments to evaluate the discomfort to the light. 
Due to the randomized sequence for each session and for each HS, we compared all 
measures to the baseline recordings done at the beginning of each session. 
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13.3. Results 
 
13.3.1. Part 1. Effects on trigeminal nociception of varying stimulation frequency  
 
 
 
 
 
 
 
 
 
 
Table 13.1 summarizes the effects of varying stimulation frequencies on pain 
threshold (PT) and 1st block amplitude of ipsi- and contralateral nociceptive blink 
reflexes.  
After light stimulation at an 8 Hz frequency we found a significant increase in the 
supraorbital pain threshold (PT) (p=0.004) (Fig. 13.1), a decrease of contralateral 1st 
block nBR (AUC) (p=0.03) (Fig. 13.2) and a trend for increased habituation of 
contralateral nBR expressed as the slope of amplitude changes over the five averaged 
blocks of 5 responses (p=0.09).  
After 10 Hz stimulation there was an increased PT (p=0.007), a decreased AUC of the 
1st block of ipsilateral (p=0.05) and contralateral nBR (p=0.02) and a trend for increased 
habituation of the contralateral nBR (p=0.09). 
The 12 Hz frequency had the greatest effect on the nBR: it increased the sensory 
threshold (ST) (p=0.021) and the PT (p=0.008) and decreased the AUC of the 1st block 
of ipsilateral (p=0.04) and contralateral (p=0.003) nBR, but had no effect on 
habituation.  
Table 13.1: Electrophysiological data (means ± sd) after variation of flash light frequency. Fixed 
parameters: Yellow colour (580 nm) as described in Chapter 12; 2000 Lux intensity. *p<0.05; **p<0.01 
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After the 15 Hz frequency we found an increased ST (p=0.021) and PT (p=0.007) and a 
decrease of the AUC of the 1st block of contralateral nBR (p=0.003).  
The 20 Hz frequency increased the PT (p=0.04) and decreased the AUC of the 1st block 
of contralateral nBR (p=0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.1: Pain Threshold (mA) changes with the variation of frequency in HS. Data are shown 
as mean ± standard error. *p<0.05; **p<0.01 
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Figure 13.2: Changes in 1st block AUC R2 nBR with variation of frequency in HS. Data are shown as 
mean ± standard error. *p<0.05; **p<0.01. 
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13.3.2. Part 2. Effects on trigeminal nociception of varying colour 
 
 
 
 
 
 
 
 
 
 
Table 13.2 summarizes the changes of PT and nBR amplitudes observed by modifying 
wavelength of the flash light stimulation.   
The shows the modulation of the Pain Threshold on the supraorbital area after 
varying colour of stimulation. 
The violet stimulation markedly increased PT (p=0.005) (Fig. 13.3) and induced a 
negative correlation between the VAS score and nBR habituation: the higher the 
discomfort score the smaller the nBR habituation. The other colours tested did not 
correlate inversely with the VAS. 
The blue colour increased the PT (p=0.003) and decreased the AUC of the 1st block of 5 
nBR responses ipsilaterally (p=0.02) and contralaterally (p=0.009). 
The green stimulation similarly increased the PT (p=0.003) and decreased the 
amplitude of ipsilateral and contralateral nBR (p=0.005 both). 
The yellow colour (see Chapter 13.3.1) increased the sensory threshold (ST) (p=0.021) 
and the PT (p=0.008) and decreased the 1st block AUC of ipsilateral (p=0.04) and 
contralateral nBR (p=0.003), without any effect on habituation.  
The orange stimulation increased the pain threshold (PT) (p=0.004) and decreased the 
AUC of the 1st nBR block only ipsilaterally (p=0.03).  
The red light increased the PT (p=0.006) but had no significant effect on nBR.
Table 13.2: Electrophysiological data (means ± sd) after variation of flash light wavelength. Fixed 
parameters: 12 Hz frequency; 2000 Lux intensity.*p<0.05; **p<0.01. NB: For yellow session see Chapter 
13.3.1. at 12 Hz 
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Figure 13.3: Pain Threshold (mA) changes with the variation of colour in HS. Data are shown as 
mean ± standard error. *p<0.05; **p<0.01. NB: For yellow session see paragraph 13.3.1 at 12 Hz. 
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13.3.3. Part 3. Effects on trigeminal nociception of varying intensity 
 
 
 
 
 
 
 
 
 
 
Table 13.3 summarizes the PT and nBR amplitude changes by different intensities of 
violet flash light stimulation. 
With a stimulation intensity of 500 Lux we found an increased pain threshold (PT) 
(p=0.021) (Fig. 13.4) and a decrease of the 1st nBR block AUC ipsilaterally and 
contralaterally (p=0.012 and p=0.006) (Fig. 13.5). 
After the 1000 Lux intensity stimulation the PT increased (p=0.024) and the AUC of 
the 1st block nBR decreased ipsilaterally and contralaterally (p=0.036 and p=0.021). 
The intensity of 1500 Lux increased PT (p=0.02), decreased of AUC of ipsilateral 
(p=0.046) and contralateral (p=0.036) 1st block nBR and tended to increase the 
habituation over the three blocks (p=0.07). 
2000 Lux increased only the PT significantly (p=0.005) but left unchanged the nBR. 
After the 3000 Lux intensity the PT increased significantly (p=0.036) and the AUC of 
the 1st block nBR decreased contralaterally (p=0.05). 
The 4000 Lux intensity increased PT (p=0.021) and decreased of the 1st block AUC of 
ipsilateral (p=0.036) and contralateral (p=0.048) nBR but left the habituation slope 
unchanged. 
As expected, 3000 Lux and 4000 Lux induced high discomfort scores on the VAS. 
Many subjects had difficulties to finish the session at these intensities. 
Table 13.3: Mean electrophysiological data (± standard deviations) after variation of flash light 
intensity. Fixed parameters: 12 Hz frequency; Violet (390 nm). *p<0.05; **p<0.01. NB: For 2000 Lux 
session see paragraph 13.3.2. Violet. 
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Figure 13.4: Pain Threshold (mA) changes with the variation of intensity in HS. Data are shown as 
mean ± standard error. *p<0.05; **p<0.01. NB: For 2000 Lux session see paragraph 13.3.2 Violet 
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Figure 13.5: AUC changes of the 1st R2 nBR block with variation of intensity in HS. Data are 
shown as mean ± standard error. *p<0.05; **p<0.01. NB: For 2000 Lux session see paragraph 
13.3.2 Violet 
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13.4. Discussion 
 
The first goal of this experiment was to confirm our finding in Chapter 10 that flash 
light stimulation is able to increase the electrical pain threshold (PT) in the supra-
orbital area and to decrease the amplitude of the nociceptive blink reflex (nBR). In HS, 
who overall, underwent 160 measurements, the PT was increased whichever 
stimulation frequency, wavelength or intensity were used. By contrast, changing 
these light parameters had a differential influence a more objective measure of 
trigeminal nociceptive processing, the nBR.  
 
For the first time this study allowed analysing the effect of the main physical 
characteristics of light in the same healthy subjects, which was rendered possible 
thanks to the conception and development of the StimLux device (see Chapter 12).  
During each session of this experiment subjects had five or six light stimulation 
sessions in the same day, which in theory could increase the risk of inducing corneal 
lesions. We must point however that no adverse effect was reported by the subjects in 
any session, except for some colour illusions at the end of each 7-minute stimulation 
that disappeared after less than 1 minute of time. Several instances of colour illusions 
were detected in Part 2 of the experiment: subjects experienced a transient alteration 
of the perception of colour at the end of the stimulation caused probably by a loss of 
the capacity of cones to be stimulated by the same wavelength for 7 minutes. This 
explanation is supported by the fact that the colour illusion was characterised by the 
perception of the opposite wavelength on the visual spectrum. For instance, after 
violet stimulation the subjects experienced a transient red perception of the 
surrounding environment while after the green session they saw the world in a pink 
hue for a few seconds.  
 
The 20 Hz frequency increased pain thresholds less than the other frequencies, 
possibly because it induced a greater light discomfort. The ipsilateral 1st nBR block 
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was decreased only by the 10 Hz and 12 Hz stimulation rates, and not by the other 
frequencies. This is in line with previous studies of light-induce changes of electrical 
brain activity. de Tommaso et al. (2005) studied the synchronisation of alpha band 
EEG during stimulations of different frequencies. They analysed the effects of low (3, 
6 Hz), frequencies (9, 12 Hz) and high frequencies (15, 18, 21, 24, and 27 Hz) 
comparing HS and migraine patients. They found that in migraine patients 9 Hz 
induced hypersynchronisation in migraine patients but not in controls. The same 
effect was observed at 24 and 27 Hz. We chose to limit the frequency to 20 Hz to 
reduce the risk for adverse effects of the light stimulation, the more so that the 
duration of stimulation in our protocol was longer (7 minutes) than in de Tommaso et 
al.’s study (between 30 and 120 seconds).  
 
We tested six different colours at precise wavelengths. However, as the stimulator 
doesn’t produce polarized light, for each colour there was at the same time a small 
amount of the rest of the visual spectrum. We chose not to use polarized light because 
we wanted to explore the effects of natural light, as much as possible. 
Other authors have studied the influence of colour using cortical evoked potentials. 
In particular Afra et al. (2000) found that the interposition of red or green filters 
increased VEP amplitudes in HS but not in migraine with aura patients. Interestingly, 
while the red wavelength is more effective to activate the visual cortex (Zerbe et al., 
1979) and to elicit photoconvulsive responses or photic driving responses in patients 
suffering from epilepsy (Takahashi et al., 1976 and 1981), in our study the red colour 
influenced the nBR response less than the lower wavelengths. It is a well-established 
fact that the energy value per quantum of light is inversely related to wavelength. 
This may explain why we found such a significant effect on the nBR with lower 
wavelengths and why red filters amplify less VEPs in migraineurs who have a 
decreased cortical preactivation excitability between attacks (Afra et al., 2000). 
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For the low intensities we chose those that can be encountered in a conference room 
(~500 Lux), for high luminance those we can find in large convention centres with 
more than 20000 people to illuminate (~2000 - 4000 Lux).We tested only HS, but 
others tried to provoke a migraine attack in patients, using 10000 Lux of continuous 
light, without success (Hougaard et al., 2013). Using the external luxmeter we were 
reliably informed on the luminance upon the subjects' eyes. 
 
Taking together, these results suggest that the 12 Hz rate and the 1500 Lux of 
intensity are the most efficient in increasing the PT and decreasing the 1st block nBR 
AUC. Regarding wavelengths, the only colour that was associated with an inverse 
correlation between the VAS discomfort score and nBR habituation is violet, although 
blue, green and orange all were able to decrease nBR amplitude. Colour seems to be 
the parameter that is associated with the greatest variability. The reason may be 
found in the visual spectrum. Using non-polarized light the main wavelength peaks 
at a fixed value of nanometres, but each of the three cone populations overlap in the 
respective logarithmic wavelength distribution and responds also to adjacent 
wavelengths (Fig. 13.6), which is confounding factor.  
 
 
 
 
 
 
 
 
 
Given the results found in this study and in Chapter 12, we designed a flash light 
stimulation protocol using the StimLux susceptible to have a therapeutic benefit in 
migraine patients and tested it in a proof-of-concept trial described in the next 
chapter.
Figure 13.6.: Visual spectrum and wavelengths 
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14. Using the top-down inhibitory control of the visual cortex on 
trigeminal nociception to treat migraine: a proof-of-concept trial. 
 
 
14.1. Introduction 
 
In the previous study we demonstrated that flash light stimulation at 12 Hz and 1500 
Lux is more effective in HS at increasing the electrical pain threshold in the supra-
orbital area and to decrease the 1st block nBR amplitude. Blue, green and orange were 
most effective on the nBR, however violet correlated inversely to the VAS score of 
discomfort perceived by the subject due to the flash light stimulation.  
The next step was thus to investigate the effect of this inhibitory pathway in episodic 
(EM) and chronic patients (CM).  
In this experiment we extended the duration of stimulation sessions from 7 to 20 
minutes and they were applied 5 days per week for two weeks.  
The effect of low wavelengths and in particular of blue light is well documented on 
seasonal affective disorder (SAD) (Golden et al., 2005), and also in non-seasonal mood 
disorders associated with circadian rhythm disturbances (jet lag, shift work or 
dementia), sleep disorders, bulimia nervosa and adult attention-deficit/hyperactivity 
disorder (Pail et al., 2011). In an unpublished study conducted in our centre, the effect 
of daily treatment with continuous blue light stimulation was tested in migraine 
patients using the Luminette® device. The results were inconclusive.  
In order to stay within the low wavelength range and to submit the patients to the 
less uncomfortable light stimulation, we chose to use the violet colour (~390 nm).
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14.2. Subjects and methods 
 
In the first part of this study, we applied 20-minute light stimulations of violet colour, 
at a frequency of 12 Hz and an intensity of 1500 Lux in 10 HS (8 females, 2 males, 
mean age 37.55 ± 10.70 [SD] years old). Before and after the stimulation we measured 
the electrical pain threshold (PT), nBR and VEP amplitude and habituation. 
In the second part, we recruited 20 migraine patients: 11 with episodic migraine (EM) 
(8 females and 3 males, mean age 40.89 ± 9.66 [SD] years old) and 9 with chronic 
migraine (CM) (8 females and 1 male, mean age 48.56 ± 13.77 [SD] years old), 
diagnosed according to ICHD 3β criteria (2013). EM patients had no a prophylactic 
treatment, while CM patients had a stable prophylactic treatment since at least one 
month before the study. Patients were recruited in our outpatient headache clinic. 
The patients had to fill in a headache diary to be eligible for the study. 
EM and CM patients had baseline recordings of nBR and VEP, where after they were 
stimulated with the StimLux device in the hospital during 2 consecutive weeks for 20 
minutes daily, 5 days a week. At the end of the 2-week treatment they underwent 
another recording of nBR and VEP.  
Therapeutic outcome measures were total days of headache/month; migraine 
days/month; headache days/month; mean attack duration in hours/month; NSAID 
intake/month; triptan intake/month; number of days/month with headache of severe 
intensity (grade 3 on a 0 to 3 categorical scale); number of days/month with moderate 
headache (grade 2) and number of days/month with mild headache (grade 1). 
We compare these outcomes measures between the 1-month baseline before the 
beginning of the therapeutic protocol and the 1-month period that followed the 1st 
stimulation session and comprised the 2 weeks of light simulation and 2 subsequent 
weeks of follow-up without stimulation. During this period CM patients were not 
allowed to modify their preventive anti-migraine drug treatment.  
Other two CM patients dropped out because they had found it difficult to come daily 
to the hospital for the stimulation sessions. 
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For more details see Chapter 6.1; 6.2.2; 6.2.3 and 13. 
 
14.3. Results  
 
In HS the flash light session significantly increased the supra-orbital PT (p=0.007) 
(Fig.14.1), tended to decrease the AUC of the 1st nBR block ipsilaterally (p=0.06) and 
decreased significantly AUC of contralateral nBR (p=0.05). It had no influence on the 
nBR habituation (Fig.14.2).  
In the post-stimulation VEP recordings we found a numerical decrease of the 1st block 
N1-P1 and P1-N2 amplitudes that did not reach significance, and no effect on 
habituation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.1: Pain Threshold (mA; means ±standard errors) in HS before and after the 20-
minute flash light stimulation.  
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Figure 14.2: Ipsilateral and contralateral nBRbefore (light violet) and after (dark violet) the 20-
minute flash light stimulation in HS. (means ± standard errors).  
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Table 14.1 shows in migraine patients the change in clinical outcome measures 
assessed with the headache diary during the month preceding the trial and during 
the subsequent month comprising 2 weeks of light stimulation and 2 weeks of follow-
up without stimulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14.1: Clinical outcome measures (means ± standard deviationin episodic and chronic 
migraine patients as assessed by the migraine calendar during the 1-month baseline before 
stimulation and during the month following the 1st stimulation session comprising 2 weeks of 
light therapy and 2 weeks follow-up without stimulation. 
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Fig. 14.3 shows the change of clinical outcome measures at three time points: before 
light stimulation, after 2 weeks of light stimulation and during the 2-week follow-up 
period after light therapy.  
In EM patients, the 50% responder rate for migraine days was 36.4%; there was a 
significant decrease in the mean duration of headache attacks and NSAID intake. 
CM patients had a significant decrease in total headache days/month, migraine 
days/month, mean duration of attacks and days per month with moderate headache. 
77.7% of CM patients had at least a 50% reduction in monthly migraine days. 
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After the 2-week light treatment we found that habituation of VEP N1-P1 was 
significantly increased in 50% CM responders (p=0.017) while habituation of the P1-
N2 component tended to increase (p=0.09) (Fig 14.4). There was no change in nBR 
parameters. 
 
 
 
 
 
 
 
 
 
 
 
14.4. Discussion 
 
Confirming our previous studies on flash light stimulation (Chapter 10), one session of 
violet flashing light (12 Hz, 1500 Lux, duration 20 minutes) increased the supra-
orbital pain threshold and decreased nBR 1st block amplitude in healthy subjects. As 
we hypothesized on basis of this anti-nociceptive effect in the trigeminal system, 
daily stimulations for 2 weeks using the same protocol had a therapeutic effect in 
migraine patients, as suggested by our pilot trial. The effect size seems to be greater in 
CM than in EM with a significant decrease in total number of headache days, 
migraine days, in duration of attacks and total number of days with moderate 
headache. The only significant electrophysiological change was an increase of VEP 
habituation in 50% CM responders.  
 
Figure 14.4.: VEP N1-P1 and P1-N2 habituation in 50%CM responders  
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To the best of our knowledge, this pilot trial is the first study using flash light 
stimulation in migraine as a prophylactic treatment. Because many migraine patients 
are light sensitive during and, to a lesser degree, between attacks, one might, indeed, 
at first thought not envisage treating them with light stimulation.  
Our findings raise several fundamental questions. Is light stimulation able to 
desensitize the nociceptive trigeminovascular system and its activation by light and is 
this the underlying mechanism for the clinical improvement in our pilot trial? Does 
daily light stimulation change responsiveness of the visual cortex in migraineurs and 
hence reduce photophobia as well as disease activity? Is it worthwhile pursuing the 
investigations on therapeutic effects of light stimulation, for instance by a sham-
controlled trial and can such a trial be blinded?  
 
It is unquestionable that migraine patients have photophobia during attacks (Choi et 
al., 2009), and also, though less so, in the interictal phase of the migraine cycle. The 
validation study of the ID Migraine® diagnostic tool suggests that photophobia is a 
specific symptom that allows to diagnose migraine in 98% of cases when associated 
with disability and nausea (Lipton et al., 2003). However, photophobia is not a 
migraine-specific symptom and it is associated with many other ocular, neurological 
and sometimes psychiatric pathologies. In ocular diseases photophobia occurs in 
anterior segment diseases such as iritis, cyclitis, and blepharitis, where the 
mechanism is presumably direct irritation of the trigeminal afferents that innervate 
the cornea and eye. Photophobia is a classical symptom in meningitis (Lamonte et al., 
1995), sub-arachnoid haemorrhage (Welty et al., 1990) or pituitary tumours or 
apoplexy (Kawasaki et al., 2002) due to irritation of the primary meningeal 
nociceptive afferents, predominantly belonging to the visceral part of the ophthalmic 
nerve (Trobe et al., 2002). In traumatic brain injury photophobia may persist for 
several weeks after the initial trauma and patients with post-concussive syndrome 
retain an increased sensitivity to light (Bohnen et al., 1991). In blepharospasm the 
cause of photophobia is unknown but thought to be due to an excitation/inhibition 
148 
 
imbalance in the brainstem blink reflex pathways (Berardelli et al., 1985). Finally 
photophobia can also be associated with progressive supranuclear palsy (PSP), where 
it seems to be more frequent than in corticobasal degeneration or Parkinson’s disease 
(Cooper et al., 2009; Hills et al., 2008). Finally, photophobia can accompany 
depression and anxiety (Bossini et al., 2009). In fact, photophobia tends to accompany 
many chronic pain disorders such as fibromyalgia (Martenson et al., 2015).  
 
The cardinal stimulus for photophobia is light; thus, afferent light pathways and their 
respective projection areas must be involved. Interestingly, photophobia can be 
experienced without image formation, as documented in some blind patients (Zaidi 
et al., 2007; Amini et al., 2006; Noseda et al., 2010 and 2011). 
Okamoto et al. (2009) recorded activation of the trigeminal nucleus caudalis (TNC) 
neurons in rats while shining light on their eyes. The responsible circuit for the 
observed effect starts in retinal photodetectors (whether rod, cone, or ipRGC is 
unclear), activates the superior salivatory nucleus, which in turn induces ocular 
vasodilation and activation of pain-sensing neurons on blood vessels. Noseda et al. 
(2010) identified a completely different circuit in animals: projections from retinal 
ganglion cells to the posterior thalamus, from where via the caudate-putamen and the 
external capsule they reach multiple cortical regions, including the binocular area of 
the primary visual cortex. Martenson et al., (2015) excluded the posterior thalamic 
relay after light exposure in rats, and showed a possible functional connection 
permitted by the olivary pretectal nucleus.  
In humans Moulton et al. (2009) performed BOLD fMRI recordings in an individual 
with photophobia associated with the overuse of contact lenses. During the 
photophobic state, activation of the trigeminal ganglia, the trigeminal nucleus 
caudalis, the ventro-postero-medial thalamus and the anterior cingulate gyrus was 
observed, while these structures were not activated when photophobia was absent. In 
a series of patients with LASIK-induced photophobia, Malecaze et al. (2001) found 
that light-induced BOLD fMRI activation was increased in the visual association 
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cortex, compared to controls. Emoto et al. (2010) used 18-fluorodeoxyglucose positron 
emission tomography (18-FDG-PET) to compare patients suffering from 
blepharospasm with or without photophobia to controls. They found that 
blepharospasm patients with photophobia had significantly increased metabolic 
activity in the thalamic ventral anterior (VA) and ventral lateral (VL) nuclei and in the 
superior colliculus. 
 
Few studies have tried to treat photophobia and most of them employed tinted 
lenses, although in 1934 already Lebelsohn wrote ‚tinted glasses as a symptomatic 
remedy for chronic photophobia are to be condemned because of both their 
ineffectiveness and their habit forming tendency‛. Since that date, not much progress 
has been made to treat photophobia. The rationale of our study was to use the light 
stimulus that causes photophobia to treat migraine by assuming that this might 
desensitize the afferent or the efferent arm of the ‚photophobia circuit‛. 
 
One clinically relevant finding was that none of our patients developed a migraine 
attack after the light stimulation. In fact, light seems to be able to trigger a migraine 
attack only when it is associated with other trigger factors such as physical exercise 
(Hougaard et al., 2013). CM patients experienced greater discomfort at the beginning 
of the session, but this uncomfortable sensation rapidly vanished during the 
stimulation. If the stimulation took place during the headache, in particular in CM 
patients, the headache intensity was attenuated during the flash light stimulation and 
even more so after the session. The repetitive nature of the light stimulation may 
explain these findings, as it contrasts with a sudden bright light stimulus that can 
cause additional discomfort in migraine patients. The flashing light probably allows 
the visual processing to habituate, hence increasing the tolerance to light. This is 
supported by the fact that in the CM group 50% responders had, after 2 weeks of 
flash light stimulation, an increase in VEP habituation. Activation of the visual cortex 
in migraineurs by anodal tDCS (Viganó et al., 2013) or high frequency rTMS (Bohotin 
150 
 
et al., 2002) was previously shown in our research unit to increase VEP habituation. 
Habituation is a complex neurobiological phenomenon that is not linearly related to 
cortical excitability. A recent study failed to find a correlation between VEP 
habituation and the magnetophosphene threshold, a direct measure of visual cortex 
excitability (Ambrosini et al., 2015), probably because habituation represents a 
dynamic response pattern of sensory cortices to repeated stimuli, reflecting the 
temporal profile of cortical reactions to incoming inputs. 
 
Regarding the trigeminal nociceptive system, one 20-minute session of flash light 
stimulation with the StimLux device decreased pain perception and nBR amplitude in 
healthy subjects, which is concordant with the results found in Chapters 10 and 13 
with shorter stimulation sessions. Contrasting with the acute light-induced changes 
found in the previous chapters, however, we found here no significant modification 
of nBR parameters after 2 weeks of daily stimulations in migraine patients. This may 
be due to the low number of patients in each group, or to physiological factors related 
to adaptation processes over long periods of stimulation. This question cannot be 
answered in our study, as we did not test the effect on the nBR or VEP immediately 
after the first stimulation in migraine patients. 
Whether the observed therapeutic effect of flash light stimulations is associated with 
an excitability change in the visual processing pathways and/or in the trigeminal 
nociceptive system needs therefore further studies.  
 
It is difficult and probably premature to compare our results with those of other 
preventive neurostimulation methods in migraine for several reasons. First our 
patients were stimulated for only 2 weeks, while in the other trials neurostimulation 
treatments are administered for one to several months. Since the StimLux device is 
not portable, the patients had to be treated in the hospital, which caused some 
inconvenience to them and may have increased a placebo effect, but on the other 
hand ensured a perfect compliance. Our trial was intended to proof a concept and 
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hence not sham-controlled. However, sham-controlled studies with neurostimulation 
methods still remain scarce. Antal et al. (2011) performed a sham-controlled trial of 
inhibitory cathodal tDCS over the visual cortex for migraine prevention in 26 
patients. They found no significant change in attack frequency, the primary efficacy 
measure, but there was a decrease in mean attack duration and intensity. A sham-
controlled study of daily anodal tDCS over the motor cortex for 20 consecutive days 
in 42 EM patients (Auvichayapat et al., 2012) significantly reduced attack frequency 
and abortive medication use at weeks 4 and 8 after treatment. In another sham-
controlled study of 10 anodal tDCS for 4 weeks over the motor cortex in 13 CM 
patients, pain intensity was significantly reduced at weeks 4, 8, and 12 (Dasilva et al., 
2012). Another study of rTMS over the motor cortex reported a significant reduction 
of headache frequency (about 85% lower at 1st week after stimulation), headache 
severity, functional disability and analgesic intake (Misra et al., 2013).  
A small (11 patients) study of 12 sessions of high frequency-rTMS over the left 
dorsolateral prefrontal cortex (LDLPFC) for preventive treatment in patients affected 
by chronic refractory migraine (Brighina et al., 2004) found a significant reduction of 
migraine attacks (about 57% lower), abortive medication use, headache index and 
migraine disability scores in the verum group. 
External trigeminal neurostimulation with the Cefaly® decreased the number of 
migraine days by 2.06 and the frequency of monthly migraine attacks by at least 50% 
in 38% of patients after 3 months in a sham-controlled trial of 67 episodic migraine 
patients (Schoenen et al., 2013). 
 
To sum up, large RCTs of neurostimulation therapies in migraine are rare. The results 
of our proof-of-concept suggest that it might be worthwhile to set up a RCT of flash 
light stimulation therapy in both EM and CM patients. As in all neurostimulation 
trials, except tDCS that induces only a very slight sensory perception, blinding could 
be a problem. This problem could nonetheless be minimized by randomizing the 
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sham group to a flash light stimulation of low intensity (< 15 lux), < 5 Hz frequency, 
and > 580 nm wavelength.  
Such a RCT would be easier to organize with a portable StimLux device, but for 
obvious financial reasons this will probably not be feasible before the outcome of a 
larger RCT is known.  
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Third Part: Conclusions 
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15. General conclusion and discussion 
 
 
15.1. Summary of results  
 
This thesis investigates and extends the connection between the cortex and the 
trigeminal nociceptive system using neurostimulation technics in healthy subjects 
and migraine patients.  
The main finding is the possible functional top-down inhibitory pathway between the 
visual cortex, the thalamus and the trigeminal nociceptive system that might protect 
constantly the brain from the onset of a new migraine attack.  
This pathway is closely related to the presence of light, and a flash light stimulation 
seems to be interesting to desensitize the subject to the light discomfort and to 
decrease at the same time the frequency and the duration of attacks.  
First of all, we measured the spontaneous blink rate (SBR) in healthy subjects and 
migraine patients during the ictal and interictal phase, in a lit or dark environment.  
The SBR had not been measured in migraine patients before, and it is known that its 
variation principally relies upon a dopaminergic pathway (Karson et al., 1982) and 
there is circumstantial evidence for a role of dopamine in migraine pathophysiology 
(Charbit et al., 2010; Barbanti et al., 2013). The modulation of SBR is also dependent 
on cortical and subcortical controls, in which the occipital cortex may play a role. The 
principal result was that the SBR is not different between HS and EM in a lit 
environment, but in the dark the SBR decreases both in HS and in ictal EM patients, 
while in interictal EM patients there was no change, suggesting a dysfunction in the 
visual cortex in the interictal phase.  
It is well known that the visual cortex is involved in the pathophysiology of migraine, 
but its connection with the trigeminal nociceptive system is unclear.  
Our second study supports the existence in healthy subjects of a functional relation 
between the visual cortex and the trigeminal nociceptive system, as assessed by nBR. 
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The relation seems to be inhibitory: when we apply inhibitory rTMS over the visual 
cortex there is a reduction in the pain threshold, and thus an increased perception of 
pain, and, as a corollary a facilitation of the nBR; when we apply excitatory rTMS 
over the visual cortex, the effect tends to be opposite, but does not reach the level of 
statistical significance.  
Notwithstanding, results in HS are not confounded by the stimulation of other 
peripheral regions, in fact the magnetic and transcutaneous stimulation over the 
occipital nerve did not have any effect on the PT and the nBR; as well as the sham 
stimulation over the visual cortex, performed putting the coil at 90° to the occipital 
region.  
In migraine patients both 1 and 10 Hz rTMS failed to induce a significant change of 
pain perception in the trigeminal V1 area and of the nBR. However, habituation of the 
contralateral nBR response was enhanced after 1 Hz rTMS in MO and MA patients 
and reduced after 10 Hz rTMS. These results suggest that the visual cortex in 
migraine patients is not able to significantly modify trigeminal pain perception and 
nBR amplitude, which we attribute to a different state of cortical responsivity in 
migraine between attacks. 
On the other hand, it is well established that stimulation of the motor cortex has 
analgesic properties (Osenbach, 2006; Galhardoni et al., 2015) including in facial pain 
(Henderson et al., 2006). This study was conceived as a comparator for our previous 
experiment on the effects of rTMS over the visual cortex. Its main result is that rTMS 
over the motor cortex does not cause the same changes of the nBR and pain 
perception as visual cortex modulation. Nonetheless, the motor cortex seems to 
increase habituation of the contralateral nBR R2 response, but this effect is similar 
with low or high frequency rTMS. 
An abnormal rhythmic activity between thalamus and cortex, namely thalamo-
cortical dysrhythmia, may be the pathophysiological mechanism subtending 
abnormal information processing in migraine (Coppola et al., 2013).  
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Increasing the thalamo-cortical drive may induce a beneficial on trigeminal pain 
perception and brainstem excitability. Using the flash light stimulation we found a 
decrease in pain perception (as assessed by the increased pain threshold), a 
diminution of the nBR amplitude, and facilitation of the habituation of the 
contralateral nBR in both HS and migraine patients. 
The study confirms our results with rTMS in HS suggesting an inhibitory control of 
the visual system on trigeminal nociception. The major difference is that this 
inhibitory effect with flash light stimulation is demonstrable in migraineurs, in whom 
we could not demonstrate it with excitatory rTMS of the visual cortex. The effect of 
flash light stimulation seems thus more robust on both trigeminal pain perception 
and the nociceptive blink reflex.  
 
That vision is able to reduce pain in humans is known since several years (Longo et 
al., 2009) and was called ‚visually-induced analgesia‛ (VIA). We showed for the first 
time that the phenomenon of visually-induced analgesia can be demonstrated in the 
trigeminal area in HS, as far as it is assessed by contact heat evoked potentials. The 
reduction of subjective pain scores, though numerically detectable, was however not 
significant and habituation of CHEPs amplitude is not modified. 
In migraine patients, VIA seems normal in the cephalic area, but abnormal changes 
with the mirror-viewing are seen at the extracephalic stimulation site: no detectable 
decrease in CHEPs amplitude and an increase in pain scores.  
 
The last part of this thesis was made possible thanks to the development of a new 
prototype of light stimulation, called ‚StimLux‛ and built by the investigators.  
Using this device, we search to evaluate photophobia in healthy subjects and 
migraine patients during and outside the migraine attack, comparing the subjective 
discomfort to the flash light stimulation to a photophobia questionnaire. We found 
that the photophobia questionnaire is useful to distinguish healthy subjects from 
migraineurs, but it doesn’t evaluate the photophobia degree between the interictal 
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and ictal phases of migraine. The main difference between HS and interictal EM is 
found at low frequencies of stimulation (5 Hz), while the main difference between 
interictal and ictal EM occurs at high frequencies (20 Hz). Sensitivity to the light is 
less influenced by colour than by frequency of the stimulus.  
 
The ultimate goal was to identify the flash light stimulation protocol that is most 
effective in reducing pain perception and nBRs in HS and could be used in a future 
trial as therapeutic strategy in migraine patients. 
Taking together, these results suggest that the 12 Hz rate and the 1500 Lux of 
intensity are the most efficient in increasing the PT and decreasing the 1st block nBR 
AUC. Regarding wavelengths, the only colour that was associated with an inverse 
correlation between the VAS discomfort score and nBR habituation is violet, although 
blue, green and orange all were able to decrease nBR amplitude. Colour seems to be 
the parameter that is associated with the greatest variability.  
We designed a flash light stimulation protocol using the StimLux susceptible to have 
a therapeutic benefit in migraine patients and tested it in a proof-of-concept trial. The 
effect size seems to be greater in CM than in EM with a significant decrease in total 
number of headache days, migraine days, in duration of attacks and total number of 
days with moderate headache. The only significant electrophysiological change was 
an increase of VEP habituation in 50% CM responders. This was not a controlled trial 
and its results have to be interpreted with caution.  
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15.2. Pathophysiological relevance  
 
Taking into account published data from human studies and animal experiments, we 
will examine step by step the various anatomical relays that are possibly involved in 
the (patho-)physiology of photophobia and relevant for its role in migraine and novel 
therapeutic approaches.   
 
The retina 
Retinal cells that are directly sensitive to light are rods (for black-white vision), cones 
(for colour vision) and intrinsically photosensitive retinal ganglion cells (ipRGCs). 
The latter are excited by light even if rods and cones are blocked and contain the 
photopigment melanopsin (Provencio et al., 2000; Lucas et al., 2001; Hattar et al., 
2003; Qiu et al., 2005) that is preferentially excited by blue light in the visual spectrum 
(~480 nm). ipRGCs represent no more than 1% of retinal cells (Berson et al., 2003) and 
they have a role in non-image-forming functions. 
The non-image-forming visual circuits play a role in the synchronisation of circadian 
rhythm through a retino-hypothalamic tract to the suprachiasmatic nucleus of 
hypothalamus and in pupillary control through the activation of the olivary pretectal 
nucleus in the midbrain; finally they lead to the release of melatonin from the pineal 
gland via the sympathetic system. ipRGCs also project to the contralateral dorsal 
lateral geniculate nucleus (dLGN), implying a contribution to more conventional 
aspects of visual discrimination. Projections from ipRGCs were also found in the 
ciliary marginal zone (Semo et al., 2014) and in the iris (Rupp et al., 2013). 
Interestingly, these projections interfere with those ocular regions that are highly 
innervated by the trigeminal nerve. Noseda et al. (2010) advanced the hypothesis that 
ipRGCs are implicated in the mechanism of photophobia, through a connection 
between meningeal and retinal afferents in the dorsal and dorso-lateral thalamus.  
Another role of ipRGCs is to regularize the general activity of the organism, the so-
called ‚masking‛ effect, i.e. the disruption of overt rhythms by external factors 
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occurring for example during the day in in diurnal species. In fact several studies 
have shown that despite removing rods or cones or melanopsin, masking still occurs 
(Mrosovsky et al., 2001; Panda et al., 2002). By contrast, the removal of all three types 
of photoreceptors and particularly of ipRGCs eliminates masking (Hattar et al., 2003; 
Panda et al., 2003; Goz et al., 2008; Guler et al., 2008; Hatori et al., 2008).  
Diseases causing loss of rods and cones do not cause photophobia, such as in X-
linked cone-rod dystrophy or in Leber’s congenital amaurosis. 
Is thus likely that light aversion is connected to ipRGCs and a melanopsin pathway, 
although it can also be induced by morphine in rats through a non-melanopsin 
pathway (Matynia et al. 2012).  
Animal models of photoallodynia, bradyopsia and corneal surface damage all 
manifest light aversion (Recober et al., 2009). Disorders affecting the anterior segment 
of the eye such as uveitis, iritis, cyclitis, blepharitis and corneal damage or 
inflammation can cause photophobia (Digre et al., 2012). Melanopsin gene mutations 
are linked to seasonal affective disorder (Roecklein et al., 2009) and in glaucoma, 
where photophobia is common, ipRGCs can be lost if inflammation from the disease 
or its medication, or ischemic tissue damage are present (Feigl et al., 2011; Kankipati 
et al., 2011).  
 
From animal studies it has been suggested that the retina itself can activate trigeminal 
neurons in response to bright light through a parasympathetic circuit (Okamoto et al., 
2010) and in humans ipRGCs project directly to the areas of the ‚pain matrix‛ (Maleki 
et al., 2012) just as in the animal model (Hattar et al., 2006) (Fig. 15.1). To support this 
hypothesis it has been shown that photophobia is present in blind migraineurs who 
are capable of light perception (cone/rod degeneration), but not in those who are 
totally blind due to complete damage of the optic nerves (Noseda et al., 2010). 
On the other hand corneal damage activates trigeminal pathways (Moulton et al., 
2009); the cornea is one of the most densely innervated structures in the body, and its 
innervation comes from the first branch of the trigeminal nerve.  
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Even if eye damage, including retinal damage, such as achromatopsia, may 
imbalance the homeostatic equilibrium and cause photophobia, it does not cause 
headache. The close relationship between migraine headache and photophobia 
implies that the mechanism is central and not ocular.  
 
The Thalamus  
The thalamus is obviously involved in the pathogenesis of photophobia and in 
migraine. In the thalamus, information carried by the optic nerve, the ‚visual 
pathway‛, reaches the lateral geniculate nucleus (LGN) and from there to the striate 
cortex. The extra-striate pathway involves the superior colliculus, the pulvinar and 
the extrastriate cortex.  
We will focus our attention on the ‚non-visual pathway‛ and particularly on the 
thalamic regions involved in the retino-trigemino-visual pathways.  
That trigeminal information converges in the thalamus, especially from the 
meningeal and also from the ocular structure, is well known animals (Davis et al., 
1988; Zagami et al., 1990; Angus-Leppan et al., 1995; Shields et al., 2005, Noseda et al., 
2010 and 2011).  
The dorsal and dorso-lateral thalamus seems to be involved in a new light-activated 
pathway. By studying rats Noseda et al. (2010) traced the path from the ipRGCs 
stimulated by light, and found that there is a contingent that conveys both retinal and 
dura-sensitive spinal trigeminal nucleus information (Fig. 15.1).  
In humans Maleki et al. (2012) demonstrated, by MR tractography, a direct 
connection between the optic nerve and the pulvinar (Fig. 15.1). Moulton et al. (2009) 
showed with fMRI in a subject with photophobia induced by contact lenses, that the 
ventro-postero-medial thalamus was activated during the photophobic state and that 
after recovery no activation occurred.  
The thalamus is one of the possible localisations of the origin of cephalic and 
extracephalic allodynia, not only for photo-allodynia: in rats stimulated by 
mechanical and thermal skin stimuli, the thalamus exhibited a long-lasting 
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hyperexcitability; in migraine patients, undergoing migraine with whole-body 
allodynia, acute thalamic activation to extracephalic brush or heat stimuli has been 
found using fMRI (Burstein et al., 2010).  
 
The Brainstem  
In the three regions that compose the brainstem we can find structures activated by 
light: the trigemino-cervical complex, the olivary pretectal nucleus and the raphe 
magnus. 
The brainstem is considered to be the generator of migraine attacks, and its 
involvement is well accepted in their repetition (see Chapter 2). In this part of the 
central nervous system is located the trigeminal nociceptive system. The activation of 
the latter by light-induced information has been documented in the animal model.  
Okamoto et al. (2009) showed that intermittent exposure to light can activate neurons 
in laminae I and II at the Vc/C1 junction and in the nucleus tractus solitaris (NST). 
The same group one year later (Okamoto et al., 2010) hypothesized that the activation 
of the trigeminal nociceptive system may occur thanks to the interposition of the 
olivary pretectal nucleus (OPN). Increased parasympathetic outflow, permitted by 
the activation of the superior salivatory nucleus, allows the transmission of light to 
connect to the Vc/C1 junction. It is known that the OPN is necessary for several light-
induced responses, such as the pupillary light reflex, eye blink and circadian 
rhythms: the inhibition of OPN blocked light-evoked Vc/C1 neural activity and tear 
formation. The authors also demonstrated that bright light also caused a prompt 
increase in ocular blood flow, and the intensity of firing by neurons in the trigeminal 
complex is dependent on vascular changes in the eye (Okamoto et al., 2012). 
Moreover, the above light-induced responses are inhibited by stimulating the 
posterior hypothalamus, acting through a sympathetic action (Katagiri et al., 2013) 
(Fig. 15.1). These findings open the possibility that the autonomic nervous system 
plays a critical role in mediating light-evoked trigeminal brainstem neural activity. 
The involvement of the OPN is also demonstrated by the group of Martenson et al., 
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(2015): the blockage of this structure can inhibit the discharge of ON and OFF-cells 
(see Chapter 3) without requirement of a trigeminal or posterior thalamic relay.  
Another structure involved regarding light information is the raphe magnus. The first 
evidence was published in 2008 (Lambert et al., 2008) showing that the raphe magnus 
in cats is interjected between a top-down excitatory relationship between the visual 
cortex and the trigeminal nociceptive system. The function of the raphe magnus is to 
supress the activity of the trigeminal activation through a serotoninergic mechanism 
(Fig. 15.1).  
 
The Limbic system  
The activation of the limbic pathways can superimpose an emotional processing of 
discomfort leading to light avoidance. The amygdala is the most involved structure, a 
principal site for processing fear and anxiety, and importantly, it also relays and 
modulates nociceptive information. Retinal ipRGCs also project to the amygdala 
(Hattar et al., 2006) (Fig.15.1) and a study conducted on mouse pups showed that 
light induced a response in the posterior thalamus and in amygdala, but not in the 
trigeminal nucleus, maybe due to the observations being made at too late a stage i.e. 
the CNS being too mature (Delwig et al., 2012). Interestingly CGRP-containing 
neurons project to the amygdala where they mediate pain responses (Han et al., 
2010).  
 
The Visual cortex  
Our findings add to the existent literature on mechanisms of photophobia the 
possible role of the visual cortex as an inhibitory sustained control on the trigeminal 
nociceptive system. In the light of our results, we have no possibility to trace 
accurately this circuit but we can speculate on possible explanations.  
On the one hand, and more probable, the visual cortex can modulate the trigeminal 
response by the interposition of the thalamus, in particular of the dorsal and dorso-
lateral thalamic nuclei (Fig. 15.1) (Noseda et al., 2010 and 2011, Maleki et al., 2012). 
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Following this point of view, our results support the theory of a thalamo-cortical 
dysrhythmia in migraineurs that we can modulate by the exposition to a flash light 
stimulation during several sessions.  
On the second hand, it is not excluded (and not confirmed yet, too) that the visual 
cortex is directly connected with the trigeminal nociceptive system and acts through a 
targeted control. This possibility fails to find in the existent literature other 
supporting studies, and further investigations, not only in humans but also in 
animals, are necessary to answer to the question. One possibility should be to analyse 
if the exposure to the light modulates the trigeminal response in thalamectomized 
animals, monitoring at the same time the visual cortex and the 2nd order neurons 
discharge in the brainstem.  
On the third hand, the role of the visual cortex should be only an epiphenomenon of 
the activation of the thalamus, which should lead simultaneously to the activation of 
the visual cortex and to the inhibition of the trigeminal nociceptive system. In this 
case, one should find the photophobia generator in the thalamic nuclei and not in the 
visual cortex. However, the «cognitive‛ role in the elaboration of the nociceptive 
information induced by the visual cortex, as we found testing the ‚visually induced 
analgesia‛ in migraineurs, suggests that the visual cortex plays a central role in the 
inhibitory control to the brainstem.  
On the fourth hand, one of these three explanations does not exclude the other one, 
the three circuits can coexist. 
For the moment, these questions are unresolved, and many further studies are need 
for the understanding of the photophobia with migraine headache.
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15.3. Perspectives 
 
The results presented in this thesis provide perspectives for a better understanding of 
photophobia and migraine pathophysiology, as well as for migraine therapy. 
To extend knowledge in these areas, several studies have to be performed.  
The first one is to detect the prevalence in the general population of isolated 
photophobia, by a detailed neurological and ophthalmological examination.  
Many studies are suggested by our results both in animals and in humans: one of the 
most important would be to investigate the role of a prolonged flash light stimulation 
on the trigeminal system in animals and verify if the same pattern can be found as the 
one we have in humans.  
In humans, we can ameliorate our knowledge on the effects of light stimulation by 
using the same light stimulator in in experimental studies in order to favour 
reliability and comparability of results. The present use of different types of 
stimulators adds a technical confounding factor that can be overcome.  
Using StimLux, our next step is to perform a ‚sham-controlled‛ trial, which is not 
easy to design, but can be implemented by choosing as sham the light stimulus 
parameters that in our studies had the smallest effect on sensitivity scores, 
nociceptive blink reflexes and visual evoked potentials.  
The device should be ameliorated by installing one efficient program of stimulation 
in a portable stimulator, easy to use and adapted for a prolonged, home-based 
treatment (two or three months akin to the neurostimulation protocols). 
Moreover, it will be also be of great interest to couple EEG recordings and coloured 
flash light stimulation, in order explore the effect of colour on the visual cortex 
activity.  
In conclusion, this thesis opens several doors for the pathophysiological and 
therapeutic research in migraine, but in particular for the study of photophobia. 
165 
 
REFERECES 
  
Adams RD, Victor M. Principles of Neurology. 2nd ed. New York: McGraw-Hill, 1981. 
Adams WH, Digre KB, Patel BC, Anderson RL, Warner JE, Katz BJ. The evaluation of light sensitivity in benign 
essential blepharospasm. Am J Ophthalmol. 2006 Jul;142(1):82-87. 
Afra J, Cecchini AP, De Pasqua V, Albert A, Schoenen J. Visual evoked potentials during long periods of pattern 
reversal stimulation in migraine. Brain 1998, 121, 233–241. 
Áfra J, Mascia A, Gerard P, Maertens de Noordhout A, Schoenen J. Interictal cortical excitability in migraine: a 
study using transcranial magnetic stimulation of motor and visual cortices. Ann Neurol 1998b; 44:209-215. 
Afra J, Sandor P, Schoenen J. Habituation of visual and intensity dependence of cortical auditory evoked 
potentials tend to normalise just before and during migraine attacks. Cephalalgia 2000;20:347. 
Afridi S, Matharu MS, Lee L, et al.A PET study exploring the laterality of brainstem activation in migraine using 
glyceryl trinitrate. Brain 2005;128:932–9. 
Akcali, D, Sayin, A, Sara, Y & Bolay, H. Does single cortical spreading depression elicit pain behavior in freely 
moving rats? Cephalalgia 2010, 30, 1195–1206. 
Ambrosini A, De Pasqua V, Afra J, Sandor PS, Schoenen J. Reduced gating of middle-latency auditory evoked 
potentials (P50) in migraine patients: another indication of abnormal sensory processing? Neurosci Lett. 2001 Jun 
22;306(1-2):132-4. 
Ambrosini A, Iezzi E, Perrotta A, Kisialiou A, Nardella A, Berardelli A, Pierelli F, Schoenen J. Correlation between 
habituation of visual-evoked potentials and magnetophosphene thresholds in migraine: A case-control study. 
Cephalalgia. 2015 Jun 8. 
Ambrosini A, Rossi P, De Pasqua V, Pierelli F, Schoenen J. Lack of habituation causes high intensity dependence 
of auditory evoked cortical potentials in migraine. Brain 2003;126:2009–15. 
Ambrosini A, Schoenen J. Electrophysiological response patterns of primary sensory cortices in migraine.J 
Headache Pain. 2006 Dec; 7(6): 377–388.  
Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJ, Larsson HB, Olesen J, Ashina M. 
Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine 
without aura: a cross-sectional study. Lancet Neurol. 2013 May;12(5):454-61. doi: 10.1016/S1474-4422(13)70067-X. 
Epub 2013 Apr 9.  
Amini A, Digre K, Couldwell WT. Photophobia in a blind patient: An alternate visual pathway. Case report. J 
Neurosurg. 2006 Nov;105(5):765-8. 
Angus-Leppan H, Olausson B, Boers P, Lambert GA. Convergence of afferents from superior sagittal sinus and 
tooth pulp on cells in the thalamus of the cat. Cephalalgia 1995;15:191–199. 
Antal A, Kriener N, Lang N, Boros K, Paulus W. Cathodal transcranial direct current stimulation of the visual 
cortex in the prophylactic treatment of migraine. Cephalalgia 2011, 31:820–828. 
Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS et al. Genome-wide association study of 
migraine implicates a common susceptibility variant on 8q22.1. Nat Genet. 2010 Oct;42(10):869-73. doi: 
10.1038/ng.652. Epub 2010 Aug 29. 
166 
 
Aramideh M, Ongerboer de Visser BW, Koelman JHTM, Majoie CB, Holstege G. The late blink reflex abnormality 
due to lesions of the lateral tegmental field. Brain 1997;120: 1685–1692. 
Arbab MA, Wiklund L, Svendgaard NA. Origin and distribution of cerebral vascular innervation from superior 
cervical, trigeminal and spinal ganglia investigated with retrograde and anterograde WGA-HRP tracing in the rat. 
Neuroscience 1986;19:695-708. 
Auvichayapat P, Janyacharoen T, Rotenberg A, Tiamkao S, Krisanaprakornkit T, Sinawat S, Punjaruk W, 
Thinkhamrop B, Auvichayapat N. Migraine prophylaxis by anodal transcranial direct current stimulation, a 
randomized, placebo-controlled trial. J Med Assoc Thai 2012, 95:1003–1012. 
Ayzenberg I, Obermann M, Nyhuis P, Gastpar M, Limmroth V, Diener HC, et al. Central sensitization of the 
trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal 
structures. Cephalalgia 2006,26:1106–1114 
Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet 2001;357:1016–7. 
Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurol Sci. 2013 May;34 Suppl 1:S67-
70. doi: 10.1007/s10072-013-1415-8.  
Barbato G, Ficca G, Muscettola G, Fichele M, Beatrice M, Rinaldi F. Diurnal variation in spontaneous eye-blink 
rate. Psychiatry Res. 2000 Mar 6;93(2):145-51. 
Barbato G, Moul DE, Schwartz P, Rosenthal NE, Oren DA. Spontaneous eye blink rate in winter seasonal affective 
disorder. Psychiatry Rex 1993, 47:7t1-85. 
Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after 
stimulation of the dura mater.Brain. 2003 Aug;126(Pt 8):1801-13. Epub 2003 Jun 23.  
Beese LC, Putzer D, Osada N, Evers S, Marziniak M. Contact heat evoked potentials and habituation measured 
interictally in migraineurs. J Headache Pain. 2015 Jan 6;16:1. doi: 10.1186/1129-2377-16-1.  
Belmaker B, Fitzgerald P, George MS, Lisanby SH, Pascual-Leone A, Schlaepfer TE, Wassermann E. Managing the 
risks of repetitive transcranial stimulation. CNS Spectr 2003;8:489. 
Bentley DE, Derbyshire SW, Youell PD, Jones AK. Caudal cingulate cortex involvement in pain processing: an 
inter-individual laser evoked potential source localisation study using realistic head models. Pain 2003 
Apr;102(3):265-71. 
Berardelli A, Rothwell JC, Day BL, Marsden CD. Pathophysiology of blepharospasm and oromandibular 
dystonia.Brain 1985; 108 ( Pt 3):593–608. 
Berkley, K. J. Sex differences in pain. Behavioral and Brain Sciences 1997, 20, 371–380. 
Berson DM. "Phototransduction in ganglion-cell photoreceptors". Pflügers Archiv 2007, 454 (5): 849–55. 
doi:10.1007/s00424-007-0242-2. PMID 17351786 
Bettucci D, Cantello R, Gianelli M, Naldi P, Mutani R. Menstrual migraine without aura: cortical excitability to 
magnetic stimulation. Headache 1992;32:345-347. 
Bjørk M, Hagen K, Stovner Lj, Sand T. Photic EEG-driving responses related to ictal phases and trigger sensitivity 
in migraine: a longitudinal, controlled study. Cephalalgia. 2011 Mar;31(4):444-55. doi: 10.1177/0333102410385582. 
Epub 2010 Nov 22.  
167 
 
Böcker KB, Timsit-Berthier M, Schoenen J, Brunia CH. Contingent negative variation in migraine. Headache 
1990;30:604–609. 
Boelhouwer AJW, Brunia CHM. Blink reflexes and the state of arousal. J Neurol Neurosurg Psychiatry 1977;40:58–
63. 
Bohnen N, Twijnstra A, Wijnen G, Jolles J. Tolerance for light and sound of patients with persistent post-
concussional symptoms 6 months after mild head injury. J Neurol. 1991; 238:443–446. 
Bohotin V, Fumal A, Vandenheede M, Gérard P, Bohotin C, Maertens de Noordhout A, Schoenen J. Effects of 
repetitive transcranial magnetic stimulation on visual evoked potentials in migraine. Brain 2002; 125:912–22. 
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal 
meningeal afferents in a migraine model. Nat Med 2002;8:136-42. 
Bono F, Salvino D, Mazza MR, Curcio M, Trimboli M, Vescio B, Quattrone A. The influence of ictal cutaneous 
allodynia on the response to occipital transcutaneous electrical stimulation in chronic migraine and chronic 
tension-type headache: a randomized, sham-controlled study. Cephalalgia 2015 Apr;35(5):389-98. doi: 
10.1177/0333102414544909. Epub 2014 Jul 30. 
Borges FP, Garcia DM, Cruz AA. Distribution of spontaneous inter-blink interval in repeated measurements with 
and without topical ocular anesthesia. Arq Bras Oftalmol. 2010; 73:329–332. [PubMed: 20944934] 
Boroojerdi B, Prager A, Muellbacher W, Cohen LG. Reduction of human visual cortex excitability using 1-Hz 
transcranial magnetic stimulation. Neurology 2000, 54:1529-1531 
Bossini L, Fagiolini A, Valdagno M, Padula L, Hofkens T, Castrogiovanni P. Photosensitivity in panic disorder. 
Depress Anxiety. 2009; 26:E34–36. 
Boulloche N, Denuelle M, Payoux P, Fabre N, Trotter Y, Géraud G. Photophobia in migraine: an interictal PET 
study of cortical hyperexcitability and its modulation by pain. J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):978-
84. doi: 10.1136/jnnp.2009.190223. Epub 2010 Jun 30. 
Brennan KC, Beltrán-Parrazal L, López-Valdés HE, Theriot J, Toga AW, Charles AC. Distinct vascular conduction 
with cortical spreading depression. J Neurophysiol. 2007 Jun;97(6):4143-51. Epub 2007 Feb 28. 
Brighina F, Giglia G, Scalia S, Francolini M, Palermo A, Fierro B. Facilitatory effects of 1 Hz rTMS in motor cortex 
of patients affected by migraine with aura. Exp Br Res 2005;161:34-38. 
Brighina F, Piazza A, Vitello G, Aloisio A, Palermo A, Daniele O, Fierro B. rTMS of the prefrontal cortex in the 
treatment of chronic migraine: a pilot study. J Neurol Sci, 2004. 227(1): p. 67-71. 
Brinciotti M, Guidetti V, Matricardi M, Cortesi F. Responsiveness of the visual system in childhood migraine 
studied by means of PEVs. Cephalalgia 1986; 6:183–185. 
Bronfort G, Nilsson N, Haas M, Evans R, Goldsmith CH, Assendelft WJ, Bouter LM. Non-invasive physical 
treatments for chronic/recurrent headache. Cochrane Database Syst Rev, 2004(3): p. CD001878. 
Buisseret P, Maffei L. Suppression of visual cortical activity during eyeblinks in the cat. Proceedings of the 
Physiological Society. Cambridge: Cambridge University Press, 1982. p. 19. 
Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, Hargreaves R, Becerra L, Borsook D. Thalamic 
sensitization transforms localized pain into widespread allodynia. Ann Neurol. 2010 Jul;68(1):81-91. doi: 
10.1002/ana.21994. 
168 
 
Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH.An association between migraine and cutaneous 
allodynia.Annals of Neurology 2000; 47:614–624. 
Bussone G, Sinatra MG, Boiardi A et al (1985) Brainstem auditory evoked potentials in migraine patients in basal 
conditions and after chronic flunarizine treatment. Cephalalgia 1985 [Suppl 2]:177–180. 
Cao Y, Welsch KM, Aurora SK, Vikingstad EM.Functional MRI-BOLD of visually triggered headache in patients 
with migraine. Arch Neurol 1999;56:548-554. 
Chan BL, Witt R, Charrow AP, Magee A, Howard R, Pasquina PF, Heilman KM, Tsao JW. Mirror therapy for 
phantom limb pain. N Engl J Med 2007, 357:2206–2207. 
Chapman B, Zahs KR, Stryker MP. Relation of cortical cell orientation selectivity to alignment of receptive fields of 
the geniculocortical afferents that arborize within a single orientation column in ferret visual cortex. J Neurosci 
1991,11(5): 1347–1358. 
Charbit AR, Akerman S, Goadsby PJ. Dopamine: what's new in migraine? Curr Opin Neurol. 2010 Jun;23(3):275-
81. doi: 10.1097/WCO.0b013e3283378d5c.  
Chen AC, Niddam DM, Arendt-Nielsen L. Contact heat evoked potentials as a valid means to study nociceptive 
pathways in human subjects. Neurosci Lett. 2001 Dec;316(2):79-82. 
Chen R, Gerloff C, Classen J, Wassermann EM, Hallet M, Cohen LG. Safety of different inter-train intervals for 
repetitive transcranial magnetic stimulation and recommendations for safe ranges of stimulation parameters. 
Electroencephalogr Clin Neurophysiol 1997;105:415-421.  
Cho P, Sheng C, Chan C, Lee R,Tam J. Baseline blink rates and the effect of visual task difficulty and position of 
gaze. Curr. Eye Res., 2000, 20: 64–70. 
Choi JY, Oh K, Kim BJ, Chung CS, Koh SB, Park KW. Usefulness of a photophobia questionnaire in patients with 
migraine.Cephalalgia. 2009 Sep;29(9):953-9. doi: 10.1111/j.1468-2982.2008.01822.x. Epub 2009 Feb 27.  
Cohen B, Feldman M. Relationship of electrical activity in pontine reticular formation and lateral geniculate body 
to rapid eye movements. J Neurophysiol 1968;31:806–17. 
Conforto AB, Amaro E Jr, Gonçalves AL, Mercante JP, Guendler VZ, Ferreira JR, Kirschner CC, Peres MF. 
Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine. 
Cephalalgia 2014 May;34(6):464-72. doi: 10.1177/0333102413515340. Epub 2013 Dec 10. 
Connolly JF, Gawel M, Rose FC. Migraine patients exhibit abnormalities in the visual evoked potential. J Neurol 
Neurosurg Psychiatry 1982; 45:464–467. 
Cooper AD, Josephs KA. Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive 
supranuclear palsy and corticobasal degeneration: a prospective study. Parkinsonism Relat Disord.2009; 15:59–61. 
Coppola G, Ambrosini A, Di Clemente L, Magis D, Fumal A, Gérard P, Pierelli F, Schoenen J. Interictal 
abnormalities of gamma band activity in visual evoked responses in migraine: an indication of thalamocortical 
dysrhythmia? Cephalalgia 2007; 27:1323–30. 
Coppola G, Currà A, Di Lorenzo C, Parisi V, Gorini M, Sava SL, Schoenen J, Pierelli F. Abnormal cortical 
responses to somatosensory stimulation in medication overuse headache. BMC Neurol. 2010 Dec 30;10:126. doi: 
10.1186/1471-2377-10-126. 
169 
 
Coppola G, De Pasqua V, Pierelli F, Schoenen J. Effects of repetitive transcranial magnetic stimulation on 
somatosensory evoked potentials and high frequency oscillations in migraine. Cephalalgia, 2012. 32(9): p. 700-9. 
Coppola G, Di Lorenzo C, Schoenen J, Pierelli F. Habituation and sensitization in primary headaches. J Headache 
Pain. 2013 Jul 30;14:65. doi: 10.1186/1129-2377-14-65.  
Coppola G, Pierelli F, Schoenen J. Habituation and migraine. Neurobiol Learn Mem. 2009 Sep;92(2):249-59. doi: 
10.1016/j.nlm.2008.07.006. Epub 2008 Aug 26. 
Coppola G, Pierelli F, Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? 
Cephalalgia. 2007 Dec;27(12):1427-39. 
Coppola G, Vandenheede M, Di Clemente L, Ambrosini A, Fumal A, De Pasqua V, Schoenen J. Somatosensory 
evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between 
attacks. Brain. 2005 Jan;128(Pt 1):98-103. Epub 2004 Nov 24. 
Crozier WJ, Pincus G. Phototropism in young rats. J Gen Physiol. 1927;10:407-417. 
Cruccu G, Aziz TZ, Garcia-Larrea L, Hansson P, Jensen TS, Lefaucheur JP, Simpson BA, Taylor RS.EFNS 
guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol, 2007. 14(9): p. 952-70. 
Cruccu G, Inghilleri M, Fraioli B, Guidetti B, Manfredi M. Neurophysiological assessment of trigeminal function 
after surgery for trigeminal neuralgia. Neurology 1987;37: 631–638. 
Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Sanchez del Rio M, Lee EJ, Rosen BR, Moskowitz MA. 
Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998;43:25-31. 
Dasilva AF, Mendonca ME, Zaghi S, Lopes M, Dossantos MF, Spierings EL, Bajwa Z, Datta A, Bikson M, Fregni F. 
tDCS-Induced Analgesia and Electrical Fields in Pain-Related Neural Networks in Chronic Migraine. Headache. 
2012 Sep;52(8):1283-95. doi: 10.1111/j.1526-4610.2012.02141.x. Epub 2012 Apr 18. 
Davis KD, Dostrovsky JO.Properties of feline thalamic neurons activated by stimulation of the middle meningeal 
artery and sagittal sinus. Brain Res 1988;454:89–100. 
De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, Ballabio A, Aridon P, Casari G. 
Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic 
migraine type 2. Nat Genet. 2003 Feb;33(2):192-6. Epub 2003 Jan 21.  
de Tommaso M, Ambrosini A, Brighina F, Coppola G, Perrotta A, Pierelli F, Sandrini G, Valeriani M, Marinazzo 
D, Stramaglia S, Schoenen J. Altered processing of sensory stimuli in patients with migraine. Nat Rev Neurosci. 
2014 10(3):144-55.  
de Tommaso M, Libro G, Guido M, Difruscolo O, Losito L, Sardaro M, Cerbo R. Nitroglycerin induces migraine 
headache and central sensitization phenomena in patients with migraine without aura: a study of laser evoked 
potentials. Neurosci Lett. 2004 Jun 17;363(3):272-5. 
De Tommaso M, Libro G, Guido M, Losito L, Lamberti P, Livrea P. Habituation of single CO2 laser-evoked 
responses during interictal phase of migraine. J Headache Pain 2005; 6:195–8. 
de Tommaso M, Losito L, Libro G, Guido M, Di Fruscolo O, Sardaro M, Sciruicchio V, Lamberti P, Livrea P. Effects 
of symptomatic treatments on cutaneous hyperalgesia and laser evoked potentials during migraine attack. 
Cephalalgia. 2005 May;25(5):359-68. 
170 
 
de Tommaso M, Santostasi R, Devitofrancesco V, Franco G, Vecchio E, Delussi M, Livrea P, Katzarava Z. A 
comparative study of cortical responses evoked by transcutaneous electrical vs CO(2) laser stimulation. Clin 
Neurophysiol 2011, 122(12): 2482–2487. 
de Tommaso M, Sciruicchio V, Guido M, Sasanelli G, Specchio LM and Puca FM. EEG spectral analysis in 
migraine without aura attacks. Cephalalgia 1998; 18: 324–328. 
Delwig A, Logan AM, Copenhagen DR, Ahn AH. Light evokes melanopsin-dependent vocalization and neural 
activation associated with aversive experience in neonatal mice. PLoS ONE. 2012;7: e43787. 
Denny-Brown DD, Chambers RA.Physiological aspects of visual perception.Vols.I and II. Archives of Neurology 
1976, 33:219-242. 
Di Clemente L, Coppola G, Magis D, Fumal A, De Pasqua V, Di Piero V, Schoenen J. Interictal habituation deficit 
of the nociceptive blink reflex: an endophenotypic marker for presymptomatic migraine? Brain 2007; 130:765–70. 
Di Clemente L, Coppola G, Magis D, Fumal A, De Pasqua V & Schoenen J. Nociceptive blink reflex and visual 
evoked potential habituations are correlated in migraine. Headache 2005, 45, 1388–1393. 
Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, Ferrari MD, Herzog J, van den 
Maagdenberg AM, Pusch M, Strom TM. Mutation in the neuronal voltage-gated sodium channel SCN1A in 
familial hemiplegic migraine.Lancet. 2005 Jul 30-Aug 5;366(9483):371-7. 
Diener HC, Scholz E, Dichgans J, Gerber WD, Jäck A, Bille A et al. Central effects of drugs used in migraine 
prophylaxis evaluated by visual evoked potentials. Ann Neurol 1989; 25:125–30. 
Digre KB, Brennan KC. Shedding light on photophobia. J Neuroophthalmol. 2012;32:68-81. 
Dionne JK, Meehan SK, Legon W, Staines WR. Crossmodal influences in somatosensory cortex: interaction of 
vision and touch. Hum Brain Mapp 2010, 31:14 –25. 
Dolgonos S, Ayyala H, Evinger C. Light-induced trigeminal sensitization without central visual pathways: another 
mechanism for photophobia. Invest Ophthalmol Vis Sci. 2011 Oct 4;52(11):7852-8. doi: 10.1167/iovs.11-7604. 
Doughty MJ. Consideration of three types of spontaneous eyeblink activity in normal humans: during reading and 
video display terminal use, in primary gaze, and while in conversation. Optom Vis Sci. 2001; 78:712–725. 
[PubMed: 11700965] 
Doughty MJ. Effects of background lighting and retinal illuminance on spontaneous eyeblink activity of human 
subjects in primary eye gaze. Eye Contact Lens. 2013 Mar;39(2):138-46. doi: 10.1097/ICL.0b013e31827124b7. 
Drake ME, Pakalnis A, Hietter SA, Padamadan H. Visual and auditory evoked potentials in migraine. 
Electromyogr Clin Neurophysiol 1990, 30:77–81. 
Drake ME, Pakalnis A, Padamadan H. Long-latency auditory event related potentials in migraine. Headache 1989, 
29:239–241 
Drummond P. A quantitative assessment of photophobia in migraine and tension headache.Headache. 
1986;26:465–469.  
Drummond PD. Photophobia and autonomic responses to facial pain in migraine. Brain 1997, 120(Pt 10): 1857–
1864. 
Drummond PD, Woodhouse A Painful stimulation of the forehead increases photophobia in migraine sufferers. 
Cephalalgia 1993, 13(5): 321–324. 
171 
 
Ebersberger A, Schaible HG, Averbeck B, Richter F. Is there a correlation between spreading depression, 
neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol 2001, 49:7–13 
Emoto H, Suzuki Y, Wakakura M, Horie C, Kiyosawa M, Mochizuki M, Kawasaki K, Oda K, Ishiwata K, Ishii K. 
Photophobia in essential blepharospasm--a positron emission tomographic study. Mov Disord. 2010; 25:433–439. 
Eschweiler GW, Wegerer C, Schlotter W, Spandl C, Stevens A, Bartels M, et al. Left prefrontal activation predicts 
therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychiatry Res 
2000; 99: 161±72. 
Evans RW, Seifert T, Kailasam J, Mathew NT. The use of questions to determine the presence of photophobia and 
phonophobia during migraine.Headache. 2008 Mar;48(3):395-7. Epub 2007 Sep 12. 
Ezendam D, Bongers RM, Jannink MJ. Systematic review of the effectiveness of mirror therapy in upper extremity 
function. Disabil  Rehabil 2009, 31:  2135-49. 
Feigl B, Mattes D, Thomas R, Zele AJ. Intrinsically photosensitive (melanopsin) retinal ganglion cell function in 
glaucoma. Invest Ophthalmol Vis Sci. 2011;52:4362-4367. 
Ferrari A, Pasciullo G, Savino AF, Cicero A, Ottani A. Bertolini and E. Sternieri. Headache treatment before and 
after the consultation of a specialized centre: a pharmacoepidemiology study. Cephalalgia 2004,24 (5): 356-62. 
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine 
treatment: a meta-analysis of 53 trials. Lancet. 2001 Nov 17;358(9294):1668-75. 
Fields HL, Heinricher MM. Anatomy and physiology of a nociceptive modulatory system. Philos Trans of the R 
Soc Lond B Biol Sci 1985;308:361-374. 
Fillingim RB, & Maixner W. The influence of resting blood pressure and gender on pain responses. Psychosomatic 
Medicine 1996, 58, 326–332. 
Fillingim R, Edwards R, Powell T.Sex-dependent effects of reported familial pain history on recent pain 
complaints and experimental pain responses. Pain 2000, 86, 87–94. 
Fillingim R, King C, Ribeiro-Dasilva M, Rahim-Williams B, Riley J. Sex, gender, and pain: a review of recent 
clinical and experimental findings. The Journal of Pain 2009, 10, 447–485. 
Fioravanti B, Kasasbeh A, Edelmayer R, Skinner DP Jr, Hartings JA, Burklund RD, De Felice M, French ED, Dussor 
GO, Dodick DW, Porreca F & Vanderah TW. Evaluation of cutaneous allodynia following induction of cortical 
spreading depression in freely moving rats. Cephalalgia 2011, 31, 1090–1100. 
Foell J, Bekrater-Bodmann R, Diers M, Flor H. Mirror therapy for phantom limb pain: Brain changes and the role 
of body representation. Eur J Pain. 2014, May;18(5):729-39. 
Fogang Y, Gérard P, De Pasqua V, Pepin JL, Ndiaye M, Magis D, Schoenen J. Analysis and clinical correlates of 20 
Hz photic driving on routine EEG in migraine. Acta Neurol Belg. 2015 Mar;115(1):39-45. 
Fogarty C, Stern J. A. Eye movements and blinks: their relationship to higher cognitive processes. Int. J. 
Psychophysiol., 1989, 8: 35–42.  
Fournier LR, Wilson GF, Swain CR. Electrophysiological, behavioral, and subjective indexes of workload when 
performing multiple tasks: manipulations of task difficulty and training. Int J Psychophysiol., 1999, 31: 129–145. 
172 
 
Frandsen JE, Llop S, Digre KB, Bernstein PS, Sharifzadeh M, Warner JE, Gellerman W, Katz BJ. Quantification of 
macular carotenoids using autofluorescence imaging in patients with photosensitive migraine and benign 
essential blepharospasm.Arch Ophthalmol. 2012 Feb;130(2):259-60. doi: 10.1001/archopthalmol.2011.1372.  
Freed WJ; Karson CN; Kleinman JE; Wyatt RJ.Increased spontaneous eye-blinks in cerebellectomized rats. 
Biological Psychiatry 1981, 16:789-792. 
Friedman DI, De ver Dye T. Migraine and the environment.Headache. 2009 Jun;49(6):941-52. doi: 10.1111/j.1526-
4610.2009.01443.x. 
Fumal A, Bohotin V, Vandenheede M, Seidel L, de Pasqua V, de Noordhout AM, Schoenen J. Effects of repetitive 
transcranial magnetic stimulation on visual evoked potentials: new insights in healthy subjects. Exp Brain Res 
2003,150(3): 332–340. 
Fumal A, Coppola G, Bohotin V, Gérardy PY, Seidel L, Donneau AF, Vandenheede M, Maertens de Noordhout A, 
Schoenen J. Induction of long-lasting changes of visual cortex excitability by five daily sessions of repetitive 
transcranial magnetic stimulation (rTMS) in healthy volunteers and migraine patients. Cephalalgia, 2006. 26(2): p. 
143-9. 
Galhardoni R, Correia GS, Araujo H, Yeng LT, Fernandes DT, Kaziyama HH, Marcolin MA, Bouhassira D, 
Teixeira MJ, de Andrade DC. Repetitive transcranial magnetic stimulation in chronic pain: a review of the 
literature. Arch Phys Med Rehabil. 2015 Apr;96(4 Suppl):S156-72. doi: 10.1016/j.apmr.2014.11.010. 
Garcia-Larrea L, Peyron R, Mertens P, et al. Electrical stimulation of motor cortex for pain control: a combined PET 
scan and electrophysiological study. Pain 1999;83:259– 73. 
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and 
years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic 
analysis for the Global Burden of Disease Study 2013.Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-
6736(15)60692-4. Epub 2015 Jun 7. 
Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during 
migraine headache. Ann Neurol 1990;28:183-187. 
Goadsby PJ. Recent advances in the diagnosis and management of migraine. Bmj 2006,332 (7532): 25-9. 
Golden RN, Gaynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, Suppes T, Wisner KL, Nemeroff CB. The efficacy 
of light therapy in the treatment of mooddisorders: a review and meta-analysis of the evidence, Am. J. Psychiatry 
2005,162(4) 656–662. 
Golla FL and Winter AL. Analysis of cerebral responses to flicker in patients complaining of episodic 
headache.Electroencephalogr Clin Neurophysiol 1959; 11: 539–549. 
Goz D, Studholme K, Lappi DA, Rollag MD, Provencio I, Morin LP.Targeted destruction of photosensitive retinal 
ganglion cells with a sapor in conjugate alters the effect so flight on mouse circadian rhythms. PLoS ONE 
2008,3:e3153.doi:10.1371/journal.pone.0003153. 
Granovsky Y, Matre D, Sokolik A, Lorenz J, Casey KL. Thermoreceptive innervation of human glabrous and hairy 
skin: a contact heat evoked potential analysis. Pain. 2005 Jun;115(3):238-47. Epub 2005 Apr 18. 
Groves PM,Thompson, RF. Habituation: A dual-process theory. Psychological Review 1970, 77, 419–450. 
173 
 
Güler AD, Ecker JL, Lall GS, Haq S, Altimus CM, Liao HW, Barnard AR, Cahill H, Badea TC, Zhao H, Hankins 
MW, Berson DM, Lucas RJ, Yau KW, Hattar S. Melanopsin cells are the principal conduits for rod-cone input to 
non-image-forming vision. Nature. 2008 May 1;453(7191):102-5. doi: 10.1038/nature06829. Epub 2008 Apr 23. 
Gutrecht JA, Lessell IM. Photophobia in trigeminal neuralgia. J Neuroophthalmol. 1994;14:122–123. 
Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, Rosen BR, 
Tootell RB, Sorensen AG, Moskowitz MA. Mechanisms of migraine aura revealed by functional MRI in human 
visual cortex. Proc Natl Acad Sci USA 2001;98:4687-4692. 
Haggard P, Iannetti GD, Longo MR. Spatial sensory organization and body representation in pain perception. 
Curr Biol. 2013, Feb 18;23(4):R164-76. 
Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF international 
workshop. Neurology 2008;71:1275–82. 
Han JS, Adwanikar H, Li Z, Ji G, Neugebauer V. Facilitation of synaptic transmission and pain responses by CGRP 
in the amygdala of normal rats. Mol Pain. 2010;6:10. 
Hatori M, Le H, Vollmers C, Keding SR, Tanaka N, Buch T, Waisman A, Schmedt C, Jegla T, Panda S. Inducible 
ablation of melanopsin-expressing retinal ganglion cells reveals their central role in non-image forming visual 
responses. PLoSONE 2008,3:e2451.doi: 10.1371/journal.pone.0002451 
Hattar S, Kumar M, Park A, Tong P, Tung J, Yau KW, Berson DM. Central projections of melanopsin-expressing 
retinal ganglion cells in the mouse. J Comp Neurol. 2006;497:326-349. 
Hattar S, Lucas RJ, Mrosovsky N, Thompson S, Douglas RH, Hankins MW, Lem J, Biel M, Hofmann F, Foster RG, 
Yau KW. Melanopsin and rod cone photoreceptive systems account for all major accessory visual functions in 
mice. Nature 2003,424, 76e81. 
Hay KM, Mortimer MJ, Barker DC, Debney LM, Good PA. 1044 women with migraine: the effect of environmental 
stimuli. Headache. 1994 Mar;34(3):166-8). 
Headache Classification Committee of the International Headache Society (IHS). The International Classification 
of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33(9) 629–808.  
Henderson JM, Lad SP. Motor cortex stimulation and neuropathic facial pain. Neurosurg Focus. 2006 Dec 
15;21(6):E6. Review. 
Hills W, Warner JE, Katz BJ, Chelune G, Foster N, Steffens J, Thulin P, Chin S, Digre K. American Academy of 
Neurology. Chicago: 2008. Neuro-ophthalmic findings that may reliably differentiate progressive supranuclear 
palsy and Parkinson’s disease. 
Hougaard A, Amin FM, Hauge AW, Ashina M, Olesen J. Provocation of migraine with aura using natural trigger 
factors. Neurology 2013 Jan 29;80(5):428-31. 
Hubel DH, Livingstone MS. Color and contrast sensitivity in the lateral geniculate body and primary visual cortex 
of the macaque monkey. J Neurosci 1990,10(7): 2223–2237. 
Imbert M, Bignall KE. [PROJECTIONS FROM THE VISUAL CORTEX IN THE THALAMECTOMIZED CAT 
WITH THE EXCEPTION OF THE LATERAL GENICULATE BODY].J Physiol (Paris). 1965 Jan-Feb;57:252-3. 
Inghilleri M, Conte A, Curra A, Frasca V, Lorenzano C, Berardelli A. Ovarian hormones and cortical excitability. 
An rTMS study in humans. Clin Neurophysiol 2004;115:1063-1068. 
174 
 
Itskovich VV, Fei DY, Harkins SW. Psychophysiological and psychophysical responses to experimental pain 
induced by two types of cutaneous thermal stimuli. Int J Neurosci. 2000 Nov;105(1-4):63-75. 
Kagan R, Kainz V, Burstein R, Noseda R. Hypothalamic and basal ganglia projections to the posterior thalamus: 
possible role in modulation of migraine headache and photophobia. Neuroscience. 2013 Sep 17;248:359-68. doi: 
10.1016/j.neuroscience.2013.06.014. Epub 2013 Jun 25. 
Kaiser EA, Kuburas A, Recober A, Russo AF. Modulation of CGRP-induced light aversion in wild-type mice by a 
5-HT(1B/D) agonist. J Neurosci. 2012 Oct 31;32(44):15439-49. doi: 10.1523/JNEUROSCI.3265-12.2012. 
Kankipati L, Girkin CA, Gamlin PD. The post-illumination pupil response is reduced in glaucoma patients. Invest 
Ophthalmol Vis Sci. 2011;52:2287-2292. 
Karson CN, Berman KF, Donnelly EF, Mendelson WB, Kleinman JE, Wyatt RJ. Speaking, thinking, and blinking. 
Psychiatry Res. 1981 Dec;5(3):243-6. 
Karson CN, Burns RS, LeWitt PA, et al. Blink rates and disorders of movement. Neurology 1984;34:677–8. 
Karson CN, Freed WJ, Kleinman JE, et al. Neuroleptics decrease blinking in schizophrenic subjects. Biol Psychiatry 
1981;16:679–82. 
Karson CN, LeWitt PA, Calne DB, et al. Blink rates in parkinsonism. Ann Neurol 1982;12:580–3. 
Karson CN. Physiology of normal and abnormal blinking. Adv Neurol 1988;49:25–37. 
Karson CN. Spontaneous eye-blink rates and dopaminergic systems. Brain 1983;106:643–53. 
Katagiri A, Okamoto K, Thompson R, Bereiter DA. Posterior hypothalamic modulation of light-evoked trigeminal 
neural activity and lacrimation.Neuroscience. 2013 Aug 29;246:133-41. doi: 10.1016/j.neuroscience.2013.04.053. 
Epub 2013 Apr 30. 
Katsarava Z, Giffin N, Diener HC, Kaube H. Abnormal habituation of 'nociceptive' blink reflex in migraine–
evidence for increased excitability of trigeminal nociception. Cephalalgia 2003, 23:814–819.  
Katsarava Z, Lehnerdt G, Duda B, Ellrich J, Diener HC, Kaube H. Sensitization of trigeminal nociception specific 
for migraine but not pain of sinusitis. Neurology. 2002 Nov 12;59(9):1450-3. 
Kaube H, Katsarava Z, Kaufer T, Diener H, Ellrich J. A new method to increase nociception specificity of the 
human blink reflex. Clin Neurophysiol 2000, 111(3): 413–416. 
Kaube H, Katsarava Z, Przywara S, Drepper J, Ellrich J, Diener HC. Acute migraine headache: possible 
sensitization of neurons in the spinal trigeminal nucleus? Neurology 2002, 58:1234–1238. 
Kawasaki A, Purvin VA. Photophobia as the presenting symptom of chiasmal compression. J Neuroophthalmol. 
2002;22:3–8. 
Kawashima N, Mita T, Yoshikawa M. Inter-individual difference in the effect of mirror reflection-induced visual 
feedback on phantom limb awareness in forearm amputees. PLoS One. 2013, Jul 25;8(7):e69324. 
Keeser D, Padberg F, Reisinger E, Pogarell O, Kirsch V, Palm U, Karch S, Möller HJ, Nitsche MA, Mulert C. 
Prefrontal direct current stimulation modulates resting EEG and event-related potentials in healthy subjects: a 
standardized low resolution tomography (sLORETA) study. Neuroimage, 2011. 55(2): p. 644-57. 
Kerr FW. Central relationships of trigeminal and cervical primary afferents in the spinal cord and medulla. Brain 
Res 1972;43:561-572. 
175 
 
Khalil NM, Legg NJ, Anderson DJ.Long term decline of P100 amplitude in migraine with aura. J Neurol 
Neurosurg Psychiatry 2000;69:507–511. 
Kimura J, Lyon LW. Orbicularis oculi reflex in Wallenberg syndrome: alteration of the late reflex by lesion of the 
spinal tract and nucleus of the trigeminal nerve. J Neurol Neurosurg Psychiatry 1972;35:228–233. 
Kimura J, Powers JM, Van Allen MW. Reflex response of orbicularis oculi muscles to supraorbital nerve 
stimulation. Study in normal subjects and in peripheral facial paresis. Arch Neurol 1969;21:193–199. 
Klein E, Kolsky Y, Puyerovsky M, Koren D, Chistyakov A, Feinsod M. Right prefrontal slow repetitive transcranial 
magnetic stimulation in schizophrenia: a double-blind sham-controlled pilot study. Biol Psychiatry 1999, 46(10): 
1451–1454. 
Klein MM, Treister R, Raij T, Pascual-Leone A, Park L, Nurmikko T, Lenz F, Lefaucheur JP, Lang M, Hallett M, 
Fox M, Cudkowicz M, Costello A, Carr DB, Ayache SS, Oaklander AL. Transcranial magnetic stimulation of the 
brain: guidelines for pain treatment research. Pain. 2015 Sep;156(9):1601-14. doi: 10.1097/j.pain.0000000000000210. 
Kosslyn SM, Pascual-Leone A, Felician O, Camposano S, Keenan JP, Thompson WL, Ganis G, Sukel KE, Alpert 
NM. The role of area 17 in visual imagery: convergent evidence from PET and rTMS. Science 1999,284:167-170. 
Kowacs PA, Piovesan EJ, Werneck LC, Tatsui CE, Lange MC, Ribas LC, da Silva HP.Influence of intense light 
stimulation on trigeminal and cervical pain perception thresholds. Cephalalgia 2001, 21(3): 184–188. 
Kropp P, Gerber WD. Contingent negative variation – findings and perspectives in migraine. Cephalalgia 
1993;13:33–36. 
Kropp P, Gerber WD. Contingent negative variation during migraine attack and interval: evidence for 
normalization of slow cortical potentials during the attack. Cephalalgia 1995; 15:123–8. 
Kugelberg E. Facial reflexes. Brain 1952;75:385–396. 
Kupers RC, Gybels JM, Gjedde A. Positron emission tomography study of a chronic pain patient successfully 
treated with somatosensory thalamic stimulation. Pain 2000; 87: 295-302. 
Lambert GA, Hoskin KL, Zagami AS. Cortico-NRM influences on trigeminal neuronal sensation. Cephalalgia. 
2008 Jun;28(6):640-52. doi: 10.1111/j.1468-2982.2008.01572.x. 
Lambert GA, Michalicek J, Storer RJ, Zagami AS. Effect of cortical spreading depression on activity of 
trigeminovascular sensory neurons. Cephalalgia 1999, 19:631–638 
Lamonte M, Silberstein SD, Marcelis JF. Headache associated with aseptic meningitis. Headache.1995; 35:520–526. 
Larsson B, Bille B, Pedersen NL. Genetic influence in headaches: a Swedish twin study. Headache 1995, 35, 513-
519. 
Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry 
1941;46:331–9. 
Lauritzen M. Pathophysiology of the migraine aura.The spreading depression theory. Brain 1994;117:199-210. 
Leão AAP. Pial circulation and spreading activity in the cerebral cortex. J Neurophysiol 1944;7:391–6.  
Leão AAP. Spreading depression of activity in cerebral cortex.J Neurophysiol 1944; 7:359–90. 
Lebensohn JE. Photophobia: mechanism and implications. Am J Ophthalmol. 1951;34:1294–1300. 
176 
 
Lee H, Sininger L, Jen JC, Cha YH, Baloh RW, Nelson SF. Association of progesterone receptor with migraine-
associated vertigo.Neurogenetics 2007, 8, 195-200. 
Lefaucheur JP, Antal A, Ahdab R, Ciampi de Andrade D, Fregni F, Khedr EM, Nitsche M, Paulus W. The use of 
repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) to relieve 
pain. Brain Stimul 2008;1:337–44. 
Lefaucheur JP, Drouot X, Keravel Y, Nguyen JP. Pain relief induced by repetitive transcranial magnetic 
stimulation of precentral cortex.Neuroreport 2001;12:2963–5. 
Lefaucheur JP, Drouot X, Ménard-Lefaucheur I, Keravel Y, Nguyen JP. Motor cortex rTMS restores defective 
intracortical inhibition in chronic neuropathic pain. Neurology 2006; 67:1568–74. 
Lefaucheur JP, Jarry G, Drouot X, Ménard-Lefaucheur I, Keravel Y, Nguyen JP. Motor cortex rTMS reduces acute 
pain provoked by laser stimulation in patients with chronic neuropathic pain. Clin Neurophysiol. 2010 
Jun;121(6):895-901. doi: 10.1016/j.clinph.2009.12.028. Epub 2010 Jan 25. 
Lehtonen JB. Visual evoked cortical potentials for single flashes and flickering light in migraine. Headache 
1974;14:1–12. 
Lev R, Granovsky Y, Yarnitsky D. Orbitofrontal disinhibition of pain in migraine with aura: an interictal EEG-
mapping study. Cephalalgia 2010,30:910–918. 
Lev R, Granovsky Y, Yarnitsky D. Enhanced pain expectation in migraine: EEG-based evidence for impaired 
prefrontal function. Headache. 2013 Jul-Aug;53(7):1054-70. doi: 10.1111/j.1526-4610.2012.02297.x. Epub 2012 Dec 6. 
Linde, M. Migraine: a review and future directions for treatment. Acta Neurol Scand 2006,114 (2): 71-83. 
Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, Harrison W. A self-administered 
screener for migraine in primary care: The ID Migraine validation study. Neurology.2003; 61:375–382. 
Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, Fischell RE, Ruppel PL, Goadsby PJ. 
Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-
blind, parallel-group, sham-controlled trial. Lancet Neurol, 2010. 9(4): p. 373-80. 
Longo MR, Betti V, Aglioti SM, Haggard P. Visually induced analgesia: seeing the body reduces pain. J Neurosci. 
2009, 29:12125–12130. 
Longo MR, Iannetti GD, Mancini F, Driver J, Haggard P. Linking pain and the body: neural correlates of visually 
induced analgesia. J. Neurosci 2012, 32(8): 2601–2607. 
Longo MR, Pernigo S, Haggard P. Vision of the body modulates processing in primary somatosensory cortex. 
Neurosci Lett 2011, 489:159–163. 
Longo MR, Schüür F, Kammers MP, Tsakiris M, Haggard P. What is embodiment? A psychometric approach. 
Cognition 2008, 107:978–998. 
Lucas RJ, Douglas RH, Foster RG. Characterization of an ocular photopigment capable of driving pupillary 
constriction in mice. Nat. Neurosci. 2001,4, 621e626. 
MacGregor EA, J Brandes, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and 
Zolmitriptan Evaluation survey. Headache 2003, 43 (1): 19-26. 
Maeda F, Keenan JP, Tormos JM, Topka H, Pascual-Leone A. Interindividual variability of the modulatory effects 
of repetitive transcranial magnetic stimulation on cortical excitability. Exp Brain Res. 2000 Aug;133(4):425-30. 
177 
 
Maertens de Noordhout A, Pepin JL, Schoenen J, Delwaide PJ. Percutaneous magnetic stimulation of the motor 
cortex in migraine. Electroencephalogr Clin Neurophysiol 1992;85:110-115. 
Maertens de Noordhout A, Rothwell JC, Day BL, Dressler D, Nakashima K, Thompson PD, Marsden CD. Effect of 
digital nerve stimuli on responses to electrical or magnetic stimulation of the human brain. J Physiol. 1992 
Feb;447:535-48. 
Maertens de Noordhout A, Timsit-Berthier M, Timsit M, Schoenen J. Contingent negative variation in headache. 
Ann Neurol 1986;19:78–80. 
Magerl W, Ali Z, Ellrich J, Meyer RA, Treede RD. C- and A delta-fiber components of heat-evoked cerebral 
potentials in healthy human subjects, Pain 1999, 82, 127– 137. 
Magis D, Gerard P, Schoenen J. Transcutaneous vagus nerve stimulation (tVNS) for headache prophylaxis: initial 
experience. J Headache Pain, 2013. 1 Suppl 1: p. P 198. 
Magis D, Sava S, d'Elia TS, Baschi R, Schoenen J. Safety and patients' satisfaction of transcutaneous Supraorbital 
NeuroStimulation (tSNS) with the Cefaly(R) device in headache treatment: a survey of 2,313 headache sufferers in 
the general population. J Headache Pain, 2013. 14(1): p. 95. 
Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. Lancet Neurol. 2012 
Aug;11(8):708-19. doi: 10.1016/S1474-4422(12)70139-4. 
Malecaze FJ, Boulanouar KA, Demonet JF, Guell JL, Imbert MA. Abnormal activation in the visual cortex after 
corneal refractive surgery for myopia: demonstration by functional magnetic resonance imaging. Ophthalmology. 
2001 Dec;108(12):2213-8.  
Maleki N, Becerra L, Upadhyay J, Burstein R, Borsook D. Direct optic nerve pulvinar connections defined by 
diffusion MR tractography in humans: implications for photophobia. Hum Brain Mapp. 2012;33(1):75-88. 
Mancini F, Bolognini N, Haggard P, Vallar G. tDCS modulation of visually induced analgesia. J Cogn Neurosci. 
2012 Dec;24(12):2419-27.  
Mancini F, Longo MR, Kammers MP, Haggard P. Visual distortion of body size modulates pain perception. 
Psychol Sci 2011, 22:325–330. 
Martenson ME, Halawa OI, Tonsfeldt KJ, Maxwell CA, Hammack N, Mist SD, Pennesi ME, Bennett RM, Mauer 
KM, Jones KD, Heinricher MM. A possible neural mechanism for photosensitivity in chronic pain.Pain.2015 Dec 9. 
Martín H, Sánchez del Río M, de Silanes CL, Álvarez-Linera J, Hernández JA, Pareja JA. Photoreactivity of the 
occipital cortex measured by functional magnetic resonance imaging-blood oxygenation level dependent in 
migraine patients and healthy volunteers: pathophysiological implications. Headache. 2011 Nov-Dec;51(10):1520-
8. doi: 10.1111/j.1526-4610.2011.02013.x. 
Matharu MS, Bartsch T, Ward N, Frackowiak RS, Weiner R, Goadsby PJ. Central neuromodulation in chronic 
migraine patients with suboccipital stimulators: a PET study. Brain. 2004 Jan;127(Pt 1):220-30. Epub 2003 Nov 7. 
Matynia A, Parikh S, Chen B, Kim P, McNeill DS, Nusinowitz S, Evans C, Gorin MB. Intrinsically photosensitive 
retinal ganglion cells are the primary but not exclusive circuit for light aversion. Exp. Eye Res. 2012, 105, 60e69. 
Misra UK, Kalita J, Tripathi GM, Bhoi SK. Is β endorphin related to migraine headache and its relief? Cephalalgia 
2013, 33(5):316–22. 
178 
 
Modugno N, Nakamura Y, MacKinnon CD, Filipovic SR, Bestman S, Berardelli A, Rothwell JC. Motor cortex 
excitability following short trains of repetitive magnetic stimuli. Exp.Brain Res 2001,140:453-459. 
Moskowitz MA, Buzzi MG. Neuroeffector functions of sensory fibres: implications for headache mechanisms and 
drug actions. J Neurol. 1991;238 Suppl 1:S18-22. 
Moskowitz MA, Nozaki K & Kraig RP. Neocortical spreading depression provokes the expression of c-Fos 
protein-like immunoreactivity within trigeminal nucleus caudalis trigeminovascular mechanisms. J. Neurosci. 
1993, 13, 1167–1177. 
Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin 1990;8:801–15 
Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of headache. 1993. Neurology 
43(6 Suppl 3):S16-20. 
Moskowitz MA. The neurobiology of vascular head pain. 1984 Ann Neurol 16 (2):157-68.  
Moskowitz MA. Trigeminovascular system. 1992. Cephalalgia 12(3):127. 
Moulton EA, Becerra L, Borsook D. An fMRI case report of photophobia: activation of the trigeminal nociceptive 
pathway. Pain 2009, 145(3): 358–363. 
Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, Borsook D. Interictal dysfunction of a brainstem 
descending modulatory center in migraine patients. PLoS One. 2008;3(11):e3799. doi: 
10.1371/journal.pone.0003799. Epub 2008 Nov 24. 
Mrosovsky N, Lucas RJ, Foster RG. Persistence of masking responses to light in mice lacking rods and cones. 
J.Biol.Rhythms 2001, 16, 585–587. doi: 10.1177/074873001129002277 
Naase T, Doughty MJ, Button NF. An assessment of the pattern of spontaneous eyeblink activity under the 
influence of topical ocular anaesthesia.Graefes Arch Clin Exp Ophthalmol.2005; 243:306– 312. [PubMed: 15864619] 
Nakamori K, Odawara M, Nakajima T, Mizutani T, Tsubota K. Blinking is controlled primarily by ocular surface 
conditions. Am J Ophthalmol.1997; 124:24–30. [PubMed: 9222228] 
Noseda R, Burstein R. Advances in understanding the mechanisms of migraine-type photophobia. Curr Opin 
Neurol. 2011 Jun;24(3):197-202. doi: 10.1097/WCO.0b013e3283466c8e. 
Noseda R, Kainz V, Jakubowski M, Gooley JJ, Saper CB, Digre K, Burstein R. A neural mechanism for exacerbation 
of headache by light. Nat Neurosci. 2010 Feb;13(2):239-45. doi: 10.1038/nn.2475. Epub 2010 Jan 10. 
Oelkers R, Grosser K, Land E, Geisslinger G, Kobal G, Brune K, Lötsch J. Visual evoked potentials in migraine 
patients: Alterations depend on pattern spatial frequency. Brain 1999, 122, 1147–1155. 
Oelkers-Ax R, Parzer P, Resch F, Weisbrod M. Maturation of early visual processing investigated by a pattern-
reversal habituation paradigm is altered in migraine. Cephalalgia 2005, 25, 280–289. 
Okamoto K, Tashiro A, Thompson R, Nishida Y, Bereiter DA. Trigeminal interpolaris/caudalis transition neurons 
mediate reflex lacrimation evoked by bright light in the rat. Eur J Neurosci. 2012 Dec;36(11):3492-9. doi: 
10.1111/j.1460-9568.2012.08272.x. Epub 2012 Sep 3. 
Okamoto K, Tashiro A, Chang Z, Bereiter DA. Bright light activates a trigeminal nociceptive pathway. Pain 2010, 
149, 235–242. 
179 
 
Okamoto K, Thompson R, Tashiro A, Chang Z, Bereiter D. Bright light produces Fos-positive neurons in caudal 
trigeminal brainstem. Neuroscience 2009, 160, 858–864. 
Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF 
in classic migraine. Ann Neurol. 1981;9:344-352. 
Olesen J. Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications. 
Cerebrovascular and brain. Metab Rev 1991;3:1-28. 
Ongerboer de Visser BW, Goor C. Electromyographic and reflex study in idiopathic and symptomatic trigeminal 
neuralgias: latency of the jaw and blink reflexes. J Neurol Neurosurg Psychiatry 1974;37:1225–1230. 
Ongerboer de Visser BW, Kuypers HGJM. Late blink reflex changes in lateral medullary lesions. An 
electrophysiological and neuroanatomical study of Wallenberg’s syndrome. Brain 1978;101:285–94. 
Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, 
Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR. Familial 
hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. 
Cell. 1996 Nov 1;87(3):543-52. 
Osenbach RK. Motor cortex stimulation for intractable pain. Neurosurg Focus. 2006 Dec 15;21(6):E7.  
Overend W. Preliminary note on a new cranial reflex.Lancet 1896;1:619. 
Ozkul Y, Bozlar S. Effects of fluoxetine on habituation of pattern reversal visually evoked potentials in migraine 
prophylaxis. Headache 2002, 42, 582–587. 
Ozkul Y, Uckardes A.  Median nerve somatosensory evoked potentials in migraine. European Journal of 
Neurology 2002, 9, 227–232. 
Pail G, Huf W, Pjrek E, Winkler D, Willeit M, Praschak-Rieder N, Kasper S. Bright-light therapy in the treatment of 
mood disorders. Neuropsychobiology. 2011;64(3):152-62. doi: 10.1159/000328950. Epub 2011 Jul 29.  
Panda S, Sato TK, Castrucci AM, Rollag MD, DeGrip WJ, Hogenesch JB, Provencio I, Kay SA. Melanopsin (Opn4) 
requirement for normal light-induced circadian phase shifting. Science 2002, 298, 2213–
2216.doi:10.1126/science.1076848 
Panda S,Provencio I,Tu DC,Pires SS,Rollag MD, Castrucci AM, Pletcher MT, Sato TK, Wiltshire T, Andahazy M, 
Kay SA, Van Gelder RN, Hogenesch JB. Melanopsin irequirefor non-image-forming photic responses in blind 
mice. Science. 2003 Jul 25;301(5632):525-7. Epub 2003 Jun 26. 
Pascual-Leone A, Valls-Solé J, Wassermann EM, Hallett M. Responses to rapid-rate transcranial magnetic 
stimulation of the human motor cortex. Brain, 1994. 117 ( Pt 4): p. 847-58 
Peinemann A, Lehner C, Mentschel C, Münchau A, Conrad B, Siebner HR. Subthreshold 5-Hz repetitive 
transcranial magnetic stimulation of the human primary motor cortex reduces intracortical paired-pulse 
inhibition. Neurosci Lett. 2000 Dec 15;296(1):21-4. 
Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic 
haemodynamics in healthy volunteers. Cephalalgia 2005;25:139–47. 
Peyron R, Garcia-Larrea L, Deiber MP, et al. Electrical stimulation of precentral cortical area in the treatment of 
central pain: electrophysiological and PET study. Pain 1995;62:275– 86. 
180 
 
Pfaffenbach DD, Layton DD, Keans TD. Ocular manifestations in progressive supranuclear palsy. Am J 
Ophthalmol 1972;74:1179–84. 
Phelps ME, Kuhl DE. Metabolic mapping of the brain's response to visual stimulation: Studies in humans. Science 
1981, 211:1445-1448. 
Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003 May;4(5):386-98. 
Polania R, Paulus W, MA Nitsche. Modulating cortico-striatal and thalamo-cortical functional connectivity with 
transcranial direct current stimulation. Hum Brain Mapp, 2011: p. Sep 16. 
Ponder E, Kennedy WP. On the act of blinking. Quarterly Journal of Experimental Physiology 1928;18:89–110. 
Price DD. Selective activation of A-delta and C nociceptive afferents by different parameters of nociceptive heat 
stimulation: a tool for analysis of central mechanisms of pain, Pain 1996, 68, 1–3. 
Provencio I, Rodriguez IR, Jiang G, Hayes WP, Moreira EF, Rollag MD. A novel human opsin in the inner retina. J. 
Neurosci. 2000, 20, 600e605. 
Qiu X, Kumbalasiri T, Carlson SM, Wong KY, Krishna V, Provencio I, Berson DM.Induction of photosensitivity by 
heterologous expression of melanopsin.Nature 2005, 433, 745e749. 
Ramachandran VS, Rogers-Ramachandran D. Synaesthesia in phantom limbs induced with mirrors. Proc Biol Sci 
1996,263:377–386. 
Rankin CH, Abrams T, Barry RJ, Bhatnagar S, Clayton DF, Colombo J, Coppola G, Geyer MA, Glanzman DL, 
Marsland S, Mc Sweeney FK, Wilson DA, Wu CF, Thompson RF. Habituation revisited: an updated and revised 
description of the behavioral characteristics of habituation. Neurobiol Learn Mem. 2009 Sep;92(2):135-8. doi: 
10.1016/j.nlm.2008.09.012. Epub 2008 Nov 6. 
Recober A, Goadsby PJ. Calcitonin gene-related peptide: A molecular link between obesity and migraine? Drug 
News Perspect. 2010 Mar;23(2):112-7. doi: 10.1358/dnp.2010.23.2.1475909. 
Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF. Role of calcitonin gene-related peptide in 
light-aversive behavior: implications for migraine. J. Neurosci. 2009, 29, 8798e8804. 
Richey ET, Kooi KA, Waggoner RW. Visually evoked responses in migraine.Electroenceph Clin Neurophysiol 
1966; 21:23–27. 
Riley JL, Robinson ME, Wise EA, Myers CD, Fillingim RB. Sex differences in the perception of noxious 
experimental stimuli: a meta-analysis. Pain 1998, 74, 181–187. 
Roecklein KA, Rohan KJ, Duncan WC, Rollag MD, Rosenthal NE, Lipsky RH, Provencio I. A missense variant 
(P10L) of the melanopsin (OPN4) gene in seasonal affective disorder.J Affect Disord. 2009;114:279-285. 
Rothgangel AS, Braun SM, Beurskens AJ, Seitz RJ, Wade DT. The clinical  aspects of mirror therapy in 
rehabilitation: a systematic review of the literature. Int J Rehabil Res 2001, 34:  1-13. 
Rubino E, Ferrero M, Rainero I, Binello E, Vaula G, Pinessi L. Association of the C677T polymorphism in the 
MTHFR gene with migraine: a meta-analysis. Cephalalgia 2009, 29, 818-825. 
Rupp A, Schmidt TM, Chew K, Yungher B, Park KK, Hattar S. ipRGCs mediate ispilateral pupil constriction. In: 
Poster Presentation at TheAssociation for Research in Vision and Ophthalmology Annual Meeting. 2013, Seattle, 
WA. 
181 
 
Sanchez del Rio M, Bakker D, Wu O, Agosti R, Mitsikostas DD, Ostergaard L, Wells WA, Rosen BR, Sorensen G, 
Moskowitz MA, Cutrer FM. Perfusion weighted imaging during migraine: spontaneous visual aura and headache. 
Cephalalgia. 1999 Oct;19(8):701-7. 
Sand T, Vingen JV. Visual, long-latency auditory and brainstem auditory evoked potentials in migraine: relation 
to pattern size, stimulus intensity, sound and light discomfort thresholds and pre-attack state. Cephalalgia 2000, 
20:804–820. 
Sándor PS, Áfra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with β-blockers and riboflavin: 
different effects on the intensity dependence of auditory evoked cortical potentials. Headache 2000; 40:30–5. 
Sándor PS, Afra J, Proietti-Cecchini A, Albert A, Schoenen J. Familial influences on cortical evoked potentials in 
migraine. Neuroreport 1999; 10:1235–8. 
Sandrini G, Tassorelli C, Cecchini AP, Alfonsi E, Nappi G. Effects of nimesulide on nitric oxide-induced 
hyperalgesia in humans – a neurophysiological study. Eur J Pharmacol 2002,450(3): 259–262. 
Schlake HP, Grotemeyer KH, Hofferberth B, Husstedt IW, Wiesner S. Brainstem auditory evoked potentials in 
migraine – evidence of increased side differences during the pain-free interval. Headache 1990,30:129–132. 
Schlote T, Kadner G, Freudenthaler N. Marked reduction and distinct patterns of eye blinking in patients with 
moderately dry eyes during video display terminal use. Graefes Arch Clin Exp Ophthalmol.2004; 242:306–312. 
[PubMed: 14747951] 
Schoenen J, Ambrosini A, Sandor PS, Maertens de Noordhout A. Evoked potentials and transcranial magnetic 
stimulation in migraine:published data and viewpoint on their pathophysiologic significance. Clinical 
Neurophysiology 2003, 114: 955-972. 
Schoenen J, D’Ostilio K, Cosseddu A, Nonis R, Sava SL, Magis D. Transcranial direct current stimulation and 
transcutaneous occipital nerve stimulation in chronic migraine: a pilot-comparison of therapeutic and 
electrophysiological effects. Submetted to the American Academy of Neurology Congress, 2016. 
Schoenen J, Gianni F, Schretlen L, Sobocki P. Cost estimates of brain disorders in Belgium. Acta Neurol Belg. 2006 
Dec;106(4):208-14.  
Schoenen J, Jamart B, Delwaide PJ. Electroencephalographic mapping in migraine during the critical and 
intercritical periods. Rev Electroencephalogr Neurophysiol Clin 1987;17:289-299. 
Schoenen J, Maertens A, Timsit-Berthier, Timsit M. Contingent negative variation (CNV) as a diagnostic and 
physiopathologic tool in headache patients. In: Rose FC, editor. Migraine. Clinical and research advances. Basel: 
Karger, 1985a. p. 17–25. 
Schoenen J, Timsit-Berthier M. Contingent negative variation: methods and potential interest in headache. 
Cephalalgia 1993;13:28–32. 
Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gérard P, Magis D. Migraine prevention 
with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology, 2013. 80(8): p. 697-704. 
Schoenen J, Wang W, Albert A, Delwaide PJ. Potentiation instead of habituation characterizes visual evoked 
potentials in migraine patients between attacks. Eur J Neurol 1995; 2:115–22. 
Schoenen J. Pathogenesis of migraine: the biobehavioural and hypoxia theories reconciled. Acta Neurol Belg. 
1994;94(2):79-86.  
182 
 
Semo M, Gias C, Ahmado A, Vugler A. A role for the ciliary marginal zone in the melanopsin-dependent intrinsic 
pupillary light reflex.Exp. Eye Res. 2014,119, 8e18. 
Shibata K, Osawa M, Iwata M. Simultaneous recording of pattern reversal electroretinograms and visual evoked 
potentials in migraine. Cephalalgia 1997; 177: 42–7. 
Shields KG, Goadsby PJ. Propranolol modulates Trigeminovascular responses in thalamic ventroposteromedial 
nucleus: a role in migraine? Brain 2005;128:86–97. 
Shinal R, Fillingim R. Overview of orofacial pain: epidemiology and gender differences in orofacial pain. Dental 
Clinics of North America 2007, 51, 1–18. 
Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002,22 (7): 491-512. 
Silberstein SD, Goadsby PJ, Lipton RB. Management of migraine: an algorithmic approach. Neurology 2000, 55 (9 
Suppl 2): S46-52. 
Siniatchkin M, Andrasik F, Kropp P, Niederberger U, Strenge H, Averkina N et al. Central mechanisms of 
controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Cephalalgia 2007; 27:1024–32. 
Siniatchkin M, Averkina N, Andrasik F, Stephani U, Gerber WD. Neurophysiological reactivity before a migraine 
attack. Neurosci Lett 2006; 400:121–4. 
Siniatchkin M, Kirsch E, Kropp P, Stephani U, Gerber WD. Slow cortical potentials in migraine families. 
Cephalalgia 2000;20:881–892. 
Siniatchkin M, Kröner-Herwig B, Kocabiyik E, Rothenberger A. Intracortical inhibition and facilitation in 
migraine--a transcranial magnetic stimulation study. Headache. 2007 Mar;47(3):364-70. 
Siniatchkin M, Kropp P, Gerber WD. Contingent negative variation in subjects at risk for migraine without aura. 
Pain 2001;94:159–167. 
Smith MJ, Adams LF, Schmidt PJ, Rubinow DR, Wassermann EM.Effects of ovarian hormones on human cortical 
excitability. Ann Neurol 2002;51:599-603. 
Smith MJ, Keel JC, Greenberg BD, Adam LF, Schmidt PJ, Rubinow DA, Wassermann E. Menstrual cycle effects on 
cortical excitability. Neurology 1999;53:2069-2072. 
Solomon S and KM Guglielmo.Treatment of headache by transcutaneous electrical stimulation.Headache, 1985. 
25(1): p. 12-5. 
Stevens R, Livermore A. Eyeblinking and rapid eye movement: Pulsed photic stimulation of the brain. Exp Neurol 
1978,60: 541–556. 
Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 
1996,16, 231-238. 
Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010 
Aug;11(4):289-99. doi: 10.1007/s10194-010-0217-0. Epub 2010 May 16. 
Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. 
Nature 1996;384:560–3. 
183 
 
Streel S, Donneau AF, Hoge A, Albert A, Schoenen J, Guillaume M. One-year prevalence of migraine using a 
validated extended French version of the ID Migraine™: A Belgian population-based study. Rev Neurol (Paris). 
2015 Oct;171(10):707-14. doi: 10.1016/j.neurol.2015.04.009. Epub 2015 Aug 1. 
Tada H, Omori Y, Hirokawa K, Ohira H, Tomonaga M. Eye-blink behaviors in 71 species of primates. PLoS One. 
2013 May 31;8(5):e66018. doi: 10.1371/journal.pone.0066018. Print 2013. 
Tagliati M, Sabbadini M, Bernardi G, Silvestrini M. Multichannel visual evoked potentials in migraine. 
Electroenceph clin Neurophysiol 1995; 96:1–5. 
Takahashi T, Tsukahara Y, Kaneda S. Influence of pattern and red color on the photoconvulsive response and the 
photic driving. Tohoku J Exp Med. 1981 Feb;133(2):129-37. 
Takahashi T, Tsukahara Y. Influence of color on the photoconvulsive  response.  Electroencephalogr. Clin 
Neurophysiol. 1976;41:124-136. 
Tepe N, Filiz A, Dilekoz E, Akcali D, Sara Y, Charles A, Bolay H. The thalamic reticular nucleus is activated by 
cortical spreading depression in freely moving rats: prevention by acute valproate administration. Eur J Neurosci. 
2015 Jan;41(1):120-8. doi: 10.1111/ejn.12753. Epub 2014 Oct 18. 
Thieme H, Mehrholz J, Pohl M, Behrens J, Dohle C. Mirror therapy for improving motor function after stroke. 
Stroke 2013. Jan;44(1):e1-2. 
Thompson RF, Spencer WA. Habituation: a model phenomenon for the study of neuronal substrates of behaviour. 
Psycholog Rev 1966; 73:16–43. 
Trobe JD. Photophobia in anterior visual pathway disease.J Neuroophthalmol.2002; 22:1–2. 
Tsubota K, Hata S, Okusawa Y, Egami F, Ohtsuki T, Nakamori K. Quantitative videographic analysis of blinking 
in normal subjects and patients with dry eye. Arch Ophthalmol.1996; 114:715–720. [PubMed: 8639084] 
Tsubota K, Nakamori K. Effects of ocular surface area and blink rate on tear dynamics. Arch Ophthalmol.1995; 
113:155–158. [PubMed: 7864746] 
Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG, Alperovitch A. Association between migraine and 
endothelin type A receptor (ETA-231 A/G) gene polymorphism. Neurology 2001, 56, 1273-1277. 
Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by 
nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. 
Neurosci Lett 1985;62:131-136. 
Valeriani M, de Tommaso M, Restuccia D, Le Pera D, Guido M, Iannetti GD et al. Reduced habituation to 
experimental pain in migraine patients: a CO(2) laser evoked potential study. Pain 2003; 105:57–64. 
Valeriani M, Le Pera D, Niddam D, Chen AC, Arendt-Nielsen L. Dipolar modelling of the scalp evoked potentials 
to painful contact heat stimulation of the human skin. Neurosci Lett. 2002 Jan 18;318(1):44-8. 
Valeriani M, Rinalduzzi S, Vigevano F. Multilevel somatosensory system disinhibition in children with migraine. 
Pain 2005; 118: 137-144. 
Valls-Sole J, Tolosa ES, Ribera G. Neurophysiological observations on the effects of botulinum toxin treatment in 
patients with dystonic blepharospasm. J Neurol Neurosurg Psychiatry 1991;54:310–13. 
van der Kamp W, MaassenVanDenBrink A, Ferrari MD, van Dijk JG. Interictal cortical excitability to magnetic 
stimulation in familial hemiplegic migraine. Neurology 1997;48:1462-1464. 
184 
 
Vanagaite J, Pareja JA, Støren O, White LR, Sand T, Stovner LJ. Light-induced discomfort and pain in migraine. 
Cephalalgia 1997,17(7): 733–741. 
Veltman JA, Gaillard AW. Physiological workload reactions to increasing levels of task difficulty. Ergonomics, 
1998, 41: 656–669. 
Viganò A, D'Elia TS, Sava SL, Auvé M, De Pasqua V, Colosimo A, Di Piero V, Schoenen J, Magis D. Transcranial 
Direct Current Stimulation (tDCS) of the visual cortex: a proof-of-concept study based on interictal 
electrophysiological abnormalities in migraine. J Headache Pain. 2013 Mar 11;14:23. doi: 10.1186/1129-2377-14-23. 
Vigil JM, Strenth CR, Mueller AA, DiDomenico J, Beltran DG, Coulombe P, Smith JE. The Curse of Curves: Sex 
Differences in the Associations Between Body Shape and Pain Expression. Hum Nat. 2015 Jun;26(2):235-54. doi: 
10.1007/s12110-015-9232-9. 
Volkmann FC, Riggs LA, Moore RK.A comparison of saccades and blinks in suppression of vision.Investigative 
Ophthalmology and Visual Science, 18(April Suppl.):140, 1979. 
Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials is pronounced in 
migraine: an indication of cortical potentiation and low serotonergic neurotransmission? Neurology 1996; 46:1404–
9. 
Wang W, Wang G P, Ding XL, Wang YH. Personality and response to repeated visual stimulation in migraine and 
tension-type headaches. Cephalalgia 1999, 19, 718–724. 
Weeks SR, Anderson-Barnes VC, Tsao JW. (2010) Phantom limb pain: theories and therapies. Neurologist 16: 277-
86. 
Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC. Brain stem activation 
in spontaneous human migraine attacks. Nat Med 1995; 1: 658–660. 
Welch KM, Cao Y, Aurora S, Wiggins G, Vikingstad EM. MRI of the occipital cortex, red nucleus, and substantia 
nigra during visual aura of migraine.Neurology. 1998 Nov;51(5):1465-9. 
Welch KM, Nagesh V, Aurora S, et al. Periaqueductal grey matter dysfunction in migraine: cause or the burden of 
illness? Headache 2001;41:629–37. 
Welty TE, Horner TG.Pathophysiology and treatment of subarachnoid hemorrhage.Clin Pharm. 1990; 9:35–39. 
Wolff HG. Headache and other head pain. 2nd edition. New York: Oxford University Press; 1963. 
Woods RP, Iacoboni M, Mazziotta JC. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous 
migraine headache. N Engl J Med. 1994 Dec 22;331(25):1689-92. 
Wu T, Sommer M, Tergau F, Paulus W. Lasting influence of repetitive transcranial magnetic stimulation on 
intracortical excitability in human subjects. Neurosci Lett 2000, 287(1): 37–40. 
Yao G, Yu T, Han X, Mao X, Li B. Therapeutic effects and safety of olcegepant and telcagepant for migraine: A 
meta-analysis. Neural Regen Res. 2013 Apr 5;8(10):938-47. doi: 10.3969/j.issn.1673-5374.2013.10.009. 
Yucesan C, Sener O, Mutluer N. Influence of disease duration on visual evoked potentials in migraineurs. 
Headache 2000;40:384–388. 
Zagami AS, Lambert GA. Stimulation of cranial vessels excites nociceptive neurones in several thalamic nuclei of 
the cat. Exp Brain Res 1990;81:552–566. 
185 
 
Zaidi FH, Hull JT, Peirson SN, Wulff K, Aeschbach D, Gooley JJ, Brainard GC, Gregory-Evans K, Rizzo JF 3rd, 
Czeisler CA, Foster RG, Moseley MJ, Lockley SW. Short-wavelength light sensitivity of circadian, pupillary, and 
visual awareness in humans lacking an outer retina. Curr Biol. 2007 Dec 18;17(24):2122-8. 
Zaman ML, Doughty MJ, Button NF. The exposed ocular surface and its relationship to spontaneous eyeblink rate 
in elderly caucasians. Exp Eye Res. 1998; 67:681–686. [PubMed: 9990332] 
Zerbe GO. Randomization analysis of the completely randomized design extended to growth and response 
curves. JASA. 1979;74:215-221. 
 
186 
 
ANNEXES 
 
- Curriculum Vitae  
 
- Sava SL, de Pasqua V, Magis D, Schoenen J. Effects of visual cortex activation on the nociceptive 
blink reflex in healthy subjects. PLoS One. 2014 Jun 17;9(6):e100198. doi: 
10.1371/journal.pone.0100198. eCollection 2014. 
 
 
- Magis D, Viganó A, Sava S, d'Elia TS, Schoenen J, Coppola G. Pearls and pitfalls: 
electrophysiology for primary headaches. Cephalalgia. 2013 Jun;33(8):526-39. doi: 
10.1177/0333102413477739. 
 
- Magis D, Sava S, d'Elia TS, Baschi R, Schoenen J. Safety and patients' satisfaction of 
transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache 
treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013 
Dec 1;14:95. doi: 10.1186/1129-2377-14-95. 
 
 
- Viganò A, D'Elia TS, Sava SL, Auvé M, De Pasqua V, Colosimo A, Di Piero V, Schoenen J, Magis 
D. Transcranial Direct Current Stimulation (tDCS) of the visual cortex: a proof-of-concept study 
based on interictal electrophysiological abnormalities in migraine. J Headache Pain. 2013 Mar 
11;14:23. doi: 10.1186/1129-2377-14-23. 
 
- Piquet M, Balestra C, Sava SL, Schoenen J. Supraorbital transcutaneous neurostimulation has 
sedative effects in healthy subjects. BMC Neurol. 2011 Oct 28;11:135. doi: 10.1186/1471-2377-11-
135. 
 
 
- Coppola G, Currà A, Di Lorenzo C, Parisi V, Gorini M, Sava SL, Schoenen J, Pierelli F. Abnormal 
cortical responses to somatosensory stimulation in medication-overuse headache. BMC Neurol. 
2010 Dec 30;10:126. doi: 10.1186/1471-2377-10-126 
 
187 
 
- Coppola G, Currà A, Sava SL, Alibardi A, Parisi V, Pierelli F, Schoenen J. Changes in visual-
evoked potential habituation induced by hyperventilation in migraine. J Headache Pain. 2010 
Dec;11(6):497-503. doi: 10.1007/s10194-010-0239-7. Epub 2010 Jul 13. 
 
1 
 
Curriculum Vitae 
 
 
Personal information  
First names / Surname Simona Liliana / Sava 
Private Address Avenue de L’Observatoire 154, boite 31, 4000 Liège, Belgium 
Professional Address CHR-Citadelle, Bd. 12ème de ligne 1, 4000 Liège, Belgium 
Telephone 
 
+32 498 75 58 06  
E-mail simonaliliana.sava@gmail.com  
Nationality Italian, Rumanian 
Date of birth 22.11.1984 
Gender 
Civil Status 
Children 
F 
Divorced  
One daughter 
 
 
Occupational field Medical Doctor, PhD Student, Resident in Neurology 
 
 
Work experience  
Dates 01.08.2010 – 31.09.2011 
Occupation Clinical Researcher, Neurology Resident 
Name and address of 
employer 
Prof. Jean Schoenen, Headache Research Unit. Department of Neurology & GIGA - Neurosciences. 
Liège University, CHU-Sart Tilman, 4000 LIEGE. Belgium 
Dates 01.10.2011 – (30.09.2016) 
Occupation Medical Doctor, Resident in Neurology and PhD Student 
Name and address of 
employer 
CHU-Sart Tilman, CHR-Citadelle, University of Liège (Ulg), 4000 Liège, Belgium 
 
 
 
 
Sector Neurology 
 
 
 
Education and training      
Dates 23.07.2010 
Title of qualification awarded Diploma in Medicine and Surgery to the University of Rome “Sapienza”, Italy, with the thesis “Study 
of the recovery cycle of the somatosensory evoked potentials in migraine patients”, final degree 
110/110 cum laude. 
 
 
 
 
2 
 
Languages Rumanian: Speaking: Mother Tongue; Listening: Mother Tongue; Writing: Mother Tongue; Reading: 
Mother Tongue. 
 
Italian: Speaking: As a native/perfect; Listening: As a native/perfect; Writing: As a native/perfect; 
Reading: As a native/perfect. 
 
French: Speaking: Very Good/fluent; Listening: Very Good; Writing: Very good; Reading: Very Good 
 
English: Speaking: Very Good/fluent; Listening: Very Good; Writing: Very good; Reading: Very 
Good 
 
 
 
 
Awards 1. Proclamation by the President of the Italian Republic C.A. Ciampi as “Alfiere” for the best 
academic results in the all region of Lazio, and 1 of 20 best students in Italy (2004) 
2. Award for the best academic results by the University of Rome “Sapienza”, Italy (2004 till 
2010) 
3. Award for the thesis abroad by the University of Rome “Sapienza”, Italy (2009)  
4. Distinction for “the younger researcher presenting a poster” by the SINC, Italy (2010) 
5. Travel Grant by the Belgian Neurological Society (2011) 
6. Travel Grant by the Belgian Neurological Society (2012) 
7. Travel Grant by the Belgian Neurological Society (2013) 
8. Travel Grant by the International Headache Society for the participation to iHead Meeting 
(2014) 
9. Price for the research project CIRF, Citadelle Hospital (2014) 
10. Travel Grant by the International Headache Society (2015) 
 
 
 
 
Congress active 
participation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. I regional congress SISC Lazio-Molise (08.11.2008) – Ospedale pediatrico Bambino Gesù, 
Roma, Italy. 
 
2.  Management of the patient with migraine (15.11.2008) – ICOT, Latina, Italy. 
 
3. Stem cell and Tissue engineerings symposium (16.03.2009) – Latina, Italy. 
 
4. Parkinson disease and demence (17.04.2010) – Orvieto, Italy 
 
5. National congress of the Italian Society of the Clinical Neurophysiology – SINC (13-
15.05.2010), Siena, Italy – distinction « the younger researcher presenting a poster »  
 
6. Belgian Brain Congress (BBC) (17-18.09.2010), Bruxelles, Belgium 
 
7. European Headache and Migraine Trust International Congress (EHMTIC), Nice, France 
(28-31.10.2010) 
 
8. 15th Congress of the International Headache Society (IHS), Berlin, Germany (23-
26.06.2011) 
 
9. 7th Congress of the European Federation of IASP Chapters (EFIC), Hamburg, Germany 
(21-24.09.2011) 
 
10. 11th Congress of the French Society of the study and treatment of pain (SFETD), Paris, 
France (16-19.11.2011) 
 
11. International Headache Academy (IHA), Copenhagen, Denmark (18-20.05.2012) 
 
12. Belgian Brain Congress (BBC), Liège, Belgium (27.09.2012) 
 
13. XXI World Congress of Neurology (WCN), Vienna, Austria (21-26.09.2013) 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publications in press/                   
Submitted articles 
 
 
14. Joint Congress of European Neurology (EFNS-ENS), Istanbul, Turkey (31.05-03.06.2014) 
 
15.  Belgian Brain Congress (BBC), Ghent, Belgium (04.10.2014) 
 
16. iHead Meeting (International Headache Society), Leiden, the Netherlands (31.10-
02.11.2014) 
 
17. 17th Congress of the International Headache Society (IHS), Valencia, Spain (14-
17.05.2015) 
 
18. Masterclass, Leading Excellence for Stroke Prevention in Non-Valvular Atrial Fibrillation, 
Rome, Italy (16-17.10.2015) 
 
19. InterUniversity Certificate Postgraduate studies in algology Course Week 2015, Spa, 
Belgium (25-30.10.2015) 
 
 
 
 
1. Coppola G, Currà A, Sava SL, Alibardi A, Parisi V, Pierelli F, Schoenen J. Changes in 
visual-evoked potential habituation induced by hyperventilation in migraine. J Headache 
Pain. 2010 Dec;11(6):497-503. 
 
2. Coppola G, Currà A, Di Lorenzo C, Parisi V, Gorini M, Sava SL, Schoenen J, Pierelli F. 
Abnormal cortical responses to somatosensory stimulation in medication-overuse 
headache. BMC Neurol. 2010 Dec 30;10:126. 
 
3. Piquet M, Balestra C, Sava SL, Schoenen JE. Supraorbital transcutaneous 
neurostimulation has sedative effects in healthy subjects. BMC Neurol. 2011 Oct 
28;11(1):135. 
 
4. Viganò A, D'Elia TS, Sava SL, Auvé M, De Pasqua V, Colosimo A, Di Piero V, Schoenen 
J, Magis D. Transcranial Direct Current Stimulation (tDCS) of the visual cortex: a proof-of-
concept study based on interictal electrophysiological abnormalities in migraine. J 
Headache Pain. 2013 Mar 11;14(1):23 
 
5. Magis D, Vigano A, Sava SL, Sasso d'Elia T, Schoenen J and Coppola G. Pearls and 
pitfalls: electrophysiology for primary headaches. Cephalalgia 2013 33(8):526-39. 
 
6. Magis D, Sava SL, d'Elia TS, Baschi R, Schoenen J. Safety and patients' satisfaction of 
transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache 
treatment: a survey of 2,313 headache sufferers in the general population. J Headache 
Pain. 2013 Dec 1;14:95 
 
7. Sava SL, de Pasqua V, Magis D, Schoenen J. Effects of visual cortex activation on the 
nociceptive blink reflex in healthy subjects. PLoS One. 2014 Jun 17;9(6) 
 
 
 
 
 
 
 
 
 
Abstracts 1. Coppola G, Sava SL, Porretta E, Alibardi A, Gorini M, Parisi V, Currà A, Pierelli F. Ciclo di 
recupero dei potenziali evocati somatosensoriali in pazienti affetti da emicrania senz’aura. 
Clinical Neurophysiology (SINC, 2010). 
 
2. Coppola G, Porretta E, Sava SL, Gorini M, Alibardi A, Parisi V, Currà A, Pierelli F. 
4 
 
Alterazione dello sviluppo temporale dell’inibizione laterale nel sistema visivo in pazienti 
affetti da emicrania senz’aura. Clinical Neurophysiology (SINC, 2010). 
 
3. Sava SL, Coppola G, De Pasqua V, Pierelli F, Schoenen J. La stimolazione magnetica 
transcranica ripetitiva sulla corteccia visiva modula il sistema nocicettivo trigeminale. 
Clinical Neurophysiology (SINC, 2010). 
 
4. Coppola G, Currà A, Gorini M, Davassi C, Sava SL, Pierelli F. Cortical silent period 
duration in medication overuse headache changes according to the drug overused. 
Clinical Neurophysiology (SINC, 2010). 
 
5. Sava SL, Coppola G, De Pasqua V, Pierelli F, Schoenen J. The visual system influences 
the nociceptive trigeminal system: possible mechanism underlying photophobia? The 
Journal of Headache and Pain (SISC, 2010) 
 
6. Coppola G, Di Lorenzo C, Sava SL, Gorini M, de Micco M, Davassi C, Pierelli F. 
Trigeminal activity in episodic cluster headache. The Journal of Headache and Pain 
(SISC, 2010) 
 
7. Currà A, Coppola G, Di Lorenzo C, Gorini M, Davassi C, de Micco M, Sava SL, Pierelli F. 
Cortical silent period duration in medication oveuse headache changes according to the 
drug overused. The Journal of Headache and Pain (SISC, 2010) 
 
8. Coppola G, Currà A, Sava SL, Di Lorenzo C, Gorini M, de Micco M, Davassi C, Parisi V, 
Pierelli F. Effects of 3 minutes forced hyperventilation on viaul evoked potential habituation 
in migraine. The Journal of Headache and Pain (SISC, 2010) 
 
9. Coppola G, Sava SL, De Pasqua V, Pierelli F, Schoenen J. Trigeminal nociceptive 
pathway is modulated by repetitive transcranial magnetic stimulation over the visual 
cortex. Neurological Sciences, (SIN, 2010). 
 
10. Coppola G, Sava SL, Di Lorenzo C, Gorini M, de Micco M, Davassi C, Parisi V, Currà A, 
Pierelli F. Impairement of temporal development of the visual system short-range lateral 
inhibition in migraine without aura patients. Neurological Sciences, (SIN, 2010). 
 
11. Currà A, Coppola G, Sava SL, Di Lorenzo C, Gorini M, Davassi C, de Micco M, Parivi V, 
Pierelli F. Effects of experimentally induced hyperventilation on visual evoked potential 
habituation in migraine. Neurological Sciences, (SIN, 2010). 
 
12. Sava SL, Coppola G, De Pasqua V, Pierelli F, Schoenen J. Repetitive transcranial 
magnetic stimulation over the visual cortex modulated trigeminjal nociceptive pathways.  
The Journal of Headache and Pain (EHMTIC, 2010). 
 
13. Coppola G, Sava SL, Di Lorenzo C, Gorini M, de Micco M, Davassi C, Parisi V, Currà A, 
Pierelli F. Impairement of temporal development of the visual system short-range lateral 
inhibition in migraine without aura patients. The Journal of Headache and Pain (EHMTIC, 
2010). 
 
14. Coppola G, Currà A, Di Lorenzo C, Gorini M, Davassi C, de Micco M, Sava SL, Pierelli F. 
Cortical silent period duration in medication oveuse headache changes according to the 
drug overused. The Journal of Headache and Pain (EHMTIC, 2010). 
 
15. Sava SL, Coppola G, De Pasqua V, Pierelli F, Schoenen J. Repetitive TMS of the visual 
cortex modulates the nociceptive blink reflex in healthy volunteers. Acta Neurologica 
Belgica (BBC, 2010). 
 
16. Sava SL, Vigano A, De Pasqua V, Magis D, Schoenen J. No effect of a 1 hour sub-
occipital transcutaneous stimulation on the nociceptive blink reflex in healthy subjects. 
Cephalalgia (IHS, 2011). 
 
17. Sava SL, Coppola G,Vigano A, De Pasqua V, Magis D, Schoenen J. Repetitive 
transcranial magnetic stimulation modulates the nociceptive-specific blink reflex in healthy 
5 
 
subjects but not in migraineurs. Cephalalgia (IHS, 2011). 
 
18. Sava SL, de Pasqua V, Magis D, Schoenen J. Changes in Visual Evoked Potentials 
induced by supraorbital electrical stimulation or capsaicin application in healthy volunteers. 
European Journal of Pain (EFIC, 2011).  
 
19. Sava SL, de Pasqua V, Magis D, Schoenen J. Can vision influence trigeminal nociception: 
a study of the effect of visual cortex activation on the nociceptive blink reflex in healthy 
subjects and migraine patients. Acta Neurologica Belgica (BBC, 2012). 
 
20. Sasso d’Elia T, Vigano A, Sava SL, Auvé M, Schoenen J and Magis D. Theta burst and 
quadripulse repetitive Transcranial Magnetic Stimulation (rTMS) may have therapeutic 
potentials in migraine prevention: a proof-of-concept study in healthy volunteers and a 
pilot-trial in migraine patients. Acta Neurologica Belgica (BBC, 2012). 
 
21. Sasso d’Elia T, Vigano A, Sava SL, Auvé M, Schoenen J, Magis D. Anodal transcranial 
direct current stimulation over the visual cortex as a preventive treatment of migraine: a 
proof-of-concept study. Acta Neurologica Belgica (BBC, 2012). 
 
22. Vigano A, Magis D, Sava SL, De Pasqua V, Auvé M, Giuliani A, Colosimo A, Di Piero V, 
Schoenen J. Anodal transcranial direct current stimulation of the visual cortex for migraine 
prevention: a proof-of-concept study. Journal of Headache and Pain 2012, Suppl, p144: 
P194. 
 
23. Sava SL, de Pasqua V, Magis D, Schoenen J. Does trigeminal nociception influence the 
visual cortex: a study of the effects of supraorbital electro- or chemo-nociceptive 
stimulation. Journal of Neurological Sciences (WCN, 2013). 
 
24. Sava SL, Roberta B, de Pasqua V, Magis D, Schoenen J. Does trigeminal nociception 
influence the visual cortex: a study of the effects of supraorbital electro- or chemo-
nociceptive stimulation. Journal of Neurological Sciences (WCN, 2013). 
 
25. Magis D, Rigaux P, Mignolet JY, Sava SL, Sasso d’Elia T, Schoenen J. Safety and 
efficiency of supraorbital transcutaneous neurostimulation with the Cefaly® device for 
headache treatment: outcome of a prospective registry on 2313 patients. Cephalalgia 
(IHS, 2013). 
 
26. Fataki M, Sasso d’Elia T, De Pasqua V, Sava SL, Magis D, Schoenen J. Thermosensitivity 
in migraine between attacks: a study of quantitative thermo-sensory testing and contact 
heat evoked potentials. Cephalalgia (IHS, 2013). 
 
27. Sasso d’Elia T, Fataki M, Sava SL, De Pasqua V, Schoenen J, Magis D. Effect of anodal 
transcranial direct current stimulation over the visual cortex on thermosensitivity. 
Cephalalgia (IHS, 2013). 
 
28. Sava SL, Baschi R, La Salvia V, de Pasqua V, Magis D, Schoenen J. Contact heat-
evoked potentials (CHEPs) in healthy subjects and patients with episodic or chronic 
migraine. European Journal of Neurology (EFNS-ENS, 2014). 
 
29. Sava SL, Baschi R, La Salvia V, de Pasqua V, Schoenen J, Magis D. Visually-induced 
facial analgesia effect on thermonociceptive cortical evoked responses in healthy subjects 
and migraine patients. Acta Neurologica Belgica (BBC, 2014). 
 
30. Sava SL, Baschi R, La Salvia V, de Pasqua V, Schoenen J, Magis D. Differences in 
contact heat-evoked potentials (CHEPs) between healthy subjects and patinets with 
episodic or chronic migraine. Acta Neurologica Belgica (BBC, 2014). 
 
31. Baschi R, Sava SL, La Salvia V, de Pasqua V, Schoenen J, Magis D. Transcranial direct 
current stimulation in chronic migraine: a pilot trial combining cathodal visual and anodal 
DLPFC stimulation. Acta Neurologica Belgica (BBC, 2014). 
 
32. Baschi R, Vecchio E, Sava SL, de Pasqua V, Schoenen J, Magis D. Neurophysiological 
6 
 
study of tDCS effects in healthy volunteers. Acta Neurologica Belgica (BBC, 2014). 
 
33. Sava SL, Baschi R, Coddeddu A, D’Ostilio K, de Pasqua V, Schoenen J, Magis D. 
Thermal pain threshold in migraine: comparaison between episodic or chronic migraine 
patients and healthy volunteers using QST. Cephalalgia (IHS, 2015). 
 
34. Sava SL, Baschi R, D’Ostilio K, de Pasqua V, Schoenen J, Magis D. Modulation of the 
nociceptive blink reflex by repetitive transcranial magnetic stimulation in healthy 
volunteers: comparison of visual or motor cortex stimulation. Cephalalgia (IHS, 2015). 
 
35. D’Ostilio K, Thibaut A, Laureys S, Cosseddu A, Sava SL, Schoenen J, Magis D. Cerebral 
FDG uptake changes after supraorbital transcutaneous electricl stimulation with the Cefaly 
device in patients with migraine. Cephalalgia (IHS, 2015) 
 
36. Magis D, D’Ostilio K, Cosseddu A, Nonis R, Sava SL, Schoenen J. Anodal trascranial 
direct current stimulation (tDCS) targeting the anterior cingulated gyrus for the treatment of 
chronic cluster headache: a proof of concept trial. Submitted to Neurology (AAN, 2016) 
 
37. Schoenen J, D’Ostilio K, Cosseddu A, Nonis R, Sava SL, Magis D. Trasncranial direct 
current stimulation and transutaneous occipital nerve stimulation in chronic migraine: a 
pilot-comparaison of therapeutic and electrophysiological effects. Submitted to Neurology 
(AAN, 2016) 
 
38. Schoenen J, D’Ostilio K, Nonis R, Sava SL, Magis D. Non-invasive vagus nerve 
stimulation with GammaCore in healthy subjects:is there electrophysiological evidence for 
activation of vagal afferents? Submitted to Neurology (AAN, 2016) 
 
 
 
 
Invited speaker 
and oral presentations 
1. SFETD, Paris, France (16-19.11.2011): “Interrelations between visual cortex and the 
nociceptif trigeminal system” 
 
2. WCN, Vienna, Austria, (21-26.09.2013): “Can vision influence trigeminal nociception: A 
study of the effect of visual cortex activation on the nociceptive blink reflex” 
 
3. EFNS-ENS Istanbul, Turkey (31.05-03.06.2014): "Visual induced analgesia in the face in 
healthy subjects and migraineurs" 
 
4. InterUniversity Certificate Postgraduate studies in algology Course Week 2015, two oral 
presentation: “Primary Headaches” and “Secondary Headaches”, Spa, Belgium (25-
30.10.2015) 
 
 
 
 
Book Chapter      1. “Tension type headache” - Wall & Melzack’s Textbook of Pain 6th edition, Philadelphia, 
USA. 
 
 
     
 
 
     
 
 
 
Effects of Visual Cortex Activation on the Nociceptive
Blink Reflex in Healthy Subjects
Simona L. Sava, Victor de Pasqua, Delphine Magis, Jean Schoenen*
Headache Research Unit, University Department of Neurology, Lie`ge University, Lie`ge, Belgium
Abstract
Bright light can cause excessive visual discomfort, referred to as photophobia. The precise mechanisms linking luminance to
the trigeminal nociceptive system supposed to mediate this discomfort are not known. To address this issue in healthy
human subjects we modulated differentially visual cortex activity by repetitive transcranial magnetic stimulation (rTMS) or
flash light stimulation, and studied the effect on supraorbital pain thresholds and the nociceptive-specific blink reflex (nBR).
Low frequency rTMS that inhibits the underlying cortex, significantly decreased pain thresholds, increased the 1st nBR block
ipsi- and contralaterally and potentiated habituation contralaterally. After high frequency or sham rTMS over the visual
cortex, and rMS over the right greater occipital nerve we found no significant change. By contrast, excitatory flash light
stimulation increased pain thresholds, decreased the 1st nBR block of ipsi- and contralaterally and increased habituation
contralaterally. Our data demonstrate in healthy subjects a functional relation between the visual cortex and the trigeminal
nociceptive system, as assessed by the nociceptive blink reflex. The results argue in favour of a top-down inhibitory pathway
from the visual areas to trigemino-cervical nociceptors. We postulate that in normal conditions this visuo-trigeminal
inhibitory pathway may avoid disturbance of vision by too frequent blinking and that hypoactivity of the visual cortex for
pathological reasons may promote headache and photophobia.
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Introduction
‘‘Photophobia’’ is the clinical term to indicate discomfort to
light. It is a common symptom of several neurological and
ophthalmological disorders: blepharospasm [1], corneal abrasion,
iritis [2], tumors compressing the anterior visual pathways [3],
trigeminal neuralgia [4] and, most characteristically, migraine [5].
The pathophysiology of photophobia remains poorly under-
stood.
Reciprocal relations between the visual system and centers
involved in trigeminal nociception have been documented in
animal studies. Acute exposure to bright light, for instance,
increases the number of Fos-like immunoreactive neurons in
superficial laminae of trigeminal subnucleus caudalis (Vc/C1) [6]
and parasympathetic outflow to the eye [7]. On the one hand, the
visual cortex is influenced by projections from the brainstem,
especially from dorsal raphe and nucleus raphe magnus [8,9]. On
the other hand, the visual cortex projects downward to brainstem
nuclei, including nucleus raphe magnus [10] where it exerts an
inhibitory effect [11] and to nucleus cuneiformis [12]. Interest-
ingly, nucleus cuneiformis is part of the descending pain control
system and was found hypoactive with fMRI in migraineurs
during thermo-nociceptive stimulation [13].
Recently, a novel retino-thalamo-cortical pathway was pro-
posed as a possible anatomo-functional substrate for exacerbation
of migraine headache by light. This concept is based on the finding
in rat of convergence of retinal afferents and trigeminovascular
nociceptive afferents in the posterior and lateral posterior thalamic
nuclei [14] whence dural-sensitive thalamic neurons project to
various sensory cortical areas including the visual cortex [15]. In
humans, MR DTI tractography has revealed a direct connection
between optic nerve fibers and the pulvinar [16].
Vanagaite et al. [17] have previously proposed convergence of
retinal and trigeminal nociceptive afferents as a possible explana-
tion for photophobia. Direct proof of their hypothesis in humans is
still missing, but in a photophobic subject due to corneal irritation
by contact lenses, Moulton et al. [13] found light-induced fMRI
activation of various structures of the trigeminal nociceptive
pathway including thalamus and anterior cingulate cortex. In
humans a reciprocal relation between visual input and trigeminal
nociception is suggested by the decreased tolerance to light after
painful stimulation of the ophthalmic branch of the trigeminal
nerve [18] and the reduction of trigeminal pain thresholds after
light stimulation in migraine patients [19,20]. In a PET study,
continuous light stimulation induced a stronger activation of the
visual cortex in migraine subjects than in healthy subjects, and,
when it was combined with a painful stimulation in the trigeminal
territory, the activation was markedly greater in migraine patients
[21].
The aim of our study was to testing healthy volunteers the
hypothesis that the visual cortex is able to modulate excitability in
the trigeminal nociceptive system, which would be relevant for
migraine-related photophobia and for migraine headache. As
indices for excitability in the trigeminal sensory system we have
chosen sensory and pain detection thresholds to supraorbital
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electrical stimuli as well as amplitude of the nociceptive-specific
blink reflex (nBR), a brain stem reflex modified by cortical and
subcortical afferents [22,23,24,25]. To modulate the visual cortex,
we used flash light stimulation or repetitive transcranial magnetic
stimulation (rTMS) at high or low stimulation frequency [26,27].
As controls, we applied sham rTMS over the visual cortex and
effective repetitive magnetic stimulation (rMS) over the greater
occipital nerve.
Materials and Methods
Ethics Statement
The project was reviewed and approved by the Ethic
Committee of the CHR Citadelle Hospital, Faculty of Medicine,
University of Lie`ge, Belgium, and was conform to the Declaration
of Helsinki. All participants gave written informed consent prior to
testing. 2 participants of 14 and 16 years old were included in our
study, a written informed consent was given by their parents.
Subjects
The experiments were performed on 63 healthy subjects (HS)
without a personal or family history of primary headache. We
applied rTMS on the visual cortex, at low and high frequency, in
21 subjects (12 females, 9 males, mean age 25.968.03) and flash
light stimulation in 22 subjects (12 females, 10 males, mean age
26.5969.29). As controls for rTMS, we used occipital sham
stimulation in 13 subjects (8 females, 5 males, mean age
25.38611.18) and effective stimulation over the greater occipital
nerve in 7 subjects (5 females, 2 males, mean age 29610.59). As
recommended for rTMS [28], all subjects were devoid of any
medical condition and had no personal or family history of
epilepsy. To avoid interference with changes of cortical excitability
due to hormonal variations, females were recorded during mid-
cycle. All subjects were naı¨ve for rTMS.
Nociceptive Blink Reflex
Subjects were seated relaxed in a comfortable armchair in an
illuminated room and were asked to leave their eyes open. The
nociceptive-specific blink reflex was elicited according to the
method described by others [29,30], before and immediately after
the rTMS session or flash light stimulation.
We used a custom-made planar concentric electrode (central
cathode: 1 mm D; insert: 8 mm; anode: 23 mm OD) placed on
the forehead close to the supraorbital foramen on the right side.
The concentric electrode has the advantage of exciting preferen-
tially Ad fibers [29,20,31,32], but at the same time C-fibers and
Ab fibers may also be recruited [33]. It seems that the recruitment
of Ab fibers may vary with regard to the site of stimulation,
stimulus repetition rate and duration as well as penetration of the
electrode in the skin [34].
Recording electrodes were placed below the orbit (active) over
the orbicularis oculi muscle and lateral to the orbit (reference) on
both sides. A ground electrode was placed on the root of the nose.
The signal was recorded with a sampling rate of 5000 Hz and
sweep duration of 150 ms (1401, Signal Averager, Cambridge
Electronic Design).
We first determined perception and pain thresholds by using
ascending and descending sequences of 0.2 mA intensity steps.
The mean number of assessments per participant was 1164 for
sensory thresholds and 1568 for pain thresholds. The electrical
stimuli consisted of monopolar square pulses with 0.2 ms duration.
To elicit the nBR, the final stimulus intensity was set at 1.5 times
the initial individual pain threshold. Interstimulus intervals varied
pseudo-randomly between 15 and 17 s. We recorded 16 rectified
EMG responses that were averaged off-line. As previously
described, the first response of each nBR recording session was
excluded from the signal analysis to avoid contamination with
startle responses [30,31,32]. The remaining 15 sweeps were
averaged in 3 sequential blocks of 5 responses. For each averaged
block, amplitude of the R2 reflex was expressed as its area under
the curve (AUC). To minimize R2 AUC variability due to inter-
individual threshold differences we used the ratio between the area
and the square of the stimulus intensity (AUC/i2) as an index of
nBR amplitude changes, as recommended by Sandrini et al. [35].
Habituation of the nBR R2 was defined as the percentage change
of the R2 area between the 1st and the 3rd block of averages.
Magnetic Stimulation
rTMS over the visual cortex. We used a Magstim Rapid
magnetic stimulator (Magstim Co. Ltd, Whitland, Dyfed, UK),
connected to a 267.0 cm figure-of-eight coil, with a maximal
stimulator output of 1.2 T. Using single pulses, we first identified
the phosphene threshold, defined as the lowest stimulation
intensity (expressed as a percentage of the maximal stimulator
output) able to evoke phosphenes in at least three out of five pulses
[36]. The coil was placed in a vertical position (its handle pointing
upward) on the inion-nasion line, with its inferior limit 1 cm above
the inion. Stimulation was applied initially at 30% of stimulator
output. The intensity of the stimulation was increased by 2% steps
until the subject reported phosphenes. Increasing and decreasing
the intensity in 1% steps then refined the threshold. In participants
who did not report phosphenes at the 100% intensity level, the
procedure was repeated with the coil placed 1 or 2 cm higher or
lower and, if necessary, to the right or to the left, before accepting
the absence of phosphenes. In this case, we placed the coil over the
left motor area and determined the motor threshold. In
accordance with recommended safety guidelines [28], stimulus
intensity was set to the phosphene threshold (PT) or to 110% of the
motor threshold, if no phosphenes were elicited.
We used two different stimulation frequencies in a randomised
order: 1 Hz (low frequency rTMS) and 10 Hz (high frequency
rTMS) with at least a 24 hour-interval between the 2 sessions, as
recommended by others for stimulation of the motor cortex [37].
1 Hz rTMS was applied in a single train without interruption for
15 minutes. 10 Hz rTMS was applied in 20 trains of 40 pulses
with inter-train intervals of 10 seconds. For both frequencies, a
same amount of 800 pulses was thus delivered.
Sham rTMS Over the Visual Cortex
In 13 subjects blinded to the stimulation protocol, 10 Hz rTMS
sham stimulation was delivered with the coil placed at a 90u angle
to the occipital region, with its anterior border pressed against the
scalp. The rTMS intensity was fixed at the intensity of the
phosphene threshold or 110% of the motor threshold. Twenty
trains of 40 pulses with an inter-train interval of 10 seconds were
delivered for 5 minutes. In the sham situation, there is an acoustic
perception of the stimulation, but no brain activation occurs [38].
We decided to enrol only subjects completely naive to rTMS in
order to ensure blinding.
rMS Over the Greater Occipital Nerve (GON)
We performed 1 Hz and 10 Hz rMS over the right GON in
7 HS by placing the figure-of-eight coil over the emergence of the
GON just beneath the superior nuchal line. We considered as
optimal the location where the sensation induced by the magnetic
pulse radiated to the parietal region of the head. The rMS
intensity was fixed at the phosphene threshold or 110% of the
motor threshold found during the previous session of effective
Vision and Pain
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rTMS, to make a comparable control protocol. The patterns of
1 Hz or 10 Hz stimulation were the same as those applied over the
visual cortex.
Flash Light Stimulation
We used the Microflash MF 9607178 stimulator (Micromed &
Co., Mogliano Veneto, IT) for flash light stimulation in 22
subjects. We placed the light stimulator in front of the subjects at a
15 cm distance, asking them to look at the stimulator during the
whole session. The stimulation was at 27.8 lux (0.63 cd). To
minimize attenuation of light perception due to continuous
stimulation without spatial or temporal contrast [39,40], flash
frequency was set at 8 Hz for 4 minutes in a quiet room with
dimmed light.
Data Processing and Statistical Analysis
STATISTICA for Windows version 8.0 (StatSoft, Inc. Tulsa,
OK, USA) was used for all statistical analyses. Wilcoxon’s test was
applied to compare the differences between pre- and post-
stimulation in perception and pain thresholds, AUC of the 1stnBR
block and slope of amplitude changes over 3 consecutive blocks of
nBR averagings, ipsilaterally and contralaterally. Mann-Whitney’s
test was used to compare the differences between stimulation
methods. Spearman’s test was used for the correlation analysis. All
results were considered significant at the 5% level (p,0.05).
Results
Transcranial magnetic stimulation – visual cortex. 12
participants out of 21 (57.14%, 3 males and 12 females) stimulated
with TMS over the visual cortex reported phosphenes. The
phosphene threshold (expressed as a percentage of the maximal
stimulator output) was 6664.7%. The motor threshold was
determined in the remaining 9 participants (42.86%, 7 males
and 2 females) and was 5868% of the maximal stimulator output.
We observed a significant relation between the presence of
phosphenes and female gender (p = 0.04). There was no correla-
tion between intensity of rTMS and the effect on the nBR. After
1 Hz rTMS over the visual cortex, the supraorbital pain threshold
was significantly decreased (p = 0.001) (Table 1), while the sensory
threshold remained unchanged.
Moreover, 1 Hz rTMS significantly increased amplitude of the
1st nBR block expressed as AUC/i2 both ipsi- and contralaterally
to the supraorbital stimulation (p = 0.024 and p = 0.036 respec-
tively) (Table 1, Fig. 1). By contrast, habituation was significantly
potentiated contralaterally to the stimulated side (p = 0.0002)
(Fig. 2).
We found no significant variation of sensation or pain
thresholds, nBR amplitude and habituation after the 10 Hz rTMS
session (Fig. 2) or after sham rTMS.
Magnetic stimulation – right GON. There was no signif-
icant change of sensory thresholds, nBR amplitude or habituation
after stimulating the right GON, neither for 1 Hz rMS, nor for
10 Hz rMS (Table 1).
Photic stimulation. Figure 3 shows an illustrative recording
of the nBR responses before and after flash light stimulation. The
latter increased pain threshold (p = 0.008) (Table 1), decreased
AUC/i2 of the 1stnBR block (p = 0.004 ipsilateral; p = 0.001
contralateral) and increased habituation contralaterally
(p = 0.002) (Fig. 1 and Fig. 2). Although both 10 Hz rTMS and
flash light stimulation are known to activate the visual cortex, the
effect on the nBR was significantly more pronounced after flash
stimulation than after excitatory rTMS. This was the case in
particular for ipsilateral (p = 0.002) and contralateral (p = 0.027) 1st
nBR blocks and even more so for increase in habituation of
ipsilateral (p = 0.00008) and contralateral responses (p = 0.00000)
(Fig. 2).
Discussion
Our data add to the existent literature experimental evidence in
humans for a functional connection between the visual cortex and
2ndorder nociceptors in spinal trigeminal nucleus.
As an objective marker of excitability in the trigeminal
nociceptive system, we have chosen the nociceptive specific blink
reflex (nBR). Ophthalmic nerve afferents, mainly Ad fibers,
mediate the R2 response and reach via the ponto-medullary
descending spinal trigeminal tract wide dynamic range 2nd order
nociceptors in caudal spinal trigeminal nucleus whence impulses
ascend to the facial nuclei in the pons via a bilateral trigemino-
facial pathway located in the lateral tegmental field [22,23,29,30].
We have found that sensation and pain thresholds of the
supraorbital electrical stimulus as well as area under the curve
(AUC) and habituation of the nBR are modulated differentially by
excitatory or inhibitory repetitive transcranial magnetic stimula-
tions (rTMS) over the visual cortex and by flash light stimulation.
As controls for visual cortex rTMS, we used sham rTMS and
repetitive magnetic stimulation (rMS) over the right greater
occipital nerve (GON).
As can be seen from figure 2, habituation of the contralateral
R2 response increases in our study whatever the experimental
intervention is. During repeated stimulation with an inter-stimulus
interval of 15–17sec as used here, nBR responses clearly habituate
bilaterally in healthy subjects, but not in migraine patients [31].
The more pronounced habituation of contralateral responses
could be related to the fact that 1st block amplitude is overall lower
on the side opposite to the supraorbital stimulus, a relation that
was also reported for visual evoked potentials [32].
We will discuss the changes induced by modulating visual cortex
activity and thereafter the possible relevance of our findings for
migraine pathophysiology.
Modulations of Visual Cortex Activity
The supraorbital pain threshold decreased after 1 Hz rTMS
over the visual cortex but increased after flash light stimulation.
Concordantly, amplitude of the 1st block of five averaged nBR
responses increased bilaterally after the former and decreased after
the latter. By contrast, 10 Hz rTMS over the visual cortex
produced no significant changes, but it was followed by a
numerical decrease of pain sensitivity and nBR amplitude. Taken
together, these results may suggest that the visual cortex exerts at
baseline a sustained top-down inhibitory effect on trigeminal
nociception. Indeed rTMS at low frequency is supposed to inhibit
the underlying cortex [26] while the flash stimulation excites visual
areas. This is in line with a study showing in healthy volunteers a
tendency for an increase of pain perception thresholds in the
innervation territories of the trigeminal and greater occipital
nerves after intense light stimulation [20]. We have found a similar
difference between low and high frequency rTMS over the visual
cortex in a study of visual evoked potentials (VEP) in healthy
subjects: 1 Hz rTMS reduced amplitude of the 1st VEP block,
while 10 Hz rTMS had no effect [41]. As a possible explanation
for these differential results, we postulated that in normal subjects
the cortical baseline activation level is close to the ‘‘ceiling’’, i.e. the
upper level of the cortical activation range, hence it cannot be
further activated by the excitatory 10 Hz rTMS but it can be
decreased by the inhibitory 1 Hz rTMS. This explanation is
supported a contrario by the finding that in migraine patients who
Vision and Pain
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may have a lowered cortical baseline activation level of the visual
cortex and a decrease in 1st block VEP amplitude at baseline,
10 Hz rTMS increases 1st block VEP amplitude whereas 1 Hz has
no effect [36]. The difference between 10 Hz rTMS and flash light
stimulation in the present study is likely due to the fact that the
former moderately increases the activation level of the visual
cortex while the latter activates more robustly the visual areas via
the retino-geniculo-cortical pathway of visual perception.
Extrageniculate visual pathways may provide an alternative
explanation. In cat and monkey there is evidence for a pathway
connecting the retina with the visual cortex via the pulvinar
[42,43]. More recently, Noseda et al. [14] have demonstrated in
animals projections from retinal ganglion cells to the posterior
thalamus, whence via caudate-putamen and external capsule they
reach multiple cortical regions, including the binocular area of the
primary visual cortex. The authors suggest that this novel pathway
may explain why even blind migraine patients experience
photophobia. One may hypothesize that these extrageniculate
pathways, if they exist also in humans, can induce an inhibitory
top-down modulation of trigeminal nociceptors by thalamic
neurons after flashing light but not after direct electro-magnetic
activation of the visual cortex.
In migraine patients the photophobia threshold is lower than in
healthy subjects after a painful stimulation applied on the forehead
[18]. Along the same line, continuous light was shown to produce
detectable oxygenation changes in the visual cortex of healthy
subjects, only if combined with painful heat stimulation in the
territory of the ophthalmic nerve [21]. The authors explain their
finding by a ‘‘bottom-up’’ activation by the trigeminal nociceptive
stimuli of visual areas rendering them responsive to a stimulus that
normally produces no detectable activation because of its
continuous nature and absence of any contrast pattern. Activation
of visual areas by pain may not be specific to the trigeminal system,
as it has also been found after pain applied to the hand [44,45]. In
our study we assume that the cortical activation by the flickering
light stimulation was sufficient to unravel an opposite ‘‘top-down’’
inhibitory control by the visual cortex of nociceptive trigeminal
processing.
Sensory terminals of the greater occipital nerve are interposed
between the coil of the magnetic stimulator and the occipital
cortex. The electro-magnetic pulses could activate some of these
peripheral neural structures and produce an afferent input that
may at least in part reach the spinal trigeminal nucleus and modify
its excitability. To exclude this possibility, we have positioned the
coil over the greater occipital nerve underneath the upper nuchal
line in control experiments. Magnetic stimuli over the GON had
no significant effect on the nBR, which suggests that putative
activation of peripheral afferents is not a confounding factor in our
rTMS results.
Gender may be a confounding factor in activation studies of the
visual cortex. Magnetophosphenes are indeed more prevalent in
females than in males in our study. A sexual dimorphism of
magnetophosphenes was not studied or reported in previous
studies. Such dimorphism is present in migraine and sex hormones
are well known to modulate cortical excitability in humans and in
animals [46]. The magnetic stimulation intensity to evoke
Figure 1. First block of 5 ispilateral and contralateral nBR responses (area under the curve in mVxms 6 sem) before (light bars) and
after (dark bars) 1 Hz rTMS, 10 Hz rTMS over the visual cortex, or flash light stimulation. ** p,0.01; * p,0.05. The inhibitory effect on
the nBR is significantly stronger after flash light stimulation than after10 Hz rTMS over the visual cortex.
doi:10.1371/journal.pone.0100198.g001
Vision and Pain
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phosphenes in our study is in line with that found in other studies
[36]. In our study we did not use phosphene thresholds after
rTMS to verify changes in excitability for several reasons. First, it
is well established that rTMS is able to modify visual cortex
excitability as indexed by visual evoked potentials (VEP) [41].
Second, although magnetophosphenes are easy to use as indicators
of visual cortex excitability, they are not very reproducible and less
reliable than VEPs [47]. Unfortunately, because of the design of
the experimental protocol and the necessity to record blink reflexes
as soon as possible after rTMS or flash stimulation, there was no
sufficient time for VEP recordings.
Another confounding factor in our study could be a change in
excitability of the facial nucleus motor neurons that contract
orbicularis oculi muscles. Although we cannot exclude this
Figure 2. Area under the curve of ipsi- and contralateral nociceptive blink reflexes in 3 successive blocks of 5 averaged responses
before (grey lines) and after (black lines) 1 Hz rTMS, 10 Hz rTMS over the visual cortex, or flash light stimulation. Vertical brackets
indicate significant differences before and after stimulation, or between stimulation modalities. ** p,0.01; * p,0.05.
doi:10.1371/journal.pone.0100198.g002
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possibility, it is highly unlikely to have influenced our results
significantly as the decrease of nBR amplitude was associated with
an increase in pain thresholds after flashing light.
Possible Physiological and Pathophysiological Relevance
The top-down relation between the visual cortex and the
trigeminal system may play a role in the pathophysiology of
photophobia. In rodents bright light is able to activate neurons at
multiple sites of the trigemino-cervical complex [6], which is
associated with activity of the olivary pretectal nucleus and the
superior salivary nucleus [7]. Given its role in saccades and blink
[48], the superior colliculus is a possible relay for the effects we
have observed. It receives indeed projections from the visual
cortex [49] as well reticular and cervical spinal cord projections
involved in eyelid movements during the blink reflex [50].
The top-down control we have shown here differs from the one
reported in cats by Lambert et al. [11]. These authors found that
cortical spreading depression (CSD) or light flash inhibits activity
of neurons in nucleus raphe magnus (NRM) and hence disinhibits
the responses of trigeminal nociceptors receiving dural input.
Multiple waves of CSD antagonized the inhibitory effect of NRM
stimulation on responses of trigeminal neurons to dural but not to
skin mechanical stimulation. The apparent discrepancy between
Lambert et al’s [11] and our results may have several explanations.
First, there are obvious methodological differences. Lambert et al.
[11] used extracellular recordings in trigeminal nucleus caudalis as
opposed to indirect assessment of the excitability of trigeminal
neurons interposed in the nBR circuit in our study. Ten Hz flash
light stimulation was applied for 10 minutes in the cats, while 8 Hz
flashes were delivered for 4 minutes to our subjects. Moreover,
species differences in visuo-trigeminal interactions cannot be
excluded considering the differences in vision between cats and
humans. Lastly, CSD, albeit starting with a brief depolarization of
cortical neurons, chiefly induces a long-lasting depression of
neuronal activity. If one accepts that such a depression might have
similar effects on the visual cortex and its connectivity as inhibitory
1 Hz rTMS, both the study in cat and ours in humans would
concord in showing that the visual cortex exerts a tonic descending
inhibitory action on trigeminal nociceptors.
An inhibitory top-down control by the visual cortex of the
trigeminal nociceptive system may have other implications in
health and disease. In normal conditions it could contribute to
avoid excessive blinking during visual attention. Viewing the
stimulated site can decrease pain perception in peripheral limbs of
healthy subjects, a phenomenon called ‘‘visual analgesia’’
[51,52,53]. In functional MRI studies, the top-down inhibitory
effect of vision on laser-heat evoked pain in the hand is associated
with diminished activation in somatosensory cortex SI and
operculoinsular cortex but not in anterior cingulate cortex [52].
Our study would be in line with a similar effect of vision in the
nociceptive trigeminal system, although a similar analgesic effect
in the trigeminal territory by viewing the face remains to be
demonstrated.
Tonic inhibition of trigeminal nociceptors by the visual cortex
could also be relevant for the pathophysiology of the migraine
headache. We have shown that between attacks most migraineurs
are characterized by lack of habituation of VEPs [54] resulting in
greater net activation of the visual cortex during repetitive
stimulation (hyper-responsivity). By contrast VEP habituation
normalizes just before and during the migraine attack [55] as well
as in chronic migraine [26,56], which reduces net activation of the
visual cortex. If our present findings are applied to the changes in
cortical activity over the migraine cycle, the trigeminal nociceptive
system would be rather inhibited at a distance from an attack
because of visual cortex hyper-responsivity, while it would be
disinhibited just before and during the attack as well as in chronic
Figure 3. Averaged ipsi- (a) and contralateral (b) nociceptive blink reflex (rectified EMG) in a subject before (grey trace) and after
(black trace) flash light stimulation.
doi:10.1371/journal.pone.0100198.g003
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migraine because of a decrease in cortical responsivity. The
finding in migraine patients of a deficient habituation of the nBR
in the interictal period and its normalization ictally [29,30,32]
favours such an excitability cycle of trigeminal nociceptors, as
habituation is inversely related to amplitude of the 1st block of
responses and thus to baseline excitability.
In addition, the migraine aura is caused by CSD that, as
mentioned above, comprises an initial brief neuronal depolariza-
tion front, followed by a long-lasting depolarization block of
neuronal activity in the visual cortex. Applying our results to the
migraine aura, the long-lasting inhibition may cause disinhibition
of trigeminal nociceptors and contribute to the CSD-induced
neuronal activation in trigeminal nucleus caudalis [57] and thus to
the migraine headache.
Conclusion
Our study demonstrates in healthy subjects a functional relation
between the visual cortex and the trigeminal nociceptive system, as
assessed by the nociceptive blink reflex. Our results favour of a
top-down inhibitory pathway from the visual areas to trigemino-
cervical nociceptors. This pathway may be functionally different
from the one attributing to the visual cortex a disinhibitory role on
nucleus raphe magnus-mediated inhibition of dural trigeminal
nociceptors in cats. In normal conditions the top-down inhibitory
pathway may avoid that too intensive blinking disturbs vision. In
case of increased responsivity of the visual cortex, like during the
interictal period in migraine, the visuo-trigeminal inhibitory
pathway may reduce trigeminal nociception. By contrast, when
visual cortex responsivity is decreased like during the migraine
attack, or in chronic migraine, reduced activation of the visuo-
trigeminal inhibitory pathway may increase excitability of
trigeminal nociceptors and hence favour headache.
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Pearls and pitfalls: Electrophysiology
for primary headaches
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Abstract
Background: Primary headaches are functional neurological diseases characterized by a dynamic cyclic pattern over time
(ictal/pre-/interictal). Electrophysiological recordings can non-invasively assess the activity of an underlying nervous
structure or measure its response to various stimuli, and are therefore particularly appropriate for the study of primary
headaches. Their interest, however, is chiefly pathophysiological, as interindividual, and to some extent intraindividual,
variations preclude their use as diagnostic tools.
Aim of the work: This article will review the most important findings of electrophysiological studies in primary headache
pathophysiology, especially migraine on which numerous studies have been published.
Results: In migraine, the most reproducible hallmark is the interictal lack of neuronal habituation to the repetition of
various types of sensory stimulations. The mechanism subtending this phenomenon remains uncertain, but it could be
the consequence of a thalamocortical dysrythmia that results in a reduced cortical preactivation level. In tension-type
headache as well as in cluster headache, there seems to be an impairment of central pain-controlling mechanisms but the
studies are scarce and their outcomes are contradictory. The discrepancies between studies might be as a result of
methodological differences as well as patients’ dissimilarities, which are also discussed.
Conclusions and perspectives: Electrophysiology is complementary to functional neuroimaging and will undoubtedly remain
an important tool in headache research. One of its upcoming applications is to help select neurostimulation techniques
and protocols that correct best the functional abnormalities detectable in certain headache disorders.
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Introduction
Primary headaches are neurological syndromes that
evolve in the absence of any underlying structural
lesion, as deﬁned by the 2nd edition of the
International Classiﬁcation of Headache Disorders
(1). They are characterized by functional disturbances
of the central nervous system at several levels, by a
dynamic pattern over time (ictal/interictal) and by com-
plex gene–environment interactions. There is no vali-
dated paraclinical diagnostic test, and the evaluation
of these diseases in a pathophysiological perspective is
diﬃcult and tricky.
Electrophysiological surface recordings are an easy
way to assess the spontaneous activity of the nervous
system, or to evaluate its response to a stimulus.
Basically, the diﬀerent components of the nervous
system (central nervous system or CNS, nerves,
muscles) generate an electrical signal which is the result
of summation of several action potentials. This signal
can be recorded, most of the time with surface electro-
des, and thereafter processed (ampliﬁcation, ﬁltering) in
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order to assess the global function of the underlying
nervous structure.
In 1947, Dow and Whitty used electroencephalog-
raphy (EEG) to detect interictal abnormalities in the
brain function of their migrainous patients (2). Ever
since, the usefulness of EEG in routine headache diag-
nosis has been controversial and is now only recom-
mended in patients with atypical symptoms suggesting
an underlying pathological process (such as thrombo-
phlebitis, encephalitis, tumour) and especially epileptic
phenomena. Evoked and event-related potential studies
started in the late 1960s and have also demonstrated
several abnormalities in headache patients, but because
of high inter- and intraindividual variability, they do
not have any usefulness in primary headache diagnosis.
Nonetheless, like EEG, they can be helpful to exclude
mimics in selected cases.
On the other hand, electrophysiological studies
have widely contributed to a better understanding of
headache pathophysiology, especially migraine.
Electrophysiology continues to be part of the headache
research armamentarium, and is complementary of
more recent techniques like functional neuroimaging.
In this article, we will review the main ‘pearls’ of the
electrophysiological ﬁndings in headache, and after-
wards describe their limitations. The last part of the
review will discuss open questions and give suggestions
for future studies.
Pearls
Electrophysiology is particularly suitable for the study
of primary headaches that are functional disorders of
the CNS. These techniques are non-invasive and the
existence of portable devices can provide a high ﬂexi-
bility in patient recordings, for example in a recent
study familial hemiplegic migraine patients were rec-
orded at home throughout Denmark (3). Moreover,
electrophysiological recordings are often technically
simple to obtain for a trained physician, are harmless
and can be repeated at many time points. The latter
aspect is of high importance in diseases with such a
dynamic pattern as headaches. Indeed, primary head-
aches are cyclic diseases characterized by the repetition
of attacks that notably diﬀer by their frequency, length
and intensity. The biological mechanisms subtending
this pattern are unknown, but thanks to the advantages
mentioned above (ﬂexibility etc.), electrophysiology
appears particularly suitable to investigate the dynam-
ics of primary headaches.
The majority of the following text will discuss elec-
trophysiological ﬁndings in migraine, which is the best-
studied headache type. We will not describe the diﬀer-
ent techniques reported here from a methodological
point of view, as this had been the aim of a previous
review article (see (4**) for more information).
Migraine
The most important electrophysiological studies per-
formed in migraine demonstrate three functional char-
acteristics of the disease, which are interrelated: 1.
habituation modiﬁcations, 2. cortical dysexcitability
and 3. abnormal functional connexions and circuits
within the CNS.
Habituation modifications. Habituation is deﬁned as a
behavioural response decrement that results from
repeated stimulations and does not involve sensory
adaptation or fatigue, that is a decrease in peripheral
receptor activity (5). The average habituation deﬁcit to
repetitive stimuli is probably the most reproducible and
redundant hallmark of episodic migraine recordings in
the interictal period, whatever the modality of stimula-
tion, that is the neuronal population that is stimulated
(see Figures 1 and 2). It is, however, not speciﬁc to
migraine as it has been found in other diseases such
as photosensitive epilepsy or tinnitus (6,7), and some
psychiatric conditions. This interictal habituation def-
icit, sometimes resulting in potentiation, has been
mainly demonstrated for visual evoked responses
(VEP, Figure 1) (8**–10), but also for auditory (AEP)
(11), somatosensory (SSEP, Figure 2) (12,13) pain
(laser, LEP) (14,15) and event-related (contingent nega-
tive variation, CNV) responses (16,17). Moreover, it
was also retrieved for the nociception-speciﬁc blink
reﬂex (nsBR, Figure 1), a subcortical brainstem electro-
myographic (EMG) response that reﬂects trigeminal
activity and is mediated by bulbopontine excitatory
interneurons (18**). Besides this habituation deﬁcit,
migraineurs exhibit an increased intensity dependence
of auditory evoked potentials (IDAP), which was found
to be correlated to the lack of habituation and perhaps
to be the consequence of it (19**). The habituation
phenomenon has been extensively studied in migrain-
eurs, and some characteristics have been drawn.
– First, the habituation deﬁcit is not constant in
migrainous patients. The studies showing a lack of
habituation are based on the averaging of numerous
patient recordings, compared with healthy volun-
teers. Therefore, the habituation deﬁcit cannot be
considered as a diagnostic criterion of migraine. In
addition, it was shown that the degree of habituation
depended on the stimulus properties, for example the
temporal or spatial frequencies of a visual pattern,
which may explain why some authors did not
retrieve any habituation deﬁcit in migrainous
patients (20).
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– Second, habituation is a dynamic parameter
that provides interesting data about the current
CNS information processing. In migraine, important
peri-ictal changes were found in habituation. During
the days preceding the attack, the habituation deﬁcit
(CNV, P300) becomes maximal (21,22). It increases
with stress which is a known migraine-provoking
factor (23), or in the pre-menstrual period (LEP,
(24)). Interestingly, most of the sensory modalities
showing an interictal lack of habituation then nor-
malize 12–24 hours before and during the migraine
attack (13,17,18**,21,22,25). It takes 24–48 hours to
get back to the abnormal habituation pattern seen in
the headache-free interval (25). These sequential
recordings have thus demonstrated that the cortical
dysfunction level varied with the migraine cycle.
Along the same line, recent data revealed that
patients suﬀering from chronic migraine and evol-
ving to episodic migraine after successful prophylac-
tic treatment exhibited a switch of visual responses
from normal habituation to potentiation (26**), as if
chronic migraine corresponded to a ‘never ending
attack’ (27) and the treatment restored the interictal
habituation deﬁcit found in the episodic form. This
is not the case in medication-overuse headache
(MOH) where habituation of SSEP remains
impaired, whereas the initial response amplitude is
increased, suggesting a sensitization of somatosen-
sory cortices in MOH patients (13). However, this
phenomenon was dependent on the drug of overuse,
as it is maximal in patients overusing NSAIDs
and almost non-existent in those who overuse only
triptans (25).
– Third, genetics appears to be a determinant factor of
the interictal dysfunction leading to deﬁcient habitu-
ation in migraine. Hence, Sa`ndor et al. studied VEP
and AEP in migrainous pairs (parents and their chil-
dren), and found that habituation was abnormal in
both parents and children, with a stronger relation-
ship between related pairs (28**). A lack of habitu-
ation was also demonstrated in healthy volunteers
with a familial history of migraine in ﬁrst-degree rela-
tives (29,30). It could thus be an endophenotypic
marker of a genetic predisposition to migraine, even
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Figure 1. The upper part of the figure represents visual evoked potential (VEP) recordings in a healthy volunteer (HV, (a)) and a
migraineur in the interictal period (b). The deep blue triangles highlight the mean VEP amplitude at the beginning of the recording (a
block corresponds to the averaging of 100 individual sweeps) and the light blue triangles show mean VEP amplitude at the end of the
recording (sixth or last block). There is an amplitude decrease with time in the HV, that is habituation (a), whereas this habituation
lacks in the migraine patient, in whom the first block amplitude is also smaller than in HV, suggesting a reduced cortical preactivation
level (b). Part (c) represents the evolution of VEP amplitudes (numerical data, mean  standard deviations) with time in a healthy
volunteer (HV), migraineurs with (MA) and without (MO) aura in the interictal period, and in a migraineur in the ictal period. Note
that both reduced initial VEP amplitude and the lack of habituation found in MO and MA normalize during the attack. The lower part of
the figure represents nociception-specific blink reflex (nsBR) recordings in a HV (a1) and a migraineur (b1) interictally. Note the lack of
habituation and the reduced initial amplitude in the migraine patient. Part (c1) of the figure is the average nsBR area under the curve
(AUC) evolution with time in a HV, a migraineur without aura (MO) and a migraineur recorded in the ictal period.
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if these conclusions cannot be applied to individuals.
Finally, Di Clemente et al. found that VEP and nsBR
habituation deﬁcits were correlated in migraineurs,
which argues in favour of a common underlying
pathological mechanism (31). However, VEP habitu-
ation and IDAP slope are not correlated (32).
– Fourth, the habituation can be modulated by exter-
nal interventions, especially drugs known to provoke
or alleviate migraine attacks, or transcranial mag-
netic stimulation (see below). Hence, various studies
demonstrated a normalization of the interictal
habituation deﬁcit with several established prevent-
ive drugs like beta-blockers (33) or topiramate (34).
This habituation deﬁcit reversal has also been shown
in children treated with behavioural therapy (35).
The relationship between the normalization of
habituation and the clinical improvement is prob-
ably more complex, as for example ﬂuoxetine, a
selective serotonin reuptake inhibitor (SSRI), is not
an eﬀective antimigraine drug but corrects the lack
of habituation of VEP in patients (36), whereas ribo-
ﬂavin, which acts on mitochondrial metabolism,
does not modify habituation (33). Moreover, the
migraine-provoking agent nitroglycerin is able to
induce nsBR and VEP changes similar to those
found before and during a migraine attack when it
is administered to healthy volunteers without any
familial history of migraine (37).
Cortical dysexcitability. Assessment of cortical excitability
by neurophysiological techniques has provided
contradictory results that have long been debated.
Interictal cortical dysexcitability has been indirectly
suggested by two main neurophysiological variables:
the cortical sensitivity to transcranial magnetic stimu-
lation (TMS) and the reduced initial evoked potential
(EP) amplitude, which is correlated to the lack of
habituation described above.
– TMS is an easy and non-invasive way to study the
excitability of the underlying cortical area. The main
studies performed on migraine used single-pulse
TMS (sTMS) to assess the visual or motor cortex
activation thresholds, or repetitive TMS (rTMS) to
inhibit (low frequencies, 1 Hz) or activate (high fre-
quencies, 10 Hz) the underlying cortex. In sTMS, the
motor threshold was found to be normal or
increased (38–41), but the latter is less relevant
than the magnetophosphene threshold (PT) to
visual cortex TMS, as an abnormal excitability of
the occipital cortex has been suspected in migraine
Somatosensory evoked potentials
Somatosensory high frequency oscillations (HFOs)
(a) (b)
(a1) (b1)
N20 N20
P25
1st block 2nd
early HFO burst late
P25
2
2
1
1
10 ms 1
 m
v
early
late HFOs late HFOs
early
10 ms 0
.1
 m
v
3
2.5
2
1.5
1
Am
pl
itu
de
 (m
v)
Am
pl
itu
de
 (m
v)
0.08
0.07
0.06
MO
HV
MA
lctal
MO
HV
lctal
0.05
0.04
0.03
0.02
0.01
0
Figure 2. The upper part of the figure represents somatosensory evoked potentials (SSEPs) of the median nerve in a healthy
volunteer (HV, (a, c)) and in migraineurs without (MO) and with aura (MA) (b, c). The typical electrophysiological abnormalities as
mentioned previously are also retrieved and normalized in the ictal period (see Figure 1). The lower part of the figure represents the
high frequency oscillations bursts (HFOs) extracted from broad-band SSEPs. Note that the early HFO burst is reduced interictally in
the migraine patient (b1) compared with the HV (a1), reflecting reduced thalamocortical activity, whereas the late HFO burst remains
normal at any time, suggesting a normal activity of cortical inhibitory interneurons.
Magis et al. 529
for a long time, especially with aura. The numerous
trials on PT in migraine between attacks gave con-
ﬂicting results, that is either increased PT suggesting
cortical hypoexcitability (40–42), or decreased PT in
favour of a hyperexcitable state (43–45). These discre-
pancies between various studies might be because of
methodological diﬀerences (subject recruitment, prox-
imity with a migraine attack, individual perception
and description of phosphenes, etc.) (46). In a study
with repetitive stimulations, Bohotin et al. revealed
that 10Hz (excitatory) rTMS was able to normalize
the interictal deﬁcient habituation, whereas 1Hz
(inhibitory) rTMS had no eﬀect on VEP in migrain-
eurs (47**). In apparent contradiction to these ﬁnd-
ings, Brighina et al. found that inhibitory rTMS
increased subjective PT in healthy volunteers but sur-
prisingly decreased it in migraine with aura (MA)
patients (42). The authors suggest that the migrainous
brain probably has a ‘non-physiological’ and para-
doxical response to rTMS, which could be attributed
to abnormal cortical processing. However, this para-
doxical eﬀect of modulating rTMS was also observed
after stimulation of the motor cortex and not only by
means of inhibitory (48,49), but also with the excit-
ability enhancer rTMS. Short trains of 5Hz (excita-
tory) rTMS delivered at 130% of resting motor
threshold determined a signiﬁcant depression of
MEP size in MA patients rather than MEP facilita-
tion as in controls (49). These paradoxical behaviours
in response to rTMS point to altered synaptic plastic
mechanisms that prevent the immediate and longer-
lasting cortical changes reﬂecting adaptation to
repeated stimulations. Further evidence comes from
a long-term study showing that rTMS is able to
induce VEP changes lasting up to several weeks in
about 50% of healthy volunteers, whereas the eﬀect
lasts only several hours in most migraineurs (50).
– The initial amplitude of the evoked CNS
responses to various sensory modalities is (or tends
to be) lower in migraineurs recorded in the interictal
period, that is VEP (8**,9,32,36,47**), AEP
(19**,32), SSEP (12) and even the subcortical
nsBR (29,31). In VEP and AEP, the initial amplitude
is negatively respectively correlated with the potenti-
ation and the IDAP (32), which suggests that a
reduced cortical preactivation level might be respon-
sible for the lack of habituation found in migraineurs
(see next section: ‘Abnormal functional connexions
and circuits: the ‘unifying’ thalamic hypothesis’).
Abnormal functional connexions and circuits: the ‘unifying’ tha-
lamic hypothesis. The habituation modiﬁcations and cor-
tical dysexcitability found in migraine were thus
probably interrelated, but the origin of these
phenomena per se remained obscure. Recent works
have pointed out possible thalamocortical dysfunc-
tional connexions that could provide an explanation
for both abnormalities.
There are two main hypotheses subtending the lack
of habituation found interictally in episodic migraine, a
reduced intracortical inhibition or an increased cortical
excitability, but neither has proved satisfactory as
yet (51**).
– Light deprivation is supposed to decrease both exci-
tatory and inhibitory processes within the cortex;
however, it did not modify the habituation deﬁcit
found in migraineurs in a recent study, which
argues against the reduced intracortical inhibition
hypothesis (52).
– As for the hyperexcitability hypothesis, the results
with TMS appear too contradictory from which to
draw any conclusions (see above). Red glasses are
known to increase the excitability of the human
visual cortex. However, Afra et al. did not observe
any signiﬁcant modiﬁcation of the VEP in MA
patients wearing red glasses, whereas healthy volun-
teers had an increase of VEP amplitude (53).
This result also disfavours the hyperexcitability
hypothesis.
A third possibility arose from one of the more repro-
ducible neurophysiological parameters, that is the ﬁnd-
ing of a recurrent reduced initial response of various
sensory cortices. As stated previously, the correlation
between this reduced initial response and the degree of
habituation suggests that a reduced cortical preactiva-
tion level is responsible for the lack of habituation
found in migraine.
Recent neurophysiological works have shed a new
light on the possible pathophysiological mechanisms
of this decreased cortical preactivation. Coppola et al.
applied a speciﬁc ﬁlter to broad-band SSEP recordings
in order to extract the high-frequency oscillations or
HFOs (Figure 2). HFOs are thought to reﬂect thalamo-
cortical cholinergic ﬁbre activity (early component) and
cortical inhibitory GABAergic interneuron activity
(late component) (51**). Interictally, the early compo-
nent of the HFO was signiﬁcantly smaller in migrain-
eurs than in healthy subjects, but became comparable
between the two populations during the attack
(Figure 2). The late component did not diﬀer between
the two groups at any time. Moreover, reduced early
HFOs were associated with worsening of the clinical
evolution of migraine (54). In a recent study, 10Hz
repetitive transcranial magnetic stimulation (rTMS)-
induced activation of the sensorimotor cortex increased
thalamocortical drive in migraineurs, because it was
low at the baseline, and induced habituation of the
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broad-band SSEP. This was not possible in healthy sub-
jects probably because their thalamocortical activity and
habituation were alreadymaximal before the rTMS (55).
Thus, the deﬁcit of habituation found in migraineurs
could be because of impaired thalamocortical activity,
namely reduced cortical preactivation, and not because
of decreased intracortical inhibition (51**). That the
thalamus abnormally controls the cortex in migraine
between attacks is further evident by the analysis of
the high-frequency oscillatory components embedded
in the visual EPs (gamma-band oscillations, GBO)
(56). Investigators observed a signiﬁcant habituation
deﬁcit of the late GBO components, supposed to be of
cortical origin, in migraineurs relative to healthy con-
trols, which was interpreted as indicative of a dysfunc-
tion in cortical oscillatory networks that could be
because of an abnormal thalamic rhythmic activity,
namely a ‘thalamocortical dysrhythmia’ (56). Coppola
et al. stressed that this thalamocortical dysrythmia could
result from a functional (or anatomical?) thalamic dis-
connection from its modulating aﬀerences, for example
the brainstem serotoninergic pathways (56). This
explanation may reconcile the controversy between
increased cortical excitability and deﬁcient inhibition,
as an insuﬃcient thalamocortical drive, namely a low
level of cortical preactivation, results in a dysfunction
of both inhibitory and excitatory cortical neurons.
Lower inhibition and cortical preactivation may thus
not be mutually exclusive, as the latter can promote
the former through a reduction of lateral inhibition.
The ﬁnal common pathway of both dysfunctions is a
heightened cortical response to repeated stimuli, that is
hyperresponsivity.
Tension-type headache
Electrophysiological data on tension-type headache
(TTH) are scarce compared with those on migraine.
Early neurophysiological studies analysed electromyog-
raphy, as pain caused by TTH was believed to be the
result of an abnormal myofascial activity. More recent
works now suggest that this is true for episodic TTH
(ETTH) but not chronic TTH (CTTH), in which cen-
tral dysnociception mechanisms are more likely
involved (57).
Electromyographic responses. More than 20 surface EMG
activity studies on TTH are available (58), but results
are contradictory, therefore EMG has no diagnostic
indication in TTH. The most common ﬁnding between
positive studies was a slightly increased EMG activity,
but this was not correlated to the intensity of the
headache.
The so-called exteroceptive suppression of tempor-
alis muscle activity corresponds to the suppression of
voluntary EMG of the temporalis muscle in response to
a painful stimulus in the trigeminal area. Two succes-
sive silence periods (ES1 and ES2) can be identiﬁed.
The duration of the late component ES2 is decreased
in CTTH but not ETTH, migraine or cluster headache
patients (59). Modulation of ES2 by various parameters
(drugs, pain, TMS) has led to the hypothesis that ES2
reﬂects the excitability of interneurons in the pontome-
dullary reticular formation (57). In CTTH, the excit-
ability of these interneurons would be impaired
because of inadequate control by the descending con-
trol from the limbic system through the serotoninergic
raphe magnus nuclei (59). Several studies have been
published on ES2 duration in TTH, with some discre-
pancies as ES2 was either shorter (60**–65) or normal
(66–68). Again, these discordant results might be attrib-
uted to methodological diﬀerences or to patient-related
factors such as age, comorbidities and headache
severity (57).
The blink reﬂex (BR) was mentioned above in the
migraine section. In TTH, most studies involved the
‘standard’ BR, that is evoked in response to stimulation
of large Aß myelinated ﬁbre activation in the supra-
orbital nerve area, contrary to the nociception-speciﬁc
BR or nsBR which is elicited by Ad nociceptive aﬀer-
ents and has been mainly studied in migraine (58). The
BR was normal in all forms of TTH (see (58) for a
more detailed review), this was also the case of the
sole nsBR study in CTTH (69). A single trial demon-
strated a decrease of the R2 recovery cycle after double
supraorbital stimulation in both ETTH and CTTH,
suggesting a reduced excitability of brainstem inter-
neurons (70).
The biceps femori ﬂexion reﬂex (BFR) is a complex
reﬂex mediated at both spinal and supraspinal levels in
response to a nociceptive stimulus. In CTTH, studies
found a lower RIII ﬂexion reﬂex threshold which might
suggest central sensitization of nociceptive circuits
(71–73) and/or be because of impaired supraspinal
descending inhibitory control (72).
Cortical responses. Few studies are available on electro-
encephalography in TTH and those few provide incon-
sistent results (58). In contrast to migraine, most
evoked potential studies (VEP, LEP, CNV) performed
in TTH did not demonstrate any recurrent abnormal-
ities like reduced preactivation or lack of habituation
(14,16,74,75). The only abnormality was found in LEP
by de Tommaso et al., who demonstrated increased N2-
P2 amplitude in CTTH after pericranial skin stimula-
tion (76,77). This higher amplitude was correlated with
the total pericranial tenderness and with anxiety scores
(the latter was interpreted as a hypervigilance to painful
stimuli), and decreased after treatment with amitriptyl-
ine (78). An interesting but unique study recorded
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SSEP in response to intramuscular trapezius electrical
stimulation using high-density EEG mapping, and
found a signiﬁcant reduction in magnitude of the dipo-
lar source during and after induced tonic muscle pain in
healthy volunteers but not in CTTH patients (79). They
concluded that this lack of magnitude reduction might
be because of impaired inhibition of the nociceptive
input in CTTH patients, suggesting an abnormal
supraspinal response to muscular pain (79).
Cluster headache
Electrophysiology could seem of modest importance to
the understanding of cluster headache (CH) patho-
physiology regarding other techniques like functional
neuroimaging. However, it remains of high interest to
study nociceptive spinal and supraspinal mechanisms,
and to understand the mode of action of recent neuro-
modulation methods.
Subcortical electromyographic responses. A study of ‘stand-
ard’ BR found that the amplitude of the contralateral
R2 response on the symptomatic side was lower than
on the healthy side in the active cluster period (80). A
further trial did not conﬁrm these ﬁndings, but
showed a decrease of R2 inhibition after supraorbital
and peripheral conditioning stimuli in CH, the latter
being partially reversed by naloxone IV (81). Another
study demonstrated an R2 habituation deﬁcit in
untreated episodic CH patients during the cluster
period, which was even more pronounced than in
migraine patients (82). A more recent study with
nsBR did not conﬁrm these ﬁndings in a population
of episodic and chronic CH patients on prophylactic
medication, both during and outwith a bout (83).
Finally, a study of nsBR found a decrease of latency
ratio (cluster side vs. healthy side), as well as an
increase of R2 area ratio in episodic CH patients
during a bout (84). Overall, these ﬁndings suggest an
impaired nociceptive processing at brainstem level in
the CH period.
This impairment of pain control systems was also
conﬁrmed by the study of BFR, which exhibited a
lower threshold in CH patients during (85) and outwith
the bout period (86). Interestingly, the modiﬁcations of
BFR have a circadian rhythm in ECH patients but not
in CCH patients (86).
Evoked potentials. As in TTH, studies of evoked poten-
tials are scarce in the CH population. Various abnorm-
alities have been highlighted in sensory evoked
potentials, but these are not as ‘homogenous’ as in
migraine (84,87–93). The intensity dependence of audi-
tory evoked potentials (IDAP, see before) is also
increased in CH patients, during and outwith the
bout, which might suggest a decreased serotoninergic
activity in the raphe-hypothalamic pathways (94).
Neuromodulation in cluster headache: mechanism of
action. Posterior hypothalamic deep brain stimulation
(hDBS) and occipital nerve stimulation (ONS) have
shown their eﬃcacy in the symptomatic treatment of
drug-resistant CCH (95–98). Electrophysiological
measurements were performed in order to understand
their mechanisms of action. The nsBR was not signiﬁ-
cantly modiﬁed after hDBS, but the latter decreased
peripheral pain thresholds (95) and increased trigeminal
cold detection and pain thresholds (99), suggesting
subtle pain-modulating processes. In ONS, nsBR was
paradoxically increased after treatment (97), which mir-
rors a more centrally located mode of action. That
brief low frequency ONS does not modify nsBR in
healthy volunteers, could also argue in favour of this
suprasegmental mechanism (100). The latter was also
proposed to explain occipital nerve steroid injection
eﬃcacy, after which CH patients have an R2 decrease,
but that is not especially correlated to clinical improve-
ment (101).
Pearls of headache electrophysiology: summary
The contribution of electrophysiology to the under-
standing of primary headache pathophysiology can be
summarized as follows.
– In episodic migraine, there is an interictal lack of
habituation of the brain to various sensory modal-
ities, which is associated with a reduced cortical (and
even subcortical) preactivation level suggesting an
abnormal underlying cortical excitability. A recent
hypothesis pointed out that the thalamus could
play a key role in these phenomena: a thalamocor-
tical dysrythmia (possibly because of a functional
disconnection of the thalamus from the brainstem)
would reduce the cortical preactivation level and
thus impair the normal habituation process.
– In tension-type headache, available studies suggest
that the chronic form would be associated with dys-
functioning supraspinal descending antinociceptive
pathways coming from the limbic system through
the serotoninergic raphe magnus nuclei to the inter-
neurons of the pontomedullary reticular formation.
This is not the case in the episodic form where an
abnormal myofascial activity was retrieved but there
were no signs of abnormal central antinociceptive
control.
– Finally, in cluster headache, electrophysiological stu-
dies are scarce and their results are conﬂicting.
Overall, impaired sensory and nociceptive processing
can be suspected but no consistent underlying
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pathophysiological hypothesis has been proposed
unlike in migraine.
Neuroimaging correlates of the lack of habituation
In order to better understand the underlying mechan-
isms of the interictal abnormalities found during the
electrophysiological recordings in migraine patients,
several studies recently focused on their neuroimaging
correlates, especially on habituation which was often
indirectly evaluated. Only a few studies are available
and diﬀer by their methodology (neuroimaging type:
functional magnetic resonance imaging (fMRI) or posi-
tron emission tomography (PET), stimulation para-
digms, etc.), leading to results discrepancies (102–105).
With 3HMR spectroscopy searching for occipital lactate
changes during visual stimulation, Sa´ndor et al. (106)
reported increased baseline lactate levels in patients suf-
fering from migraine with pure visual auras, whereas
patients with complex neurological auras had normal
baseline levels, but lactate increases, mimicking lack of
habituation, during visual stimulation. In an fMRI
study, an initial weaker blood-oxygen-level dependent
(BOLD) signal was found during visual stimulation in
10 migraine patients (with and without aura). By con-
trast, a progressive increase of cortical occipital BOLD
was found during sustained visual stimulation in
migraineurs, a pattern resembling the VEP habituation
deﬁcit, whereas there was a habituation in healthy vol-
unteers (107). More recently, Boulloche et al. (103) and
Martin et al. (105) studied the visual cortex response in
H2
15O PET (103) and fMRI-BOLD (105), using diﬀer-
ent stimulation paradigms in episodic migraineurs.
Although the ﬁrst authors indirectly found a lack of
habituation (or a cortical hyperexcitability) to light,
the second authors failed to demonstrate any lack of
habituation to repetitive light stimuli in migraineurs.
Aderjan et al. used a painful olfactive stimulation to
study habituation over several days, unlike electro-
physiological studies where the latter is often evaluated
within minutes (102). The pain perception did not diﬀer
with time between healthy volunteers and migraine
patients but the BOLD signal activity level of some anti-
nociceptive structures (such as the prefrontal cortex, ros-
tral cingulate cortex, red nucleus) decreased in
migraineurs and increased in healthy volunteers, sug-
gesting existing alterations of pain inhibitory circuits.
Finally, another fMRI-BOLD trial designed with
paired face stimuli speculated that the absence of haemo-
dynamic refractory eﬀects in migraineurs was the neuro-
vascular correlate of the lack of habituation found in
electrophysiology (104). However, habituation in face
perception areas has never been studied in electrophysio-
logical trials as it would require intracranial recordings
(104). However, even recognizing that these interictal
fMRI studies did not use completely comparable stimu-
lus parameters to those typically used to demonstrate
habituation with EPs, they conﬁrm that cortical respon-
sivity to repeated stimuli is abnormal in migraineurs.
Pitfalls
Methodological considerations
Methodological problems were extensively reviewed in
a previous article (4**). Electrophysiological recordings
can be easily contaminated by artefacts of various ori-
gins (external: alternative current etc., or internal/
organic: ECG, EMG, drugs). There are also several
recommendations in terms of signal sampling frequency
and ﬁltering, as well as stimulation frequencies for
evoked responses. The latter have been pointed out as
a possible explanation for discrepancies found in
evoked potential studies, especially in migraine (46).
Hence, there is a need for a better standardization,
and some proposals for methodological optimization
of recordings have been suggested before (4**).
Unfortunately, only part of the nervous system is
accessible to non-invasive electrophysiological record-
ings. Deep structures are not easily reached (hypothal-
amus etc.), but indirect neurophysiological assessment
methods can be found for some of them, for example
analysis of HFOs as representing thalamocortical activ-
ity (51**,55). Moreover, not all structures provide a
clear ‘witness’ of activation (for example the cerebel-
lum, orbito-frontal cortex, hypothalamus) and knowing
if they are being stimulated could be diﬃcult.
Patient phenotypes
Diﬀerences between populations included in electro-
physiological studies can also explain the variability
of results and the lack of interindividual reproducibil-
ity. It is well known that evoked potential modiﬁcations
can occur with age and coexisting comorbidities
such as depression and anxiety. Between EP studies,
inconsistencies can also be because of concomitant
acute or preventive drugs, or even caﬀeine intake
(82,83,108–110).
Intrinsic recording discrepancies may also happen.
In women, the menstrual cycle aﬀects pain perception
and should be considered when recordings are per-
formed (24). The dynamic electrophysiological pattern
of migraine can be used to situate a patient in his/her
migraine ‘cycle’ at the time of the recording (see before,
proximity to the last/next attack), using headache dia-
ries and phone calls. It is important to emphasize again
here that even in the interictal period not all migrain-
eurs exhibit a habituation deﬁcit or reduced initial
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response amplitudes, and that these electrophysio-
logical traits were statistically demonstrated on aver-
aged measures of several patients compared with
healthy volunteers.
Heterogeneity of the disease
Headaches are heterogeneous polygenic diseases, and
ICHD-II classiﬁcation of primary headaches (1) is
probably not accurate enough to classify patients into
homogenous subgroups for electrophysiological stu-
dies. For example in migraine, the severity of the dis-
ease is an essential factor: studying a migraineur with
high attack frequency in interictal period is a real chal-
lenge, and this patient cannot be reasonably considered
as similar to another migraineur with one attack every
other month. The extremity of this clinical spectrum is
chronic migraine, now considered a ‘never ending
attack’ (27), as patients exhibit similar electrophysio-
logical patterns to those during the ictal state (111).
In many older studies the chronic migraine sub-
groups included patients with and without various
kinds of acute medication overuse; however, the elec-
trophysiological proﬁle of both patient types appears
diﬀerent, suggesting diverse mechanisms leading to
headache chroniﬁcation (13). Further subclassiﬁcations
of headache patients, especially migraineurs, have
been proposed according to associated symptoms like
photophobia or vertigo. This method has already been
employed in genetics (latent class analysis) but results
were disappointing.
Conclusions: open questions and
recommendations for future studies
Overall, the contribution of electrophysiology to the
understanding of primary headache pathophysiology
is more signiﬁcant for migraine than for other primary
headaches, where studies are comparatively rarer and
often disclose a high variability of results for similar
methods.
The reduced preactivation level of sensory cortices
and the lack of habituation to sensory stimuli found in
migraine could be the consequence of a thalamocortical
dysrythmia as suggested by recent works (51**,55,56).
A thalamic involvement in migraine pathophysiology is
also suspected by other studies using diﬀerent research
methods (112–114). The activity of the thalamus itself is
modulated by several aﬀerences, among them inputs
from the aminergic nuclei of the dorsal rostral pons.
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Figure 3. This figure presents two non-invasive neurostimulation techniques that are able to modify visual evoked potential (VEP)
recordings in healthy volunteers (HV). VEP traces (six blocks of recordings) are represented before (a, a1) and after (b, b1) the
application of intermittent theta burst stimulation (i-TBS, upper part of the figure) or inhibitory quadripulse (QPI, lower part) in one
HV. Part (c, c1) shows average baseline N1P1 and P1N2 VEP amplitudes in 13 HV, and their evolution 3 hours after stimulation with i-
TBS (upper part) or QPI (lower part). Part (d, d1) shows VEP habituation slopes values before and 3 hours after stimulation with i-TBS
(upper part) or QPI (lower part). The degree of habituation is expressed as a negative slope, that is the more negative value, the higher
the habituation.
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– Future electrophysiological works must understand
the role of each structure in the dynamic mechanisms
that lead to the migraine cycle, from one attack to
the next, and from episodic to chronic migraine.
– Given the heterogeneity of the disease, patients
should be carefully selected as mentioned before,
and perhaps classiﬁed according to their electro-
physiological proﬁle, which might subtend diﬀerent
underlying mechanisms.
– Moreover, further studies should focus on the connec-
tions between the cortex, the thalamus and the brain-
stem (trigeminal structures), and especially their
modulations by excitatory and/or inhibitory stimuli.
– One of the upcoming applications of electrophysi-
ology would be to help select neurostimulation tech-
niques and protocols that would be able to correct
the functional abnormalities detectable in certain
headache disorders such as the lack of habituation
in migraine (see example in Figure 3, (115)). Hence,
previous results provided by electrophysiological
measurements lead to therapeutic neurostimulation
trials that gave encouraging results (115), these
translational research protocols should be highly
promoted in future.
– Conversely, electrophysiology remains a simple
method to appreciate the mode of action of vari-
ous pharmacological and non-pharmacological
treatments.
Pearls, pitfalls and perspectives
Pearls
. Electrophysiology is a non-invasive and easy way to
access the activity of the nervous system, and is
therefore particularly suitable for the study of pri-
mary headaches which are CNS functional disorders
characterized by a dynamic pattern (ictal/interictal).
. The most reproducible electrophysiological abnor-
mality is the lack of habituation to repetitive stimuli
found in migraine patients in the interictal period,
whatever is the sensory modality. This lack of
habituation could be the consequence of a thalamo-
cortical dysrythmia resulting in a reduced preactiva-
tion level of sensory cortices.
Pitfalls
. As a result of high inter- and intraindividual vari-
ability, electrophysiological measurements cannot be
used for diagnosis of primary headaches but can be
helpful to rule out mimics in some cases (secondary
headaches, epileptic syndromes).
. The discrepancies between electrophysiological stu-
dies might be because of methodological diﬀerences
as well as patients’ dissimilarities.
Perspectives
. Electrophysiology will remain an important tool
in the headache research armamentarium. One of
the upcoming applications of electrophysiology
would be to help select neurostimulation tech-
niques and protocols able to correct the func-
tional abnormalities detectable in certain
headache disorders such as the lack of habituation
in migraine.
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http://www.thejournalofheadacheandpain.com/content/14/1/95RESEARCH ARTICLE Open AccessSafety and patients’ satisfaction of transcutaneous
Supraorbital NeuroStimulation (tSNS) with the
Cefaly® device in headache treatment: a survey of
2,313 headache sufferers in the general
population
Delphine Magis*, Simona Sava, Tullia Sasso d’Elia, Roberta Baschi and Jean SchoenenAbstract
Background: Transcutaneous supraorbital nerve stimulation (tSNS) with the Cefaly® device was recently found
superior to sham stimulation for episodic migraine prevention in a randomized trial. Its safety and efficiency in
larger cohorts of headache sufferers in the general population remain to be determined.
The objective of this study was to assess the satisfaction with the Cefaly® device in 2,313 headache sufferers who
rented the device for a 40-day trial period via Internet.
Methods: Only subjects using specific anti-migraine drugs, and thus most likely suffering from migraine, were
included in the survey. Adverse events (AEs) and willingness to continue tSNS were monitored via phone interviews
after the trial period. A built-in software allowed monitoring the total duration of use and hence compliance in
subjects who returned the device to the manufacturer after the trial period.
Results: After a testing period of 58.2 days on average, 46.6% of the 2,313 renters were not satisfied and returned
the device, but the compliance check showed that they used it only for 48.6% of the recommended time. The
remaining 54.4% of subjects were satisfied with the tSNS treatment and willing to purchase the device. Ninety-nine
subjects out of the 2,313 (4.3%) reported one or more AEs, but none of them was serious. The most frequent AEs
were local pain/intolerance to paresthesia (47 subjects, i.e. 2.03%), arousal changes (mostly sleepiness/fatigue,
sometimes insomnia, 19 subjects, i.e. 0.82%), headache after the stimulation (12 subjects, i.e. 0.52%). A transient local
skin allergy was seen in 2 subjects, i.e. 0.09%.
Conclusions: This survey of 2,313 headache sufferers in the general population confirms that tSNS with is a safe
and well-tolerated treatment for migraine headaches that provides satisfaction to a majority of patients who tested
it for 40 days. Only 4.3% of subjects reported AEs, all of them were minor and fully reversible.
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Figure 1 Area covered by the tSNS electrode.
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http://www.thejournalofheadacheandpain.com/content/14/1/95Clinical relevance summary
Transcutaneous supraorbital neurostimulation with the
Cefaly® device is a safe and satisfactory treatment modal-
ity for migraine headache sufferers in the general popu-
lation who tested it for 40 days. Treatment failure may
be partly due to poor compliance.
Background
Migraine is a highly prevalent primary headache dis-
order and one of the most disabling diseases worldwide
according to the recent epidemiologic data [1]. Prevent-
ive anti-migraine drug therapies have incomplete effi-
cacy and many of them have cumbersome side effects
[2]. Blumenfeld et al. (2013) [3] have recently found that
only 28.3% and 44.8% of subjects suffering respectively
from the episodic and chronic forms of migraine (ICHD-
III beta criteria 1.1, 1.2 and 1.3 [4]) were currently using a
preventive medication [3]. The reasons for treatment dis-
continuation were lack of efficacy and side effects in an
equal proportion. Furthermore, over the last decade hardly
any novel migraine preventive drug has been marketed.
Hence, there is a need for new preventive therapies with
similar or better clinical efficacy, and most importantly
fewer treatment-related side effects.
Peripheral nerve stimulation (PNS) has shown promis-
ing preventive properties in episodic and chronic migraine
[5]. PNS conveys its effects by the electrical stimulation of
peripheral nerves branches either sub- or percutaneously
with implantable devices, or transcutaneously via superfi-
cial skin electrodes linked to external neurostimulators.
Due to its invasiveness percutaneous PNS like occipital
nerve stimulation (ONS) was used hitherto only in the
most disabled migraine patients [5-7]. Transcutaneous
PNS have the advantage of being non-invasive and thus
applicable also in less severely disabled subjects suffering
from episodic migraine.
We have shown previously in a randomized double-blind
sham-controlled trial that transcutaneous supraorbital neu-
rostimulation (tSNS) is effective in the preventive treat-
ment of episodic migraine (the PREMICE trial, [8]). In this
study, subjects were treated with an external ultra-portable
and user-friendly tSNS device stimulating both supra-
orbital nerves, the Cefaly® device (CEFALY Technology,
Herstal, Belgium). After daily 20 minutes tSNS sessions
for 3 months, the 50% responder rate was 38.2% for ac-
tive tSNS vs.12.1% for sham stimulation [8]. The effect
was significant, and within the range of other migraine
preventive therapies. Moreover, there were no side ef-
fects or drop-outs due to device-related adverse events.
However, the number of subjects included in this trial
was limited to 67 patients recruited in tertiary headache
clinics. It remains therefore to be studied how tSNS with
the Cefaly® device performs in larger cohorts of headache
sufferers in the general population. For this purpose, wehave conducted a survey of subjects who rented the device
via Internet for 40 days, in order to assess safety and satis-
faction of tSNS in a large cohort of more than 2000 head-
ache sufferers.
Methods
Subjects
A prospective registry of 2,573 headache sufferers who
rented the tSNS Cefaly® device (CEFALY-Technology,
Liège, Belgium) was established between September 2009
and June 2012. Most subjects were French or Belgian citi-
zens, while a minority lived in Switzerland, three countries
where subjects can directly rent and buy the device via the
Internet without medical prescription. The device can be
rented at a cost of 49€ for 40 days, where after the patient
has to decide either to return the device or to keep it and
pay the balance between its cost of 295€ and the rental fee.
Transcutaneous supraorbital neurostimulation
tSNS was delivered with an external self adhesive elec-
trode placed on the forehead (Figure 1, Cefaly® device,
CEFALY Technology, Liège, Belgium). The bipolar elec-
trode (30 mm × 94 mm) covers bilaterally the origins of
the supraorbital nerves (branches of 1st trigeminal
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impedance of 2.2 KΩ) generates biphasic rectangular
impulses with an electrical mean equal to zero (pre-
ventive stimulation protocol: impulse width 250 μS, fre-
quency 60 Hz, maximum intensity 16 mA). All subjects
received an explicative leaflet advising to perform tSNS
at least once daily in order to obtain a preventive anti-
migraine effect. As single sessions have a fixed duration
of 20 minutes, the recommended minimal total time of
use was 800 minutes in subjects renting the device for
40 days. A built-in electronic system allowed recording
of the total time of tSNS use in subjects who returned
then device to the manufacturer after the trial period.
Data collection and processing
The objectives of this survey were to record self-reported
adverse events and to assess the satisfaction of subjects
who received the tSNS Cefaly® device at home with its ac-
cessories for the rental period.
After the end of this rental period they were contacted
to answer to the following questions:
1. Which kind of medication do you usually take to
treat your headache attack?
2. Did you have side effects when using tSNS or any
complaint or comment about the device?
3. Did you encounter technical issues with the device?
4. Are you satisfied with tSNS and do you want
continue the treatment?
“Satisfied” subjects who wanted to keep on the treat-
ment had to purchase the device (i.e. to pay 246€),
whereas “unsatisfied” subjects sent it back by surface
mail.
The devices collected from unsatisfied subjects were
analyzed for the total time of tSNS use in order to esti-
mate compliance.
A trained medical secretary was paid by the manufac-
turer to contact all subjects by phone or e-mail after the
rental period. Phone contact was tried in the morning,
at noon and in the afternoon; an e-mail was sent in case
the person did not answer the phone. This was repeated
for up to 2 weeks until a formal contact was achieved.
A total of 2,573 patients rented the device during the
29 months of the survey; 26 never responded to the
phone calls or e-mails; 234 were not using triptans and
were not included in the survey, as they were assumed
not to suffer from migraine. In the three involved coun-
tries (Belgium, France and Switzerland) triptans are in-
deed only delivered and/or reimbursed with a medical
prescription certifying that the patient has a diagnosis of
migraine according to ICHD-II criteria [9].
The diagram in Figure 2 depicts the sequential steps of
the survey.According to European regulations on non-interventional
studies with medical devices (CE directive 93/42 and
ISO 13485) this survey did not require ethics committee
approval.
Results
According to the triptan use selection criterion, 2,313 head-
ache sufferers were included in the survey (age 14–87 years,
1641 females i.e. 70.95% and 672 males i.e. 29.05%): 1,208
(52.2%) from France, 999 (43.2%) from Belgium and 106
(4.6%) from Switzerland. The average rental period, com-
puted from the day they received the device until they were
actually contacted to answer the questions, was 58.2 ±
33.6 days.
Safety
Ninety-nine subjects reported at least one adverse event
(AE) during tSNS therapy, i.e. 4.3% of all subjects. In the
subgroup of unsatisfied patients the AEs rate was 5.48%
(59 patients) and it was 3.24% (40 patients) in the sub-
group of satisfied patients. Five patients reported more
than one AE, one in the satisfied subgroup and four in
the unsatisfied subgroup. Forty-six subjects, i.e. 2%,
stopped tSNS because of an AE. None was serious and
all were fully reversible. The most remarkable AE was a
forehead skin allergy in 2 subjects (0.09%).
Table 1 is an exhaustive list of all AEs recorded.
The most frequent AE was intolerance to the paresthesia
induced by the electrical stimulation (N= 31, 46% of all
AEs), despite the fact that the subjects were allowed to
interrupt the gradual intensity increase from 0 to 16 mA
by pressing the “on” button as soon as the forehead sensa-
tion became uncomfortable. All subjects complaining of
paresthesia intolerance stopped the treatment. Some other
painful feelings were reported: 3 strong pressure feelings
on the forehead, 2 dental and 2 cervical pains during the
session. Two subjects felt paresthesia more on one side of
the forehead. While the paresthesia stopped in most sub-
jects at the end of the stimulation, 4 individuals reported
that the forehead paresthesia persisted for several hours
after the end of the stimulation.
Twelve subjects (0.52%) complained after the tSNS
session of tension-type like headache that led to treat-
ment interruption.
Arousal and sleep changes were the second most fre-
quently reported AEs (19 subjects or 18.6% of all AEs).
Among them, sleepiness during the stimulation was re-
ported by 12 subjects, while 4 complained of insomnia.
Three subjects (3.03%) complained of a feeling of stress
during the tSNS session.
Three subjects had nausea and vomiting at the end of
a session, but did not complain of headache.
Two subjects reported not being able to keep their eyes
open during the stimulation. Two reported increased
n=2,573
Subjects not includedNo Triptan
use
Patients not satisfied, 
Cefaly® device returned 
and time of use analysed 
(46.6%)
No
Patients satisfied
(53.4%)
Yes 
Internet order of a 
Cefaly® device
for a 40- day rental  
period
Home delivery of 
Cefaly® and start 
of the rental period
Willing to keep 
(and purchase) the 
Cefaly® device?
Phone contact at 
the end of the 
rental period
AE reporting
Subjects not includedNo contact
n=26
Question on acute 
medication use
n=234
n=2,313
Contact succeeded
Triptan users
Subjects included
n=1,236
n=1,077
Figure 2 Study flow chart.
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Table 1 AE reported by the patients within the trial period
Number of patients Percentage of AE Percentage of patients
Do not like the feeling and do not want to continue using the device 29 29.29% 1.25%
Sleepiness during the Cefaly® session 12 12.12% 0.52%
Headache after a Cefaly® session 12 12.12% 0.52%
Reversible forehead skin irritation 5 5.05% 0.22%
Insomnia 4 4.04% 0.17%
Feeling of fatigue 3 3.03% 0.13%
Persistent forehead paresthesia for several minutes after the session 3 3.03% 0.13%
Feeling of stress during the session 3 3.03% 0.09%
Allergic skin reaction 2 2.02% 0.09%
Dental pain during the session or at the beginning 2 2.02% 0.09%
Inability to keep eyes open during sessions 2 2.02% 0.09%
Feeling of contusion on the forehead during a few days 2 2.02% 0.09%
Pre-existing tinnitus increased during the session 1 1.01% 0.04%
Tinnitus appearing during some sessions 1 1.01% 0.04%
Red eye after a session 1 1.01% 0.04%
Eyes weeping during a session 1 1.01% 0.04%
Wake up during night with a feeling of anxiety and tremor 1 1.01% 0.04%
Vertigo during the first session 1 1.01% 0.04%
Vomiting after a session 1 1.01% 0.04%
Forehead skin burning sensation during a session 1 1.01% 0.04%
Cervical pain during sessions 1 1.01% 0.04%
Cervical pain with nausea after the two first sessions 1 1.01% 0.04%
Short feeling of electrical shock 1 1.01% 0.04%
Slight pain at one eyebrow during the first session 1 1.01% 0.04%
Nausea and vertigo during sessions 1 1.01% 0.04%
Nausea during sessions 1 1.01% 0.04%
More head pain when using the device during a headache 1 1.01% 0.04%
Forehead and cranial anaesthesia feeling during a few hours after a session 1 1.01% 0.04%
Pressure feeling between the eyebrows during sessions 1 1.01% 0.04%
Numbness at the back of the head after a session 1 1.01% 0.04%
Stronger paresthesia feeling on the left side 1 1.01% 0.04%
Stronger paresthesia feeling on the right side 1 1.01% 0.04%
Subjective tachycardia during a session 1 1.01% 0.04%
Migraine feeling during sessions 1 1.01% 0.04%
Complaints reported by patients.
Magis et al. The Journal of Headache and Pain 2013, 14:95 Page 5 of 8
http://www.thejournalofheadacheandpain.com/content/14/1/95tinnitus during the session, one a red eye and another
one tearing.
Five subjects (5%) complained about transient skin ir-
ritation and 2 subjects had a local cutaneous reaction,
probably allergic to the electrode gel containing acrylate
(2% of all AEs, and 0.09% of all subjects) (Figure 3).
These patients did not report a history of allergy to ad-
hesive tapes but one of them had previously suffered
from an allergic skin reaction.The four remaining AEs were single and mild: numb-
ness at the back of the head, slight pain over one eye-
brow, feeling of abrupt electrical variation, tachycardia
during one session.
Satisfaction
Out of 2,313 subjects, 1,236 (53.4%) were satisfied with
the tSNS therapy and wanted to continue the treatment.
These subjects purchased the Cefaly® device. On the
Figure 3 Allergic skin reaction.
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tSNS and sent back the device.
Compliance
The devices collected back from the 1,077 non-satisfied
subjects who discontinued the therapy were analyzed for
time of use (Table 2). A built-in electronic system in each
device recorded the total time of use. In these 1,077 unsat-
isfied subjects the mean time of use was 583 ± 903 mi-
nutes, for an average rental period of 49.5 ± 26.7 days. As
the recommended treatment schedule was one session of
20 minutes per day, their time of use was 58.8% of the rec-
ommended time.
Interestingly, 4.46% of “unsatisfied” subjects (N = 48,
2.08% of all subjects) did not even switch on the device,
and 19.03% used it less than 60 minutes. Conversely,
40% of the discontinuers applied the tSNS for more than
400 minutes over the rental period (N = 431, 18.63% of
all subjects), which was probably sufficient to achieve a
therapeutic effect. If we exclude from the survey subjects
who never switched on the device, i.e. who did not try
the treatment at all, the percentage of satisfied subjects
raises to 55.51%. Also, if one accepts that 400 minutes of
treatment are necessary to obtain a treatment effect,
only 18.63% of all subjects would be classified as non-Table 2 Compliance in the 1,077 unsatisfied subjects
Total time of use (minutes) Number of subjects (percentage)*
0 48 (4,46%)
1 to 20 58 (5,39%)
21 to 40 46 (4,27%)
41 to 60 53 (4,92%)
60 to 100 78 (7,24%)
100 to 200 174 (16,16%)
200 to 400 189 (17,55%)
> 400 431 (40.02%)
*Number (and percentage) of unsatisfied subjects who used the device for the
time indicated in the first column i.e. 48 “unsatisfied” subjects did not switch
on the device, 58 used the device between 1 and 20 minutes, 46 between 21
and 40 minutes, etc.responders; the compliance of the other discontinuers
(N = 646) was not large enough to assess a treatment
response.
Out of the 646 patients who used their device less than
400 minutes 56 reported AEs (8.64%), i.e. twice more the
AE rate for all subjects. In patients who used the device at
least 400 minutes the AE rate was 1.85%.
Discussion
This survey on a large cohort of 2,313 headache suf-
ferers in the general population provides important data
on tolerance and safety of tSNS with the Cefaly® device
as well as some information about its performance.
First, it underscores the safety of tSNS and the low in-
cidence of self-reported AEs (4.3% of 2,313 subjects).
About half (2%) of these subjects discontinued the ther-
apy because of an AE. In the PREMICE trial [8] the 34
subjects randomized to the effective tSNS (verum) arm
reported no AE and none dropped out, which can be ex-
plained by the small number of patients. In the present
survey the most frequent adverse effect was intolerance
to forehead paresthesia that was perceived as painful
burning sensations. As a matter of fact, paresthesia is a
“normal” sensation linked to every PNS, and responsible
for the difficulty in effectively blinding such studies. It is
common experience, however, that a number of subjects
in the general population do not tolerate the sensations
induced by cutaneous electrical stimuli even at low inten-
sities. This intolerance may be pronounced in migraine
sufferers and might be related to the cutaneous allodynia
that may persist in some of them between attacks [5]. Sub-
jects reporting sleepiness confirm that tSNS can have seda-
tive properties, as shown previously in a study of healthy
volunteers [10]. Finally, the most remarkable and cumber-
some AE was skin allergy under the forehead electrode
(0.09%). Though very rare, such an allergic reaction is well
known for self-adhesive electrodes and attributed to the
acrylate component of the electrode gel [11]. It is fully re-
versible within 10 days after removing the electrode and
can be avoided by using a newly developed hypoallergenic
gel without acrylate.
Second, this survey indicates that 53.4% of subjects
were satisfied with the tSNS after a trial period of on
average 58 days, and decided to continue the treatment
and to purchase the device. Although this is a purely
subjective global assessment, patients’ satisfaction could
somehow parallel treatment effectiveness. In the PRE-
MICE trial, 70.6% of episodic migraineurs were satisfied
with the treatment (29.4% very, 41.2% moderately satis-
fied) [8]. The global rate of satisfaction is lower in the
present survey, but one has to take into account that
subjects had to pay 246€, i.e. the difference between the
full price and the rental cost, to purchase the Cefaly® to
keep the device for treatment continuation, and that the
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pliance to tSNS therapy was 58.8% in subjects who dis-
continued the treatment while in the PREMICE study it
was 61.7% in the total group of patients. This slight dif-
ference can be due to the fact that only the devices of
unsatisfied subjects could be analyzed for time of use.
Moreover, patients included in the PREMICE trial were
recruited by established headache specialists and thus
well educated in headache management including the
use of headache diaries while the majority of subjects in-
cluded in the present survey had no regular neurological
follow-up.
If we exclude from the analysis those 48 unsatisfied
subjects who never used the device, the rate of satisfied
subjects raises to 55.5%. It is likely that non-satisfied
subjects who used the device for less than 400 minutes
(N = 646, 27.9% of the 2,313 subjects and 59.98% of the
unsatisfied subjects) were not sufficiently dosed to expect
a therapeutic effect, although they may have experienced
adverse effects. Conversely, those 40% of unsatisfied sub-
jects (18.6% of the 2,313 subjects) who applied tSNS for
more than 400 minutes, i.e. for a potentially effective dur-
ation, are most probably genuine non-responders.
The survey presented here has several weaknesses. The
major one is that we have no certainty about the precise
diagnosis of included subjects, which is the reason why we
have focused our analysis on safety and tolerance. We
assume that a majority of them probably suffered from
migraine because they were using triptans for the treat-
ment of headache attacks. In the three involved countries
(Belgium, France and Switzerland) triptans are not avail-
able over-the counter, but delivered and reimbursed only
with a medical prescription certifying that the patient suf-
fers from migraine according to ICHD-II criteria [9]. Trip-
tan users are thus most likely to have been diagnosed as
migraineurs by a general practitioner and/or a neurologist.
Whether they suffer from episodic or chronic migraine,
from migraine with or without aura cannot be determined
in our survey. Possible diagnostic confounders are mis-
diagnosed headache, tension-type headache, medication
overuse headache and cluster headache.
Other weaknesses are the absent control for concur-
rent drug treatment and for natural history of the head-
ache disorder, as well as the outcome parameter and the
time point at which it was assessed. As mentioned above,
patients’ satisfaction, the only parameter available here, is a
composite subjective outcome measure combining efficacy,
tolerance, adverse effects, expectations and, in this case,
willingness to pay. It is not a recommended primary meas-
ure of efficacy, like the number of headache days, and it
does not necessarily parallel a reduction in headache fre-
quency. Despite its shortcomings, however, patients’ satis-
faction is considered to be valuable in pragmatic trials such
as ours, according to the IHS guidelines for controlledtrials of drugs in migraine [12]. The time point of about
60 days of tSNS at which the subjects’ satisfaction was
assessed may not be optimal. In the PREMICE trial the
treatment period was 3 months and the reduction in mi-
graine day frequency was maximal at the end of the 3rd
month [8]. The tSNS efficiency may thus be underesti-
mated in our survey, though this would probably concern
only a minority of subjects, since the therapeutic advantage
over sham stimulation was already significant at the end of
the 2nd month of treatment in the PREMICE trial [8].
Finally, we cannot exclude the possibility that some indi-
viduals in whom the device was effective did not purchase
it for financial reasons, which would have led to an over-
estimation of the proportion of non-satisfied subjects.
Because of these shortcomings no definitive conclu-
sion about therapeutic efficacy can be drawn from this
survey.
Conclusions
This survey of 2,313 headache subjects treated with tSNS
is to the best of our knowledge the largest database avail-
able for a neuromodulation treatment in headache. Its
major contribution is to confirm the safety and excellent
tolerance of tSNS therapy with the Cefaly® device. Adverse
events were reported by only 4.3% of subjects and they
were all minor and reversible. The most frequent AE was
intolerance to the local paresthesia, which is a common,
though rare, reason for treatment interruption in every
PNS therapy. About 2% of subjects stopped the tSNS ther-
apy because of an AE, which is remarkably low compared
to preventive anti-migraine drugs [3]. Although this sur-
vey does not allow reliable deductions about efficacy for
methodological reasons, it provides some clinically useful
indications about patients’ satisfaction and compliance.
Among the 2,313 subjects, 53.4% were satisfied with the
treatment and the device, and decided to buy it. The mean
time of tSNS use in those subjects who discontinued the
therapy was 58.8% of the recommended time; 4.46% of
“unsatisfied” subjects did not even switch on the device,
and 19.03% used it for less than 60 minutes. Hence, low
compliance to tSNS is an issue that might explain lack of
efficacy in a number of subjects.
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http://www.thejournalofheadacheandpain.com/content/14/1/23RESEARCH ARTICLE Open AccessTranscranial Direct Current Stimulation (tDCS)
of the visual cortex: a proof-of-concept study
based on interictal electrophysiological
abnormalities in migraine
Alessandro Viganò1,3,4, Tullia Sasso D’Elia1,4, Simona Liliana Sava1, Maurie Auvé1, Victor De Pasqua1,
Alfredo Colosimo3, Vittorio Di Piero4, Jean Schoenen1,2† and Delphine Magis1*†Abstract
Background: Preventive pharmacotherapy for migraine is not satisfactory because of the low efficacy/tolerability
ratio of many available drugs. Novel and more efficient preventive strategies are therefore warranted. Abnormal
excitability of cortical areas appears to play a pivotal role in migraine pathophysiology. Transcranial direct current
stimulation (tDCS) is a non-invasive and safe technique that is able to durably modulate the activity of the
underlying cerebral cortex, and is being tested in various medical indications. The results of small open studies
using tDCS in migraine prophylaxis are conflicting, possibly because the optimal stimulation settings and the brain
targets were not well chosen. We have previously shown that the cerebral cortex, especially the visual cortex, is
hyperresponsive in migraine patients between attacks and provided evidence from evoked potential studies that
this is due to a decreased cortical preactivation level. If one accepts this concept, anodal tDCS over the visual
cortex may have therapeutic potentials in migraine prevention, as it is able to increase neuronal firing.
Objective: To study the effects of anodal tDCS on visual cortex activity in healthy volunteers (HV) and episodic
migraine without aura patients (MoA), and its potentials for migraine prevention.
Methods: We recorded pattern-reversal visual evoked potentials (VEP) before and after a 15-min session of anodal
tDCS over the visual cortex in 11 HV and 13 MoA interictally. Then 10 MoA patients reporting at least 4 attacks/
month subsequently participated in a therapeutic study, and received 2 similar sessions of tDCS per week for 8
weeks as migraine preventive therapy.
Results: In HV as well as in MoA, anodal tDCS transiently increased habituation of the VEP N1P1 component. VEP
amplitudes were not modified by tDCS. Preventive treatment with anodal tDCS turned out to be beneficial in MoA:
migraine attack frequency, migraine days, attack duration and acute medication intake significantly decreased
during the treatment period compared to pre-treatment baseline (all p < 0.05), and this benefit persisted on
average 4.8 weeks after the end of tDCS.
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Conclusions: Anodal tDCS over the visual cortex is thus able to increase habituation to repetitive visual stimuli in
healthy volunteers and in episodic migraineurs, who on average lack habituation interictally. Moreover, 2 weekly
sessions of anodal tDCS had a significant preventive anti- migraine effect, proofing the concept that the low
preactivation level of the visual cortex in migraine patients can be corrected by an activating neurostimulation.
The therapeutic results indicate that a larger sham-controlled trial using the same tDCS protocol is worthwhile.
Keywords: Migraine, Habituation deficit, tDCS, Treatment, Visual cortexBackground
Finding the ‘right’ migraine preventive treatment often
remains a challenge in many patients. The drugs currently
used in migraine prophylaxis (such as antiepileptics, beta
blockers. . .) are not migraine-specific, unlike acute thera-
pies like triptans or gepans, which were designed to treat
headache. Moreover, they are not devoid of side-effects
and their efficacy rarely exceeds 50-60% for the best of
them [1]. Chronic migraine patients, i.e. the presence of at
least 15 days of headache per month, of which at least 8
migraine attacks, represent almost the 2-3% of the popula-
tion and they are particularly difficult to manage as their
response to existing preventive therapies is often unsatis-
factory [2,3]. There is thus a need for new effective and
well-tolerated treatments in migraine prophylaxis. The
latter should ideally be more disease-specific, i.e. designed
to counteract the dysfunctions known to be involved in
migraine pathogenesis.
Migraine is a complex and heterogeneous disorder, in
which genetics and environment interact to generate
dysfunctioning paths and loops at several levels of the
central nervous system. These intricate phenomena are
responsible for the multifaceted clinical features of the
disease and especially its dynamics characterized by a cyclic
ictal-interictal pattern and the repetition of attacks [4].
It has been known for a long time that the brain excit-
ability is abnormal in migraine during the interictal
period [5]. However many past studies on cortical excit-
ability had provided conflicting results, and whether the
brain was hyperexcitable [6-8] or hypoexcitable [9-12]
remained extensively debated for years. A recent theory
proposed a semantic modification that was able to unify
these opposite hypotheses, i.e. that the brain cortex was
not hyperexcitable per se but hyperresponsive to sensory
stimuli in migraine between attacks [13]. A reproducible
hallmark mirroring this hyperresponsiveness is the lack
of habituation to repeated sensory or cognitive stimu-
lations reported in both evoked potentials and neuroi-
maging trials (for review, see [14]). Habituation is defined
as a behavioural response decrement that results from
repeated stimulations and does not involve sensory
adaptation or fatigue, i.e. a decrease in peripheral receptor
activity [15]. According to Groves and Thompson, habitu-
ation relies on the balance of two opposite mechanisms,facilitation and depression of brain responses to a sensory
stimulus.
In the interictal period of migraine, many evoked poten-
tials studies to various sensory modalities found on average
lower initial response amplitudes followed by a decreased
habituation -or even a potentiation- of subsequent re-
sponses, whereas in healthy subjects a higher initial re-
sponse preceded a more pronounced habituation. These
results paved the way to the hypothesis that the lack of ha-
bituation was possibly due to a lower preactivation level of
brain sensory cortices, according to the ceiling theory [16].
Recent studies suggested that this lower preactivation
level could be the consequence of impaired functional
thalamocortical loops, the so-called Thalamocortical Dys-
rhythmia, a dysfunction, which is also involved in other
neurological diseases [17,18]. Further works demonstrated
that the lack of habituation was not constant and normal-
ized just before and during the migraine attack. Interest-
ingly, it was recently shown that in chronic migraine
patients habituation was normal [19] but evolved to po-
tentiation when these chronic migraineurs went to re-
mission towards episodic migraine [20], suggesting that
chronic migraine could be considered as a “never-ending
attack” [21].
In the last decade there has been an increasing interest
for neuromodulation in migraine treatment [22]. Even if
randomized controlled trials are scarce, some preliminary
results are encouraging and peripheral and central
neuromodulating techniques are considered as promising
alternatives to pharmacological treatment. Among them, 2
central non-invasive techniques appear particularly suit-
able for migraine preventive treatment: repetitive transcra-
nial magnetic stimulation (rTMS) and trancranial Direct
Current Stimulation (tDCS). Both are able to durably
modify the excitability of the underlying cortex and could
potentially correct the functional abnormalities found in
migraine patients. They were already applied in several
other neurological diseases with some success [23]. High
frequency (around 10 Hz) rTMS stimulation can increase
brain excitability, while low frequency rTMS (about 1 Hz)
is able to decrease it [23,24]. Anodal tDCS appears to
increase brain excitability, while cathodal tDCS stimula-
tion decreases it [23,25-27] though not all studies agreed
on this point [28].
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migraine prevention, and their results were conflicting
[29-31]. This could be due to dissimilarities in their stimu-
lation protocols, as stimulated brain regions as well as
stimulation frequencies, length and intensities were diffe-
rent and depended on the baseline pathophysiological
hypothesis, mainly the belief that the migrainous brain was
hyperexcitable or, on the contrary, hypoexcitable. More-
over, these trials did not assess the brain excitability before
and after treatment. In a previous study, we had reported
that a single 10 Hz excitatory rTMS session was able to
restore normal habituation and initial amplitude of visual-
evoked responses (VEPs) in migraineurs, and that this
effect lasted at least 9 minutes. In a subsequent trial, this
stimulation was applied on 5 successive days, but the VEPs
normalization did not exceed several hours in most
migraineurs. However, these results had not been applied
in a preventative therapeutic study for now, and
whether the normalization of habituation was associated
to a clinical improvement remained unknown [12,32].
We therefore performed a pilot proof-of-concept study
combining the two approaches for the first time, but
we used anodal (i.e. excitatory) tDCS instead of 10 Hz-
rTMS. This was a 2-step trial: we first repeated the
electrophysiological study in healthy volunteers and
migraineurs in order to ensure that anodal tDCS could
modulate habituation and correct the impaired interictal
excitability in migraineurs like rTMS, then in the second
phase the same stimulation paradigm was converted into
a preventive therapy for episodic migraine in a prospective
pilot trial.
Methods
1. Subjects and clinical records
Eleven healthy volunteers (HV) were enrolled for the
electrophysiological study (5 males and 6 females, mean
age 25.8 ± SD 5.7 years). Exclusion criteria were: age below
18 or above 65 years, a personal history of recurrent head-
ache or other neurological diseases especially seizures,
familial history of recurrent headache, child migraine
equivalents (motion sickness, cyclic vomiting or recurrent
abdominal pain, somnambulism etc.. . .), chronic pain
syndromes, analgesics intake at the time of recording, and
contra-indications to tDCS neurostimulation (metal pros-
thetics in the head or internal stimulation like a pace-
maker). They were compared to 13 migraineurs without
aura (MoA) according to the second International Classifi-
cation of Headache Disorders (ICHD-IIR) criteria (2 males
and 11 females, mean age 29.3 ± 5.1). Patients had more
than 2 and less than 8 attacks/month and were not under
preventive therapy for at least 3 months before the experi-
mental day. All volunteers and patients were naive to anykind of neurostimulation, i.e. they never got this type of
treatment before (central or peripheral neurostimulation),
whatever the indication was. Patients were recruited
in the outpatient clinic through headache-specialized
consultations (DM and JS).
The therapeutic study involved 10 migraineurs suffering
from episodic MoA (2 males and 8 females, mean age
38.4 ± 16.3) with a frequency ranging between 3 and 8
attacks/month, knowing that none of them fulfilled the cri-
teria for chronic migraine. Only two of them were previ-
ously involved in the electrophysiological study. Intake of a
drug preventive treatment was allowed in the therapeutic
study only, but this pharmacological therapy had to be
stable for at least 2 months. Five out of the 10 enrolled pa-
tients were under preventive therapy at the moment of the
trial: one was taking riboflavin alone, two riboflavin associ-
ated with a beta-blocker (metoprolol or propranolol), the
other two were under topiramate. All of them had treat-
ment for several months and this treatment did not give
them any satisfaction. The average time under prophylactic
therapy at inclusion was 3.2 months (2 patients were under
preventive therapy for 2 months, the other 3 for 4 months).
During the whole therapeutic study period the patients
were asked to fill a headache diary to record migraine
attacks, migraine and headache days, pain intensity in a
scale from 1 (light) to 3 (severe), duration of attack (hours),
medication intake, and associated symptoms (nausea,
vomiting, photo- and phonophobia). This headache
diary had to be completed at least 2 months before
the treatment initiation, in order to have a 2-month
pretreatment baseline.
All subjects participating in the electrophysiological
and/or the therapeutic studies received detailed oral
and written explanations of the whole experiment
provided by the experimenter (AV or TSD) and gave
written informed consent. This study was approved
by the local Ethics Committee of the CHR Citadelle
Hospital of Liège, Belgium.
2. Material and stimulation protocols
Electrophysiological study
For the electrophysiological study we recorder pattern
reversal visual evoked potentials (PR-VEPs), as described
before [33]. PR-VEPs were selected as they are one of
the best studied electrophysiological responses in migraine,
where a decreased preactivation level and a lack of habitu-
ation has been reported in many studies [34]. Briefly,
subjects sat in a comfortable armchair in a quite dark room
at a +/− 90 cm distance from the monitor. They were
asked to relax and to fix a red sticker in the centre of the
screen (Nicolet™; 24 × 18 cm) with their right eye, the left
eye being covered by a patch. The visual stimulus was a
checkerboard pattern of black and white squares (15 mm
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temperature 9500 K) alternating at a frequency of 3.1 Hz.
Pin-electrodes were used to record the signal: the active
electrode was inserted at Oz and was referenced to Fz
according to the 10–20 system [34]. The ground electrode
was fixed to the right forearm. During uninterrupted
stimulation, 600 cortical responses were recorded
(CED™ 1902 preamplifier and CED™Micro1401 converter;
Cambridge Electronic Design Ltd, Cambridge, UK). Two
hundred and fifty milliseconds of the poststimulus period
were sampled at a rate of 4000 Hz.
Acquisitions were made at baseline (T0), immediately
after (T1) and 3 hours after (T2) a single anodal tDCS
session (see below). At the end of the first VEPs recording
(T0), the place of the pin electrodes was marked with a
pen, in order to ensure that their locations remained the
same in the subsequent recordings (T1 and T2). Hence,
after T1 the subjects had a 3-hour free time before coming
back to the laboratory for T2 acquisition. During this
period, they were not allowed to smoke, to drink alcohol
or beverages containing caffeine or other energy drinks,
and to take a nap. All recordings were distant from at least
72 hours of a migraine attack. The time of the last attack
was checked on patient’s diary and the absence of an
attack occurrence within the next 72 hours after the
experiment was checked by phone call. To avoid changes
of cortical excitability due to hormonal variations, all
female subjects performed the experiment in the first half
of the menstrual cycle.6° Block
5° Block
3° Block
4° Block
2° Block
1° Block
P1
N1 N2
N1 N2
P1
Figure 1 The time-dependent changes of N1P1 and P1N2
components of visual evoked potentials in a healthy subject.
Over six blocks of 100 averaged single trial responses a reduction in
amplitude of both components is shown, in the representative example.Anodal tDCS
Anodal tDCS stimulation was performed using a program-
mable DC stimulator (NeuroConn, Ilmeanu, Germany©)
with 2 rubber electrodes (5x7cm). The anode was placed in
the occipital region near Oz in order to stimulate the
underlying visual cortex, and the cathode was fixed
on the chin. We chose to put the cathode outside
the cranial vault in order to avoid a concomitant
inhibition of other cerebral cortices, for example the
frontal cortex when Fz had been chosen as cathode.
The subjects were stimulated at 1 mA intensity and
each session lasted 15 minutes. To decrease their
possible discomfort the stimulation increased gradually
during the first 8 seconds and decreased progressively
within the last 8 seconds of the tDCS.
Thus, the electrophysiological study comprised a
single tDCS session and in the therapeutic pilot
study anodal tDCS was applied twice a week for 8 weeks,
i.e. 16 sessions, using the same tDCS parameters.
The 2 weekly sessions were fixed, i.e. were always
applied the same days during the whole treatment
period of a single patient (for example, every Tuesday
and Friday).3. Data analysis and statistics.
In the electrophysiological study, the 600 PR-VEP
responses were averaged off-line into six blocks of 100
responses using Signal™ software version 4 (Cambridge
Electronic Design Ltd, bandpass 1–100 Hz). The peak-to
-peak N1–P1 and P1-N2 amplitudes were measured, N1
being the most negative point around 70 ms latency after
the stimulus (range 60–90), P1 the most positive around
100 ms latency (range 80–130) and N2 the most negative
point following P1 between 90 and 200 ms. To visualize
better the slope of N1P1 and P1N2 amplitude changes over
the total duration of visual stimulation, a linear regression
analysis of the mean amplitudes in the 6 blocks of 100
averages responses was performed and considered as the
reflect of habituation degree (see Figure 1). Hence, a
normal habituation gave a negative slope value, while
potentiation gave a positive slope. We calculated means
and standard deviations for the first block amplitude (first
100 averaged N1P1 VEP responses, ìV, which reflects
cortical preactivation level – see above introduction) and
N1P1 and P1N2 habituation slopes, at T0, T1 and T2, and
compared them between HV and MoA.
In the therapeutic study we followed prospectively the
evolution of migraine attack frequency, migraine days,
mean pain intensity, attack duration and acute drugs intake
during treatment with tDCS, compared to the baseline.
We compared baseline clinical variables (2nd month) with
those of the 2nd month of tDCS treatment, to study the
cumulative effect of the repeated stimulation.
Statistical calculations were carried out using
STATISTICA (version 7, StatSoft, Oklahoma, USA).
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tion of the variables. Since most of them did not fit the
normal distribution, we used Wilcoxon signed-rank test
(paired samples) to study modifications induced over
time by tDCS within the same subjects, and we employed
Whitney–Mann U-test to compare electrophysiological
values between HV and MoA groups. The time-dependent
changes in habituation were assessed with one-way analysis
of variance (ANOVA) for repeated measures. We also did
a post-hoc comparison with Wilcoxon signed-rank test. All
results were considered significant at p < 0.05.
Results
Electrophysiological study
The results of the electrophysiological study are presented
in Table 1 and Figure 2.
In baseline (T0), HV and MoA did not differ in first
PR-VEP block amplitude, nor in N1P1 habituation slopes
(p > 0.05). However, P1N2 habituation slope was signifi-
cantly deeper in HV than in MoA (−0.23 in HV vs. -0.05
in MoA; p = 0.04), which mirrors a lack of habituation in
MoA compared to HV.
In the HV group, anodal tDCS stimulation had no effect
on PR-VEP first block amplitude (N1P1: 6.1 μV ±2.0 at T0
vs. 6.8 μV ±2.6 at T1; p = 0.45; P1N2: 6.6 μV ±2.1 at T0 vs.
6.5 μV ±2.0 at T1; p = 0.49), and did not modify the ampli-
tude of subsequent blocks (Table 1). However, the habitu-
ation slope of N1P1 amplitude became more negative
after tDCS stimulation, i.e. tDCS was able to strengthen
habituation in HV at T1 (p = 0.024, Figure 2 Panel A) but
this change in habituation did not persist after 3 hours
(T2) where it returned on average to baseline values.
In the MoA group, anodal tDCS did not induce any
significant effect on VEP amplitudes as well (Table 1).
However, like in HV, N1P1 and P1N2 habituations in-
creased immediately after anodal tDCS (T1), and for
N1P1 slope this change was significant ( −0.11 to −0.24Table 1 This table shows the results of the electrophysiologic
and P1N2, μV), and habituation slopes in healthy volunteers
and 3 h after anodal tDCS
Groups and VEP comparison First block amplitude (μV
Before After
Healthy volunteers
(n=11)
N1P1 6.1±2.0 6.8±2.6
P1N2 6.6±2.1 6.5±2.0
Episodic migraineurs
(n=13)
N1P1 7.1±2.9 7.3±3.1
P1N2 6.6±2.6 6.4±2.9
The * mark corresponds to a significant change (p < 0.05).after tDCS, p = 0.04, Figure 2 Panel C), meaning that
tDCS was also able to increase the habituation level in
MoA. These changes did not last for a long time and
returned to baseline at T2 as well.
Therapeutic study
The results of the pilot therapeutic study with anodal tDCS
in MoA are presented in Figure 3 and are encouraging.
Hence, during the 8 weeks of anodal tDCS treatment,
there was already on average a significant reduction of
migraine frequency, which was decreased from 9.6 days
in 2 months to 6.3 (34%,p = 0.005), while there was a re-
markable reduction in the number of migraine days from
15 to 8 (47%, p = 0.01). The average cumulative attack
duration over 2 months decreased from 184 to 119 hours
(35%, p = 0.043), and the average acute treatment intake
dropped from 18 tablets to 13 in two months (p = 0.041).
The duration of each attack slightly decreased as well, but
in a non-significant manner (p = 0.70).
We performed a further subanalysis where we only
considered the outcome within the last 4 weeks of tDCS,
which was compared to the baseline diary of the month
preceding tDCS application, on the assumption that the
clinical effect would improve with the repetition of tDCS
sessions. Migraine frequency reduction was more pro-
nounced during the second month of therapy, with a
mean decrease from 5 to 3 attacks (−38%; p = 0.03),
the number of migraine days also decreased from 8
to 4.3 (48%, p = 0.002), and noteworthy the average
attack duration dropped from 88.5 to 33.2 (60%, p = 0.02).
The drug intake tended to decrease from 9 pills/month to
6 pills/month (28%, p = 0.06).
To rule out a pure long-term pharmacological effect of
the ongoing preventive therapy we then compared
patients with (N = 5) and without (N = 5) migraine
preventive treatment. The evolution under tDCS treat-
ment was similar in both groups: patients without drugal study: Pattern Reversal-VEP initial amplitudes (N1P1
(HV) and episodic migraineurs (MoA), before, just after
) Habituation slope (over six blocks)
+ 3h Before After + 3h
6.3±2.2 -0.07±0.14 -0.21±0.14* -0.08±0.14
6.0±1.6 -0.18±0.19 -0.14±0.16 -0.12±0.25
7.2±2.7 -0.10±0.11 -0.24±0.18* -0.11±0.17
6.8±2.5 -0.01±0.21 -0.17±0.24 -0.07±0.21
Figure 2 Time-dependent changes of habituation slope after anodal tDCS. From the up to the bottom of the table the changes on
habituation slopes induced by anodal tDCS on N1P1 and P1N2 in healthy volunteers (HV, Panel A and Panel B) and episodic migraine patients
(MoA, Panel C and Panel D) at T0, T1 and T2. The habituation value is expressed as the decrement of the response with stimulus repetition so a
more negative value of the slope corresponds to a stronger habituation. The value of the slope at T0, T1, T2 was reported at every time point as
it is obtained by the interpolation of mean values in all blocks by linear regression equation. The x axis corresponds to the time (T0 = baseline;
T1 = immediately after the stimulation; T2 = after 3 hours).
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± 2.19 attacks in two months (p = 0.04), while in patients
under preventive therapy the frequency decreased from
10 ± 1.4 to 7.2 ± 1.8 attacks in two months (p = 0.04). No
inter-group difference was found (p = 0.45). In addition,
when we compared the sustained post-treatment be-
nefit, we found no difference between the 2 groups in
terms of attack recurrence: the group without any
drug preventive therapy returned to the baseline migraine
frequency 4.2 ± 3.8 weeks after the end of tDCS, while the
group under prophylaxis returned to baseline migraine
frequency after 5.4 ± 3.7 weeks (p = 0.62). Hence, a delayed
effect due to the drug preventive treatment seems unlikely.Adverse events
No adverse events were reported by patients, neither in
the electrophysiological nor in the therapeutical tDCS
study, but a light itching sensation that invariantly
disappeared in few minutes after the end of stimulation.Discussion
As we said before, the lack of cortical habituation to
repetitive sensory stimuli is the more reproducible elec-
trophysiological hallmark of the migrainous brain when
recordings are made interictally. As far as we know, this
is the first study using excitatory tDCS in order to modify
habituation, especially to normalize it in migraineurs, andtrying afterwards to translate these findings into a new
kind of preventive therapy.
Electrophysiological study
The results of our electrophysiological study are in line
with those found previously with rTMS, where an exci-
tatory 10 Hz stimulation was able to increase the initial
lower VEP response and restore normal habituation in
migraineurs [12]. The latter supported the idea that
the habituation deficit could be due to a lower
preactivation level of the brain cortex, and suggested
that transcutaneous central neurostimulation could
have therapeutic potentials in migraine.
We chose to perform anodal, i.e. “excitatory” tDCS
along the same line, in order to increase visual cortex
preactivation and subsequently correct the lack of
habituation in migraineurs. However we did not find any
enhancement of the VEP initial amplitude, neither in
healthy subjects nor in migraineurs, but surprisingly
tDCS increased habituation of the second component of
the VEP in both groups. Like in the rTMS [12] the
duration of tDCS effect on habituation was brief and VEP
recordings performed after 3 hours (T2) demonstrated that
habituation slopes had come back to baseline values. The
significant increase of habituation in absence of any initial
amplitude modification, i.e. any cortical preactivation level
enhancement with tDCS, is difficult to explain. It could be
attributed to the different mechanisms of action of tDCS
p=0.005 
PANEL F AVERAGE DURATION OF EACH
ATTACK
PANEL E DRUGS INTAKE
PANEL D MEAN PAIN INTENSITYPANEL C DURATION OF MIGRAINE ATTACKS
PANEL B DAYS OF MIGRAINEPANEL A MIGRAINE ATTACK FREQUENCY
Figure 3 This figure shows the outcome of the therapeutic pilot trial. The averages and standard deviations (black lines) of the following
clinical parameters are displayed at baseline and for the whole period of tDCS treatment: migraine frequency (Panel A), days with migraine (Panel B),
cumulated duration of all headache attacks (Panel C), pain intensity per attack (Panel D), acute drug intake (Panel E) and duration of each single
attack (Panel F).
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cortical dysexcitability found in migraine could also be
related to abnormal inhibitory circuits within the cortex,
and that an impaired habituation does not necessary
requires a lower preactivation level [35].
The relationship between the electrophysiological
abnormalities and the patient clinical state is still obscure
and complex; and whether the normalization of electro-
physiological responses with neuromodulation could lead
to a concomitant significant clinical improvement in
migraineurs remains debated. Hence, we had shown a
while ago that effective prophylaxis with betablockers was
correlated to an average normalization of auditory evoked
potentials (AEP), but not effective riboflavine therapy,
which did not modify AEP, suggesting 2 distinct mecha-
nisms [36]. In another study we had found similar electro-
physiological abnormalities in healthy volunteers with afamilial history of migraine, although they did not have
any headache themselves at the time of the recordings
[37]. A recent publication found that topiramate [38], one
of the most effective drugs in migraine prevention, was
able to normalize habituation in these patients. At baseline,
episodic migraineurs showed a significant lack of habitu-
ation, which disappeared after 2 months of treatment with
topiramate, and the individual improvement of habituation
was positively correlated with the clinical benefit.
This underlined the need for a proof-of-concept clinical
trial using a central neuromodulation technique able to
normalize habituation, such as anodal tDCS.
Therapeutic study
The results of our pilot trial with anodal tDCS in only
10 MoA patients are encouraging and most clinical vari-
ables already significantly improved within 8 weeks of
Viganò et al. The Journal of Headache and Pain 2013, 14:23 Page 8 of 9
http://www.thejournalofheadacheandpain.com/content/14/1/23treatment. Migraine frequency, migraine days, painkillers
intake and attack duration decreased, and this improve-
ment was even stronger in the second month of treat-
ment (except for acute medications), which underlines
that anodal tDCS preventive therapy sessions should
be continued on a regular basis for at least 2 months,
like drug prophylaxis or other non-invasive neurosti-
mulation techniques, for example supraorbital nerve stimu-
lation [39]. Migraine days and attack duration exhibited the
strongest average improvement with respectively 48% and
60% reduction. However, we are aware that our study has
some shortcomings. A placebo effect cannot be ruled out
without a randomized controlled trial. Moreover, some pa-
tients might have a long-term response to drug prophylaxis,
but the comparison between treated and untreated patients
could argue against this hypothesis (both responded simi-
larly to tDCS), as well as the attack recurrence observed in
most patients after the end of tDCS, within a variable time
interval. Finally, the improvement of patients under
long-term tDCS therapy contrasts with the results of
the electrophysiological study, where one single tDCS
session over the visual cortex only induced a very
short-term habituation modification (<3 h). However,
the repetition of tDCS sessions over 8 weeks could
have been responsible for neuroplastic changes and
induce sustained modifications within the underlying
visual cortex. Unfortunately, we did not record VEPs
before and after the 8 weeks of tDCS therapy. These
measures could be worthwhile in a next study.
In a pathophysiological point of view, these results
emphasize that the lack of habituation is probably playing
a key role in the genesis of migraine headache, even if
other pathological mechanisms may also be involved.
There are few existing trials on migraine prevention
using central non-invasive neurostimulation methods, i.e.
rTMS or tDCS, and their stimulation paradigms differed
according to the author’s baseline pathophysiological
hypotheses. Thus, in order to correct an eventual cortical
hyperexcitability, Teepker et al. [30] and Antal et al. [31]
applied inhibitory stimulations, respectively 1Hz-rTMS
and cathodal tDCS over the vertex and the visual cortex,
leading to minor or negative clinical results. This could
eventually be due to an incorrect baseline assumption.
Chronic migraine management is often challenging and
thus non-invasive neurostimulation could offer a new hope
to these patients. The patients included in our clinical
study did not fulfill the criteria for chronic migraine, and
we stress that excitatory stimulations paradigms could even
be counterproductive in these patients. Even if the excita-
tory 10 Hz-stimulation of the dorsolateral prefrontal cortex
(DLPFC), known for its implication in pain control [40],
was able to slightly improve chronic migraine patients [29],
these results were also uncontrolled and there was a
comorbid state of depression which might have been amajor confounding factor. Hence, beyond depression,
chronic migraine seems to differ from episodic migraine in
terms of brain excitability. While habituation deficit is a
hallmark of the disease in episodic migraine, in
chronic migraine, surprisingly, habituation does not
differ from control subjects [19]. Recent works suggest that
in chronic migraine, the cerebral cortical excitability
increases as the activity of cortical inhibitory interneurons
decreases, which finally leads to a normal habituation, at
least in visual areas (for details, see [41]). When the same
chronic patients are successfully treated and evolve to
episodic migraine, the lack of habituation reappears. These
data support the idea that chronic migraine could be a
“never-ending attack [20,21]. Thus, we believe that chronic
migraine should paradoxically be treated using inhibitory
stimulations unlike episodic migraine and that excitatory
stimulations, like anodal tDCS reported in the present
study, could be ineffective or even worsen these patients.
More neurostimulation studies are warranted to confirm
this assumption.
Conclusion
This study demonstrates for the first time that a 15-min
session of anodal tDCS over the visual cortex is able to
transiently increase habituation in healthy volunteers but
also in episodic migraineurs. Its mechanism of action
does not seem to involve cortical preactivation modifica-
tions as the initial amplitude of the visual evoked potentials
is not modified.
The same excitatory paradigm applied twice a week
during 8 weeks as preventive therapy in 10 episodic
migraineurs results in a significant reduction of migraine
attack frequency, migraine days, painkiller intake and
attack duration. All positive effects seem to improve with
time, suggesting that preventive therapy with anodal tDCS
should be performed on a regular basis, and could involve
additional slow neuromodulating processes.
These encouraging results need to be confirmed in a
well-designed randomized controlled trial.
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Abstract
Background: Transcutaneous neurostimulation (TNS) at extracephalic sites is a well known treatment of pain.
Thanks to recent technical progress, the Cefaly® device now also allows supraorbital TNS. During observational
clinical studies, several patients reported decreased vigilance or even sleepiness during a session of supraorbital
TNS. We decided therefore to explore in more detail the potential sedative effect of supraorbital TNS, using
standardized psychophysical tests in healthy volunteers.
Methods: We performed a double-blind cross-over sham-controlled study on 30 healthy subjects. They underwent
a series of 4 vigilance tests (Psychomotor Vigilance Task, Critical Flicker Fusion Frequency, Fatigue Visual Numeric
Scale, d2 test). Each subject was tested under 4 different experimental conditions: without the neurostimulation
device, with sham supraorbital TNS, with low frequency supraorbital TNS and with high frequency supraorbital TNS.
Results: As judged by the results of three tests (Psychomotor Vigilance Task, Critical Flicker Fusion Frequency,
Fatigue Visual Numeric Scale) there was a statistically significant (p < 0.001) decrease in vigilance and attention
during high frequency TNS, while there were no changes during the other experimental conditions. Similarly,
performance on the d2 test was impaired during high frequency TNS, but this change was not statistically
significant.
Conclusion: Supraorbital high frequency TNS applied with the Cefaly® device decreases vigilance in healthy
volunteers. Additional studies are needed to determine the duration of this effect, the underlying mechanisms and
the possible relation with the stimulation parameters. Meanwhile, this effect opens interesting perspectives for the
treatment of hyperarousal states and, possibly, insomnia.
Background
Neurostimulation is a therapeutic method where action
potentials are elicited by depolarizing nerve fibres with
electrical impulses produced by a current generator
device generally called neurostimulator. This method is
used percutaneously with implantable neurostimulators
and electrodes positioned over the spinal cord or per-
ipheral nerves, or transcutaneously via superficial skin
electrodes and external neurostimulators.
Percutaneous neurostimulation (PNS) of the spinal
cord has been developed in the last decade for the man-
agement of intractable pain [1,2], but also for the treat-
ment of several neurological disorders such as spasticity
[3], parkinsonian tremor [4] or epilepsy [5], More
recently, PNS has been explored for the treatment of
intractable headaches [6-11].
Transcutaneous neurostimulation (TNS) is a classical
technique which has demonstrated its efficacy in the treat-
ment of pain [12,13] and is nowadays largely in use in pain
clinics and physical therapy centres. It has the advantage
of being non-invasive, safe and almost devoid of adverse
effects contrary to PNS which needs a surgical interven-
tion to implant the electrodes and the neurostimulator.
TNS at cephalic sites has been technically difficult and
usually rather painful. STX-Med company has recently
developed a headset for TNS of supratrochlear and
supraorbital nerves, both branches of the ophthalmic
division of the trigeminal nerve (V1), making the techni-
que comfortable and easy to use [14]. Consequently, the
utility of TNS in the treatment and prevention of head-
aches and migraine has been investigated [15] and several
clinical trials are underway. Subjects enrolled in those
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trials have repeatedly reported that supraorbital TNS
tended to affect vigilance and decrease attention with a
tendency to fall asleep during the stimulation.
Cephalic electrical stimulation has been used many
years ago to induce sleep or decrease anxiety. The
method known as “Cranial Electrotherapy Stimulation
(CES)”, also called transcranial or transcerebral electrosti-
mulation differs from TNS in that its objective is to gen-
erate different types of electrical currents through the
head and not to specifically stimulate cranial nerves like
TNS. For this purpose, CES uses generally an anterior
frontal or a jaw electrode and a posterior electrode placed
over the mastoid process [16,17]. CES was reported to
have some effects on anxiety, depression and insomnia
[18-20].
Given the anecdotal reports by patients of TNS-
induced sedative effects, not hitherto reported in the lit-
erature, and the reported mental effects of CES, we
decided to explore the effect on vigilance of supraorbital
TNS with the headset developed by STX-Med in a dou-
ble blind cross-over study.
Methods
We performed a double-blind crossover sham-controlled
study of 30 subjects to assess the effect on vigilance of
different protocols of supra-orbital TNS. Each subject
was tested in 4 different experimental conditions: without
neurostimulation device (blank control: BC), with a sham
neurostimulation (Sham control: SC), with a low fre-
quency neurostimulation (LFN) and with a high fre-
quency neurostimulation (HFN). The study protocol was
approved by the local ethics committee (CE B200-2010-
074-2010-05-03).
Subjects
We included 30 healthy subjects: 15 men and 15 women
ranging in age from 19 to 29 years (mean age = 23,9 +/-
2.4).
To be eligible, subjects had to be right-handed, drink
no more than 1 cup of tea or coffee per day and no
more than 2 glasses of alcohol per week. Exclusion cri-
teria were a history of serious surgical, medical or psy-
chiatric disease, smoking, and drug intake. Informed
consent was obtained for all subjects prior to the study.
Neurostimulation
Supra-orbital neurostimulation was delivered with an
external self adhesive electrode placed on the forehead
(see Figure 1). The bipolar electrode is designed in order
to cover the supratrochlear and supraorbital nerves bilat-
erally. Its dimensions are 30 mm × 94 mm.
The neurostimulator was a Cefaly® device (STX-Med,
Liège, Belgium). It is a constant current generator for a
maximum skin impedance of 2.2 KΩ. It generates
biphasic rectangular impulses with an electrical mean
equal to zero. The impulses have the following para-
meters: impulse width 250 μS, maximum intensity 14
mA. Low frequency neurostimulation (LFN) was deliv-
ered at a frequency of 2.5 Hz, high frequency neurosti-
mulation (HFN) at 120 Hz. The neurostimulation lasted
20 minutes. For both LFN and HFN, the intensity
reached was above perception threshold, so that all sub-
jects experienced paresthesias and tingling under the sti-
mulation electrodes. For sham neurostimulation (SC) we
used a Cefaly® device with a low current intensity of
1 mA that was below the perception threshold and pro-
duced no sensation detectable by the subjects.
Psychophysical measures
Four psychophysical tests were selected to detect seda-
tive effects.
1) The Psychomotor Vigilance Task (PVT) was devel-
oped [21] to measure performance during mental fatigue.
It is regarded as the gold standard for sleepiness.
We used the PEBL [22] implementation of the PVT
(PPVT). Briefly, the subject sits in front of a black
Figure 1 The stimulation electrode placed on the forehead
covers the supratrochlear and supraorbital nerves.
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computer screen. As soon as a red dot appears, the sub-
ject is supposed to hit the space bar of the computer key-
board. The reaction time is recorded in milliseconds. In
total 12 reaction times measures are measured for each
PVT test, separated randomly by intervals of 2 to 12 sec-
onds. The results are expressed as the mean value of the
12 measures.
2) The Critical Flicker Fusion Frequency (CFFF) test is
defined as “the highest or lowest temporal frequency, at a
given percentage modulation, that can be resolved” [23],
i.e. the frequency at which the subject is able to distinguish
a flashing from a steady light. The CFFF decreases with
fatigue. A portable device powered with a 9 V battery and
equipped with a blue LED was used to vary flicker fre-
quency by 0.5 Hz steps. The device starts with a steady
light and the flicker frequency is decreased until the sub-
ject reports that the light is flashing. This frequency is
recorded as the CFFF for that experiment.
3) The d2 test for attention and concentration [24]
allows to assess visual attention and the ability to concen-
trate on a task. It consists of 14 lines of a combination of
the letters “d” and “p” with one to four dashes placed
above and/or below the letter. The objective is to mark
all “d” with two dashes within 20 seconds for each line.
Three scores are evaluated: GZ ("Gesamtzahl der bearbei-
teten Zeichen”) is the total number of letters marked; KL
("Konzentrationsleistungswert”) is the number of correct
letters marked minus the number of non correct letters;
and F% ("Fehlerprozentwert”) representing the percen-
tage of errors compared to the number of characters
marked (GZ). As this test can be biased by a learning
effect, it is only presented once during the session with-
out recording of a baseline.
4) For the subjective evaluation of fatigue we used the
Fatigue Visual Numeric Scale (FVNS - Stanford Patient
Education Research Centre [25]. This is a visual analo-
gue scale where the subject scores fatigue from 0 (not
tired at all) to 10 (very tired).
Procedures
Two groups of 8 subjects and two groups of 6 groups
performed the experiments as depicted in Table 1. The
sessions were separated by at least 6 hours as to ensure
there was no remaining effect of the stimulation.
At the first session, each subject of the group is ran-
domly assigned to one of the 4 experimental conditions:
• LFN, where the subjects get a Low Frequency
Neurostimulation
• HFN, where the subjects get a High Frequency
Neurostimulation
• SC, where the subjects get a sham neurostimula-
tion (Sham Control)
• BC, where the subjects do not have a device (Blank
Control)
Two subjects are assigned to each condition. In the
subsequent sessions, the same subjects are re-assigned
to another condition in order for each of them to have
been through each condition after the 4 sessions.
The subjects are sitting comfortably in a chair in front
of a wall to avoid any distraction. Once the session has
started, each subject fills in the FVNS and performs the
PPVT test where after the CFFF is determined. After
these baseline tests, the neurostimulation is started for all
subjects assigned to conditions LFN, HFN and SC while
no neurostimulation is applied for the subjects assigned
to condition BC. After 10 minutes of stimulation for
LFN, HFN and SC or a 10-minute waiting time for BC,
the subjects perform the d2 test that lasts 280 s. There-
after they score FVNS once more, redo the PPVT test
and finally have the CFFF measured again. The psycho-
physical tests are thus studied in the same sequence
under every experimental condition.
This means in practice that we have a set of results for
FVNS, PPVT and CFFF as measured before the applica-
tion of the neurostimulator. A second set of results is
obtained while the neurostimulator is applied since ± 15
minutes. The results can therefore also be expressed as a
percentage of the measurement during the neurostimula-
tion compared to the baseline value recorded before the
neurostimulation.
Statistical Analysis
We compared the results of the psychophysical tests for
each of the 4 experimental conditions: LFN, HFN, SC
and BC. For FVNS, PPVT and CFFF we used the varia-
tion in percentage between pre- and perstimulation
values to verify the effects of the 4 conditions. Since the
Table 1 Schedule of the experiments for each group
First
Experiment
Second
Experiment
Third
Experiment
Fourth
Experiment
Group I Tuesday 8 AM Tuesday 2 PM Thursday 8 AM Thursday 2 PM
Group II Tuesday 9 AM Tuesday 3 PM Thursday 9 AM Thursday 3 PM
Group III Tuesday 10 AM Tuesday 4 PM Thursday 10 AM Thursday 4 PM
Group IV Tuesday 11 AM Tuesday 5 PM Thursday 11 AM Thursday 5 PM
Piquet et al. BMC Neurology 2011, 11:135
http://www.biomedcentral.com/1471-2377/11/135
Page 3 of 7
results did not have a Gaussian distribution, we used the
Wilcoxon test to measure the significance of the varia-
tion observed.
For the d2 test, we compared GZ, KL and the F%
between the 4 conditions (as there was no control values
to compare with). We have used the Mann-Whitney test
to verify the significance of the differences observed.
Results
PPVT Test
The mean reaction times (RT) for the PPVT (N = 30)
before the session was 339 ms+176 for LFN, 304 ms + 37
for HFN, 294 ms + 44 for SC and 306 ms + 46 for BC.
Reaction time increased during HFN, while it was stable
for the LFN, SC and BC conditions (Figure 2).
As explained in the methods section, for FVNS, PPVT
and CFFF the statistical analysis was performed on the
ratio (in percentage) between the mean value during
and before the experimental condition for each subject.
The mean percentage increase in RT is significant only
during the HFN condition (p = 0.0002).
CFFF Test
The mean values for CFFF (N = 30) before the session was
38.2 Hz + 2.5 for LFN, 39.7 Hz + 2.7 for HFN, 39.9 Hz +
3.3 for SC and 38.2 Hz + 2.2 for BC. During HFN there
was a significant decrease of CFFF (p < 0.0001) while
CFFF was significantly increased during LFN (Figure 3).
d2 Test
Table 2 shows the results for the d2 test. Mean values of
GZ, KL and F% are given during each experimental con-
dition the. Numerically the total number of letters
marked (GZ) and the number of correct letters marked
(KL) were the lowest in the HFN condition, while the
percentage of errors was the highest, but this difference
was not statistically significant.
Fatigue Visual Numeric Scale
The FVNS fatigue score tended to increase during all
four conditions. However, the statistical analysis for the
averaged individual changes showed that the increase
was significant only during HFN (Figure 4).
Discussion
Taken together our results suggest that supraorbital neu-
rostimulation using the Cefaly® device decreases arousal
and induces fatigue. This cannot be considered at this
stage as a hypnotic effect in the sense of inducing sleep
and decreasing sleep latency but rather as a sedative effect
in terms of a reduction of alertness and vigilance. Interest-
ingly, this is only the case with high (120 Hz-HFN) and
not with low frequency (2.5 Hz-LFN) stimulation. LFN
even has an opposite effect in one psychophysical test, the
critical flicker fusion frequency. Below we will examine
these results in more detail and speculate on possible
mechanisms.
The Psychomotor Vigilance Task measures the reac-
tion time (RT) and is considered as the gold standard for
measuring sleepiness [21]. That it is readily reproducible
is demonstrated by the fact that during the blank condi-
tion (BC) the change compared to baseline was less than
1.5%. Sham (SC) and LFN induced non significant
increases in RT of respectively 8.9 ms and 8.6 ms. By
contrast, HFN increased RT by an average of 36.7 ms, i.e.
by more than 10%. Critical flicker fusion frequency is
known to decrease with fatigue. While unchanged during
SC and minimally increased during BC (+ 0.9 Hz), it
increased during LFN (+ 1.9 Hz) possibly suggesting a
mild increase in vigilance. Again HFN contrasted with all
other conditions by a marked decrease (-4.6 Hz) in CFFF,
indicating a decrease in arousal. This result is concordant
with that of the subjective fatigue rating on the Fatigue
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Figure 2 Mean PPVT reaction time change during the
experimental conditions expressed as a percentage of the
baseline value (*** = p < 0.001) (mean+/-SEM).
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Figure 3 Mean CFFF change during the experimental
conditions expressed as a percentage of the baseline value (**
= p < 0.01; *** = p < 0.001) (mean+/-SEM).
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Visual Numerical Scale (FVNS). The subjects rated their
fatigue higher during all experimental conditions than at
baseline, which was not significant and might be related
to the mental strain due to the recordings or to a learning
effect in using the numerical scale. However, the increase
of the FVNS score during HFN was three times greater
(+ 72.1%). The d2 test for attention and concentration
was in our study the only one for which the HFN condi-
tion induced no significant effect. Nevertheless the
numerical changes during HFN are in line with the other
results as they show a lower number of total letters
marked and of correct letters marked as well as a higher
number of errors. The lack of significance could have at
least two explanations. First, the d2 test was administered
at an earlier time point (between 10 and 15 minutes) dur-
ing the experimental condition compared to the other
tests (from 15 minutes onwards). The duration of HFN
might thus not have been long enough to produce signifi-
cant d2 test changes. Second, this test was performed
only once to avoid a learning effect and the pre- and per-
condition comparison had therefore to be replaced by a
comparison between conditions, hence weakening the
sensitivity of the test to detect a change.
To the best of our knowledge, this is the first time that
the effect of transcutaneous neurostimulation on arousal
and fatigue was studied in humans and there are no simi-
lar studies available in animals. The neurobiological
mechanisms through which HFN induces sedation remain
therefore speculative. Some insight can nonetheless be
gained from the studies of transcutaneous neurostimula-
tion in Alzheimer’s patients and from those in experimen-
tal animals of the central nervous system consequences of
electroacupuncture. A Dutch group reported in a series of
publications that transcutaneous electrostimulation was
able to improve memory, alertness [26,27] and rest-activity
rhythm [28] in Alzheimer’s disease. This effect was attrib-
uted to activation of the hippocampus and the suprachias-
matic nucleus both by direct spinal cord afferents [29] and
via the dorsal raphe nucleus and locus coeruleus [30,31].
Although vigilance was not specifically measured in these
studies, the observed cognitive and behavioural effects
would suggest increased arousal and vigilance rather than
sedation like in our study. This opposite effects can prob-
ably be explained by the different stimulation protocols.
First, Alzheimer patients received transcutaneous neuro-
stimulation over paravertebral back muscles daily during 6
[26] or 3 hours [27,28] for 6 weeks while we used a single
20-minute session of supraorbital neurostimulation. In a
more recent randomized sham-controlled pilot trial of
right median nerve stimulation, Scherder et al [32] found
no significant effect on memory in Alzheimer’s disease
and the same group reported that cranial electrostimula-
tion had no effect on rest-activity rhythm neither at low
frequency [33] nor at high frequency [34]. More interest-
ingly, we found a hypnotic effect with high frequency (120
Hz) stimulation, whereas the beneficial effects in Alzhei-
mer’s disease were obtained with burst of stimuli (9 pulses
at 160 Hz) delivered at a low frequency of 2 Hz, a fre-
quency that in our study concordantly increased critical
flicker fusion frequency. One may assume that high and
low frequency stimulations can have different effects on
central nervous system structures and thus on arousal, but
this remains to be proven in an adequate study.
Transcranial direct current stimulation (tDCS) is able to
modulate cortical activity under certain conditions and in
certain brain areas. It is extremely unlikely, however, that
the supraorbital TNS used in this study influences directly
the underlying brain structures, i.e. the frontal lobes, for at
least two reasons. First, The small electrode surface (7
cm²) and distance between the two electrodes (5 mm)
restrict the skin surface affected by the current as well as
current penetration into deeper structures. Second, the
TNS applied current is composed of biphasic rectangular
impulses with an electrical mean equal to zero, while
tDCS uses a direct current. The current characteristics
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Figure 4 Mean change in FNVS score during the experimental
conditions expressed as a percentage of the baseline value
(*** = p < 0.001) (mean+/-SEM).
Table 2 d2 results
N = 30 LFN HFN SC BC
Mean value of GZ 560 ± 77 544 ± 80 587 ± 57 562 ± 70
Mean value of KL 215 ± 40 214 ± 50 229 ± 42 217 ± 43
Mean value of F% 6.95% ± 6.81 8.37% ± 8.38 6.02% ± 5.98 6.72% ± 6.16
Piquet et al. BMC Neurology 2011, 11:135
http://www.biomedcentral.com/1471-2377/11/135
Page 5 of 7
and the mechanisms of action are thus different between
trigeminal TNS and tDCS. Moreover, in a recent study
[35], weak transcranial electrical DC or AC currents over
the prefrontal cortex had no effect on mood or EEG in
healthy subjects. Interestingly, sleepiness was reported
rarely both in the active (0.11%) and sham stimulation
groups (0.08%).
Experimental studies on the mode of action of electroa-
cupuncture in pain are relevant to this discussion
because many of the central nervous system structures
activated by electroacupuncture like the monoaminergic
brain stem nuclei, the hypothalamic arcuate nucleus or
the periaqueductal gray matter also play a role in vigi-
lance states (36,37,38,39). A simple straightforward expla-
nation for the sedative effects found in our study would
be an effect of the transcutaneous stimulation on monoa-
minergic brain stem nuclei such as locus coeruleus that
receives direct spinal input [40]. The locus coeruleus is
also thought to mediate the anti-epileptic effect of high
frequency transcutaneous stimulation of the ophthalmic
nerve [41]. However, in animals high frequency electroa-
cupuncture was found to increase neuronal activity in
brain stem nuclei [36], in particular in dorsal raphe
nuclei [37]. Increased activity of these nuclei that belong
to the ascending activating reticular system would be
associated with increased rather than decreased arousal
and vigilance. Electroacupuncture over peripheral nerves
also activates the hypothalamic arcuate nucleus in ani-
mals [39]. The arcuate nucleus plays a pivotal role in
electroacupuncture-induced cardiovascular inhibition
[39], but also in vigilance states via its reciprocal connec-
tions with orexin-containing lateral hypothalamic neu-
rons and the ventrolateral periaqueductal gray matter
(38,42). A change in activity levels of the orexin-arcuate-
periaqueductal gray matter circuit could occur during
supraorbital neurostimulation and might explain the
decrease in vigilance. Future studies of supraorbital neu-
rostimulation coupled to functional cerebral imaging stu-
dies could verify this hypothesis. Further studies are also
needed to verify whether the sedative effects of HFN as
evidenced here by psychophysical tests have electroence-
phalographic correlates and if they are associated with
hypnotic effects such as sleep latency reduction.
Conclusion
To sum up, we have shown in healthy volunteers that
supraorbital high frequency neurostimulation applied
with the Cefaly® device modifies concordantly several
psychophysical tests in a way that is compatible with
decreased vigilance and arousal, while sham stimulation
has no effect and low frequency neurostimulation, if
anything, tends to increase arousal. The precise mechan-
isms of action of HFN on the CNS arousal systems are
not known and warrant further studies. Meanwhile
supraorbital HFN with the Cefaly® device opens inter-
esting perspectives for an adverse effect-free treatment
of hyperarousal states, and possibly sleep disorders.
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Abnormal cortical responses to somatosensory
stimulation in medication-overuse headache
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Abstract
Background: Medication-overuse headache (MOH) is a frequent, disabling disorder. Despite a controversial
pathophysiology convincing evidence attributes a pivotal role to central sensitization. Most patients with MOH
initially have episodic migraine without aura (MOA) characterized interictally by an absent amplitude decrease in
cortical evoked potentials to repetitive stimuli (habituation deficit), despite a normal initial amplitude (lack of
sensitization). Whether central sensitization alters this electrophysiological profile is unknown. We therefore sought
differences in somatosensory evoked potential (SEP) sensitization and habituation in patients with MOH and
episodic MOA.
Methods: We recorded median-nerve SEPs (3 blocks of 100 sweeps) in 29 patients with MOH, 64 with MOA and
42 controls. Episodic migraineurs were studied during and between attacks. We measured N20-P25 amplitudes
from 3 blocks of 100 sweeps, and assessed sensitization from block 1 amplitude, and habituation from amplitude
changes between the 3 sequential blocks.
Results: In episodic migraineurs, interictal SEP amplitudes were normal in block 1, but thereafter failed to
habituate. Ictal SEP amplitudes increased in block 1, then habituated normally. Patients with MOH had larger-
amplitude block 1 SEPs than controls, and also lacked SEP habituation. SEP amplitudes were smaller in triptan
overusers than in patients overusing nonsteroidal anti-inflammatory drugs (NSAIDs) or both medications combined,
lowest in patients with the longest migraine history, and highest in those with the longest-lasting headache
chronification.
Conclusions: In patients with MOH, especially those overusing NSAIDs, the somatosensory cortex becomes
increasingly sensitized. Sensory sensitization might add to the behavioral sensitization that favors compulsive drug
intake, and may reflect drug-induced changes in central serotoninergic transmission.
Background
Medication-overuse headache (MOH) is a complication
of episodic headaches characterized by more than 15
headache days per month and arising from an excessive
intake of analgesics or specific anti-migraine drugs, or
both [1]. MOH is a disabling health problem that affects
2-4% of the general population and causes considerable
long-term morbidity and disability [2]. Most patients
attending headache clinics for chronic daily headache
have MOH [1,3]. Although MOH evolves from primary
as well as secondary headaches the most prevalent initial
headache type is episodic migraine without aura and
most patients return to the episodic pattern after drug
withdrawal [1].
How and why medication overuse leads to chronic
episodic headache is unknown. Possible culprits for pain
chronification include central sensitization and defective
central pain control systems [4]. The addictive behavior
and high relapse rates after withdrawal may depend on
orbitofrontal cortex hypofunction [5]. The observation
that MOH develops predominantly in migraineurs with-
out aura suggests that this headache type possesses
pathophysiological peculiarities that could favour drug-
induced chronification.
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During the pain-free interval in episodic migraine
without aura repeated sensory stimuli delivered using
various modalities elicit abnormal cortical responses
characterized by deficient habituation contrasting with a
normal-amplitude initial evoked potential elicited by a
small number of stimuli [6]. Current hypotheses attri-
bute this neurophysiological abnormality to cortical
hyper-excitability probably arising from deficient intra-
cortical inhibition [7], or to low sensory cortical pre-
activation levels ultimately due to abnormal functioning
of monoaminergic projections from the brainstem [6,8].
Habituation is considered a protective mechanism
intended to prevent neuronal stress and excessive accu-
mulation of metabolites such as lactate and protons that
are likely to induce cortical spreading depression or tri-
geminovascular activation, or both. Evidence suggesting
that lack of habituation can promote migraine attacks
comes from the observation that it culminates just
before the onset of an attack, in the pre-ictal phase
[9-11]. During the attack, habituation normalizes, thus
transiently activating the protective mechanisms thought
to prevent attack recurrence [10-14].
A neurophysiological technique ideally suited to inves-
tigate how sensory cortices respond to repetitive stimu-
lation consists of testing somatosensory evoked
potentials (SEPs). SEPs are obtained by weak sensory
stimuli ideal for disclosing sensitization (reflected by an
increased response amplitude to low numbers of
stimuli) and habituation (reflected by a decrease in
response amplitude after high numbers of stimuli)
[15,16], and proved highly sensitive in disclosing abnor-
mal habituation in migraineurs studied interictally, i.e. a
clear-cut lack of habituation from the 2nd block of aver-
aged responses onwards [17]. To the best of our knowl-
edge no study has investigated SEP sensitization and
habituation in patients with MOH. Having this informa-
tion may shed light on the mechanisms underlying
headache chronification during acute medication
overuse.
We used therefore SEPs to investigate whether medi-
cation overuse sensitizes the sensory cortices, whether
sensitization varies according to the drug overused, and
whether the cortical response patterns, sensitization and
habituation, differ between patients with episodic
migraine without aura recorded in ictal and interictal
phases and those with MOH. We also sought possible
correlations between the electrophysiological patterns
and clinical features including duration of migraine his-
tory, duration of headache chronification and class of
drugs overused.
Methods
Subjects-Among consecutive patients attending our
headache clinic, 93 patients gave informed consent to
participate in the study (Table 1), which was approved
by the local ethics committee.
According to the revised ICHD-II criteria [1], 29
patients (35 ± 11 years; 23 women) were diagnosed as
having MOH during their first visit, a diagnosis that
was confirmed 2 months after withdrawal treatment.
These patients were stratified according to the class of
drug overused: triptans (n = 9), nonsteroidal antiin-
flammatory drugs (NSAIDs) (n = 10) or a combination
of both (n = 10). Before progressing to MOH, all
patients had a clear-cut history of episodic migraine
without aura (ICHD-II code 1.1). With the exception
of 2 patients who had a mild headache, all MOH
patients (n = 27) underwent the SEP recordings in a
pain-free state. The 2 patients who had a headache
had no associated migrainous features. Because MOH
patients tend to take acute medications compulsively
and frequently during the day, it was impossible to
prevent them from taking a medication on the day of
recordings. We managed, however, to perform the
recordings at least 3 hours after last medication intake.
The 64 patients who had episodic migraine without
aura (ICHD-II code 1.1) were assigned to two sub-
groups: 41 patients (34 ± 9 years; 23 women) were
recorded during the interictal period, i.e. at least three
days before and after an attack, and 23 patients (33 ±
12 years; 20 women) during the ictal period, i.e. from
12 hours before to 12 hours after an attack. The latter
were not allowed to take any acute medication before
the end of recordings.
For comparison we recorded SEPs in 42 healthy
volunteers of comparable age and sex distribution
(mean age: 33 ± 13; 26 women); they had no personal
or familial history (1st or 2nd degree relatives) of
migraine and no detectable medical condition.
To avoid variability due to hormonal changes, women
were recorded outside their pre-menstrual or menstrual
periods.
Data acquisition
SEPs were elicited by electrical stimulation applied to
the right median nerve at the wrist using a constant cur-
rent square wave pulse (0.1 ms width, cathode proxi-
mal), a stimulus intensity set at 1.5 times the motor
threshold, and a repetition rate of 4.4 Hz. The active
electrodes were placed over the contralateral parietal
area (C3’, 2 cm posterior to C3 in the International
10-20 system) and on the fifth cervical spinous process
(Cv5), both referenced to Fz; the ground electrode was
on the right arm [18]. SEP signals were amplified with a
Digitimer™ D360 pre-amplifier (Digitimer Ltd, UK)
(band-pass 0.05-2500 Hz, Gain 1000) and recorded with
a CED™ power1401 device (Cambridge Electronic Design
Ltd, Cambridge, UK).
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Subjects sat relaxed in a comfortable chair in a well-lit
room with eyes open. They were asked to fix attention
on the stimulus-induced thumb movement. During con-
tinuous median-nerve stimulation at the wrist, we
collected 300 sweeps of 50 ms, sampled at 5000 Hz. All
recordings were averaged off-line using the Signal™ soft-
ware package version 3.10 (CED Ltd).
Three hundred artefact-free evoked responses
recorded in each subject were averaged ("grand aver-
age”). After digital filtering of the signal between 0-450
Hz, the various SEP components (N13, N20, P25 and
N33) were identified according to their respective laten-
cies. We measured peak-to-peak amplitudes of the cer-
vical N13 component (recorded under the active Cv5
electrode), and the cortical N20-P25 and P25-N33 com-
ponents (recorded under the active C3’ scalp electrode).
Thereafter, the 300 evoked responses were partitioned
in 3 sequential blocks of 100 responses (Figure 1). Each
block was averaged off-line ("block averages”) and ana-
lyzed for N20-P25 amplitudes. Sensitization was defined
as an increased N20-P25 amplitude recorded during
block 1 (after a low number of 100 stimuli), whereas
habituation was expressed as the change in N20-P25
amplitude in blocks 2 and 3 compared to block 1 (over
a high number of 300 repetitive stimuli).
Statistical Methods
We used the Statistical Package for the Social Sciences
(SPSS) for Windows, version 15.0 for all analyses. For
grand average SEPs, component amplitudes were tested
in a one-way analysis of variance (ANOVA) with group
factor “subjects” (MOH patients, episodic migraineurs
without aura studied ictally or interictally, and healthy
subjects). To assess changes in SEP amplitude between
blocks 1, 2 and 3 SEP N20-P25 amplitudes were tested
first with a repeated-measure ANOVA with group factor
“subjects” and repeated measures factor “block” then
using as group factor “MOH subgroups” (MOH-triptans,
MOH-NSAIDs, MOH-combination, and normal sub-
jects). Tukey’s test was used for post hoc analyses. Pear-
son’s correlation coefficient was calculated to test
correlations between SEP amplitudes or habituation and
clinical data (disease duration, days with headache, num-
ber of tablets taken per month, duration of chronic
headache). P values less than 0.05 were considered to
indicate statistical significance.
Results
Assessable SEP recordings were obtained from all patients
and controls participating in the study (Figure 1). On
grand average SEP recordings after electrical median nerve
stimulation latencies of N13, N20, P25 and N33 compo-
nents were not different between groups (for each
measure F(3,131), p > 0.05) whereas their amplitudes
significantly differed between groups (F(3,131) = 2.75,
p = 0.045). Post hoc analysis showed a higher N20-P25
amplitude in patients with MOH and migraineurs without
aura studied ictally than in the subgroup studied interic-
tally and controls (Figure 2).
ANOVA testing SEP amplitude block averages
disclosed a main effect for factors group (F(3,131) =
3.83, p = 0.01) and block (F(2,262) = 4.13, p = 0.017),
and a significant interaction of group by block
(F(6,262) = 2.42, p = 0.027). Post hoc analysis showed
in each block a higher N20-P25 amplitude in patients
with MOH and migraineurs without aura studied
ictally than in the subgroup studied interictally and
controls (Figure 3). In controls and migraineurs with-
out aura studied ictally, N20-P25 amplitude decreased
from block 1 to block 3, i.e. habituated, while in
Table 1 Demographics data of study participants and headache profiles of patients
HV
(n = 42)
MOii
n = 41)
MOi
(n = 23)
MOH
(n = 29)
Triptans
(n = 9)
NSAIDs
(n = 10)
Both
(n = 10)
Women (n) 26 23 20 23 7 8 8
Age (years) 32 ± 13 34 ± 9 33 ± 12 35 ± 11 32 ± 8 35 ± 9 34 ± 12
Duration of history of migraine (years) 18.0 ± 12.7 16.7 ± 10.9 18.4 ± 11.0 18.3 ± 9.6 22.4 ± 9.2 13.0 ± 13.7
Days with headache/month (n) 2.1 ± 1.9 3.5 ± 2.3 25.9 ± 6.1 22.1 ± 6.2 25.0 ± 7.4 29.4 ± 1.6
Severity of headache attacks (0-10) 6.8 ± 0.8 7.2 ± 1.2 7.2 ± 0.8 7.4 ± 1.1 7.2 ± 0.5 7.1 ± 0.8
Nausea/vomiting (n) 25 16 24 8 9 7
Photophobia (n) 37 21 27 8 10 9
Phonophobia (n) 31 20 27 7 10 10
Pulsating (n) 38 21 26 9 9 8
Duration of the chronic headache (years) 3.0 ± 3.2 1.9 ± 1.8 3.5 ± 3.1 3.3 ± 3.9
Tablet intake/month (n) 74.2 ± 80.8 28.7 ± 16.3 50.5 ± 38.5 127.3 ± 106.5
Motor threshold (mA) 8.4 ± 1.3 8.6 ± 1.3 8.5 ± 1.5 8.7 ± 1.2 8.8 ± 1.3 9.1 ± 1.1 8.3 ± 1.1
Data expressed as mean ± SD. HV healthy volunteers; MOii episodic migraneurs without aura studied interictally; MOi episodic migraneurs without aura studied
ictally; N number of subjects.
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patients with MOH and migraineurs with aura studied
interictally it remained unchanged from block 2
onwards, i.e. did not habituate.
Conversely, ANOVA testing block 1 SEP amplitudes
showed a main effect only for factor group (F(3,131) =
2.73, p = 0.046) (Figure 3). Post hoc analysis showed
that N20-P25 amplitudes were higher in patients with
MOH and migraineurs without aura studied ictally than
in the subgroup studied interictally and controls.
When we stratified the data for patients with MOH
according to the class of drugs overused, triptans,
NSAIDs or both combined, ANOVA for SEP amplitudes
in the various blocks, showed a main effect for factor
“drug” (F(2,26) = 3.57, p = 0.042). Post hoc analysis dis-
closed smaller N20-P25 amplitudes in patients overusing
triptans than in those overusing NSAIDs or both medi-
cations combined. In addition, group analysis between
triptan overusers and controls showed that the N20-P25
amplitude in block 1 was normal in patients (F(1,49) =
1.08, p = 0.3) (Figure 4).
Pearson’s test disclosed various correlations between
SEP amplitude and clinical variables. In patients with
MOH, N20-P25 amplitude on SEP grand average corre-
lated negatively with disease duration (i.e. combined
duration of episodic and chronic headache phases,
r = -0.411, p = 0.046). Conversely, grand average N20-
P25 amplitude (r = 0.477, p = 0.016) as well as block 1
N20-P25 amplitude (r = 0.454, p = 0.023) correlated
positively with duration of the chronic headache phase.
Discussion
The distinct changes we found in cortical responses to
low and high numbers of sensory stimuli in patients
with MOH suggest that the underlying brain mechan-
isms are altered and differ from those acting in patients
with episodic migraine without aura. Low numbers of
Figure 1 Illustrative traces of somatosensory evoked potentials habituation in a healthy volunteer, MO Interictally and ictally, and
MOH patient.
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Figure 2 Somatosensory evoked potential (SEP) amplitude grand average in each study group (HV, healthy volunteers; MOii, migraine
without aura interictally; MOi, migraine without aura Ictally; MOH, medication overuse headache; data expressed as mean ± SEM).
Figure 3 Somatosensory evoked potential (SEP) amplitude block averages in each study group (HV, healthy volunteers; MOii, migraine
without aura interictally; MOi, migraine without aura Ictally; MOH, medication overuse headache; data expressed as mean ± SEM).
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median nerve electrical stimuli (block 1) disclosed
sensory cortex sensitization in patients with MOH and in
episodic migraineurs recorded ictally, whereas amplitude
changes over sequential block averagings were consistent
with habituation in healthy volunteers and episodic
migraineurs recorded ictally, but not in MOH patients
and episodic migraineurs recorded interictally. In MOH
patients, SEP amplitude was lowest in those with the
longest history of migraine, whereas it was highest in
those with the longest period of headache chronification,
suggesting that the electrophysiologic changes reflect
chronification. Patients who overused triptans had lower
SEP amplitudes than those who overused NSAIDs or
both anti-migraine medications combined, indicating
that sensitization varies according to the drug overused.
The combination of an initial SEP amplitude increase
(sensitization) along with the subsequent lack of habi-
tuation suggests that the electrophysiological pattern
underlying MOH differs from that underlying episodic
migraine. In episodic migraine, SEP recordings show
two characteristic changes: a lack of habituation on
interictal recordings, and sensitization during the attack.
The habituation deficit normalizes during attacks,
whereas sensitization disappears between attacks, but in
the immediate pre-ictal phase both sensitization and
absent habituation may co-exist [9-11]. The electrophy-
siological pattern we found in MOH may therefore sug-
gest that the sensory cortex is locked in a pre-ictal state
associating both hyper-sensitivity (due to sensitization)
and hyper-responsiveness (due to deficient habituation),
which contrasts with episodic migraine where these cor-
tical states alternate. It is likely that the disclosure of
this peculiar electrophysiological pattern was made pos-
sible by the fact that we avoided to record MOH
patients during a full-blown migraine attack. The SEP
pattern associating sensitization and lack of habituation
that we compared with a “persistent pre-ictal state”, clo-
sely resembles the response patterns generated by cen-
tral sensitized neuronal circuits. Sensitization refers to a
facilitatory process that competes with its opposite,
habituation to determine the final behavioural outcome
after stimulus repetition. This has been called the “dual
process” theory [15,16]. Illustrative of central sensitiza-
tion are the plastic changes in neural structures belong-
ing to the “pain matrix” [19] that result in decreased
nociceptive thresholds and increased responsiveness to
noxious and innocuous peripheral stimuli [20]. Studies
in animals [21] and humans [22] show that SEP ampli-
tudes increase when transient intense activation of noci-
ceptive afferents induces central sensitization, as
Figure 4 Somatosensory evoked potential (SEP) amplitude block averages in patients with medication overuse headache (MOH)
subgroups and a healthy volunteer (HV) (data expressed as mean ± SEM).
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happens in clinical pain conditions including chronic
headache. Our study shows that sensitization, as
reflected by increased initial SEP amplitudes, is common
to MOH and migraine attacks, although we did not
record MOH patients during an attack. A clinical conse-
quence of central sensitization is cutaneous allodynia. It
was shown to be prevalent during episodic migraine
attacks at cephalic and extracephalic sites [23,24], but
even more so in chronic migraine [25]. It is associated
with increased nociceptive reflexes [26,27], but, interest-
ingly, in MOH trigeminal evoked potentials were
increased, whereas nociceptive blink reflexes remained
unchanged, suggesting as in our study that sensitization
takes place at supraspinal levels [28].
Our finding that the SEP amplitude increase in MOH
is proportional to the duration of headache chronifica-
tion suggests that medication overuse and increased
headache frequency promote or reinforce central sensiti-
zation, but leaves open the question of the culprit. Con-
versely, since total duration of the migraine disorder
correlates inversely with SEP amplitudes, the SEP ampli-
tude increase is likely related to factors other than
migraine duration and simply repetition of attacks. In
keeping with this interpretation, patients who overused
triptans alone had no initial SEP amplitude increase
indicating that the major culprit for central sensitization
in MOH could be NSAIDs. The neurobiological under-
pinning for this difference remains to be determined.
An observation that might favour of NSAIDs consump-
tion as a factor promoting sensitization is that NSAIDs
increase spinal expression of inducible cyclo-oxygenase-
2 [29], an enzyme that contributes to sensitization in a
rat model of inflammatory pain [30].
Another possible link between central sensitization,
migraine and anti-migraine drugs is monoaminergic
transmission in the central nervous system (CNS).
Although both triptan and NSAID overuse lead to head-
ache chronification, only the latter is accompanied by
SEP sensitization. We hypothesize that this difference is
due to a more profound decrease of 5-HT transmission
after NSAID overuse. Between attacks, migraine patients
have low blood 5-HT levels whereas the reverse is true
ictally [31]. Serotonin synthesis in the brain increases
during attacks, and this increase is partly counteracted
by acute triptan treatment [32]. Chronic administration
of triptans in rats, however, increases 5-HT synthesis in
several cortical projection areas of the dorsal raphe
nucleus [33] possibly reflecting down-regulation or
desensitization of 5-HT1 receptors. By contrast, in rats
chronically treated with analgesics, 5-HT2A receptors
are down-regulated [34] and the 5-HT transporter is
up-regulated in the cortex [34] and in platelets [35].
Upregulated platelet 5-HT transporters [35] and
decreased whole blood 5-HT levels [36] tend to
normalize after drug withdrawal. Collectively, these
experimental data suggest that anti-migraine drug over-
use can disrupt central 5-HT transmission. In chronic
triptan overuse both pre- and postsynaptic 5-HT1
receptors may become desensitised with the ensuing net
effect that serotonergic transmission may be only mildly
impaired. During analgesic and NSAID overuse, how-
ever, the combination of receptor desensitisation and
transporter upregulation may lead to serotonergic
hypoactivity. Together with noradrenaline and dopa-
mine, serotonin is crucial for tuning cortical excitability
including sensitization and habituation processes and its
effect in animals varies with concentration and duration
of application [37]. A more severe hypofunction of 5-
HT transmission after NSAID overuse may thus explain
the SEP sensitisation observed in this subgroup of MOH
patients. Whether the difference between the drug
classes with regard to central sensitisation is related to
the clinical observation that withdrawal headache is
much shorter after triptan than after analgesic overuse
[38] remains to be determined in a properly designed
prospective study comparing clinical outcome and elec-
trophysiological patterns.
The association of electrophysiological sensitisation, i.
e. increased 1st block SEP amplitude, and lack of habi-
tuation.in MOH patients overusing NSAIDs is intri-
guing. It is at odds with the electrophysiological pattern
associating high amplitude in 1st block and normal habi-
tuation found during migraine attacks [10-14], but, as
mentioned before, it has been described in the pre-ictal
phase [9-11]. One possible explanation for the lack of
habituation in episodic migraineurs between attacks is
the “ceiling theory” [39] postulating that there is a low
preactivation level of sensory cortices, also responsible
for the low 1st block amplitudes, would allow a larger
range of activation before habituation occurs [6,8]. The
habituation deficit in NSAIDs overusers cannot be
explained by the “ceiling theory” since their high 1st
block amplitude indicates rather that the somatosensory
cortex is sensitised. There is at present no straight for-
ward explanation for this pattern. It is likely, however,
that other neurobiological mechanisms that participate in
the production of habituation are impaired. For instance,
inhibitory interneurons could be hypofunctioning
because of the reduction in serotonergic transmission
induced by the prolonged NSAID overconsumption. This
hypothesis can be tested experimentally by searching if
habituation normalizes during full-blown attacks in
MOH patients like in episodic migraine and by exploring
inhibitory cortical interneurons with dedicated neurophy-
siological studies such as that of cortical silent periods
using transcranial magnetic stimulation. Given the simi-
lar neural mechanisms underlying sensory and beha-
vioural sensitization [40], the interesting question arises
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whether the sensory sensitization in patients with MOH
parallels behavioural sensitization. Behavioural sensitiza-
tion is paradigmatic of how the serotonergic, dopaminer-
gic, and noradrenergic systems interact and contribute to
central sensitization [41]. Brain circuits involved in addic-
tive behaviour include ventral and dorsal striatum, amyg-
dala and orbitofrontal cortex and are heavily modulated
by dopaminergic projections from the ventral tegmental
area of the midbrain, serotonergic projections from the
median and dorsal raphe nuclei, and noradrenergic pro-
jections from the locus coeruleus [4,42]. According to
DSM-IV criteria, many MOH patients manifest a depen-
dence behaviour [43]. The latter has been associated with
orbito-frontal cortex hypoactivity [44], an abnormality
also found in subgroups of MOH patients [5]. The
orbito-frontal cortex is thought to modulate habituation
mechanisms [45] and orbito-frontal lesions induce SEP
sensitization and lack of habituation [46], precisely the
two sensory abnormalities we found in patients with
MOH. Our findings along with current knowledge on the
neurobiology of drug overuse therefore suggest that
future studies seeking correlations between electrophy-
siological and metabolic measures should focus on the
orbito-frontal cortex. In our study we did not control for
associated depression and anxiety. Despite the evidence
that cortical pain-related evoked potentials in MOH do
not differ between subgroups of patients with or without
depressive symptoms [28], it may still be appropriate to
control for psychiatric comorbidity in future studies.
Conclusions
Cortical responses to repetitive sensory stimuli are
abnormal in patients with MOH. Increased response
amplitudes after low numbers of stimuli indicate sensory
sensitization and lack of amplitude decrease during sub-
sequent stimulations reflects a habituation deficit. This
cortical response pattern is similar the one found in the
immediate pre-ictal phase in episodic migraine, but dif-
ferent from the interictal and ictal patterns. It suggests
that the somatosensory cortex has become persistently
sensitized and that the migraine generating mechanisms
in the central nervous system are not shut off. The sen-
sitization is obvious in patients overusing NSAIDs and
almost non-existent or masked in those who overuse
only triptans. The different electrophysiological pattern
between drug classes may be related to the clinical
observation that withdrawal headache is shorter lasting
in triptan overusers than in NSAID overusers. We pos-
tulate that the abnormal sensory processing in MOH
patients reflects a drug-induced impairment of central
serotonin neurotransmission, that the decrease of sero-
tonergic activity is more profound after chronic
NSAID overconsumption and that the cortical sensory
sensitization parallels the behavioural sensitization that
accompanies drug overuse and is crucially modulated
by the medial orbitofrontal cortex.
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Abstract Hyperventilation is often associated with stress,
an established trigger factor for migraine. Between attacks,
migraine is associated with a deficit in habituation to visual-
evoked potentials (VEP) that worsens just before the att-
ack. Hyperventilation slows electroencephalographic (EEG)
activity and decreases the functional response in the occipital
cortex during visual stimulation. The neural mechanisms
underlying deficient-evoked potential habituation in migrai-
neurs remain unclear. To find out whether hyperventilation
alters VEP habituation, we recorded VEPs before and after
experimentally induced hyperventilation lasting 3 min in 18
healthy subjects and 18 migraine patients between attacks. We
measured VEP P100 amplitudes in six sequential blocks of
100 sweeps and habituation as the change in amplitude over
the six blocks. In healthy subjects, hyperventilation decreased
VEP amplitude in block 1 and abolished the normal VEP
habituation. In migraine patients, hyperventilation further
decreased the already low block 1 amplitude and worsened the
interictal habituation deficit. Hyperventilation worsens the
habituation deficit in migraineurs possibly by increasing
dysrhythmia in the brainstem-thalamo-cortical network.
Keywords Migraine  Hyperventilation 
Visual-evoked potentials  Habituation  Brainstem 
Thalamo-cortical activity
Introduction
Stress is a well known trigger factor for migraine [1]. Stress
is often associated with hyperventilation (HV). HV induces
several physiological changes in the human central nervous
system and does so by altering eucarbia, local cerebral blood
flow, brain tissue oxygenation, pH and lactate [2–5]. For
instance, HV slows the electroencephalogram (EEG) by
increasing delta-power and decreasing alpha-power [6, 7]. It
also changes somatosensory-evoked potential latency [8],
reduces the long-latency somatosensory-evoked magnetic
fields [9], shortens the cortical silent period [10], and redu-
ces the phospene threshold [11] elicited by transcranial
magnetic stimulation (TMS). On functional neuroimaging
studies, HV decreases or even abolishes the occipital cortex
response to visual stimulation [12, 13]. The physiological
changes induced in the brain culminate just after experi-
mentally induced HV begins [14, 15].
A widely accepted and standardized test to assess
excitability in the occipital cortex is the visual-evoked
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potential (VEP). As happens for other sensory modalities,
during repeated stimulation the VEP habituates or adapts,
i.e. progressively decreases in amplitude. Besides inter-
vening in learning processes [16], habituation serves as a
protective mechanism against excessive neuronal stress
and accumulation of metabolites such as lactate and
protons [17]. In healthy subjects, various stimulation pro-
cedures modulate VEP habituation. For example, low-
frequency repetitive TMS [18] and tonic pain induced in
the hand during a cold pressor test [19] abolish, whereas
psychoactive drugs such as fluoxetine improve habituation
[20].
In migraine patients, VEP habituation is reduced or
abolished between attacks [21, 22]. Low-frequency
(inhibitory) rTMS worsens the habituation deficits whereas
high-frequency (facilitatory) repetitive TMS reverses it
[18]. By contrast, tonic pain induced by the cold pressor
test leaves the habituation deficit unchanged [23]. In
migraineurs, evoked responses recorded from the visual
cortex therefore display an abnormal VEP habituation
pattern and the visual cortex responds inadequately to
specific external or internal factors, for example HV. The
neural mechanisms underlying deficient-evoked potential
habituation in migraineurs remain unclear. Nor is it clear
whether HV induces similar changes in habituation in
healthy subjects and patients with migraine. A better
neurobiological insight into habituation mechanisms would
help understand the interictal pathophysiology of migraine.
In this study, to investigate the potential role of HV in
modulating the interictal abnormal information processing
in migraine, we studied whether and how HV influences
visual (occipital) cortical responses. In healthy subjects and
migraine patients without aura studied between attacks
before and after deep-breathing-induced HV, we recorded
VEPs to checkerboard stimulation, measured N1–P1 and
P1–N2 amplitudes to a low number of stimuli and assessed
VEP habituation over subsequent amplitude blocks.
Moreover, we search for correlations among the VEP
amplitude changes and clinical variables.
Methods
Subjects
We enrolled a group of 18 consecutive migraine patients
without aura (MO, ICHD-II code 1.1) (11 women and 7
men, mean age 30.5 years) who underwent VEP recordings
during the interictal period, i.e. attack-free for at least
3 days before and after the recording sessions, and a group
of 18 age-matched healthy subjects (12 women and 6 men,
mean age 27.1 years) recruited from among medical school
students and healthcare professionals. Inclusion criteria
were absence of any overt medical condition, and no per-
sonal or family history of migraine or epilepsy. Women
participants were always recorded at mid-cycle.
All participants received a complete description of the
study and granted informed consent. The project was
approved by the ethical review board ‘‘Sapienza’’ Univer-
sity of Rome, Polo Pontino. Participants taking regular
medications and subjects who failed to reach a best cor-
rected visual acuity of [8/10 were excluded.
Visual-evoked potentials
Subjects were sitting in a semi-dark, acoustically isolated
room in front of a TV monitor surrounded by a uniform
luminance field of 5 cd/m2. To obtain a stable pupillary
diameter, each subject adapted to the ambient room light
for 10 min before VEP recording. VEPs were elicited by
monocular right eye stimulation. Visual stimuli consisted
of full-field checkerboard patterns (contrast 80%, mean
luminance 250 cd/m2) generated on a TV monitor and
reversed in contrast at a rate of 3.1 s-1. At the viewing
distance of 114 cm, the single check edges subtended a
visual angle of 15 min. Subjects were instructed to fixate
with their right eye a red dot in the middle of the screen
with the contralateral eye covered by a patch to maintain
stable fixation. VEPs were recorded from the scalp through
silver cup electrodes positioned at Oz (active electrode)
and at Fz (reference electrode 10/20 system). A ground
electrode was placed on the right forearm. Signals were
amplified by DigitimerTM D360 pre-amplifiers (band-pass
0.05–2,000 Hz, gain 1,000) and recorded by a CEDTM
power 1401 device (Cambridge Electronic Design Ltd,
Cambridge, UK). A total of 600 consecutive sweeps each
lasting 200 ms were collected and sampled at 4,000 Hz.
After applying off-line a 35 Hz low-pass digital filter,
cortical responses were partitioned in six sequential blocks
of 100, consisting of at least 95 artifact-free sweeps.
Responses in each block were averaged off-line (‘‘block
averages’’) using the SignalTM software package version
3.10 (CED Ltd).
VEP components were identified according to their
latencies: N1 was defined as the most negative peak
between 60 and 90 ms, P1 as the most positive peak fol-
lowing N1 between 80 and 120 ms, and N2 as the most
negative peak following P1 at between 125 and 150 ms
(Fig. 1). We measured the peak-to-peak amplitude of both
the N1–P1 and P1–N2 complex. Habituation was defined
both as the change in amplitude of N1–P1 and P1–N2
recorded during the six blocks and the slope of the linear
regression line for the six blocks. VEP habituation was
evaluated before and immediately after HV. All recordings
were collected in the morning (between 09.00 and 11.00
a.m.) by the same investigator.
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Hyperventilation
The subjects were instructed to practice voluntary HV for
3 min by breathing deeply at a constant rate paced by a
metronome at 40 times per minute. The post-HV VEP was
recorded immediately after HV.
Statistical analysis
We used the Statistical Package for the Social Sciences
(SPSS) for Windows, version 15.0 for all analyses. We
constructed a multivariate analysis of variance (ANOVA)
taking as a within-subject factor ‘‘block’’ and as between-
subject factors ‘‘Group’’ (HS, MO) and ‘‘time’’ (before
and after HV). A regression analysis was used to disclose
linear trends in VEP amplitude across blocks in each
condition and group (slope). Student’s paired-sample t test
was used to compare block 1 VEP amplitude before and
after HV in both groups. Fisher’s least significant differ-
ence (LSD) test was used for post hoc analysis. Pearson’s
correlation test was used to search for correlations among
the VEP amplitude slopes and clinical variables. P values
less than 0.05 were considered to indicate statistical
significance.
Results
VEP recordings from all participants yielded analyzable
data (Table 1).
During the third minute of HV most subjects com-
plained of light headedness and a sensation of cold. One
subject had a mild right carpal spasm that resolved rapidly
with normal breathing. The mean breathing rate per minute
was similar in healthy subjects and patients (P [ 0.05).
ANOVA testing amplitude in averaged N1–P1 VEP
amplitude blocks disclosed a main effect for factor block
[F(5,340) = 6.76, P \ 0.001], a significant two-way inter-
action of group by block [F(5,340) = 2.73, P= 0.019], and
session by block [F(5,340) = 4.45, P = 0.001], but not a
three-way interaction of block by session and group
[F(5,340) = 0.58, P = 0.708]. Linear regression analysis
showed that VEP amplitudes recorded in all blocks differed
between sessions in both groups [in healthy subjects
F(1,34) = 9.02, P = 0.005 and in patients F(1,34) = 5.50,
P = 0.025]. Post hoc analysis showed that before induced
hyperventilation in healthy subjects the linear trend in VEP
amplitudes decreased from blocks 1 to 6 (-0.12), whereas
in patients it increased [?0.03; F(1,34) = 9.49, P = 0.004].
Conversely, after hyperventilation, the linear trend in
Fig. 1 Representative
recordings of visual-evoked
potential (VEP) habituation at
baseline (left) and after 3-min
hyperventilation (right) in a
healthy subject [HS] and a
migraine patient without aura
[MO]
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VEP amplitudes increased from blocks 1 to 6 in both
groups [in healthy subjects ?0.04, in patients ?0.19;
F(1,34) = 4.19, P = 0.04] (Fig. 2). Paired t test showed that
the baseline block 1 VEP amplitude decreased significantly
after hyperventilation in both groups [healthy subjects,
t(1,17) = 3.18, P = 0.005, and patients t(1,17) = 3.12,
P = 0.006].
ANOVA testing amplitude in averaged P1–N2 VEP
amplitude blocks disclosed a main effect for factor block
[F(5,340) = 2.47, P = 0.032], a significant interaction of
session by block [F(5,340) = 3.34, P = 0.006], but not of
block by group [F(5,340) = 0.32, P = 0.89] and of block by
session and group [F(5,340) = 1.09, P = 0.365]. Linear
regression analysis showed that VEP amplitudes recorded
in all blocks differed between sessions in the healthy
subjects group only [in healthy subjects F(1,34) = 15.51,
P \ 0.001 and in patients F(1,34) = 0.78, P = 0.383]. Post
hoc analysis showed that before induced hyperventilation
in healthy subjects the linear trend in VEP amplitudes
decreased from blocks 1 to 6 (-0.11), whereas in patients it
increased [?0.05, F(1,34) = 9,66, P = 0.003 vs. controls].
Conversely, after hyperventilation, the linear trend in VEP
amplitudes increased from blocks 1 to 6 in both groups [in
healthy subjects ?0.11, in patients ?0.17, F(1,34) = 0.42,
P = 0.517] (Fig. 2). Paired t test showed that the baseline
block 1 VEP amplitude was unchanged after hyperventi-
lation in both groups [healthy subjects, t(1,17) = 0.29,
P = 0.588, and patients t(1,17) = 0.17, P = 0.677].
Pearson’s test disclosed no significant correlation
between clinical characteristics and both VEP amplitude
slopes in migraine patients.
Discussion
In the healthy subjects and patients with migraine without
aura recorded between attacks, we studied 3-min deep-
breathing-induced HV significantly changed the VEPs to
Table 1 Clinical and demographic characteristics of healthy subjects
(HS) and migraine patients without aura (MO)
Characteristics HS (n = 18) MO (n = 18)
Women (n) 12 11
Age (years) 27.1 ± 7.7 30.5 ± 9.5
Duration of migraine history
(years)
18.0 ± 3.1
Attack frequency/month (n) 2.0 ± 1.4
Attack duration (hours) 20.2 ± 18.3
First minute of hyperventilation
(rate/min)
44.1 ± 5.1 44.7 ± 4.8
Second minute of hyperventilation
(rate/min)
48.4 ± 5.2 44.8 ± 4.7
Third minute of hyperventilation
(rate/min)
49.8 ± 4.3 47.7 ± 3.8
Data are expressed as mean ± SD
Fig. 2 Visual-evoked potential
N1–P1 block amplitudes
(mean ? SEM) before and after
hyperventilation lasting 3 min
in healthy subjects and migraine
patients without aura
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checkerboard stimulation. Another finding was that HV
induced similar changes in VEP patterns in healthy sub-
jects and migraine patients. After HV, VEP amplitudes to a
low number of stimuli, i.e. in the first block of 100 aver-
aged responses, decreased and the normal VEP amplitude
habituation between the first and sixth block of aver-
aged responses disappeared. These changes in cortical
responsiveness confirm that deep-breathing-induced HV
induces transient physiologic changes in brain functions,
and does so by influencing the visual (occipital) cortex
activation. As expected, subjects reported experiencing
classic HV-induced symptoms including light headedness
and sensations of cold, suggesting that they hyperventi-
lated effectively. Two participants, a healthy woman and
a male migraineur, also manifested symptoms of mild
spasmophilia.
The reduced amplitudes in the N1–P1 first amplitude
block after HV in healthy subjects and patients receive
support from current neurobiological knowledge on HV-
induced changes in hemodynamic status and EEG activity.
In healthy subjects, HV reduces cerebral blood flow and
causes marked EEG slowing [4]. The EEG changes may
reflect causes other than reduced blood flow, given that
cerebral vasoconstriction without concomitant alkalosis
and a low partial pressure of carbon dioxide (pCO2) leave
the EEG unchanged [24–26]. After HV, EEG delta power
increases and alpha power decreases [6, 7, 24]. Observa-
tions that are especially relevant to the reduced amplitudes
we found in the first N1–P1 amplitude block are that EEG
alpha activity predominates in occipito-parietal areas and
studies using simultaneous EEG and near-infrared spec-
troscopy show that low alpha amplitudes in healthy sub-
jects are related to small oxygenation responses and low
VEP amplitude [27]. For sake of completeness, we report
that some early studies showed no significant HV-induced
effects on VEP amplitude [28, 29]. However, relevant
technical and methodological considerations render unli-
kely a direct comparison of findings from these studies
with those hereby presented (different stimulus parameters,
frequency of pattern reversal, spatial features of checks,
sweep recording times, and experimental procedure for
VEP acquisition during or after HV).
Several observations help explain which brain areas
mediate the HV-induced EEG changes in VEP amplitudes.
Because cortical rhythmic activity arises from an interplay
between thalamic relay cells with cells in the reticular
nuclei and cortico-cortical reverberant loops [30, 31], the
VEP changes we recorded after deep-breathing-induced
HV could plausibly depend on thalamic neuronal hyper-
polarization. This neural mechanism accords perfectly with
early evidence that lesions involving the anterior pole of
the thalamus (nucleus centralis lateralis) abolish the corti-
cal response to HV [32, 33]. Another major brain nervous
structure involved in HV-induced EEG changes is the
reticular formation. The mesencephalic reticular formation
is as sensitive to CO2 as the classic respiratory centres, and
hypocapnia may disinhibit the normally inhibited neurons
in the mesencephalic reticular formation that synchronize
cortical activity thereby resulting in slow-wave EEG
[34, 35]. Hypercapnia can produce cortical arousal and
hypocapnia cortical depression by acting directly on mes-
encephalic structures [35]. Stimuli activating the mesence-
phalic reticular formation also facilitate oscillatory activity
in the gamma-frequency range and enhance the stimulus-
specific synchronization of neuronal spike responses in the
visual cortex of cats [36]. The HV-induced reduction in
N1–P1 VEP first block amplitude we found in healthy sub-
jects and migraineurs might reflect a transient thalamic
dysfunction possibly arising when hypocapnia related to HV
interferes with neural activity in brainstem respiratory
centres [26, 37, 38].
The second distinctive finding in our study is that in
healthy subjects (both N1–P1 and P1–N2 amplitudes) and
patients with migraine (N1–P1 amplitude only), experi-
mentally induced-HV dampened VEP amplitude habitua-
tion. A possible explanation calls into question the
temporal relationship between VEP recordings and the
duration of HV-induced EEG changes. Alpha power
recovers rapidly soon after HV ends [15], and the recovery
time course matches that of the blood-oxygen-level-
dependent (BOLD)-contrast functional MRI signal [39].
Our VEP recordings started immediately after induced HV
began and lasted ±200 s. We might therefore have recor-
ded the last six blocks of 100 responses during the alpha
activity recovery phase that leads to an increase in VEP
amplitude after the first block, and thus lack of habituation
measured over successive blocks. Although this explana-
tion receives apparent support from our finding that VEP
amplitude tends to habituate between the fourth and sixth
block (-18.8%) (Fig. 2), HV induced no 4–6 block
habituation in migraine patients (-3.2%, P = 0.07 vs.
controls), possibly because other external and internal
factors intervened.
Our new findings also expand our previous report
describing deficient VEP habituation at rest in migraine
patients between attacks [21, 22] now showing that HV
worsens this deficit mainly by decreasing further the
already abnormally low amplitude in the first VEP block.
In patients, unlike healthy subjects, habituation failed to
return between the fourth and sixth blocks suggesting that
in migraineurs the brain mechanisms responsible for
habituation are malfunctioning. In an earlier study we
showed that the late evoked component of VEP gamma
band oscillations, which reflects visual stimulus processing
by cortical neurons, does not habituate normally in mi-
graineurs [40]. We attributed this finding to a functional
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thalamus disconnection due to hypofunctioning serotoner-
gic projections from the brainstem [40, 41] and thus pro-
posed including migraine in the so-called thalamo-cortical
dysrhythmia syndromes [42, 43]. The so-called chemically
addressed state-setting brain stem nuclei modulate thal-
amo-cortical activity and cortical excitability [44]. These
state-setting systems in the brain stem contain noradren-
ergic, serotoninergic and histaminergic neurons that are
chemosensitive to CO2 tensions [45–47]. Evidence that
serotonergic raphe neurons, for instance, increase their
firing rate during hypercapnia explains their role in respi-
ratory control but also in arousal. If their firing rate
decreases during HV then decreased firing might further
aggravate their hypofunction in migraineurs and worsen
the thalamocortical dysrhythmia. Here, whether the known
persistent increase in lactate levels induced by HV [2, 4,
48] plays a role in the VEP changes remains to be deter-
mined. Collectively the above-mentioned findings seem to
support our earlier hypothesis that the interictal habituation
deficit in migraine reflects reduced thalamocortical drive
and hence a low preactivation level of sensory cortices
[21, 22].
In our study, VEP changes could in theory also derive
from reduced efficiency of inhibitory circuits. But com-
parison between the time course of HV-induced modifica-
tions in inhibitory mechanisms as revealed by TMS studies
(5–10 min after HV ends [10, 11]) and in our sensorial
responses following repetitive stimulation (immediately
after HV ends) renders unlikely that our HV-induced VEP
amplitude changes derive from transient inhibitory cortical
dysfunction.
Finally, certain limitations of the present study should
be acknowledged. First, investigators were not blinded for
subjects’ diagnosis, thing that typically happens in this kind
of study. Second, although all participants to the study
reported classic HV-induced symptoms or manifested mild
spasmophilia, the investigators performed no measure of
end-tidal pCO2 to ensure adequate hyperventilation level.
Such a missing data should not be considered detrimental
since a study comparing EEG modifications induced by
standardized (i.e. with end tidal pCO2 measures) and non-
standardized hyperventilation (i.e. without end tidal pCO2
measures) showed that both procedures changed the spec-
tral power density of EEG in all frequency bands [6].
In conclusion, experimentally induced-HV lasting 3 min
decreases VEP amplitudes to a low number of stimuli (first
block) and abolishes normal VEP habituation during sub-
sequent visual stimulation. The VEP changes in healthy
subjects and migraine patients suggest that hypocapnia
induces changes in chemosensitive aminergic nuclei in the
brain stem. In migraine patients the HV-induced changes
worsen patients’ pre-existing thalamo-cortical dysrhyth-
mia. These findings raise the intriguing question of how
hyperventilation changes VEPs in migraine patients
recorded during the attack, when VEP habituation becomes
normal [49].
Conflict of interest None.
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